Nov 12, 2014 - For Early Programs, international participants can pick up printed Certificates of Attendance. (not CME certificates for U.S. participants) on ...
AMERICAN SOCIETY OF NEPHROLOGY
Pennsylvania Convention Center
ONSITE PROGRAM
Unlock the potential of Acthar by visiting Booth #1227 to learn more
H.P. Acthar ® Gel and Questcor ® are registered trademarks of Questcor Pharmaceuticals, Inc. ©2014 Questcor Pharmaceuticals, Inc. PM-01-03-1210 09/14 Printed in USA.
New for ASN Kidney Week® 2014 Poster Information Please note that this book contains poster sessions but not individual abstract titles and authors. For abstract titles, authors, and more, please refer to the Kidney Week Mobile App, the “Locate Me” Kiosks for Posters and Exhibits in the exposition halls, or the Abstract Supplement pdf at www.asn-online.org/KidneyWeek.
Certificates of Attendance For Early Programs, international participants can pick up printed Certificates of Attendance (not CME certificates for U.S. participants) on Wednesday, November 12 at the programs. For the Annual Meeting, international participants can access online Certificates of Attendance (not CME certificates for U.S. participants) from November 14, 2014 through February 13, 2015 at https://www.showreg.net/ASN1411S/CERT. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit the ASN Service Center in the Grand Hall of the convention center.
Attention U.S. Physicians To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148), ASN reserves the right to provide information to applicable manufacturers and applicable GPOs about U.S. physicians (and their spouses) who participate in selected ASN activities. Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers. ASN makes reasonable attempts to collect and maintain the following information about its U.S. physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license. In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose. U.S. physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below. To learn more, please go to the U.S. Government’s Center for Medicare & Medicaid Services (CMS) website (http://www.cms.gov/Regulations-and-Guidance/Legislation/ National-Physician-Payment-Transparency-Program/Downloads/Physician-fact-sheet. pdf). Additional information can be found at the American Medical Association’s website (http://www.ama-assn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financialtransparency-reports.page). American Society of Nephrology (ASN), www.asn-online.org 1510 H Street, NW, Suite 800, Washington, DC 20005 Copyright © 2014 ASN
1a
Future Meeting Dates ASN Highlights U.S. 2015 “ASN Highlights: Translating Kidney Week into Clinical Practice” Chicago, Illinois . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . February 13, 2015 (full day) Houston, Texas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . February 20, 2015 (full day) Orlando, Florida . . . . . . . . . . . . . . . . . . . . . . . . . . . . . February 27–28, 2015 (2 half days)
ASN Highlights International 2015 Berlin, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . January 31–February 1, 2015 Ouro Preto, Brazil . . . . . . . May 23–25, 2015 (Brazilian Society of Nephrology Congress) London, United Kingdom . . . . . . . . . . . . . . . . . May 28–31, 2015 (ERA-EDTA Congress) Mexico City, Mexico . . . . . . . . . . June 24–26, 2015 (Mexican Institute of Nephrological Research Meeting)
ASN Board Review Course & Update 2015 July 25–31, 2015 Fairmont Chicago at Millennium Park Chicago, Illinois
ASN Kidney Week 2015 November 3–8, 2015 San Diego Convention Center San Diego, California
Visit the ASN Website (www.asn-online.org) for more information and updates.
2a
Table of Contents Kidney Week 2014 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1a Welcome to Kidney Week . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6a ASN Council, Committees, Past Presidents, and Staff . . . . . . . . . . . . . . . . . . . . . . . . . 6a ASN Foundation for Kidney Research Grant Recipients 2014 . . . . . . . . . . . . . . . . . . 10a
General Educational Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13a Purpose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13a Learning Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13a Target Audience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13a Accreditation and Continuing Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13a Program Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14a Certificates of Attendance for International Participants . . . . . . . . . . . . . . . . . . . . . . 15a Disclosure Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15a Kidney Week Mobile App . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15a Kidney Week On-Demand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16a Microscope Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16a
Abstract Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17a Posters On-Demand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17a Abstract Category Chairs and Reviewers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18a Top Oral Abstracts by Trainees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25a NIH and Informational Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29a
Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34a Conference Services and Travel Information . . . . . . . . . . . . . . 36a ADA Compliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36a ASN Management Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36a ASN Service Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36a Baggage and Coat Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36a Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36a Cell Phone Charging Stations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37a Children and Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37a Cyber Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37a Hotel List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37a Housing Desk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38a Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38a Meeting Locations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38a Overcrowding Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38a Photography and Audio/Video . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39a Power Stations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39a
3a
Table of Contents (cont.) Conference Services and Travel Information (cont.) Press Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39a Registration and Materials Pick-Up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39a Restaurant Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39a Safety and First Aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40a Shuttle Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40a Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41a Wireless Internet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41a
ASN Organizational Functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42a Ancillary Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44a Learning Pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49a Geriatric Nephrology–Related Sessions . . . . . . . . . . . . . . . . . . . 78a Pediatric Nephrology–Related Sessions . . . . . . . . . . . . . . . . . . . 79a Public Policy–Related Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82a Fellows Functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83a Trainees Track . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84a Early Programs (Tuesday–Wednesday) Advances in Research Conference—Building a Kidney: From Stem Cells to Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Coming to a Unit near You: Cluster-Randomized Trials in Hemodialysis . . . . . . . . . . . . 4 Critical Care Nephrology: 2014 Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Diagnosis and Management of Disorders of Acid-Base, Fluid, and Electrolyte Balance: Challenging Issues for the Clinician . . . . . . . . . . . . . . . . . . . . . . 8 Fundamentals of Renal Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Glomerulonephritis Update: Diagnosis and Therapy 2014 . . . . . . . . . . . . . . . . . . . . . . 13 Human Genetics in Nephrology: Clinical Fundamentals and Research Advances . . . . 15 Innovation in Kidney Disease, Dialysis, and Vascular Access . . . . . . . . . . . . . . . . . . . . 17 Kidney Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Maintenance Dialysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Maintenance of Certification: NephSAP Review and ABIM Modules . . . . . . . . . . . . . . 25 Nephro-Pharmacology across the Spectrum of Kidney Diseases . . . . . . . . . . . . . . . . 27 Professional Development Seminar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
4a
Annual Meeting Program (Thursday–Sunday) Includes Plenary Sessions, Basic and Clinical Science Symposia, Clinical Nephrology Conferences, Oral Abstract Sessions, Posters, and Special Sessions Thursday Program Day-at-a-Glance and Details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Friday Program Day-at-a-Glance and Details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Saturday Program Day-at-a-Glance and Details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 Sunday Program Day-at-a-Glance and Details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Faculty Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173 Scientific Exposition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1b Exposition Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1b Career Fair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1b Children and Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1b “Locate Me” Kiosks for Posters and Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1b Exhibitor Spotlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2b Innovators Place . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3b Exhibitor List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4b Exhibitor Company/Product Descriptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8b
Exposition Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Foldout 2014 Corporate Supporters . . . . . . . . . . . . . . . . . . . . . . Inside Back Cover
Program is subject to change.
5a
Welcome to ASN Kidney Week® 2014 Building New Paths to Kidney Health The American Society of Nephrology (ASN) proudly welcomes you to Kidney Week 2014, the world’s premier nephrology meeting. Kidney professionals from around the globe will discuss and debate the latest scientific and medical advances that will build new paths to kidney health. At ASN Kidney Week, the world’s leading experts share new approaches to health care, research, education, and policy. Participants have opportunities to network with fellow specialists, advance their careers, learn best practices for treating and improving the lives of people with kidney disease, and collaborate with colleagues from around the world. Leading the fight against kidney disease for more than 45 years, ASN represents health professionals whose intellectual rigor, integrity, and ingenuity advance kidney research, treatment, and policy, and improve the lives of millions of patients.
ASN Council Sharon M. Moe, MD, FASN President
Bruce A. Molitoris, MD, FASN Past President
Jonathan Himmelfarb, MD, FASN President-Elect
John R. Sedor, MD, FASN Secretary-Treasurer
Councilors Raymond C. Harris, MD, FASN Eleanor D. Lederer, MD, FASN
Mark D. Okusa, MD, FASN Mark E. Rosenberg, MD, FASN
6a
2014 Postgraduate Education Committee Patrick H. Nachman, MD, FASN, Chair Phyllis August, MD Roy D. Bloom, MD Michael J. Choi, MD Sarah Faubel, MD Areef Ishani, MD Kamyar Kalantar-Zadeh, MD, PhD, FASN Elaine S. Kamil, MD Abhijit V. Kshirsagar, MD Helen Liapis, MD Charmaine E. Lok, MD Thomas D. Nolin, PhD, PharmD, FASN
Suzanne M. Norby, MD, FASN Mark A. Perazella, MD, FASN Jai Radhakrishnan, MD, FASN Mitchell H. Rosner, MD, FASN Prabir Roy-Chaudhury, MD, PhD, FASN B. Peter Sawaya, MD, FASN Karin A. True, MD, FASN Delphine S. Tuot, MD Katherine R. Tuttle, MD, FASN Suzanne Watnick, MD Alexander S. Yevzlin, MD
2014 Program Committee Susan E. Quaggin, MD, Chair Lloyd G. Cantley, MD, FASN Thomas J. Carroll, PhD Michel Chonchol, MD Mark E. Cooper, MBBS, FASN Debra J. Hain, PhD, APRN Brenda Hemmelgarn, MD, PhD T. Alp Ikizler, MD, FASN Christoph Licht, MD, FASN
Xun-Rong Luo, MD, PhD Samir M. Parikh, MD Maria Pia Rastaldi, MD, PhD Andrew J. Rees, MBChB Andrey S. Shaw, MD Wendy L. St. Peter, PharmD, FASN Timothy A. Sutton, MD, PhD, FASN Jens Titze, MD Paul A. Welling, MD
7a
ASN Past Presidents 2012–2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Bruce A. Molitoris, MD, FASN 2011–2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ronald J. Falk, MD, FASN 2010–2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Joseph V. Bonventre, MD, PhD, FASN 2009–2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sharon Anderson, MD, FASN 2008–2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thomas M. Coffman, MD, FASN 2007–2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Peter S. Aronson, MD, FASN 2006–2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . William L. Henrich, MD, FASN 2005–2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thomas D. DuBose Jr., MD, FASN 2004–2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tomas Berl, MD, FASN 2003–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . William E. Mitch, MD, FASN 2002–2003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Norman J. Siegel, MD, FASN 2001–2002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roland C. Blantz, MD, FASN 2000–2001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert J. Alpern, MD 1999–2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thomas H. Hostetter, MD 1998–1999 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . William M. Bennett, MD, FASN 1997–1998 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Wadi N. Suki, MD 1996–1997 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert G. Luke, MD 1995–1996 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . William G. Couser, MD 1994–1995 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ramzi S. Cotran, MD 1993–1994 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thomas E. Andreoli, MD 1992–1993 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Alfred F. Michael, MD 1991–1992 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Richard L. Tannen, MD 1990–1991 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Craig Tisher, MD 1989–1990 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Michael J. Dunn, MD 1988–1989 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jay H. Stein, MD 1987–1988 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thomas F. Ferris, MD 1986–1987 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Barry M. Brenner, MD 1985–1986 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Saulo Klahr, MD 1984–1985 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Juha P. Kokko, MD, PhD 1983–1984 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Richard J .Glassock, MD 1982–1983 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert W. Schrier, MD 1981–1982 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roscoe R. Robinson, MD 1980–1981 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Maurice B. Burg, MD 1979–1980 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert L. Vernier, MD 1978–1979 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Belding H. Scribner, MD 1977–1978 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Laurence E. Earley, MD 1976–1977 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Floyd C. Rector Jr., MD 1975–1976 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Carl W. Gottschalk, MD 1974–1975 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . William B. Schwartz, MD 1973–1974 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jack Orloff, MD 1972–1973 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert H. Heptinstall, MD 1971–1972 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gerhard H. Giebisch, MD 1970–1971 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . George E. Schreiner, MD, PhD 1969–1970 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Louis G. Welt, MD 1968–1969 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert W. Berliner, MD 1967–1968 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Donald W. Seldin, MD 1966–1967 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Neal S. Bricker, MD
8a
ASN Staff Danette Broughton . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Director of Operations Lisa Cain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Graphic Design Specialist Charyl Delaney . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Education Coordinator Gisela Deuter . . . . . . . . . . . . . . . . . . . . Director of Continuing Professional Development Rhonda Dozier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Operations Associate Cele Fogarty . . . . . . . . . . . . . . . . . Vice President of Meetings and Member Experience Alyson Freitas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Member Services Coordinator Amber Garner . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Marketing Coordinator Lauren Gay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Education Assistant Pamela Gordon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Membership Manager Bob Henkel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Director of Communications Cara Hill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meetings Coordinator Tod Ibrahim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Executive Director Mark Kerlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Information Services Coordinator Jin Soo Kim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Director of Education Phillip Kokemueller . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chief Learning Officer Sara Bloom Leeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Communications Assistant Shari Leventhal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Managing Editor of CJASN Mark Lukaszewski . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Policy Associate Laura McCann . . . . . . . . . . . . . . . . . . . . Manager of Governance and External Relations Dawn McCoy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Executive Editor Rachel Meyer . . . . . . . . . . . . . . . . . . . . . . . . Manager of Policy and Government Affairs Ryan Murray . . . . . . . . . . . . . . . . . . . . . . . . . . Kidney Health Initiative Project Associate Hal Nesbitt . . . . . . . . . . . . . . . . . . . . . . . . Director of Marketing and Information Services Lisa Netha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Coordinator for Continuing Education Bonnie O’Brien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Managing Editor of JASN Grant Olan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Policy Associate Kara Page . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Director of Development Kurtis Pivert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Content and Media Analyst Melanie Robey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Development and Grants Associate Hector Ruiz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Director of Financial Operations Ryan Russell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Education Coordinator Jessica Stevens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Marketing Assistant Beth Strelitz . . . . . . . . . . . . . . . Associate Director of Meetings and Member Experience Daniel Tadesse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Senior Registration Manager Melissa West . . . . . . . . . . . . . . . . . . . . . . . Project Director of the Kidney Health Initiative Rasheena Wilson . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meetings and Exhibits Coordinator Alisha Workman . . . . . . . . . . . . . . . . . . . . . . . . . . . Project Manager of Distance Learning Sara de la Torre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meetings Intern
9a
ASN Foundation for Kidney Research Grant Recipients 2014 Carl W. Gottschalk Research Scholar Grants
John Merrill Grant in Transplantation
Michael Butterworth, PhD* University of Pittsburgh Aldosterone-Regulated MicroRNAs and Sodium Transport in the Distal Kidney Nephron
Martin H. Oberbarnscheidt, MD, PhD University of Pittsburgh Intragraft Recipient Antigen Presenting Cells in Allograft Rejection
Kirk N. Campbell, MD Ichan School of Medicine at Mount Sinai Role of Dendrin in Glomerular Disease Progression
The NephCure Foundation– ASN Foundation for Kidney Research Grant
Krzysztof Kiryluk, MD Columbia University GWAS-Based Pathogenesis Model of IgA Nephropathy
Heon Yung Gee, MD, PhD* Boston Children’s Hospital Mutations in KANK2 and ARHGAP4 Cause Nephrotic Syndrome by Defects in RHO GTPase Signaling
Timmy C. Lee, MD, FASN* University of Alabama at Birmingham Natural History of Arteriovenous Fistula Maturation
The William and Sandra Bennett Clinical Scholars Program
Ethan P. Marin, MD, PhD Yale School of Medicine A Novel Mode of Vascular Function Regulation by Protein Palmitoylation Brian B. Ratliff, PhD* New York Medical College Posttranslational and Redox Modification Regulation of HMGB1 during Kidney Injury Matthias Wolf, MD* University of Texas Southwestern Medical Center The Role of Mucin 1 in Protection against Nephrolithiasis by Regulation of the Renal Calcium Channel TRPV5
Jane O. Schell, MD University of Pittsburgh Medical Center An Innovative Communication Curriculum Designed to Improve Nephrology Trainees’ Knowledge and Skills in Discussing Advance Care Planning and End of Life
*ASN Kidney Week 2014 Oral and/or Poster Abstract Presenter
10a
Ben J. Lipps Research Fellowship Program Ben J. Lipps Research Fellows
Joseph A. Carlucci Research Fellow
Akinwande A. Akinfolarin, MBBS Brigham and Women’s Hospital The Role of DNA Damage Mediators in Kidney Fibrosis following Tubular Injury
Gene-Yuan Chang, MD University of California, San Francisco Characterizing Renal Gluconeogenesis and Its Regulation in Wild-Type, InsulinResistant, and Diabetic Rats
Pei-Lun Chu, MD, PhD* University of Virginia Defining the Role of Endothelial Collectrin in Blood Pressure Homeostasis
Donald E. Wesson Research Fellow
Daniel Fantus, MD University of Pittsburgh Medical Center Role of Mechanistic Target of Rapamycin (mTOR) Complexes in Regulation of Alloimmunity and Transplant Rejection
Nicholas Zwang, MD Massachusetts General Hospital Pharmacologic Phosphatidylinositol-3 Kinase Inhibition in Regulatory T Cells
Silvia Ferrè, PhD University of Texas Southwestern Medical Center Understanding the Regulation of HNF-1 Beta Expression by ER Stress Effectors
ASN Foundation for Kidney Research Fellows
Michelle M. O’Shaughnessy, MbChB Stanford University School of Medicine Trends in the Incidence, Clinical Characteristics, and Outcomes of Patients with End-Stage Renal Disease due to Glomerulonephritis
Sharon Anderson Research Fellow
Javier A. Neyra, MD* University of Texas Southwestern Medical Center Klotho and Acute Kidney Injury: A Case‑Control Study in Humans Rabi Yacoub, MD* Ichan School of Medicine at Mount Sinai Nephrin’s Role in Maintaining an Intact Slit Diaphragm in Adult Mice
Moshe Shashar, MD Boston Medical Center Role of Uremic Solutes in Thrombosis The Ben J. Lipps Research Fellowship Program is supported by donations from American Renal Associates Foundation, Inc., Amgen, ASN, Baxter, and Fresenius Medical Care.
*ASN Kidney Week 2014 Oral and/or Poster Abstract Presenter
11a
ASN Foundation for Kidney Research Grant Recipients 2014 (cont.) Student Scholar Grants Nicholas Apostolopoulos Yale University School of Medicine An Investigation into Alternative M2 Macrophage Activation after Renal Ischemia/Reperfusion Injury Beatriz M. Cole Mount Sinai School of Medicine KIBRA Signaling in Glomerular Disease Alexander Cypro Washington State University Reliability of Diagnosis for AKI in the Administrative Record of Hospitalized Patients Colin P. Dunn Albert Einstein College of Medicine De Novo Sirolimus as Primary Immunosuppression in Renal Transplantation: A Single-Center Study Raymond W. Keller Jr. Emory University School of Medicine Effects of Uremia on Urea Transporter Expression in Rat Eccrine Glands and the Sweat: Blood Ratio of Urea, Sodium, and Potassium Robyn Nicole Levine University of North Carolina School of Medicine The Relationship between Health/ Functional Literacy and Hospitalizations for Children, Adolescents, and Young Adults with CKD
Christopher J. Loftus Cleveland Clinic Effect of Vitamin D Supplementation on Renal Stone Risk and Composition George Maliha University of Pennsylvania School of Medicine VaSera Basic Study Kailey Minnings The Hospital for Sick Children The Rivas 1000 Cohort Validation Study Richard T. Rogers Emory University Urea Transport and Blood Pressure Regulation Tyler J. Stephenson University of Kansas Medical Center Characterizing the Effects of Cardiotrophin-Like Cytokine Factor 1 on Differentiated Podocytes Heywan M. Tesfaye Keck School of Medicine of USC Molecular Mechanisms Responsible for the Blood Pressure–Lowering Effect of CYP4A1 Expression Harry Philip Tseng Albany Medical College BK Virus Serostatus Effects on Viremia and Nephropathy Post Renal Transplantation
*ASN Kidney Week 2014 Oral and/or Poster Abstract Presenter
12a
General Educational Information Purpose • Learn basic and clinical science along with advances in clinical practice. • Network with nephrology luminaries and colleagues from around the globe. • Enjoy the camaraderie of friends and the culture of Philadelphia.
Learning Objectives At the conclusion of this activity, participants will have increased knowledge in the field of nephrology and will be able to: 1. Identify recent discoveries in basic, translational, and clinical research in nephrology. 2. Construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines. 3. Translate recent advances in the areas of general nephrology, dialysis, transplantation, and hypertension into new standards and approaches to clinical care of patients with kidney diseases and related disorders.
Target Audience • Physicians • PhDs and Other Researchers • Medical and Other Trainees—including medical students, residents, graduate students, post-docs, and fellows • Nurses and Nurse Practitioners • Pharmacists • Physician Assistants • Other Health Care professionals
Continuing Medical Education Credit (Annual Meeting 2014, November 13–16) The American Society of Nephrology (ASN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASN designates this live activity for a maximum of 31.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 31.0 hours of Category 1 credit for completing this program. Participants should accurately estimate total CME hours spent at one or more of the following educational sessions: Basic and Clinical Science Symposia, Clinical Nephrology Conferences, Special Sessions, Educational Symposia, Oral Abstract Sessions, and Plenary Sessions.
13a
General Educational Information (cont.) Please follow the “Program Evaluation” instructions on the following page to complete the evaluation, claim continuing education credit, and print your certificate of participation by December 10, 2014. Note: For Early Program credit, please refer to pages 2–30.
Continuing Nurse Education Credit (Annual Meeting 2014, November 13–16) The School of Nursing at the University of North Carolina at Chapel Hill is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. The School of Nursing at the University of North Carolina at Chapel Hill designates this educational activity for a maximum of 29.5 ANCC hours. Participants should only claim credit commensurate with the extent of their participation in the activity. To successfully complete this learning activity, participants must complete the Annual Meeting evaluation at www.asn-online.org/cme by December 10, 2014. Instructions to print your certificate of completion will be available at this website. Note: CNE credit is not available for Early Programs (November 11–12).
Continuing Pharmacy Education Credit (Annual Meeting 2014, November 13–16) The University of Minnesota, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is eligible for up to 29.5 contact hours of continuing pharmacy education credit. Please complete the Annual Meeting evaluation at www.asn-online.org/cme by December 10, 2014. This will ensure that the CPE credit that you earn is added to your NAPB e-profile. Note: CPE credit is available for the Nephro-Pharmacology Early Program (November 12) but not the other Early Programs.
Program Evaluation ASN values each participant’s review and comments on the quality of ASN’s educational activities. Please complete the Annual Meeting evaluation at www. asn‑online.org/cme by December 10, 2014. Instructions are available on the ASN website and onsite at the ASN Service Center in the convention center (in Exhibit Hall B during exposition hours, and in the Grand Hall of the convention center during non‑exposition hours).
14a
Certificates of Attendance for International Participants For Early Programs, international participants can pick up printed Certificates of Attendance (not CME certificates for U.S. participants) on Wednesday, November 12 at the programs. For the Annual Meeting, international participants can access online Certificates of Attendance (not CME certificates for U.S. participants) from November 14, 2014 through February 13, 2015 at https://www.showreg.net/ASN1411S/CERT. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit the ASN Service Center in the Grand Hall of the convention center.
Disclosure Statement It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN’s sponsored continuing education (CE) activities are expected to provide full disclosure for both themselves and their spouse/ partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 12 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside U.S. Food and Drug Administration (FDA)–approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations. ASN requires all individuals in a position to control content for Kidney Week 2014 to complete disclosure forms. Responses are listed on the ASN website (www.asn-online. org/kidneyweek/faculty) and on the Kidney Week 2014 mobile app.
Kidney Week Mobile App For easy access to dynamic meeting information at your fingertips, download the Kidney Week 2014 mobile app using this QR code or at www.asn-online.org/KidneyWeek. Kidney Week Mobile App support is provided by Amgen.
15a
General Educational Information (cont.) Kidney Week On-Demand™ Over 300 hours of Kidney Week 2014 will be made available in January 2015 to fully paid participants of the Annual Meeting at no additional cost ($595 value). Sessions to be captured include: Plenary Sessions, Basic and Clinical Science Symposia, Clinical Nephrology Conferences, Special Sessions, and select Early Programs. Each captured session will include complete audio files and slides (with speaker permission) and will be displayed as streaming media to your computer, with searchable content, speaker information, and links to additional resources (if available). Fully paid participants of the Annual Meeting will receive a voucher inside the meeting bag redeemable at one of the Kidney Week On-Demand supporters’ exhibit booths. Exchange the voucher for an electronic access code, log in at www.asn-online.org/ LearningCenter, and experience Kidney Week anytime, anyplace. Note: CME, CNE, and CPE credits are not available for Kidney Week On-Demand.
Microscope Room
Room 110
You are invited to sign up (outside Room 110) for a hands-on review session of all the glass slides from the “Renal Biopsy: Clinical Correlations” session vignettes prior to Saturday, November 15, with renal pathologists onsite to direct your study of the cases and to provide individual instruction. There is no fee to visit the Microscope Room; however, space is limited and will be reserved on a first-come, first-served basis.
Microscope Room Hours Thursday, November 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9:30 a.m. – 4:30 p.m. Friday, November 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9:30 a.m. – 4:30 p.m. Saturday, November 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9:30 a.m. – 12:00 p.m.
Renal Biopsy: Clinical Correlations Session Saturday, November 15 . . . . . . . . . . . . . . . . . . . . . . . . . 4:30 p.m. – 6:30 p.m., Room 113 Renal pathologists and a clinical nephrologist discuss key histologic and clinical aspects of specific parenchymal renal diseases.
ASN® Trademark The American Society of Nephrology®, ASN®, Kidney Week®, CJASN®, JASN®, NephSAP®, and ASN Kidney News® are registered trademarks of ASN.
16a
Abstract Information ASN publishes Kidney Week abstracts in electronic form only. The 2014 Abstracts CD offers a concise and effective way to view and archive abstracts and the program. To get your complimentary CD, take your CD voucher in your meeting bag to Sanofi Renal at Booth #1315 in Exhibit Hall B. CDs are limited and are available while supplies last. All abstracts and the complete Kidney Week program are viewable online through the Program Builder at www.asn-online.org/KidneyWeek with features including keyword search and PDA download. Abstracts2View CD support is provided by Sanofi Renal. Online Abstracts2View and Program Builder support is provided by OPKO Health Renal Division. New for 2014: Please note that this book contains poster sessions but not individual abstract titles and authors. For abstract titles, authors, and more, please refer to the Kidney Week Mobile App, the “Locate Me” Kiosks for Posters and Exhibits in the exposition halls, or the Abstract Supplement pdf at www.asn-online.org/KidneyWeek.
Posters On-Demand™ Fully paid participants can access electronic versions of the Kidney Week 2014 posters at no additional cost. Search and locate posters easily by authors, categories, or keywords during and after the meeting. The Posters On-Demand computer kiosk is located on the Bridge of the convention center, or posters can be accessed online at www.asn-online.org/KidneyWeek/PostersOnDemand. Note: CME credit will not be awarded for these materials. Posters On-Demand support is provided by OPKO Health Renal Division.
17a
Abstract Category Chairs and Reviewers ASN thanks the following experts for assistance with the abstract process.
Acute Kidney Injury 001 AKI: Basic Steven C. Borkan, MD, Category Chair Michael T. Eadon, MD, Category Chair Ramon G. Bonegio, MD, PhD Patrick Cunningham, MD, FASN Mark P. De Caestecker, PhD Takashi Hato, MD Gur P. Kaushal, PhD Gilbert R. Kinsey, PhD Jerrold S. Levine, MD Matthew D. Plotkin, MD Prabhleen Singh, MD 002 AKI: Basic Repair David P. Basile, PhD, Category Chair Erika I. Boesen, PhD Aaron J. Polichnowski, PhD Didier Portilla, MD Scott K. Van Why, MD 003 AKI: Clinical Jay L. Koyner, MD, Category Chair Rajit K. Basu, MD Josee Bouchard, MD Steven G. Coca, DO Kent Doi, MD, PhD, FASN Zoltan H. Endre, MD, FASN Michael Heung, MD Edward D. Siew, MD Karina Soto, MD, PhD Ashita J. Tolwani, MD Sushrut S. Waikar, MD Ron Wald, MD Michael Zappitelli, MD
Bioengineering and Informatics 101 Bioengineering and Informatics Shuvo Roy, PhD, Category Chair Stephen R. Ash, MD Steven Kim, MD Timothy W. Meyer, MD Julie M. Yabu, MD, FASN
Cell and Matrix Biology 201 Cell Signaling/Oxidative Stress Katalin Susztak, MD, PhD, Category Chair Roland C. Blantz, MD, FASN Farhad R. Danesh, MD, FASN Carolyn M. Ecelbarger, PhD Josephine M. Forbes, PhD Jeffrey R. Schelling, MD 202 Extracellular Matrices and Their Receptors Christos Chatziantoniou, PhD, Category Chair Jean-claude Dussaule, MD, PhD Oliver Gross, DrMed Fan Fan Hou, MD, PhD Carol A. Pollock, MD, PhD 203 Apoptosis, Proliferation, Autophagy, Cell Senescence, Cell Transformation Jesus Egido, MD, PhD, Category Chair Ricardo J. Bosch, MD, PhD Yusuke Suzuki, MD 204 Growth Factors, Chemokines, Autacoids Jürgen Floege, MD, Category Chair Kumar Sharma, MD Frederick W.K. Tam, MD, PhD Motoko Yanagita, MD, PhD
18a
Chronic Kidney Disease 301 CKD: Complications Adeera Levin, MD, Category Chair Catherine M. Clase, MbChB, FASN Ashley B. Irish, MD Sarbjit Vanita Jassal, MD, PhD Francois Madore, MD Patrick S. Parfrey, MD, FASN Mark J. Sarnak, MD, FASN Manish M. Sood, MD, FASN Paul E. Stevens, MD David C. Wheeler, MD Nadia Y. Zalunardo, MD
304 CKD: Health Services, Prevention Amy Barton Pai, PharmD, FASN, Category Chair Kerri L. Cavanaugh, MD Paul Komenda, MD Andrew S. Narva, MD, FASN Julie A. Wright Nunes, MD 305 CKD: Health Disparities L. Ebony Boulware, MD, Category Chair Deidra C. Crews, MD, FASN Raquel Charles Greer, MD Vanessa Grubbs, MD Susanne B. Nicholas, MD, PhD, FASN
302 CKD: Estimating Equations, Incidence, Prevalence, Special Populations Josef Coresh, MD, PhD, FASN, Category Chair Brad C. Astor, PhD Meredith C. Foster, DO Stein I. Hallan, MD, PhD Paul Muntner, PhD C. Rebholz, PhD
Developmental Biology and Inherited Kidney Diseases
303 CKD: Epidemiology, Outcomes Linda F. Fried, MD, FASN, Category Chair Juan Jesus Carrero, PhD Ron T. Gansevoort, MD, PhD Claudine T. Jurkovitz, MD Holly J. Kramer, MD Manjula Kurella Tamura, MD Julie Lin, MD, FASN Rulan S. Parekh, MD, FASN Carmen A. Peralta, MD Kalani L. Raphael, MD Dena E. Rifkin, MD Stephen L. Seliger, MD Lynda Szczech, MD, FASN Daniel E. Weiner, MD, FASN Carmine Zoccali, MD, FASN
402 Stem Cells and Regeneration Akio Kobayashi, PhD, Category Chair Neil A. Hukriede, PhD Melissa H. Little, PhD Ryuichi Nishinakamura, MD, PhD Paola Romagnani, MD
401 Developmental Biology Denise K. Marciano, MD, PhD, Category Chair Zubaida R. Saifudeen, PhD Sunder Sims-Lucas, PhD Kameswaran Surendran, PhD Rebecca A. Wingert, PhD
403 Pediatric Nephrology Mark Mitsnefes, MD, Category Chair Katherine M. Dell, MD Bethany J. Foster, MD Jens W. Goebel, MD Benjamin L. Laskin, MD Karen Mcniece Redwine, MD Colin T. White, MD, FASN
19a
Abstract Category Chairs and Reviewers (cont.) Diabetes 501 Diabetes Mellitus and Obesity: Basic Experimental Radko Komers, MD, PhD, Category Chair Denis Feliers, PhD Paolo Fiorina, MD, PhD Alessia Fornoni, MD, PhD, FASN Chris R. Kennedy, PhD Joan C. Krepinsky, MD Rama Natarajan, PhD, FASN Jorge E. Toblli, MD, PhD, FASN Volker Vallon, MD 502 Diabetes Mellitus and Obesity: Clinical Karin Jandeleit-Dahm, MD, PhD, Category Chair Hanna E. Abboud, MD Luigi Gnudi, MD, FASN Jan Menne, MD Rowan G. Walker, MD, FASN
Dialysis 601 Standard Hemodialysis for ESRD James S. Kaufman, MD, Category Chair Susan T. Crowley, MD, FASN John T. Daugirdas, MD, FASN Eduardo K. Lacson, MD, FASN Jochen G. Raimann, MD 602 Dialysis for AKI: Hemodialysis, CRRT, SLED, Others William Fissell, MD, Category Chair Sevag Demirjian, MD Mark R. Marshall, MBChB Balazs Szamosfalvi, MD Anitha Vijayan, MD, FASN 603 Hemodialysis: Vascular Access Charmaine E. Lok, MD, Category Chair Timmy C. Lee, MD, FASN Jennifer M. MacRae, MD Kevan Polkinghorne, PhD, MBChB Tushar J. Vachharajani, MD, FASN Monnie Wasse, MD, FASN Alexander S. Yevzlin, MD
604 Home and Frequent Dialysis Mark L. Unruh, MD, Category Chair Christopher T. Chan, MD Joel D. Glickman, MD Mark Rohrscheib, MD Brigitte Schiller, MD, FASN 605 Dialysis: Anemia and Iron Metabolism Steven Fishbane, MD, Category Chair Jeffrey S. Berns, MD, FASN Anatole Besarab, MD David M. Charytan, MD Kamyar Kalantar-Zadeh, MD, PhD, FASN Naveed N. Masani, MD Hitesh H. Shah, MD, FASN Bruce S. Spinowitz, MD Jay B. Wish, MD 606 Dialysis: Epidemiology, Outcomes, and Clinical Trials: Cardiovascular Stephen M. Sozio, MD, FASN, Category Chair Nisha Bansal, MD Steven M. Brunelli, MD Tara I. Chang, MD, FASN Charles A. Herzog, MD Michal L. Melamed, MD Albert J. Power, MD Sylvia E. Rosas, MD, FASN Tariq Shafi, MBBS, FASN 607 Dialysis: Epidemiology, Outcomes, and Clinical Trials: Non-Cardiovascular Csaba P. Kovesdy, MD, Category Chair Anthony J. Bleyer, MD, FASN Joline L.T. Chen, MD, FASN Elvira Gosmanova, MD, FASN Joanna Hudson, PharmD, FASN Bernard G. Jaar, MD, FASN Miklos Zsolt Molnar, MD, PhD, FASN Istvan Mucsi, MD, PhD Connie Rhee, MD Mihaly B. Tapolyai, MD, FASN
20a
608 Peritoneal Dialysis Jeffrey Perl, MD, Category Chair Joanne M. Bargman, MD Neil Boudville, MBBS Edwina A. Brown, MD Beth M. Piraino, MD Anjali B. Saxena, MD Rafael Selgas, MD, PhD Isaac Teitelbaum, MD Angela Yee Moon Wang, MD, PhD 609 Dialysis: Palliative and End-of-Life Care Michael J. Germain, MD, Category Chair Nwamaka Denise Eneanya, MD Alvin H. Moss, MD Steven J. Rosansky, MD Jennifer S. Scherer, MD
Ethics in Transplant, CKD, and Dialysis 701 Ethics in Transplant, CKD, and Dialysis Beth L. Fromkin, MD, Category Chair Mauro Braun, MD, FASN Cynthia G. Kristensen, MD Dianne T. Sandy, MD Bessie A. Young, MD, FASN
Fluid, Electrolytes, and Acid‑Base 801 Acid-Base: Basic Sylvie Breton, PhD, Category Chair Dennis Brown, PhD Nuria M. Pastor-Soler, MD, PhD, FASN Michael F. Romero, PhD 802 Water/Urea/Vasopressin, and Organic Solutes Mitsi A. Blount, PhD, Category Chair Guangping Chen, PhD Robert A. Fenton, PhD, FASN Enno Klussmann Rikke Norregaard, PhD Janos Peti-Peterdi, MD, PhD
803 Na+, K+, and Cl- Basic Kenneth R. Hallows, MD, PhD, FASN, Category Chair Robert S. Hoover, MD, FASN Pablo A. Ortiz, PhD Arohan R. Subramanya, MD, FASN WenHui Wang, MD 804 Fluid, Electrolyte, and Acid-Base Disorders Robert J. Unwin, MD, PhD, Category Chair Giovambattista Capasso, MD Pascal Houillier, MD, PhD Qi Qian, MD Carsten A. Wagner, MD
Genetic Diseases of the Kidney 901 Cystic Kidney Diseases Michal Mrug, MD, Category Chair William M. Bennett, MD, FASN Charles L. Edelstein, MD, PhD Marie C. Hogan, MD, PhD, FASN Peter Igarashi, MD, FASN Dorien J.M. Peters, PhD Stefan Somlo, MD Marie Trudel, PhD Terry J. Watnick, MD 902 Non-Cystic Mendelian Diseases Jeffrey B. Kopp, MD, FASN, Category Chair Rasheed A. Gbadegesin, MD Robert Kleta, MD, PhD, FASN John F. O’Toole, MD M. Sampson, MD 903 Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases Detlef Bockenhauer, MD, Category Chair Barry I. Freedman, MD Oemer Necmi Goek, MD Matthias Kretzler, MD Masaomi Nangaku, MD, PhD Maria R. Wing, PhD
21a
Abstract Category Chairs and Reviewers (cont.) Geriatric Nephrology 1001 Geriatric Nephrology Andrew D. Rule, MD, Category Chair Sharon Anderson, MD, FASN Pierre Delanaye, MD, PhD Richard J. Glassock, MD Ann M. O’Hare, MD
Hypertension 1101 Hypertension: Basic Dominik N. Müller, PhD, Category Chair Steven D. Crowley, MD Susan B. Gurley, MD, PhD Karl F. Hilgers, MD, FASN Ulrich O. Wenzel, MD 1102 Hypertension: Clinical James M. Luther, MD, Category Chair Sandra J. Taler, MD Raymond R. Townsend, MD Matthew R. Weir, MD Adam Whaley-Connell, DO, FASN
Mineral Disease 1201 Mineral Disease: Ca/Mg/PO4 Orson W. Moe, MD, Category Chair Bryan R. Kestenbaum, MD Rajiv Kumar, MBBS, FASN Makoto Kuroo, MD, PhD Leigh Darryl Quarles, MD 1202 Mineral Disease: Vitamin D, PTH, FGF-23 Ian H. de Boer, MD, Category Chair Ishir Bhan, MD Michelle Denburg, MD Orlando M. Gutierrez, MD Jessica B. Kendrick, MD Sankar D. Navaneethan, MD, FASN Cassianne Robinson-Cohen, PhD
1203 Mineral Disease: CKD-Bone Tamara Isakova, MD, Category Chair Antonio Bellasi, MD Aline Martin, PhD Tom Nickolas, MD Sagar U. Nigwekar, MD Julia J. Scialla, MD Anna L. Zisman, MD 1204 Mineral Disease: Nephrolithiasis David S. Goldfarb, MD, FASN, Category Chair Benjamin Canales, MD, MPH Kamel S. Kamel, MD John C. Lieske, MD, FASN
Nephrology Education 1301 Educational Research Manjula Gowrishankar, MD, Category Chair Jean L. Holley, MD Joanne E. Kappel, MD Jolanta A. Karpinski, MD 1302 Fellows Case Reports Markus Ketteler, MD, Category Chair Geoffrey A. Block, MD, FASN Pieter Evenepoel, MD, PhD William F. Finn, MD Masafumi Fukagawa, MD, PhD, FASN Takayuki Hamano, MD, PhD Joachim H. Ix, MD, FASN Martin K. Kuhlmann, MD Orfeas Liangos, MD, FASN Rajnish Mehrotra, MD, FASN Rainer Oberbauer, MD, FASN Ivan Rychlik, MD, PhD, FASN Georg Schlieper, MD Nigel David Toussaint, MBBS Marc G. Vervloet, MD, PhD
22a
Nutrition, Inflammation, and Metabolism 1401 Nutrition, Inflammation, and Metabolism George A. Kaysen, MD, PhD, FASN, Category Chair Branko Braam, MD, PhD, FASN Harold A. Franch, MD Kirsten L. Johansen, MD Ravindra L. Mehta, MD, FASN Dominic S. Raj, MD, FASN
Glomerular and Tubulointerstitial Disorders 1501 Basic/Experimental Immunology Ulf Panzer, MD, Category Chair Kline Bolton, MD, FASN Dorin-Bogdan Borza, PhD Kathrin Eller, MD 1502 Basic/Experimental Inflammation Matthew D. Griffin, MbChB, Category Chair Sophie M. De Seigneux, MD, PhD Mark Alan Little, MD, PhD Sundararaman Swaminathan, MD 1503 Basic/Experimental Pathology Vivette D. D’Agati, MD, Category Chair H. Terence Cook, MBBS Jeremy Stuart Duffield, MD, PhD J. Charles Jennette, MD Gilbert W. Moeckel, MD, PhD, FASN Marcus J. Moeller, MD Michio Nagata, MD, PhD 1504 Extracellular Matrix Biology, Fibrosis, Cell Adhesion Jeffrey H. Miner, PhD, Category Chair Jeffrey L. Barnes, PhD Allison A. Eddy, MD, FASN Ivica Grgic, MD Ambra Pozzi, PhD Shougang Zhuang, MD, PhD
1505 Cell Biology: Glomerular Peter H. Mundel, MD, Category Chair Kirk N. Campbell, MD Lawrence B. Holzman, MD Jordan A. Kreidberg, MD, PhD Valerie A. Schumacher, PhD Agnieszka Swiatecka-Urban, MD, FASN Astrid Weins, MD, PhD 1506 Clinical/Diagnostic Renal Pathology and Lab Medicine Charles E. Alpers, MD, Category Chair Kerstin U. Amann, MD Ingeborg M. Bajema, MD, PhD Behzad Najafian, MD Samih H. Nasr, MD Michael B. Stokes, MBChB 1507 Clinical Glomerular and Tubulointerstitial Disorders Daniel C. Cattran, MD, Category Chair Sharon G. Adler, MD, FASN Sean Barbour, MD Rosanna Coppo, MD Fernando C. Fervenza, MD, PhD, FASN Colin C. Geddes, MBChB Michelle A. Hladunewich, MD, FASN Zhihong Liu, MD Alain Y. Meyrier, MD David Philibert, MD Howard Trachtman, MD, FASN
Patient Safety 1601 Patient Safety Adriana Hung, MD, Category Chair Khaled Abdel-Kader, MD Clarissa Jonas Diamantidis, MD Diana I. Jalal, MD James B. Wetmore, MD
23a
Abstract Category Chairs and Reviewers (cont.) Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 1701 Pharmacokinetics (PK)/ Pharmacodynamics (PD)/ Pharmacogenomics Katie E. Cardone, PharmD, Category Chair Mariann D. Churchwell, PharmD Rachel F. Eyler, PharmD Thomas D. Nolin, PhD, PharmD, FASN
Transplantation 1801 Transplantation: Basic and Experimental Geetha Chalasani, MD, Category Chair Marie-Josee Hebert, MD Martin H. Oberbarnscheidt, MD, PhD Hamid Rabb, MD, FASN Leonardo V. Riella, MD, PhD, FASN 1802 Transplantation: Clinical and Translational Peter P. Reese, MD, Category Chair Deborah B. Adey, MD Sandra Amaral, MD Ulf H. Beier, MD Christopher D. Blosser, MD David J. Cohen, MD Mona D. Doshi, MD Richard Formica, MD Joseph Kim, MD, PhD Krista L. Lentine, MD, PhD, FASN Sumit Mohan, MD Stephen O. Pastan, MD Rachel E. Patzer, PhD Deirdre L. Sawinski, MD Francis L. Weng, MD
Vascular Biology 1901 Vascular Biology: Atherosclerosis, Inflammation, Endothelium Benjamin D. Humphreys, MD, PhD, FASN, Category Chair Hermann G. Haller, MD Rafael Kramann, MD Anton Jan Van Zonneveld, PhD 1902 Vascular Calcification Myles S. Wolf, MD, Category Chair Farah N. Ali, MD Ming Chang Hu, MD, PhD Wei Ling Lau, MD Rosa M.A. Moyses, MD, PhD Jason R. Stubbs, MD 1903 Vascular Biology: Blood and Lymphatic Development, Function, and Homeostasis Adrian S. Woolf, MD, Category Chair Dominic E. Cosgrove, PhD Michael S. Goligorsky, MD, PhD S. Ananth Karumanchi, MD Maria Luisa S. Sequeira Lopez, MD Adrian S. Woolf, MD
24a
Top Oral Abstracts by Trainees ASN is pleased to highlight the Top Oral Abstracts by young investigators and physicians-in-training as lead authors.
Acute Kidney Injury TH-OR028 FR-OR001 FR-OR008
A Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Conferring Risk for Acute Kidney Injury— Bixiao Zhao, Yale University. Thursday, November 13, 4:30 p.m., Room 108 Heme Oxygenase-1 (HO-1) Expression Regulates Trafficking of Myeloid Cells in Acute Kidney Injury—Ahmed Kamal, University of Alabama at Birmingham, Mansoura University. Friday, November 14, 4:30 p.m., Room 107 IL-233 Fusion Cytokine: A Novel Therapeutic Approach for Acute Kidney Injury—Marta Stremska, University of Virginia. Friday, November 14, 5:54 p.m., Room 107
Bioengineering and Informatics TH-OR038
Recellularization of Vascular and Tubular Compartments of Rat Kidney Scaffolds with Embryonic Stem Cells— Barbara Bonandrini, IRCCS Mario Negri Institute. Thursday, November 13, 4:30 p.m., Room 115-C
Cell and Matrix Biology FR-OR011
Exploring the Pathophysiological Functions of Resident Fibroblasts in the Kidney—Jin Nakamura, Kyoto University. Friday, November 14, 4:30 p.m., Room 104
Chronic Kidney Disease TH-OR050 TH-OR051 FR-OR021
FR-OR030
Slope of Glomerular Filtration Rate Decline as Clinical Trial Endpoint—Misghina Weldegiorgis, University Medical Center Groningen. Thursday, November 13, 4:54 p.m., Room 202 The Association between Kidney Function and Major Bleeding in People with Atrial Fibrillation Initiating Warfarin Therapy— Min Jun,University of Calgary. Thursday, November 13, 5:06 p.m., Room 202 Infection Is a Risk Factor for Faster Progression to Renal Replacement Therapy and Death in Chronic Kidney Disease— Hicham Cheikh Hassan, St. Paul’s Hospital, University of New South Wales. Friday, November 14, 5:06 p.m., Room 204-C Independent Predictors of Uromodulin Excretion in a Large Population Survey: The CARTaGENE Study— Catherine Delmas‑Frenette, Hopital du Sacre-Cœur de Montreal. Friday, November 14, 4:54 p.m., Room 204-A
25a
Top Oral Abstracts by Trainees (cont.) Chronic Kidney Disease (cont.) SA-OR015
Association of Serum Erythropoietin with Cardiovascular Events, Kidney Function Decline, and Mortality: The Health ABC— Pranav Garimella, Tufts Medical Center. Saturday, November 15, 5:18 p.m., Room 105
Developmental Biology and Inherited Kidney Diseases SA-OR023 SA-OR043
Patterning of the Renal Stroma Does Not Require Input from the Nephron Progenitors, the Ureteric Bud, or Their Derivatives— Amrita Das, University of Texas Southwestern Medical Center. Saturday, November 15, 5:30 p.m., Room 109 Using Human Pluripotent Stem Cells to Model Kidney Disease Pathophysiology and Therapy—Benjamin Freedman, Brigham and Women’s Hospital. Saturday, November 15, 5:30 p.m., Room 201-A
Diabetes TH-OR149 FR-OR119 SA-OR033
Tubular Dysfunction Results in Altered Nucleoside Metabolism in Diabetic Nephropathy—Anna Mathew, University of Michigan. Thursday, November 13, 4:42 p.m., Room 118-B Circulating Tumor Necrosis Factor Receptors 1 and 2 Correlate with Glomerular Structure in Type 2 Diabetes—Gudeta Fufaa, National Institutes of Health–NIDDK. Friday, November 14, 5:06 p.m., Room 115-B Overexpression of Heterogeneous Nuclear Ribonucleoprotein F Attenuates Tubular Apoptosis and Tubulointerstitial Fibrosis in Type 2 Diabetic Mice—Chao-Sheng Lo, University of Montreal. Saturday, November 15, 5:30 p.m., Room 114
Dialysis TH-OR084 TH-OR146 FR-OR047 SA-OR109
Validation of Criteria Diagnosing Catheter-Related Bloodstream Infections in Hemodialysis Patients—Friederike Quittnat Pelletier, University Health Network, University of Toronto. Thursday, November 13, 5:42 p.m., Room 204-A Remote Ischaemic Preconditioning in Haemodialysis: An Initial Randomised Controlled Trial—Lisa Crowley, Royal Derby Hospital. Thursday, November 13, 6:06 p.m., Room 204-C Hyperthyrotropinemia and Mortality in a National Incident Hemodialysis Cohort—Connie Rhee, University of California, Irvine. Friday, November 14, 4:54 p.m., Room 118-B Longitudinal Effect of Biocompatible Solutions on Peritoneal Solute Transport: Results from the Global Fluid Study— Emma Elphick, Keele University. Saturday, November 15, 5:18 p.m., Room 202
26a
Fluid, Electrolytes, and Acid-Base TH-OR114 FR-OR099
Distal Nephron Remodeling Occurs in Response to a Loss of Thiazide-Sensitive Sodium-Chloride Channel Phosphorylation—P. Richard Grimm, University of Maryland. Thursday, November 13, 5:42 p.m., Room 203 Sirtuin 7 Modulates Renal Acid-Base Homeostasis through Deacetylation of the K+:Cl- Cotransporter, KCC4—Zesergio Melo, INCMNSZ-IIB-UNAM. Friday, November 14, 4:30 p.m., Room 203
Glomerular and Tubulointerstitial Disorders TH-OR073 TH-OR127 TH-OR137 TH-OR155 FR-OR079 FR-OR126 SA-OR050
Reassessment of suPAR in Kidney Disease—Joann Spinale, Children’s Hospital of Philadelphia. Thursday, November 13, 5:30 p.m., Room 114 Genetic Activation of Hypoxia-Signaling Restores Erythropoietin Synthesis in Renal Myofibroblasts—Tomokazu Souma, Tohoku University, Northwestern University. Thursday, November 13, 6:18 p.m., Room 119-B The Glomerular Filter as an Electrical Powerhouse: How Much Voltage Is Required to Prevent Proteinuria?—Turgay Saritas, University Hospital RWTH Aachen. Thursday, November 13, 6:18 p.m., Room 119-A Unraveling the Mechanism of Action of Glucocorticoids in Glomerulonephritis—Christoph Kuppe, RWTH Aachen. Thursday, November 13, 4:30 p.m., Room 109 B Cell–Derived IL-4 Induces Proteinuria and Foot Process Effacement—Alfred Kim, Washington University. Friday, November 14, 4:30 p.m., Room 111 Epithelial-Derived Wnt Ligand Drives Interstitial Fibrosis through Paracrine Signaling—Omar Maarouf, Brigham and Women’s Hospital. Friday, November 14, 4:30 p.m., Room 109 In Vivo Serial Multiphoton Imaging of the Early Changes in Glomerular Structure and Function in Nephrotic NEP25/PodocinConfetti Mice—Kengo Kidokoro, University of Southern California, Kawasaki Medical School. Saturday, November 15, 4:54 p.m., Room 108
27a
Top Oral Abstracts by Trainees (cont.) Hypertension TH-OR095 FR-OR072
Elevated Blood Pressure Index and Decreased Nocturnal Dip Are Risk Factors for Cognitive Dysfunction in Children and Young Adults—Nina Laney, Children’s Hospital of Philadelphia. Thursday, November 13, 5:54 p.m., Room 111 Ablation of Dendritic Cells Prevents Hypertension in Mice Infusedwith Angiotensin II Plus High Salt Diet—Daniel Hevia, Universidad deChile. Friday, November 14, 4:30 p.m., Room 105
Mineral Disease FR-OR113
Uromodulin Upregulates the Epithelial Magnesium Channel TRPM6 by Impairing Dynamin II–Dependent Endocytosis—Matthias Wolf, University of Texas Southwestern Medical Center. Friday, November 14, 5:54 p.m., Room 119-B
Patient Safety FR-OR043
Is Erythropoietin Resistance Index (ERI) Merely a Proxy for Inflammation?—Anirudh Rao, UK Renal Registry. Friday, November 14, 6:06 p.m., Room 115-C
Transplantation TH-OR176
Salt Reduces Regulatory T Cells and Accelerates Allograft Rejection—Kassem Safa, Brigham and Women’s Hospital, Massachusetts General Hospita. Thursday, November 13, 4:42 p.m., Room 112
Genetic Diseases of the Kidney TH-OR003 TH-OR062
mTORC1 Regulates Polycystin-1 Expression Levels Possibly Explaining Renal Cystogenesis in Tsc1 Mutant Mice—Monika Pema, DIBIT-San Raffaele Scientific Institute. Thursday, November 13, 4:54 p.m., Room 118-C GWAS Results in the PediGFR Consortium Identify Six Genomic Loci Associated with GFR and Proteinuria—Matthias Wuttke, University Medical Center Freiburg. Thursday, November 13, 5:18 p.m., Room 201-A
Vascular Biology TH-OR012 SA-OR064
Glomerular Filtration Rate in the Contralateral Kidney Falls after Successful Revascularization of Stenotic Kidney— Sandra Herrmann, Mayo Clinic. Thursday, November 13, 5:18 p.m., Room 105 Warfarin Promotes Medial Vascular Calcification in Humans— Ekamol Tantisattamo, Emory University. Saturday, November 15, 5:42 p.m., Room 203
28a
NIH and Informational Posters Thursday, November 13 – Saturday, November 15 Exhibit Hall A NIH01 NIH02 NIH03 NIH04 NIH05
Training, Career Development, and Contacts* Resources: Basic, Translational, and Clinical Research* Funding and Research Opportunities* NKDEP: Translating NIH Research into Improved CKD Outcomes* GUDMAP: GenitoUrinary Development Molecular Atlas Project, an Open Resource* *P rogram Directors, Division of Kidney, Urologic and Hematologic Diseases, NIDDK
INFO01
Duke O’Brien Center for Kidney Research (DOCK)—Mary H. Foster, Uptal Patel, Laura Svetkey, Beth Hauser, Robert Spurney, Steven Crowley, Susan B. Gurley, Thomas M. Coffman, Duke University.
INFO02
Pittsburgh Center for Kidney Research: A George M. O’Brien Kidney Research Core Center—Thomas R. Kleyman, Ora A. Weisz, Dept of Medicine, University of Pittsburgh.
INFO03
The George M. O’Brien Kidney Center at Yale—Peter S. Aronson, Stefan Somlo, Section of Nephrology, Yale University School of Medicine.
INFO04
UAB-UCSD O’Brien Core Center for Acute Kidney Injury (AKI) Research—Anupam Agarwal, Paul W. Sanders, University of Alabama at Birmingham; Ravindra L. Mehta, University of California, San Diego.
INFO05
UT Southwestern O’Brien Kidney Research Core Center— Peter Igarashi, Michel Baum, Thomas Carroll, Chou-Long Huang, Robert Lenkinski, Christopher Lu, Orson Moe, James Richardson, Robert Toto, Wanpen Vongpatanasin, Depts of Internal Medicine, Pediatrics, Pathology, and Radiology, University of Texas Southwestern Medical Center.
INFO06
O’Brien Center for Advanced Renal Microscopy and Analysis at Indiana University—Bruce A. Molitoris, Kenneth W. Dunn, Simon J. Atkinson, Div of Nephrology, Indiana University School of Medicine.
INFO07
The George M. O’Brien Kidney Translational Core Center at the University of Michigan—Frank C. Brosius, Gonçalo Abecasis, James Cavalcoli, Crystal Gadegbeku#, Debbie Gipson, Jennifer Hawkins, Subramaniam Pennathur, Roger Wiggins, Denise L. Taylor-Moon, Matthias Kretzler. University of Michigan, #Temple University.
29a
NIH and Informational Posters (cont.) INFO08
Vanderbilt Center for Kidney Disease—Raymond C. Harris, Ambra Pozzi, Div of Nephrology and Hypertension, Vanderbilt University Medical School.
INFO09
Announcement of the Newly Formed Neonatal Kidney Collaborative (NKC)—David J. Askenazi, Children’s of Alabama/University of Alabama at Birmingham; Carolyn Abitbol, University of Miami; Namasivayam Ambalavanan, Children’s of Alabama/University of Alabama at Birmingham; Jennifer R. Charlton, University of Virginia; Ronnie Guillet, University of Rochester; Jennifer Jetton, University of Iowa; Alison Kent, Australian National University Medical School/Centenary Hospital for Women and Children; Maroun J. Mhanna, Metrohealth Medical Center; David Selewski, University of Michigan; Frederick Kaskel, Albert Einstein School of Medicine.
INFO10
NIDDK P50DK096418: Critical Translational Studies in Pediatric Nephrology—Prasad Devarajan, Cincinnati Children’s Hospital.
INFO11
Pediatric Center of Excellence in Nephrology: Opportunities to Learn Methods in Epigenetics, Cell Fate Analysis, and Kidney Injury/Repair—Ariel Gomez1, Samir El-Dahr2, Robert Chevalier1, Maria Luisa Sequeira Lopez1. 1University of Virginia, 2Tulane University.
INFO12
Identifying Genetic Causes of Autosomal Dominant Interstitial Kidney Disease: Establishing a Registry of UMOD, REN, and MUC1 Families— Anthony Bleyer, Section on Nephrology, Wake Forest School of Medicine; Stanislav Kmoch, Charles University First Faculty of Medicine, Prague, Czech Republic.
INFO13
UKIVAS: The UK and Ireland Vasculitis Registry and Biobank— Jan Sznajd1,2, Alan D. Salama3, David Jayne4, Afzal Chaudhry4, Michael Robson5, Joe Rosa1, Neil Basu6, Michal Clarkson7, Michael Venning8, Asheesh Sharma9, Peter Lanyon, Raashid Luqmani1, Richard Watts11, Mark A. Little10. 1NDORMS, University of Oxford, UK, 2 Medical College of Jagiellonian University, Poland, 3UCL Centre for Nephrology, Royal Free, 4Dept of Medicine, Addenbrooke’s Hospital, University of Cambridge, 5King’s College London, 6Dept of Epidemiology, University of Aberdeen, 7Cork University Hospital, 8Manchester Royal Infirmary, 9University Hospital Aintree Liverpool, 10Trinity Health Kidney Centre, Trinity College Dublin, Ireland, 11Dept of Rheumatology, Ipswich Hospital NHS Trust, UK.
INFO14
National Transplantation Pregnancy Registry (NTPR)—Lisa Coscia1, Serban Constantinescu2, Michael J. Moritz3, Vincent T. Armenti1. 1 National Transplantation Pregnancy Registry, Gift of Life Institute, 2 Medicine, Temple University School of Medicine, 3Surgery, Lehigh Valley Health Network.
30a
INFO15
The Collaborative Study Group: A Non-Profit Academic Research Organization Dedicated to Nephrology—Jamie P. Dwyer1, Tomas Berl2, Tom Greene3, Lawrence G. Hunsicker4, Marc A. Pohl5, Roger A. Rodby6, Mohammed Sika1, Katherine R. Tuttle7, Kausik Umanath8, Mohamed Zidan8, Edmund J. Lewis6, Julia B. Lewis1, for the Collaborative Study Group. 1 Vanderbilt University Medical Center, 2University of Colorado, 3 University of Utah, 4University of Iowa, 5Cleveland Clinic, 6Rush University Medical Center, 7University of Washington, 8Henry Ford Hospital.
INFO16
Rare Kidney Stone Consortium: A Rare Disease Center of the NIDDK and Office of Rare Diseases Research—Dawn S. Milliner, Mayo Clinic; John C. Lieske, Mayo Clinic; David S. Goldfarb, NYU Langone Medical Center; Vidar Edvardsson, Landspitali The National University Hospital, Reykjavik, Iceland.
INFO17
PKD Research Biomaterials and Cellular Models Core— Darren P. Wallace, Gail A. Reif, Dept of Internal Medicine, The Kidney Institute, University of Kansas Medical Center.
INFO18
Mayo Translational Polycystic Kidney Disease Center—K. Hopp, M.V. Irazabal, J.L. Sundsbak, H. Ye, C.M. Heyer, L.T. Kline, C.D. Madsen, M.C. Hogan, C.R. Sussman, J. Hu, B.F. King, B.J. Erickson, S.C. Ekker, P.C. Harris, V.E. Torres, Mayo Clinic.
INFO19
NEPTUNE: Nephrotic Syndrome Study Network—Matthias Kretzler, Larry B. Holzman*, Crystal Gadegbeku#, Chrysta C. Lienczewski, Denise L. Taylor‑Moon, Debbie Gipson, on behalf of the Nephrotic Syndrome Study Network. University of Michigan, *University of Pennsylvania, #Temple University.
INFO20
The NEPTUNE Digital Pathology Protocol for Evaluation of Nephrotic Syndrome—L. Barisoni1, C.C. Nast2, J.C. Jennette3, J.B. Hodgin4, C. Avila‑Casado5, K.V. Lemley6, L. Merlino1, A.Z. Rosenberg7,10, J.B. Kopp8, M. Kretzler9, C. Lienczewski9, S. Bagnasco10, M. Palmer11, A.H. Gassim3, C.M. Conway12, S.M. Hewitt7. 1Dept of Pathology, University of Miami, Miller School of Medicine, 2Dept of Pathology Cedars-Sinai Medical Center, 3 Dept of Pathology, University of North Carolina, 4Dept of Pathology, University of Michigan, 5Dept of Pathology, University Health Network Toronto, 6Dept of Pediatrics, Div of Pediatric Nephrology, Children’s Hospital Los Angeles, 7Laboratory of Pathology, NCI, NIH, 8Kidney Disease Section, NIDDK, NIH, 9Dept of Internal Medicine, Nephrology, University of Michigan, 10Dept of Pathology, John Hopkins University, 11Dept of Pathology, University of Pennsylvania, 12Leica Biosystems, Dublin, IR.
31a
NIH and Informational Posters (cont.) INFO21
RITUXILUP: An Open Label Randomised Multicentre Controlled Trial of RITUXImab and Mycophenolate Mofetil (MMF) without Oral Steroids for the Treatment of LUPus Nephritis—Liz Lightstone1, Deborah Ashby8, Tom Cairns1, H. Terence Cook1, Caroline Gordon2, Megan Griffith1, David Isenberg5, David R.W. Jayne6, Jeremy B. Levy1, Stephen D. Marks4, Matthew C. Pickering1, Brad H. Rovin3, Ronald Van Vollenhoven7. 1 Imperial Lupus Centre, Imperial College London, UK, 2University of Birmingham, UK, 3Ohio State University, 4Great Ormond Street Hospital, UK, 5University College London, UK, 6Addenbrookes Hospital, UK, 7 The Karolinska Institute, Sweden, 8Imperial College Clinical Trials Unit, UK.
INFO22
Rationale and Study Design of Pyridoxamine Dihydrochloride in Subjects with Nephropathy due to Type 2 Diabetes (PIONEER‑CSG-17)—Jamie P. Dwyer1, Mohammed Sika1, Laura E. Greene1, Kausik Umanath2, Mohamed Zidan2, Bob Peterson3, J. Wesley Fox3, Julia B. Lewis1. 1Vanderbilt University Medical Center, 2 Henry Ford Hospital, 3NephroGenex, Inc.
INFO23
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches–Chronic Kidney Disease (ISCHEMIA-CKD) Trial—Sripal Bangalore, New York University School of Medicine; Glenn M. Chertow, Stanford School of Medicine; Charles Herzog, Hennepin County Medical Center/University of Minnesota; David Charytan, Brigham and Women’s Hospital; David Maron, Stanford School of Medicine; Judith S. Hochman, New York University School of Medicine.
INFO24
MENTOR–Membranous Nephropathy Trial of Rituximab— Fernando C. Fervenza1, Daniel Cattran2, Edward T. Casey1, John J. Dillon1, Stephen B. Erickson1, Eddie L. Greene1, LaTonya J. Hickson1, Marie C. Hogan1, Nelson Leung1, Sanjeev Sethi1. 1Mayo Clinic Rochester, 2 University of Toronto, Canada. Conducted in collaboration with: Nabeel Aslam, Ivan Porter, Mayo Clinic Jacksonville; Leslie Thomas, Irvin Cohen, Mira Keddis, Mayo Clinic Scottsdale; Michelle Hladunewich, Heather Reich, University of Toronto, Canada; Patrick Gipson, Matthias Kretzler, Brett Plattner, Deb Gipson, Laura Mariani, Puneet Garg, Panduranga Rao, University of Michigan at Ann Arbor; Jai Radhakrishnan, Andrew Bomback, Pietro Canetta, Jonathan Hogan, Wooin Ahn, Columbia University; Brad Rovin, Samir Parikh, Anthony Alvarado, Ohio State University; John Sedor, John O’Toole, Case Western Reserve University; Ajay Singh, Joshua Hundert, Brigham and Women’s; Richard Lafayette, Neiha Arora, Preeti Nargund, Stanford University; Ashley Jefferson, Peter Nelson, University of Washington; Duvuru Geetha, Paul Segal, John Hopkins, Dana Rizk, University of Alabama at Birmingham; Ellen McCarthy, Sri Yarlagadda, Kansas University Medical Center; Lada Beara‑Lasic, Olga Zhdanova, New York University; Samuel Blumenthal, Hariprasad Trivedi, Medical College of Wisconsin, Froedtert Hospital; Luis Juncos, University of Mississippi Medical Center; Dollie Green, Adela Mattiazzi, University of Miami; James Simon, Surafel Gebreselassie,
32a
Cleveland Clinic; Amy Sussman, Bijin Thajudeen, University of Arizona, Tucson; Sean Barbour, Adeera Levin, Providence Health Care/St. Paul’s Hospital, University of British Columbia. INFO25
Phase 2a Study of AKB-6548: A Novel Hypoxia-Inducible Factor ProlylHydroxylase Inhibitor (HIF-PHI) in Patients with End-Stage Renal Disease (ESRD) Undergoing Hemodialysis (HD)—Charlotte S. Hartman, Tasha M. Farmer, Karen Annis, Farhad Kazazi, Paul Pollack, Robert Shalwitz, Akebia Therapeutics.
INFO26
REPRISE: A Phase 3b Multicenter Trial of Tolvapan in Adult Subjects with ADPKD—V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, E.Higashihara, R.D. Perrone, J. Ouyang, O. Sergeyeva, L. Debuque, J.Blais, F.S. Czerwiec, Mayo Clinic.
INFO27
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy—Fernando C. Fervenza, Edward T. Casey, John J. Dillon, Stephen Erickson, Marie Hogan, Nelson Leung, Shirley Jennison, Lori Riess, Mayo Clinic.
33a
Schedule-at-a-Glance Thursday, November 13
AM
6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30
Plenary Session Basic and Clinical Science Symposia & Special Sessions Clinical Nephrology Conferences & Special Sessions Educational Symposia Oral Abstract Sessions Poster Sessions
Ask the Author
Scientific Exposition
Exhibitor Spotlight
Friday, November 14
AM
6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30
Educational Symposia Plenary Session Basic and Clinical Science Symposia & Special Sessions Clinical Nephrology Conferences & Special Sessions Oral Abstract Sessions Poster Sessions
Ask the Author
Scientific Exposition
Exhibitor Spotlight
Saturday, November 15
AM
6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30
Educational Symposia Plenary Session Basic and Clinical Science Symposia & Special Sessions Clinical Nephrology Conferences & Special Sessions High-Impact Clinical Trials
Oral Abstract Sessions Poster Sessions
Ask the Author
Scientific Exposition
Exhibitor Spotlight
Sunday, November 16
AM
6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30
Plenary Session and ASN Business Meeting Basic and Clinical Science Symposia Clinical Nephrology Conferences & Special Sessions
34a
PM 12:00 12:30 1:00
1:30
2:00
2:30
3:00
3:30
4:00
4:30
5:00
5:30
6:00
6:30
1:30
2:00
2:30
3:00
3:30
4:00
4:30
5:00
5:30
6:00
6:30
1:30
2:00
2:30
3:00
3:30
4:00
4:30
5:00
5:30
6:00
6:30
Exhibitor Spotlight PM 12:00 12:30 1:00
Exhibitor Spotlight PM 12:00 12:30 1:00
Exhibitor Spotlight PM 12:00
35a
Conference Services and Travel Information ADA Compliance ASN makes every effort to comply with the Americans with Disabilities Act (ADA). Scooters can be rented from Scootaround by calling 888-441-7575. Rented scooters will be delivered to the FedEx office inside the convention center for pick-up and return. For other assistance, please call the ASN Management office at 215-418-2028.
ASN Management Office
Room 304, Phone 215-418-2028
ASN Service Center During exposition hours, visit the ASN Service Center in Booth 1327 to access ASN’s onsite services: • General Conference Information and Assistance • Membership (renew your 2015 ASN membership) • CME/CNE/CPE Information • Maintenance of Certification Products (NephSAP, Practice Improvement Modules) • Publications (JASN, CJASN, and Kidney News) • Career Center • Kidney Health Initiative • ASN Foundation for Kidney Research During non-exposition hours, visit the ASN Service Center in the Grand Hall of the convention center.
Baggage and Coat Check A baggage and coat check area is available from Tuesday, November 11, through Sunday, November 16. This service is located in the 100 level lobby of the convention center, and there is a $3 fee per item per day. Please refer to the onsite signs for specific hours. Note: All bags are subject to a security search, and no laptop computers are accepted. ASN accepts no liability for items in the check area.
Business Center
Phone 215-925-1218
FedEx Office is the onsite business service center, providing shipping, mailing, faxing, photocopying, and other services (including poster printing). FedEx Office is located on the 200 level between Exhibit Halls B & C of the convention center.
36a
Cell Phone Charging Stations Cell phone charging stations are placed throughout the convention center. Each station has the capability to simultaneously charge a variety of cell phones including the iPhone, Droid, Blackberry, Motorola, Samsung, and Nokia. Note: You must remain with your cell phone at all times. ASN accepts no liability for cell phones and other personal items left unattended. Cell Phone Charging Station support is provided by OPKO Health Renal Division.
Children and Child Care ASN has obtained the name of a child care provider used by several Philadelphia hotels to provide in-room child care services. ASN makes no endorsement of these provides and accepts no liability should you employ their services. For further information and rates, contact Your Other Hands at 215-790-0990. Note: Children younger than 12 years of age are not permitted in any ASN meeting or session room, poster session, or the Scientific Exposition at any time.
Cyber Center This service located in Exhibit Hall C gives attendees full Internet capability. Internet access is time-limited. Cyber Center support is provided by Shire.
Hotel List Hotel Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Main Phone # Courtyard by Marriott Philadelphia Downtown . . . . . . . . . . . . . . . . . . . . . . 215-496-3200 Doubletree Hotel Philadelphia Center City . . . . . . . . . . . . . . . . . . . . . . . . . 215-893-1600 Embassy Suites Philadelphia Center City . . . . . . . . . . . . . . . . . . . . . . . . . . 215-561-1776 Four Points by Sheraton Philadelphia Center City . . . . . . . . . . . . . . . . . . . 215-496-2700 Four Seasons Hotel Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-963-1500 Hampton Inn Philadelphia City Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-665-9100 Hilton Garden Inn Philadelphia Center City . . . . . . . . . . . . . . . . . . . . . . . . . 215-923-0100 Holiday Inn Express Midtown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-735-9300 Holiday Inn Express Penn’s Landing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-627-7900 Home2 Suites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-627-1850 Homewood Suites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-382-1111 Hotel Monaco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-925-2111 Hotel Palomar Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-563-5006 Hyatt at The Bellevue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-893-1234 Hyatt Regency Philadelphia at Penn’s Landing . . . . . . . . . . . . . . . . . . . . . 215-928-1234
37a
Conference Services and Travel Information (cont.) Hotel List (cont.) Hotel Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Main Phone # Inn at Penn, a Hilton Hotel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-222-0200 Le Meridien Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-422-8200 Loews Philadelphia Hotel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-627-1200 Omni Hotel Independence Park . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-925-0000 Philadelphia Marriott Downtown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-625-2900 Radisson Blu-Warwick Hotel Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . 215-735-6000 Ritz Carlton Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-523-8000 Sheraton Philadelphia Downtown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-448-2000 Sheraton Society Hill Hotel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-238-6000 Sheraton University City . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-387-8000 Sofitel Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-569-8300 Sonesta Hotel Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-561-7500 Westin Philadelphia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-563-1600 Windsor Suites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-981-5678 Wyndham Hotel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215-923-8660
Housing Desk
Phone 215-418-2027
ASN welcomes you to Philadelphia and hopes that you enjoy your stay. If you have any concerns regarding your hotel reservation, please feel free to stop by the Housing Desk on the Bridge near Registration in the convention center. This service is open from Tuesday, November 11, through Saturday, November 15.
Lost and Found Lost and found items should be turned into the convention center’s Security Department. If you have lost or found an item, please use one of the many house phones throughout the lobby areas of the convention center to contact guest services by dialing extension 2118. Security personnel will provide further instructions.
Meeting Locations Kidney Week sessions, exhibits, and posters are held in the Pennsylvania Convention Center. Educational Symposia are held at the Philadelphia Marriott Downtown; specific details on these symposia are included in the Guide to Educational Symposia, which is in the meeting bag. Non–ASN-sponsored Ancillary Meetings are held at nearby hotels; specific details on these meetings can be found on pages 44a–48a.
Overcrowding Policy Overcrowding of meeting rooms can be a serious safety concern. ASN staff will monitor each meeting room to ensure a safe learning environment or social venue. When a room reaches capacity (based on facility limits and activity set-up), ASN staff will shut down access to the room. No other participant/guest will be allowed to enter the room, regardless of the number of participants/guests who exit the room during the activity.
38a
Photography and Audio/Video Attendees are NOT permitted to take photographs or audio/video recordings at Kidney Week. This includes, but is not limited to, sessions, posters, and exhibits. Individuals in violation may be asked to leave the area. ASN and its contractors may photograph or audio/videotape events at Kidney Week. By attending Kidney Week, attendees acknowledge these activities and agree to allow their image to be used in ASN’s publications, website, and promotional materials.
Power Stations ASN has created several charging station areas throughout the convention center. Please stop by the foyer areas and inside the exposition halls to take advantage of these charging stations. Note: You must remain with your computer at all times. ASN accepts no liability for computers and other personal items left unattended. Power Station support is provided by Shire.
Press Room
Room 303-B
The Press Room, available to journalists reporting on Kidney Week, is located in the convention center.
Press Room Hours Thursday, November 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:30 a.m. – 6:00 p.m. Friday, November 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:30 a.m. – 6:00 p.m. Saturday, November 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m. – 5:00 p.m.
Registration and Materials Pick-Up
Phone 215-418-2025
Kidney Week Registration and Materials Pick-Up are located in the Grand Hall of the convention center.
Onsite Registration Hours Wednesday, November 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m. – 6:00 p.m. Thursday, November 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 6:00 p.m. Friday, November 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:30 a.m. – 5:00 p.m. Saturday, November 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:30 a.m. – 4:30 p.m.
Restaurant Reservations The City of Philadelphia hosts a restaurant reservation counter on the Bridge and 100 level of the convention center. Whether you need a recommendation or assistance with reservations, stop by and make plans to taste what Philadelphia has to offer.
39a
Conference Services and Travel Information (cont.) Safety and First Aid The Professional Convention Management Association (PCMA) has developed the following safety recommendations for conference attendees: • Do not display large amounts of cash when tipping or paying for taxis. • Use all locking devices on your door when you are in your hotel room. • If the streets around the hotel are deserted, take a taxi or shuttle bus. • Walk with another person whenever possible, particularly at night. • Remain alert at all times, especially in crowded areas. • DO NOT WEAR YOUR BADGE or openly carry convention material with you outside the hotel or convention center. Obvious conventioneers are prime targets for thieves. First aid is administered in the First Aid room in Hall B of the convention center. If you are in need of urgent medical attention, please contact any ASN staff member or convention center employee for assistance. Please DO NOT contact 911 emergency services directly. The convention center has many entrances and exits, and center employees and first aid personnel know the best way to communicate with 911 emergency services to provide the quickest response to any medical need.
Shuttle Services Convention Center Shuttle Service
Phone 619-921-0307
Complimentary shuttle service is available from Tuesday, November 11, through Sunday, November 16 between the convention center and all participating hotels except: Courtyard by Marriott Philadelphia Downtown, Four Points by Sheraton Philadelphia Center City, Hampton Inn Philadelphia City Center, Hilton Garden Inn Philadelphia Center City, Home2 Suites, Le Meridien Philadelphia, Loews Philadelphia, and Philadelphia Marriott Downtown. These hotels are within a comfortable walking distance of the convention center. Shuttle schedules will be posted in hotel lobbies and at the convention center. Room rates may reflect a shuttle transportation subsidy of up to $5. Shuttle Bus support is provided by Keryx Biopharmaceuticals, Inc.
Airport Shuttle Service Airport Shuttle is available to transport all attendees to the airport from the convention center. Service will leave the convention center every 30 minutes from 3:30 p.m. to 6:30 p.m. on Saturday, November 15 and every 30 minutes from 10:15 a.m. to 1:45 p.m. on Sunday, November 16. The fee is $10; cash only. To return to the airport, call 619-921-0307. Kidney Week attendees may also stop by the Shuttle Desk outside the Arch Street entrance of the convention center on Saturday, November 15 (10:00 a.m. – 7:00 p.m.) or Sunday, November 16 (7:30 a.m. – 1:00 p.m.). Reservation is required at least 90 minutes prior to bus departure.
40a
Speaker Ready Room
Third Floor Overlook, Phone 215-418-2033
ASN requires all speakers to visit the Speaker Ready Room in the convention center at least 4 hours before their sessions to ensure that we have the latest version of the presentation. ASN audiovisual support is available onsite to address faculty needs.
Early Program Speaker Hours Tuesday, November 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 6:00 p.m. Wednesday, November 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 6:00 p.m.
Annual Meeting Speaker Hours Thursday, November 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 6:00 p.m. Friday, November 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 6:00 p.m. Saturday, November 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 6:00 p.m. Sunday, November 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 a.m. – 11:00 a.m. Note: Faculty can pick up their badges, meeting materials, and other items (if applicable) at Speaker Registration in the Grand Hall of the convention center. Speaker Ready Room support is provided by OPKO Health Renal Division.
Wireless Internet — Complimentary ASN has set up a wireless Internet connection throughout the convention center. To access, please choose “Kidney Week” as the Wi-Fi network; no password is needed. Please open your browser, and then click the connect button. Wi-Fi access is available from Tuesday, November 11, through Sunday, November 16, throughout the meeting rooms, lobby areas, and “hot spots” in the exposition halls of the convention center. Complimentary Wi-Fi Service is provided by Shire.
ASN Gives Back Kidney Week’s host city plays an important part in the meeting experience. In appreciation, ASN partners with the Pennsylvania Convention Center to donate leftover, usable food items to local shelters. ASN also works with Developmental Enterprises Corporation, which provides employment to individuals with developmental disabilities.
41a
ASN Organizational Functions (in alphabetical order; as of 8/28/2014)
The following functions are by invitation only. Acute Kidney Injury Advisory Group Thursday, November 13, 6:45–7:45 a.m. Convention Center, Room 302
Forum for International Kidney Organizations Wednesday, November 12, 2:30–4:30 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon D
Biosciences Research Advisory Group Saturday, November 15, 6:45–7:45 a.m. Convention Center, Room 308
Geriatric Nephrology Advisory Group Thursday, November 13, 6:45–7:45 a.m. Convention Center, Room 301
Chronic Kidney Disease Advisory Group Saturday, November 15, 6:45–7:45 a.m. Convention Center, Room 302
Glomerular Diseases Advisory Group Friday, November 14, 6:45–7:45 a.m. Convention Center, Room 308
CJASN Editorial Board Meeting Saturday, November 15, 12:30–2:00 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 1
Grants Review Committee Thursday, November 13, 12:30–2:00 p.m. Convention Center, Room 301
CJASN Editors Business Meeting Friday, November 14, 12:30–2:00 p.m. Philadelphia Marriott Downtown, Rooms 309–310
Hypertension Advisory Group Friday, November 14, 6:45–7:45 a.m. Convention Center, Room 301 Interventional Nephrology Advisory Group Thursday, November 13, 6:45–7:45 a.m. Convention Center, Room 300
CJASN’s Live eJournal Club (LeJC) Luncheon Thursday, November 13, 12:30–2:00 p.m. Convention Center, Room 104 Dialysis Advisory Group Friday, November 14, 6:45–7:45 a.m. Convention Center, Room 307-A
JASN Editorial Board Meeting Thursday, November 13, 12:30–2:00 p.m. Philadelphia Marriott Downtown, Liberty Ballroom, Salon A
Division Chiefs Meeting Wednesday, November 12, 4:00–6:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon I
JASN Editors Business Meeting Friday, November 14, 12:30–2:00 p.m. Philadelphia Marriott Downtown, Room 308
Education Committee Friday, November 14, 12:30–2:00 p.m. Convention Center, Room 301
KHI Open House Friday, November 14, 12:30–1:45 p.m. Philadelphia Marriott Downtown, Independence Ballroom, Salon I
Exhibitor Advisory Committee Friday, November 14, 3:00–4:00 p.m. Convention Center, Room 302
42a
KHI Workgroup: Endpoints – Vascular Access Thursday, November 13, 12:30–2:00 p.m. Philadelphia Marriott Downtown, Rooms 309–310
Summit for US Kidney Organizations Wednesday, November 12, 10:00 a.m.–2:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon D
Kidney News Editorial Board Saturday, November 15, 12:30–2:00 p.m. Philadelphia Marriott Downtown, Room 308
Training Program Director’s Meeting Wednesday, November 12, 3:30–6:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon K
NephSAP Editorial Board Thursday, November 13, 12:30–2:00 p.m. Convention Center, Room 308
Training Program Director’s Executive Committee Saturday, November 15, 6:45–7:45 a.m. Convention Center, Room 301
OncoNephrology Forum Friday, November 14, 6:45–7:45 a.m. Convention Center, Room 302 Practicing Nephrologists Advisory Group Friday, November 14, 6:45–7:45 a.m. Convention Center, Room 300
Transplant Advisory Group Saturday, November 15, 6:45–7:45 a.m. Convention Center, Room 300 Workforce Committee Saturday, November 15, 12:30–2:00 p.m. Convention Center, Room 302
Public Policy Board Thursday, November 13, 12:30–2:00 p.m. Convention Center, Room 302 Research Advisory Committee Saturday, November 15, 12:30–2:00 pm Convention Center, Room 300
43a
Ancillary Events (in alphabetical order; as of 8/26/2014) Albert Einstein College of Medicine of Yeshiva University Einstein/Montefiore Reception Friday, November 14, 6:45–8:45 p.m. Philadelphia Marriott Downtown, Room 405
American Society of Pediatric Nephrology Clinical Affairs Committee Friday, November 14, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 3
American Heart Association Council on Kidney in Cardiovascular Disease Young Investigator Symposium Wednesday, November 12, 7:00–8:30 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon A
American Society of Pediatric Nephrology Communications Committee Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 5
American Heart Association Council on Kidney in Cardiovascular Disease Reception Wednesday, November 12, 8:30–10:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon B American Journal Physiology - Renal Editoral Board Reception Friday, November 14, 7:00–10:00 p.m. Loews Philadelphia Hotel, Commonweatlh Hall, A1/A2 By Invitation Only American Kidney Fund Clinical Scientist in Nephrology Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Independence Ballroom, Salon III By Invitation Only American Society of Pediatric Nephrology Business Meeting Thursday, November 13, 6:45–8:45 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon E
American Society of Pediatric Nephrology Council Meeting Wednesday, November 12, 7:00 a.m.–6:00 p.m. Philadelphia Marriott Downtown, Rooms 403–404 American Society of Pediatric Nephrology Foundation Meeting Friday, November 14, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 4 American Society of Pediatric Nephrology Guidelines Task Force Saturday, November 15, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 3 American Society of Pediatric Nephrology Member Education Committee Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 6
44a
American Society of Pediatric Nephrology Membership Committee Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 3
American Society of Pediatric Nephrology Workforce Committee Friday, November 14, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 5
American Society of Pediatric Nephrology Mentorship Program Committee Friday, November 14, 6:45–8:15 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 4
Arbor Research Collaborative for Health CureGN Dinner Wednesday, November 12, 6:00–9:30 p.m. Loews Philadelphia Hotel, Howe By Invitation Only
American Society of Pediatric Nephrology Public Policy Committee Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 4
Brigham and Women’s Hospital Division Reception Thursday, November 13, 9:30–11:59 p.m. Philadelphia Marriott Downtown, Liberty Ballroom, Salons A/B
American Society of Pediatric Nephrology Research Committee Friday, November 14, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 4 American Society of Pediatric Nephrology Therapeutic Development Committee Friday, November 14, 6:45–7:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 3
Children’s Hospital of Philadelphia CKiD Study Investigator Meeting Friday, November 14, 12:45–1:45 p.m. Loews Philadelphia Hotel, Commonwealth Hall, B By Invitation Only Chinese American Society of Nephrology 2014 CASN Annual Meeting Friday, November 14, 6:45–11:59 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 1–2
American Society of Pediatric Nephrology Training Program Directors Committee Saturday, November 15, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 4
45a
Ancillary Events (cont.) ERA-EDTA EuDial Business Meeting Thursday, November 13, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Conference Suite I By Invitation Only
McMaster University PHASE 2 Trial Friday, November 14, 12:45–1:45 p.m. Loews Philadelphia Hotel, Congress Hall, Salon B/C By Invitation Only
Frenova Renal Research Friday, November 14, 8:00 a.m.–4:00 p.m. Philadelphia Marriott Downtown, Conference Suite I
NIDDK Funded ADPKD Modifier Project Annual Meeting for the Steering Committee of ADPKD Modifier Project Tuesday, November 11, 12:00–4:00 p.m. Loews Philadelphia Hotel, Regency Ballroom, Salon C1 By Invitation Only
Indiana University Nephrology Reception Saturday, November 15, 6:45–8:45 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon I By Invitation Only
Phosphate Therapeutics PT20 201 Study Meeting Friday, November 14, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Room 405 By Invitation Only
International Society for Hemodialysis Business Meetings Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 7
Renal Pathology Society Annual Board of Directors Meeting Thursday, November 13, 6:45–8:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 11 By Invitation Only
International Society of Renal Nutrition & Metabolism Council Meeting Friday, November 14, 6:30–7:45 a.m. Philadelphia Marriott Downtown, Room 308 Mayo Clinic Rare Kidney Stone Consortium Meeting Saturday, November 15, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 2 By Invitation Only Mayo Nephrology Collaborative Group 26th Annual Mayo Nephrology Collaborative Group Educational Symposium Friday, November 14, 6:45–10:00 p.m. Loews Philadelphia Hotel, Commonwealth Hall, Salon C/D By Invitation Only
Renal Pathology Society Annual Business Meeting Friday, November 14, 7:00–8:00 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 12 Renal Pathology Society Annual Reception Friday, November 14, 8:00–10:00 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 11 Renal Physicians Association Clinical Practice Committee Thursday, November 13, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Room 404 By Invitation Only
46a
Renal Physicians Association Government Affairs Committee Meeting Thursday, November 13, 6:45–7:45 p.m. Philadelphia Marriott Downtown, Room 404 By Invitation Only
University of California, San Diego Nephrology Alumni Gathering Wednesday, November 12, 7:00–10:00 p.m. Philadelphia Marriott Downtown, Room 410 By Invitation Only
Renal Physicians Association Health Care Payment Committee Friday, November 14, 6:45–7:45 a.m. Philadelphia Marriott Downtown, Room 404 By Invitation Only
University of California San Francisco Reunion Friday, November 14, 8:00–11:00 p.m. Philadelphia Marriott Downtown, Room 403
Renal Physicians Association Nephrology Coverage Advocacy Program Friday, November 14, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 1 By Invitation Only Renal Physicians Association Quality, Safety, and Accountability Thursday, November 13, 12:45–1:45 p.m. Philadelphia Marriott Downtown, Room 404 By Invitation Only
University of Kansas Medical Center (KUMC) – Kidney Institute Reception Thursday, November 13, 6:45–9:00 p.m. Philadelphia Marriott Downtown, Independence Ballroom, Salon I University of Michigan Health System Wine and Cheese Reception Friday, November 14, 7:00–9:00 p.m. Philadelphia Marriott Downtown, Independence Ballroom, Salon III
Stanford University Nephrology Reception Friday, November 14, 6:45–10:00 p.m. Capital Grille, 1338 Chestnut St.
University of Pittsburgh HALT PKD Steering Committee Meeting Wednesday, November 12, 6:00–10:00 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 11 By Invitation Only
University of Alabama at Birmingham Reception Saturday, November 15, 7:00–9:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon K By Invitation Only
University of Pittsburgh Medical Center Renal-Electrolyte Division Reception Friday, November 14, 6:45–11:59 p.m. Loews Philadelphia Hotel, Congress Room, Salon A
47a
Ancillary Events (cont.) Veterans Health Administration Kidney Disease & Dialysis Meeting Friday, November 14, 6:45–8:30 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 8
Yale University Nephrology/Department of Cellular and Molecular Physiology Reunion Thursday, November 13, 9:00–11:59 p.m. Philadelphia Marriott Downtown, Franklin Hall, Salon 13
Women In Nephrology Annual Luncheon— Nancy E. Gary Memorial Lecture “Exploring Gender Differences in Career Advancement and Discrepancies in Equity in Work Environment, Opportunities and Work-Life Balance” Saturday, November 15, 12:45–1:45 p.m. Convention Center, Room 104
48a
Learning Pathways The list of learning pathways will help you locate sessions in your area of interest: • Acute Kidney Injury • Bone and Mineral Metabolism • Cell and Transport Physiology • Chronic Kidney Disease • Development • Diabetes • Dialysis • Genetic Diseases of the Kidney • Glomerulonephritis • Hypertension and Cardiovascular Disease • Novel Translational Approaches • Pathology • Transplantation and Immunology • Other
Course/Session Types EP = Early Programs BCSS = Basic and Clinical Science Symposia CNC = Clinical Nephrology Conferences SS = Special Sessions OR = Oral Abstract Sessions PO = Poster Sessions
49a
Learning Pathway: Acute Kidney Injury Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
AKI: Basic – Fresh Takes on Classic Models; AKI: Basic Repair; AKI: Biomarkers; AKI: Risk Factors (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
SS
The World Stage of Kidney Disease—ASN/ISN Joint Session (Room 108)
2:00 p.m. – 4:00 p.m.
BCSS
A Riddle Wrapped in a Mystery inside an Enigma: The Mitochondria in AKI (Room 201-A)
BCSS
The Road Less Traveled: Evolving Therapeutic Pathways in AKI (Room 202)
CNC
Kidney–Liver Service 911 (Ballroom B)
OR
AKI: Cellular Responses to Injury and Repair – I (Room 107)
OR
AKI: Interventions, Biomarkers, Genetics, and More (Room 108)
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
AKI: Basic – Off the Beaten Path; AKI: Epidemiology and Outcomes (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Drugs, Devices, and Development of AKI (Ballroom A)
2:00 p.m. – 4:00 p.m.
BCSS
Hiding in Plain Sight: The Cellular Origin of Kidney Repair after AKI (Room 201-A)
4:30 p.m. – 6:30 p.m.
CNC
Perspectives on Volume, Fluids, and Urine: How They Impact AKI (Ballroom B)
OR
AKI: Cellular Responses to Injury and Repair – II (Room 107)
50a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
AKI: Meta-Analysis, Nephrotoxins, and Special Populations (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Bug Off: Surviving AKI with Sepsis (Ballroom A)
2:00 p.m. – 4:00 p.m.
BCSS
I’m Hot and Bothered: Kidney Inflammation in AKI (Room 201-A)
4:30 p.m. – 6:30 p.m.
CNC
The ABCs of Kidney Disease in HIV (Ballroom A)
OR
AKI: Risk, Epidemiology, and Outcomes of Clinical AKI (Room 111)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
Targeting the Microvascular Environment in AKI during Injury and Repair (Room 201-A)
CNC
Extracorporeal Therapies for Intoxications and Drug Overdoses (Room 103)
51a
Learning Pathway: Bone and Mineral Metabolism This learning pathway is supported by an independent educational grant from OPKO Health Renal Division.
Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Mineral Disease: CKD-Bone; Mineral Disease: Vitamin D, PTH, and FGF-23 – I; Vascular Calcification – I (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
The Brain behind the Bones: Osteocytes in Renal Osteodystrophy (Room 119-A)
4:30 p.m. – 6:30 p.m.
OR
Advances in Vascular Biology (Room 105)
OR
Mineral Disease: Vitamin D, PTH, and FGF-23 (Room 115-B)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Mineral Disease: Vitamin D, PTH, and FGF-23 – II; Vascular Calcification – II; Vascular and Lymphatic Development, Function, and Homeostasis (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
The Moving and Hurting Together: The Muscle–Bone Unit in CKD, Including the Jack W. Coburn, MD, Endowed Lectureship (Room 201-C)
4:30 p.m. – 6:30 p.m.
OR
Mineral Disease: Ca/Mg/PO4 (Room 119-B)
52a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Mineral Disease: Ca/Mg/PO4; Mineral Disease: Nephrolithiasis; Vascular Biology: Atherosclerosis, Inflammation, and Endothelium (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Controversies in Nephrology: Debate 1—Bicarbonate in Dialysis, Debate 2—Phosphorus Binders in NDD-CKD (Ballroom B)
2:00 p.m. – 4:00 p.m.
BCSS
Mapping the Alignment of the Spheres of Phosphate, FGF23, and Klotho (Ballroom B)
4:30 p.m. – 6:30 p.m.
OR
Mechanisms of Vascular Calcification (Room 203)
OR
Stones and Bones: Pathogenesis and Treatment (Room 204‑A)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
Vascular Calcification: Molecular Mechanism and Clinical Implications (Room 201-C)
CNC
Update on Evaluation and Management of Kidney Stones (Room 204-C)
53a
Learning Pathway: Cell and Transport Physiology Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Cell Signaling/Oxidative Stress (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Ubiquitin Meets Kidney Salt Transport and Blood Pressure Regulation (Room 111)
4:30 p.m. – 6:30 p.m.
OR
Na+, K+, and Cl- Basic (Room 203)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Renal Transport Mechanisms (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Glutamate Signaling in the Kidney and Beyond (Room 105)
BCSS
Gout Genes Identified (Room 111)
BCSS
Sorting It Out in Endosomes: An Emerging Concept in Renal Epithelial Cell Transport Regulation (Room 115-C)
OR
Mechanisms of Acid-Base Balance and Disease (Room 203)
OR
Oxidative Pathways to Cell Damage (Room 112)
4:30 p.m. – 6:30 p.m.
54a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Fluid, Electrolyte, and Acid-Base Disorders; Water/Urea/ Vasopressin and Organic Solutes (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Finding the Way Home: Recent Discoveries in Polarized Trafficking (Room 118-C)
BCSS
Novel GPCR Signaling in Electrolyte Balance and Hypertension (Room 115-C)
OR
Water/Urea/Vasopressin, and Organic Solutes (Room 112)
4:30 p.m. – 6:30 p.m.
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
Salt and Hypertension: How Does Potassium and Chloride Flip the Switch? (Room 104)
55a
Learning Pathway: Chronic Kidney Disease Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
CKD: Complications – I; CKD: Epidemiology and Outcomes – I; Novel Interventions and Screening Approaches to Prevent CKD (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Moving from Science into Practice to Care for People with CKD (Room 113)
CNC
Nephrology Quiz and Questionnaire (Room 103)
SS
What’s New in KDIGO Guidelines and Conferences (Room 114)
BCSS
Residual Cardiovascular Disease Risk in CKD (Ballroom B)
BCSS
When Our Care System Fails to Care for Kidney Patients (Room 105)
OR
CKD: Epidemiology and Outcomes (Room 202)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
CKD: Complications – II; CKD: Epidemiology and Outcomes – II; Geriatric Nephrology; Multidisciplinary Team Approaches and Innovative Health Service Delivery Models (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Anemia Management Revisited (Room 113)
4:30 p.m. – 6:30 p.m.
OR
CKD: Complications and Outcomes (Room 204-C)
OR
CKD: Estimating Equations, Incidence, Prevalence, and Special Populations (Room 204-A)
56a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
CKD: Epidemiology and Outcomes – III; CKD: Estimating Equations, Incidence, Prevalence, and Special Populations; CKD: Health Disparities (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Getting the Word Out: Education and CKD (Room 204-C)
CNC
Recognizing Disparities in CKD Care (Room 103)
BCSS
The Path to CKD: Fibrosis to Sclerosis (Room 204-C)
SS
The Older Patient with CKD: Optimizing Patient-Centered Care (Room 119-A)
SS
USRDS: New Perspectives on ESRD and Its Management in the United States (Room 114)
CNC
Doctor, Your Patient Is Getting Worse! Are You Sure the Drug Dose Is Right? (Room 204-C)
CNC
Matters of the Mind in CKD (Room 103)
OR
Biomarkers in CKD (Room 105)
OR
No Borders: Globalizing CKD Prevention Strategies (Room 104)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m.
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
The Gut–Kidney Connection (Room 105)
CNC
Emerging Fronts in Endo-Nephrology (Room 107)
57a
Learning Pathway: Development Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. –12:00 p.m.
PO
Pediatric Nephrology; Stem Cells and Regeneration (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Stem Cells in Kidney Regeneration (Room 103)
4:30 p.m. – 6:30 p.m.
CNC
Pediatric Nephrology: 2014 Update (Room 201-C)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Developmental Biology (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Regulation of Nephron Number (Room 202)
58a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
2:00 p.m. – 4:00 p.m.
BCSS
Live Imaging and Cell Movements during Kidney Development (Room 109)
4:30 p.m. – 6:30 p.m.
OR
Developmental Biology (Room 109)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
59a
Learning Pathway: Diabetes This learning pathway is supported by an independent educational grant from AbbVie.
Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Diabetes Mellitus and Obesity: Basic/Experimental – I (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Circadian Pacemakers in Health and Diseases (Room 109)
BCSS
SGLT2 Inhibition: From Basic to Clinical (Room 114)
BCSS
Sweet Beginnings: New Targets for Diabetic Nephropathy (Room 201-C)
CNC
High-Risk Groups for Diabetic Kidney Disease: Who Are They and What to Do? (Room 113)
OR
Renal Epithelial Biology in Diabetes (Room 118-B)
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Diabetes Mellitus and Obesity: Clinical – I (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
SS
Diabetes and Advanced CKD: Diabetologists and Nephrologists on the Frontline—ASN/ADA Joint Session (Room 113)
4:30 p.m. – 6:30 p.m.
OR
Monitoring and Treatment of Diabetic Nephropathy (Room 115-B)
60a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Diabetes Mellitus and Obesity: Basic/Experimental – II; Diabetes Mellitus and Obesity: Clinical – II (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Update in the Genetics and Epigenetics of Diabetic Nephropathy (Room 201-C)
4:30 p.m. – 6:30 p.m.
OR
Diabetic Nephropathy: Experimental (Room 114)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
Role of Reactive Oxygen Species in Diabetic Nephropathy (Room 203)
61a
Learning Pathway: Dialysis Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Dialysis: Anemia and Iron Metabolism; Dialysis: Epi, Outcomes, Trials – Noncardiovascular – I; Hemodialysis for ESRD; Peritoneal Dialysis – I (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Are We Missing the Achilles Heel in Hemodialysis Survival? (Ballroom A)
2:00 p.m. – 4:00 p.m.
BCSS
Dialysis in the Old World: Is It Time to Implement in the New World? (Ballroom A)
SS
The Dialysis Outcomes and Practice Patterns Study Program: Newest Findings and Expanded Scope (Room 204-A)
OR
Hemodialysis for ESRD: Techniques and Vascular Access (Room 204-A)
OR
Pathogenesis, Risk Factors, and Improving Cardiovascular Outcomes in Dialysis Patients (Room 204-C)
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Dialysis for AKI: Hemodialysis, CRRT, SLED, and Others; Dialysis: Epi, Outcomes, Trials – Cardiovascular – I; Dialysis: Palliative and End-of-Life Care; Mechanisms of Vascular Access Function and Complications (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Choosing Wisely When More Is Not Better (Room 204-C)
2:00 p.m. – 4:00 p.m.
BCSS
Timely Topics in PD: From Membrane Physiology to Therapeutic Advances (Room 109)
4:30 p.m. – 6:30 p.m.
CNC
The Expanding Role of Interventional Nephrology (Room 201-C)
OR
Dialysis: Anemia and Iron Metabolism (Room 115-C)
OR
Dialysis: Identifying Risk Factors and Improving Noncardiovascular Outcomes (Room 118-B)
62a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Clinical Science of Vascular Access Function and Complications; Dialysis: Epi, Outcomes, Trials – Cardiovascular – II; Dialysis: Epi, Outcomes, Trials – Noncardiovascular – II; Home and Frequent Dialysis; Peritoneal Dialysis – II; Standard Hemodialysis for ESRD (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Intensive Dialysis: The Good, the Bad, and the Unnoticed (Room 119-B)
4:30 p.m. – 6:30 p.m.
OR
What’s New in Peritoneal Dialysis? Updates from the Bench and the Bedside (Room 202)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
CNC
HD Infection Update (Ballroom A)
63a
Learning Pathway: Genetic Diseases of the Kidney Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
New Approaches to Genetic Kidney Diseases (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Keeping the Tubule in Shape: Preventing Cyst Growth in PKD, Including the Robert W. Schrier, MD, Endowed Lectureship (Room 119-B)
4:30 p.m. – 6:30 p.m.
OR
Advances in Understanding PKD Pathogenesis (Room 118‑C)
OR
Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases (Room 201-A)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Cystic Kidney Diseases: Basic and Translational Science; Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases (Exhibit Hall)
4:30 p.m. – 6:30 p.m.
CNC
Cystic Kidney Disease in Children: Beyond Polycystic (Room 103)
64a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State-ofthe-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Cystic Kidney Diseases: Clinical Studies and Promising Therapeutics in Animal Models (Exhibit Hall)
4:30 p.m. – 6:30 p.m.
OR
Diagnostic and Therapeutic Advances in Cystic Kidney Diseases (Room 201-A)
OR
New Genetic Approaches to Glomerular Disease (Room 107)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
Complement and Kidney Disease: Entering a New Era? (Room 108)
65a
Learning Pathway: Glomerulonephritis Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Glomerular and Tubulointerstitial Disease: Clinical Trials and Outcomes (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Lupus Nephritis: The Wheels Are Turning, but Are We Moving? (Ballroom B)
2:00 p.m. – 4:00 p.m.
BCSS
A Glomerulus Potpourri: It’s All about the Podocyte, Including the Barry M. Brenner, MD, Endowed Lectureship (Room 113)
BCSS
Getting to the Action: Renal Microphages and Dendritic Cells in Homeostasis and Injury (Room 108)
OR
Glomerular Biomarkers: Progress and Pitfalls (Room 114)
OR
New Perspectives on Permeability and the Glomerular Barrier (Room 119-A)
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Cell Biology: Glomerular – I; Glomerular and Tubulointerstitial Disease: Lupus Nephritis and IgA Nephropathy (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Primary and Secondary Membranous Nephropathy (Ballroom B)
2:00 p.m. – 4:00 p.m.
BCSS
Minimal Change and FSGS: So What’s the Difference? (Ballroom B)
BCSS
Seeing in a New Light: Recent Breakthroughs in Imaging the Kidney (Room 114)
OR
Glomerular Disease: Treatment and Outcomes (Room 108)
OR
Immunopathogenesis of Glomerulonephritis (Room 111)
4:30 p.m. – 6:30 p.m.
66a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Cell Biology: Glomerular – II; Glomerular and Tubulointerstitial Disease: Biomarkers (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Hepatitis C and the Kidney (Room 113)
2:00 p.m. – 4:00 p.m.
BCSS
ANCA-Associated Vasculitis: Beyond ANCA (Ballroom A)
4:30 p.m. – 6:30 p.m.
OR
Mechanisms of Glomerular Cell Function and Disease (Room 108)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
67a
Learning Pathway: Hypertension and Cardiovascular Disease Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Hypertension: Renal Transport, Salt Sensitivity, RAAS, and Renal Nerves (Exhibit Hall)
4:30 p.m. – 6:30 p.m.
CNC
Blood Pressure in Dialysis: Striking a Balance between Highs and Lows (Ballroom A)
OR
Hypertension: Novel Biomarkers and Target Organ Damage (Room 111)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:30 a.m. – 12:30 p.m.
CNC
Atrial Fibrillation: An Emerging Source of Morbidity and Mortality in CKD (Room 103)
SS
Lessons Learned about Renal Artery Stenosis from the CORAL Trial—ASN/AHA Joint Session (Room 108)
BCSS
Breaking Bad: The New Chemistry and Metabolomics of Cardiovascular Disease (Ballroom A)
BCSS
Immune Cells in CVD: Good, Bad, or Just Ugly? (Room 204‑A)
BCSS
Sudden Cardiac Arrest: The Silent Killer (Room 204-C)
CNC
Obstetric Nephrology (Ballroom A)
OR
Hypertension: Understanding Immune Cells, Hormones, and Salt and Mineral Excretion (Room 105)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m.
68a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Hypertension: Clinical (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Blood Pressure Is Only Skin Deep (Room 118-B)
BCSS
Clearance beyond Tubular Function: Lymph Vessels in Renal and Cardiovascular Disease (Room 105)
SS
New Hypertension Guidelines and Consensus Recommendations—ASN/ASH Joint Session (Room 103)
CNC
Hypertension: Kidney Is King (Ballroom B)
4:30 p.m. – 6:30 p.m.
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
RAAS Action inside and outside the Kidney (Room 204-A)
69a
Learning Pathway: Novel Translational Approaches Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
2:00 p.m. – 4:00 p.m.
BCSS
The Inflammasomes: Novel Players of the Intercellular Cross-Talk (Room 118-C)
BCSS
Unconfound It! Strategies in Comparative Effectiveness Research (Room 118-B)
OR
Bioengineering Advances for Next-Generation Renal Replacement Technologies (Room 115-C)
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Bioengineering (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Metabolic Foundations of Kidney Disease (Room 118-B)
BCSS
Personalized Medicine: A Primer on Pharmacogenomics, Including the Michelle P. Winn, MD, Endowed Lectureship (Room 119-B)
70a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
2:00 p.m. – 4:00 p.m.
BCSS
Urine Proteomics to Diagnose Renal Disease (Room 107)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
71a
Learning Pathway: Pathology Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Clinical/Diagnostic Renal Pathology: Glomerular Disorders and Diabetic Nephropathy (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
Amyloidosis and the Kidney: Novel Discoveries and Therapies (Room 115-C)
4:30 p.m. – 6:30 p.m.
OR
New Mechanisms in Renal Injury (Room 119-B)
OR
Renal Inflammation: Novel Mechanisms and Therapeutic Targets (Room 109)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Basic/Experimental Pathology – I; Extracellular Matrix Biology, Fibrosis, and Cell Adhesion – I; Renal Inflammation: Novel Mechanisms and Targets (Exhibit Hall)
4:30 p.m. – 6:30 p.m.
OR
Autophagy and Cellular Stress Mechanisms (Room 104)
OR
New Molecular Pathways in Fibrosis (Room 109)
72a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Basic/Experimental Pathology – II; Clinical/Diagnostic Renal Pathology: Tubulointerstitial Disorders and Novel Techniques; Extracellular Matrix Biology, Fibrosis, and Cell Adhesion – II (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
BCSS
The Renal Tissue Can Tell You More (Room 204-A)
SS
ClinicoPathologic Conference (Room 108)
CNC
Alport Syndrome: From Genetics to Genomics and Back to Basics (Room 201-C)
CNC
Renal Biopsy: Clinical Correlations (Room 113)
4:30 p.m. – 6:30 p.m.
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
73a
Learning Pathway: Transplantation and Immunology Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Kidney Donor and Recipient Outcomes in Transplantation: Novel Risk Factors; Renal Immunology and Inflammation; Transplant Epidemiology and Health Services Research (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
“Do You Want the Good or Bad News?” Counseling Your Patient about the New National Kidney Allocation Policy (Room 204-C)
2:00 p.m. – 4:00 p.m.
BCSS
Belatacrolizumab XL: The Latest Potpourri of Emerging Immunosuppression (Room 204-C)
4:30 p.m. – 6:30 p.m.
CNC
Becoming the Biggest Loser: Obese Transplant Recipients (Room 103)
OR
Translational Transplantation (Room 104)
OR
Transplantation: Basic and Experimental (Room 112)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Optimizing Graft Outcomes: Transplant Immunology, Therapeutics, and Adherence; Transplantation: Basic and Experimental (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Antibody-Mediated Rejection: Under the Microscope (Room 201-C)
2:00 p.m. – 4:00 p.m.
BCSS
Costimulation Blockade and Kidney: Two Sides to the Story (Room 118-C)
BCSS
Novel Cellular Therapies for Transplantation Tolerance (Room 103)
CNC
Living on the Edge: Where Should We Draw the Line with Medically Complex Living Donors? (Room 113)
OR
Innovation in Clinical Transplantation (Room 201-A)
4:30 p.m. – 6:30 p.m.
74a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m.– 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Advances in Clinical and Translational Transplantation (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
CNC
Big Brother Watching You: Regulation in Kidney Transplantation (Room 201-C)
2:00 p.m. – 4:00 p.m.
BCSS
The Good and Bad Bugs in Kidney Diseases and Transplantation (Room 202)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
B Cells Behaving Badly (Room 202)
75a
Learning Pathway: Other Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State‑of‑the‑Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Fellows Case Reports: AKI and Interstitial Nephritis; Fellows Case Reports: Dialysis; Patient Safety (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
SS
Tweets, Likes, and Blogs: How to Use Social Media for Your Patients and Your Benefit (Room 201-C)
2:00 p.m. – 4:00 p.m.
SS
Patient-Centric Clinical Trial and Regulatory Pathways: Patient-Reported Outcomes and Patient Preferences (Room 107)
SS
The Future Direction of Nephrology: How Shall We Live Long and Prosper?, Including the Christopher R. Blagg, MD, Lectureship in Renal Disease and Public Policy (Room 115‑B)
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Ethics in Transplant, CKD, and Dialysis; Fellows Case Reports: Glomerulopathies and Vasculitis; Fellows Case Reports: Hereditary Kidney Diseases and Electrolytes; Growth Factors, Chemokines, and Autacoids; Inflammation, Biomarkers, and Outcomes; P harmacokinetics/ Pharmacodynamics/ Pharmacogenomics (Exhibit Hall)
10:30 a.m. – 12:30 p.m.
BCSS
Clinical Trial End Points: Jumping the Barriers (Room 114)
2:00 p.m. – 4:00 p.m.
SS
Boost Your Teaching Skills to Become a Contemporary Nephrology Educator (Room 107)
SS
Highlights from the ERA-EDTA Congress in Amsterdam (Room 108)
SS
State of the Union of Federal Investment in Kidney Research (Room 115-B)
OR
Frailty and Sarcopenia: What’s in the Definition (Room 118‑C)
4:30 p.m. – 6:30 p.m.
76a
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
PO
Educational Research; Effect of Diet on Outcomes and Metabolism; Fellows Case Reports: Myeloma, Thrombotic Microangiopathy, and More; Fellows Case Reports: Transplantation (Exhibit Hall)
2:00 p.m. – 4:00 p.m.
SS
ESRD Innovation Pathway: Breaking Ground in Collaborations between FDA, Industry, and Academia (Room 111)
SS
Government Policy for ESRD Care: The Year in Review as the Dust Is Settling (Room 115-B)
Sunday, November 16 Time
Type
Title and Room
8:00 a.m.– 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
77a
Geriatric Nephrology–Related Sessions Thursday, November 13 Time
Type
Title and Room
10:30 a.m. – 12:30 p.m.
CNC
“Do You Want the Good or Bad News?” Counseling Your Patient about the New National Kidney Allocation Policy (Room 204-C)
2:00 p.m. – 4:00 p.m.
SS
Patient-Centric Clinical Trial and Regulatory Pathways: Patient-Reported Outcomes and Patient Preferences (Room 107)
4:30 p.m. – 6:30 p.m
CNC
Blood Pressure in Dialysis: Striking a Balance between Highs and Lows (Ballroom A)
Friday, November 14 Time
Type
Title and Room
10:30 a.m. – 12:30 p.m.
CNC
Atrial Fibrillation: An Emerging Source of Morbidity and Mortality in CKD (Room 103)
CNC
Choosing Wisely When More Is Not Better (Room 204-C)
BCSS
Sudden Cardiac Arrest: The Silent Killer (Room 204-C)
SS
Boost Your Teaching Skills to Become a Contemporary Nephrology Educator (Room 107)
CNC
Living on the Edge: Where Should We Draw the Line with Medically Complex Living Donors? (Room 113)
OR
Frailty and Sarcopenia: What’s in the Definition (Room 118‑C)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m
Saturday, November 15 Time
Type
Title and Room
2:00 p.m. – 4:00 p.m.
SS
Government Policy for ESRD Care: The Year in Review as the Dust Is Settling (Room 115-B)
SS
New Hypertension Guidelines and Consensus Recommendations—ASN/ASH Joint Session (Room 103)
SS
The Older Patient with CKD: Optimizing Patient-Centered Care (Room 119-A)
SS
USRDS: New Perspectives on ESRD and Its Management in the United States (Room 114)
CNC
Matters of the Mind in CKD (Room 103)
4:30 p.m. – 6:30 p.m
78a
Pediatric Nephrology–Related Sessions Thursday, November 13 Time
Type
Title and Room
10:30 a.m. – 12:30 p.m.
CNC
Lupus Nephritis: The Wheels Are Turning, but Are We Moving? (Ballroom B)
SS
Tweets, Likes, and Blogs: How to Use Social Media for Your Patients and Your Benefit (Room 201-C)
BCSS
A Glomerulus Potpourri: It’s All about the Podocyte (Room 113)
BCSS
Keeping the Tubule in Shape: Preventing Cyst Growth in PKD (Room 119-B)
BCSS
The Road Less Traveled: Evolving Therapeutic Pathways in AKI (Room 202)
CNC
Pediatric Nephrology: 2014 Update (Room 201-C)
OR
Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases (Room 201-A)
OR
Transplantation: Basic and Experimental (Room 112)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m
79a
Pediatric Nephrology–Related Sessions
(cont.)
Friday, November 14 Time
Type
Title and Room
10:30 a.m. – 12:30 p.m.
CNC
Anemia Management Revisited (Room 113)
CNC
Antibody-Mediated Rejection: Under the Microscope (Room 201-C)
BCSS
Hiding in Plain Sight: The Cellular Origin of Kidney Repair after AKI (Room 201-A)
BCSS
Minimal Change and FSGS: So What’s the Difference? (Ballroom B)
SS
Boost Your Teaching Skills to Become a Contemporary Nephrology Educator (Room 107)
CNC
Cystic Kidney Disease in Children: Beyond Polycystic (Room 103)
CNC
Perspectives on Volume, Fluids, and Urine: How They Impact AKI (Ballroom B)
OR
Dialysis: Anemia and Iron Metabolism (Room 115-C)
OR
Glomerular Disease: Treatment and Outcomes (Room 108)
OR
Innovation in Clinical Transplantation (Room 201-A)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m
80a
Saturday, November 15 Time
Type
Title and Room
2:00 p.m. – 4:00 p.m.
BCSS
ANCA-Associated Vasculitis: Beyond ANCA (Ballroom A)
BCSS
The Good and Bad Bugs in Kidney Diseases and Transplantation (Room 202)
BCSS
Urine Proteomics to Diagnose Renal Disease (Room 107)
CNC
Alport Syndrome: From Genetics to Genomics and Back to Basics (Room 201-C)
OR
Developmental Biology (Room 109)
OR
Diagnostic and Therapeutic Advances in Cystic Kidney Diseases (Room 201-A)
OR
New Genetic Approaches to Glomerular Disease (Room 107)
OR
What’s New in Peritoneal Dialysis? Updates from the Bench and the Bedside (Room 202)
4:30 p.m. – 6:30 p.m
Sunday, November 16 Time
Type
Title and Room
10:00 a.m. – 12:00 p.m.
BCSS
Complement and Kidney Disease: Entering a New Era? (Room 108)
CNC
Update on Evaluation and Management of Kidney Stones (Room 204-C)
81a
Public Policy–Related Sessions Thursday, November 13 Time
Type
Title and Room
10:30 a.m. – 12:30 p.m.
CNC
Moving from Science into Practice to Care for People with CKD (Room 113)
CNC
“Do You Want the Good or Bad News?” Counseling Your Patient about the New National Kidney Allocation Policy (Room 204-C)
BCSS
When Our Care System Fails to Care for Kidney Patients (Room 105)
SS
Patient-Centric Clinical Trial and Regulatory Pathways: Patient-Reported Outcomes and Patient Preferences (Room 107)
SS
The Future Direction of Nephrology: How Shall We Live Long and Prosper? (Room 115-B)
2:00 p.m. – 4:00 p.m.
Friday, November 14 Time
Type
Title and Room
10:30 a.m. – 12:30 p.m.
BCSS
Clinical Trial End Points: Jumping the Barriers (Room 114)
2:00 p.m. – 4:00 p.m.
SS
State of the Union of Federal Investment in Kidney Research (Room 115-B)
4:30 p.m. – 6:30 p.m
CNC
Living on the Edge: Where Should We Draw the Line with Medically Complex Living Donors? (Room 113)
Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:30 a.m. – 12:30 p.m.
CNC
Big Brother Watching You: Regulation in Kidney Transplantation (Room 201-C)
CNC
Recognizing Disparities in CKD Care (Room 103)
SS
ESRD Innovation Pathway: Breaking Ground in Collaborations between FDA, Industry, and Academia (Room 111)
SS
Government Policy for ESRD Care: The Year in Review as the Dust Is Settling (Room 115-B)
SS
USRDS: New Perspectives on ESRD and Its Management in the United States (Room 114)
2:00 p.m. – 4:00 p.m.
82a
Fellows Functions ASN is expecting more than 800 nephrology fellows at Kidney Week this year. See old friends and make new connections at these fellows functions: • ASN Welcome Reception for Fellows and Other Trainees November 12, 6:00–7:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon H • AHA Council on Kidney in Cardiovascular Disease Young Investigator Symposium and Reception November 12, 7:00–9:00 p.m. Philadelphia Marriott Downtown, Grand Ballroom, Salon A • Fellows-in-Training (FIT) Bowl Session November 14, 2:00–4:00 p.m. Convention Center, Room 119-A Two teams comprised of five to six fellows will be presented with a challenging case and asked to decide the final diagnosis. Pathology slides and other diagnostic tests will assist in the final determination. • Meet-the-Experts Session November 15, 9:30–10:00 a.m. Convention Center, Hall D Immediately following the plenary session, fellows have the opportunity to sit down with the Robert G. Narins, John P. Peters, and Belding H. Scribner award recipients. • Fellows Forum November 15, 10:30–11:30 a.m. Convention Center, Room 203 Learn about and discuss essential steps for establishing careers in academics, basic and clinical research, and private practice. • Fellows Poster Discussion Session November 15, 2:00–4:00 p.m. Convention Center, Room 112 This session spotlights top-rated posters selected from abstracts submitted by fellows with oral presentation of each poster and question/answer discussion with the audience.
83a
Trainees Track The ASN Workforce Committee has developed a suggested learning track for medical students and residents. This track is intended to help trainees gain the most from their participation in the ASN Annual Meeting and Scientific Exposition. ASN has organized the learning track by both meeting day/time and session type. Please note that trainees have several choices within the suggested track during some time periods—all of these selections should be of interest to medical students and residents. Finally, please note that this learning track is intended as a guide: Trainees are free to attend any sessions not included in the learning track.
Session Types BCSS = Basic and Clinical Science Symposia CNC = Clinical Nephrology Conferences SS = Special Sessions OR = Oral Abstract Sessions PO = Poster Sessions
84a
Thursday, November 13 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Opening Plenary: President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture (Hall D)
10:30 a.m. – 12:30 p.m.
CNC
Moving from Science into Practice to Care for People with CKD (Room 113)
SS
Tweets, Likes, and Blogs: How to Use Social Media for Your Patients and Your Benefit (Room 201-C)
BCSS
A Glomerulus Potpourri: It’s All about the Podocyte (Room 113)
SS
The Future Direction of Nephrology: How Shall We Live Long and Prosper? (Room 115-B)
CNC
Becoming the Biggest Loser: Obese Transplant Recipients (Room 103)
CNC
High-Risk Groups for Diabetic Kidney Disease: Who Are They and What to Do? (Room 113)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m.
Friday, November 14 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: ASN Foundation for Kidney Research Named Grants Announcement, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:30 a.m. – 12:30 p.m.
CNC
Choosing Wisely When More Is Not Better (Room 204-C)
SS
Lessons Learned about Renal Artery Stenosis from the CORAL Trial—ASN/AHA Joint Session (Room 108)
BCSS
Personalized Medicine: A Primer on Pharmacogenomics (Room 119-B)
BCSS
The Moving and Hurting Together: The Muscle–Bone Unit in CKD (Room 201-C)
CNC
Perspectives on Volume, Fluids, and Urine: How They Impact AKI (Ballroom B)
CNC
The Expanding Role of Interventional Nephrology (Room 201-C)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m.
85a
Trainees Track (cont.) Saturday, November 15 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State‑of‑the-Art Lecture (Hall D)
10:30 a.m. – 12:30 p.m.
CNC
Bug Off: Surviving AKI with Sepsis (Ballroom A)
OR
High-Impact Clinical Trials (Hall D)
SS
ClinicoPathologic Conference (Room 108)
SS
New Hypertension Guidelines and Consensus Recommendations—ASN/ASH Joint Session (Room 103)
CNC
Doctor, Your Patient Is Getting Worse! Are You Sure the Drug Dose Is Right? (Room 204-C)
CNC
Renal Biopsy: Clinical Correlations (Room 113)
2:00 p.m. – 4:00 p.m.
4:30 p.m. – 6:30 p.m.
Sunday, November 16 Time
Type
Title and Room
8:00 a.m. – 9:30 a.m.
SS
Plenary: In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture (Hall D)
10:00 a.m. – 12:00 p.m.
BCSS
Salt and Hypertension: How Does Potassium and Chloride Flip the Switch? (Room 104)
CNC
Update on Evaluation and Management of Kidney Stones (Room 204-C)
86a
AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2014 DAY-AT-A-GLANCE Advances in Research Conference—Building a Kidney: From Stem Cells to Function Page 2 Page 3
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Coming to a Unit near You: Cluster-Randomized Trials in Hemodialysis Page 4
Wednesday, November 12, 2014
Critical Care Nephrology: 2014 Update Page 6 Page 7
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Diagnosis and Management of Disorders of Acid-Base, Fluid, and Electrolyte Balance: Challenging Issues for the Clinician Page 8 Page 9
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Fundamentals of Renal Pathology Page 10 Page 11
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Glomerulonephritis Update: Diagnosis and Therapy 2014 Page 13 Page 14
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Human Genetics in Nephrology: Clinical Fundamentals and Research Advances Page 15 Page 16
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Innovation in Kidney Disease, Dialysis, and Vascular Access Page 17
Wednesday, November 12, 2014
Kidney Transplantation Page 19 Page 20
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Maintenance Dialysis Page 22 Page 23
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Maintenance of Certification: NephSAP Review and ABIM Modules Page 25 Page 26
Tuesday, November 11, 2014 Wednesday, November 12, 2014
Nephro-Pharmacology across the Spectrum of Kidney Diseases Page 27
Wednesday, November 12, 2014
Professional Development Seminar Page 29
Wednesday, November 12, 2014
1
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Advances in Research Conference—Building a Kidney: From Stem Cells to Function ASN thanks the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases for assistance with this program.
This conference focuses on exploring concepts, innovations, and best practices in tissue regeneration as it relates to the kidney. The expert faculty address engineering new kidney tissue based on the embryo, as well as kidney repair and regeneration using cellular approaches. This conference brings together leading scientists, physician-scientists, clinicians, and trainees from diverse areas with common interests in tissue regeneration. A white paper will be developed based on a panel discussion with participation of invited faculty and participants outlining the current successes, challenges, and next steps—pushing the boundaries and directing future studies so that building a kidney becomes a reality. Upon completion of this program, the participant will be able to: 1) describe the fundamental aspects of kidney development, stem cells, induced pluripotent stem (iPS) and reprogramming technology, and bioengineering; and 2) discuss in-depth current progress in developing a bioengineered kidney. Program is subject to change.
PROGRAM CHAIRS Thomas J. Carroll, PhD, and Jing Yu, PhD
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
7:50 a.m.
Welcome and Introduction Thomas J. Carroll, PhD, Jing Yu, PhD
8:00 a.m.
Overview of Kidney Biogenesis: Research Strategies/Challenges Andrew P. McMahon, PhD
I. Building Blocks in the Developing Kidney 8:30 a.m.
Overview of Origins of Cell Types and Promise/Pitfalls in Engineering Leif Oxburgh, PhD
9:00 a.m.
3D Intestinal Epithelioids: What Is Known Jason R. Spence, PhD
9:30 a.m.
Break
10:00 a.m.
Nephron Progenitor Cells Raphael Kopan, PhD
10:30 a.m.
Ureteric Bud Stem Cells Frank Costantini, PhD
11:00 a.m.
Development of the Vasculature and Mural Cells Doris A. Herzlinger, PhD
11:30 a.m.
Lunch and Breakout Discussions (lunch provided)
II. Recreating and Validating Renal Progenitors and Beyond 12:30 p.m.
Induced Renal Progenitors: What Are They and What Can They Become? Thomas M. Schultheiss, MD, PhD
1:00 p.m.
Regenerating Kidney Structure and Function: The Industry Perspective Joydeep Basu, PhD
1:30 p.m.
IPS Cells toward Nephron Progenitors: What Is Next Juan Carlos Izpisua Belmonte, PhD
2:00 p.m.
Screening for Novel Compounds Driving Renal Differentiation Kenji Osafune, MD, PhD
2
2:30 p.m.
Proximal Tubule, Collecting Duct, or Other: How Do We Know if We Really Made a Kidney Tubule? Dennis Brown, PhD
3:00 p.m.
Break
III. Renal Bioengineering for Organ Replacement 3:30 p.m.
Nephron Stem/Progenitor Cell-Based Strategies for Renal Repair Benjamin Dekel, MD, PhD
4:00 p.m.
The Trachea: The First Tissue-Engineered Organ? Jeroen Meulemans, MD
4:30 p.m.
Engineering 3D Tubules Using Silk Matrices David Kaplan, PhD
5:00 p.m.
Decellularized Matrices Jason Wertheim, MD, PhD
5:30 p.m.
Using iPS Cells to Model Disease Joseph V. Bonventre, MD, PhD, FASN
6:00 p.m. -
Summary Comments
6:15 p.m.
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
IV. Endogenous Cells for Renal Repair/Regeneration 8:00 a.m.
Overview of Endogenous Cell Sources and Progenitor Cells for Kidney Repair and Strategies for Enhancing/Prolonging Productive Repair Benjamin D. Humphreys, MD, PhD, FASN
8:30 a.m.
Epigenetic Regulation of Liver Injury and Regeneration Hao Zhu, MD
9:00 a.m.
Proximal Tubular Subpopulations in Renal Repair Bart Smeets, PhD
9:30 a.m.
A Novel Source of Cells for Podocyte Turnover Stuart J. Shankland, MD, FASN
10:00 a.m.
Break
10:30 a.m.
Zebrafish as a Model to Study Kidney Regeneration: What Can It Tell Us? Alan J. Davidson, PhD
11:00 a.m.
Conservation of Renal Progenitor George Daley, MD, PhD
12:00 p.m.
Lunch and Breakout Discussions (lunch provided)
1:00 p.m.
Keynote Presentation: Cardiac Regeneration Eric Olson, PhD
V. Exogenous Cells for Renal Repair/Regeneration 2:00 p.m.
Overview of the Exogenous Cell Sources for Renal Repair/Regeneration, Strategies, and Validation Fangming Lin, MD, PhD, FASN
2:30 p.m.
Exogenous MSCs Michael Matthay, MD
3:00 p.m.
Break
3:30 p.m.
Bone Marrow–Derived MSCs for AKI: A Drug Development Perspective Robert M. Brenner, MD
4:00 p.m.
An MSC in the Kidney Can Contribute to Collecting Duct Joan Li, PhD
4:30 p.m.
Adult Mesenchymal Stem Cells: The New Medicine Arnold I. Caplan, PhD
5:00 p.m. 5:30 p.m.
Summary, Closing Remarks, and Future Directions—NIH Deborah Hoshizaki, PhD
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
3
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Coming to a Unit near You: Cluster-Randomized Trials in Hemodialysis Trial-level evidence is scarce in the setting of hemodialysis care. Individually randomized trials are expensive, many prohibitively so in light of the potential return on investment given the limited size of the hemodialysis population. Cluster-randomized trials constitute a novel approach to evidence development that is particularly suitable for the hemodialysis setting. An opportunity exists to capitalize on the recent interest and funding available for such trials through a number of funding agencies. Upon completion of this program, the participant will be able to: 1) describe both the broad meaning and the subtle details of what constitutes a cluster-randomized trial; 2) discuss the ethical controversies regarding the requirement for individual informed consent; 3) define what constitutes a suitable topic for a cluster-randomized trial; and 4) describe the major technical details necessary to design, plan, and propose such a trial. Program is subject to change.
PROGRAM CHAIRS Laura M. Dember, MD, FASN, and Wolfgang C. Winkelmayer, MD, ScD, FASN
Wednesday, November 12, 2014 7:00 a.m.
Registration and Continental Breakfast
I. Setting the Stage Moderators:
Laura M. Dember, MD, FASN, and Wolfgang C. Winkelmayer, MD, ScD, FASN
8:00 a.m.
Welcome and Roadmap Laura M. Dember, MD, FASN
8:15 a.m.
Trial Types: Where Does Cluster Randomization Fit In? Alfred K. Cheung, MD
9:45 a.m.
Cluster-Randomization in Hemodialysis: An Attractive Proposition Steven M. Brunelli, MD
10:15 a.m.
Break
II. Planning a Cluster-Randomized Hemodialysis Trial Moderators:
Steven M. Brunelli, MD, and Wolfgang C. Winkelmayer, MD, ScD, FASN
10:30 a.m.
Design Considerations Tom Greene, PhD
11:15 a.m.
Engagement of Stakeholders L. Ebony Boulware, MD
12:00 p.m.
Lunch (on your own)
III. Regulatory and Ethical Issues Moderators:
Alfred K. Cheung, MD, and Laura M. Dember, MD, FASN
1:00 p.m.
Ethical and Regulatory Challenges of Pragmatic CRTs Jeremy Sugarman, MD
1:30 p.m.
Institutional Review Board Oversight with Multiple Sites Emily Sheffer
2:00 p.m.
Informed Consent: Necessary or Not? Steven Joffe, MD
2:30 p.m.
Discussion
3:00 p.m.
Break
4
IV. Real-Life Example: The TiME Trial Moderators:
Michael F. Flessner, MD, PhD, and Paul L. Kimmel, MD, FASN
3:30 p.m.
A Network for Collaborative Pragmatic Trials in ESRD Laura M. Dember, MD, FASN
4:00 p.m.
The Research Question John T. Daugirdas, MD, FASN
4:30 p.m.
Implementation Approaches Eduardo K. Lacson, MD, FASN
5:00 p.m. 5:30 p.m.
Data Collection: Clustered and Pragmatic Wolfgang C. Winkelmayer, MD, ScD, FASN
ASN designates this live activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM.
5
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Critical Care Nephrology: 2014 Update This program is designed for trainees and practicing nephrologists who care for critically ill patients with kidney disease. The first day reviews general topics in critical care medicine that are relevant to practicing nephrologists, including hemodynamic support and management and the pathobiology and treatment of sepsis and acute lung injury; management of critical illness in the patient with ESRD; ethical issues in the critically ill patient with kidney disease; the evolving definition of AKI; and the management of AKI in specific clinical settings, including the patient with cancer, cardiorenal syndrome, and liver disease. The second day’s primary focus is the management of AKI in critically ill patients including the management of renal replacement therapy and the treatment of intoxications. Upon completion of this program, the participant will be able to: 1) describe the tools and clinical approaches to the management of septic shock and acute lung injury; 2) apply current definitions and staging criteria for AKI; 3) summarize current management of patients with AKI in the setting of cancer, cardiorenal syndrome, and liver failure; 4) integrate the use of conventional and novel biomarkers into the diagnosis of AKI; 5) discuss the long-term risks of CKD and ESRD in patients who survive an episode of AKI; and 6) choose among the modalities of renal replacement therapy (RRT) and select the most appropriate dose of RRT in critically ill patients with AKI. Program is subject to change.
PROGRAM CHAIRS Jay L. Koyner, MD, Kathleen D. Liu, MD, and Paul M. Palevsky, MD, FASN
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
8:00 a.m.
Welcome and Introduction Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
8:15 a.m.
Invasive Hemodynamic Monitoring Lakhmir S. Chawla, MD
8:45 a.m.
Vasopressors and Inotropes Kathleen D. Liu, MD
9:15 a.m.
What’s New in Sepsis Lakhmir S. Chawla, MD
9:45 a.m.
Clinical Case (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
10:00 a.m.
Break
10:30 a.m.
Advances in Extracorporeal Life Support Jesus Eduardo Rame, MD
11:00 a.m.
What’s New in ARDS/Mechanical Ventilation? Roy G. Brower, MD
11:30 a.m.
Fluid as Drug John A. Kellum, MD
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Clinical Case (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
1:15 p.m.
The Critically Ill ESRD Patient Steven D. Weisbord, MD, FASN
1:45 p.m.
Functional Outcomes after Critical Illness Catherine (Terri) L. Hough
2:15 p.m.
Ethics: When Can You Say No? Alvin H. Moss, MD
2:45 p.m.
Clinical Case (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
3:00 p.m.
Break
6
3:30 p.m.
Defining AKI John A. Kellum, MD
4:00 p.m.
AKI and Cancer Benjamin D. Humphreys, MD, PhD, FASN
4:30 p.m.
Cardiorenal Syndrome Jay L. Koyner, MD
5:00 p.m.
AKI and Liver Disease Florence Wong, MD, MBBS
5:30 p.m. 6:00 p.m.
Clinical Case, Questions, and Day I Wrap-Up (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
8:00 a.m.
Welcome and Introduction Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
8:15 a.m.
Pathophysiology of Intrinsic AKI Anupam Agarwal, MD, FASN
8:45 a.m.
Pharmacologic Therapy for AKI: Does Anything Work? Mitchell H. Rosner, MD, FASN
9:15 a.m.
AKI and CKD Kathleen D. Liu, MD
9:45 a.m.
Clinical Case (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
10:00 a.m.
Break
10:30 a.m.
Biomarkers of AKI Jay L. Koyner, MD
11:00 a.m.
Contrast-Induced AKI: Can We Prevent It? Does It Matter? Steven D. Weisbord, MD, FASN
11:30 a.m.
Extracorporeal Therapy of Intoxications David S. Goldfarb, MD, FASN
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Clinical Case (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
1:15 p.m.
Timing of RRT in AKI Ron Wald, MD
1:45 p.m.
Selecting a Modality of RRT Paul M. Palevsky, MD, FASN
2:15 p.m.
Practical Considerations in the Management of CRRT Ashita J. Tolwani, MD
2:45 p.m.
Clinical Case (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
3:00 p.m.
Break
3:30 p.m.
Using Prolonged Intermittent RRT in the Intensive Care Unit Mark R. Marshall, MBChB
4:00 p.m.
Dosing RRT Paul M. Palevsky, MD, FASN
4:30 p.m.
Advanced Extracorporeal Therapies David J. Askenazi, MD
5:00 p.m.
Drug Dosing in AKI Bruce A. Mueller, PharmD, FASN
5:30 p.m. 6:00 p.m.
Clinical Case, Questions, and Day II Wrap-Up (Audience Response) Jay L. Koyner, MD, Kathleen D. Liu, MD, Paul M. Palevsky, MD, FASN
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
7
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Diagnosis and Management of Disorders of Acid-Base, Fluid, and Electrolyte Balance: Challenging Issues for the Clinician Supported by an independent educational grant from ZS Pharma.
This program is designed to provide an up-to-date review of the diagnosis and management of important disorders of acid-base, fluid, and electrolyte balance with an emphasis on challenging issues commonly faced by the practicing clinician. Emerging new concepts and areas of controversy are particularly stressed. Disorders of acid-base, fluid, and electrolyte balance are common, particularly in seriously ill patients. Most important, their presence can have a dramatic impact on clinical outcome. In the last several years, there have been substantial advances in our knowledge of their pathophysiology, their value, and the limitations of diagnostic studies utilized for their assessment, the type and severity of adverse effects, and the most effective methods of their management. This program addresses the following issues: 1) What are the most effective methods for the diagnosis of lactic acidosis, how should patients be monitored, and what novel treatments are available? 2) What are the pathophysiology, prevalence, adverse effects, and recommended treatment of the acidosis of CKD? 3) What are the pathogenesis, adverse effects, and appropriate treatment of severe alkalemia in the intensive care unit? 4) What acid-base disorders are present in dialysis patients and what therapies are indicated? 5) What are the pathogenesis and most effective treatment of resistant edema? 6) What therapy should be used in the treatment of severe hyponatremia? 7) What is the role of vaptans in treatment of hyponatremia? 8) What is the pathogenesis of disorders of potassium balance in CKD and what is the appropriate management? 9) What are the acid-base and fluid and electrolyte complications of parenteral nutrition and what is the appropriate management? 10) What crystalloids are available for treatment and what are their benefits and complications? In all instances, didactic sessions elucidating important concepts are complemented by actual cases that illustrate the approach of experts in the field. Upon completion of this program, the participant will be able to: 1) utilize knowledge of the pathophysiology of lactic acidosis, metabolic acidosis of CKD, and acid-base disorders in dialysis patients, alkalemia in the intensive care unit, severe hyponatremia, abnormalities of potassium balance in CKD, acid-base and electrolyte complications of parenteral nutrition, resistant edema, and severe volume depletion and hypotension to generate a systematic approach to the diagnosis and management of each of these disorders; 2) discuss the impact of each of these disorders on morbidity and mortality of patients; and 3) describe gaps in our knowledge and areas of controversy for each of the disorders requiring further basic and clinical research. Program is subject to change.
PROGRAM CHAIRS Horacio J. Adrogue, MD, Jeffrey A. Kraut, MD, and Nicolaos E. Madias, MD, FASN
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
7:55 a.m.
Welcome and Introduction Horacio J. Adrogue, MD, Jeffrey A. Kraut, MD, Nicolaos E. Madias, MD, FASN
8:00 a.m.
Lactic Acidosis: An Update; Questions and Answers Nicolaos E. Madias, MD, FASN
9:00 a.m.
Metabolic Acidosis of CKD: An Update; Questions and Answers Jeffrey A. Kraut, MD
10:00 a.m.
Break
10:30 a.m.
Illustrative Cases Jeffrey A. Kraut, MD, Nicolaos E. Madias, MD, FASN
8
11:30 a.m.
Questions and Answers Michael Emmett, MD
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Metabolic Alkalosis in the ICU; Questions and Answers Michael Emmett, MD
2:00 p.m.
Renal Replacement Therapy and Acid-Base Homeostasis 2014; Questions and Answers F. John Gennari, MD
3:00 p.m.
Break
3:30 p.m.
Management of Resistant Edema; Questions and Answers David H. Ellison, MD, FASN
4:30 p.m.
Illustrative Cases David H. Ellison, MD, FASN, Michael Emmett, MD, F. John Gennari, MD
5:30 p.m. 6:00 p.m.
Questions and Answers Jeffrey A. Kraut, MD
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
8:00 a.m.
Management of Severe Hyponatremia; Questions and Answers Horacio J. Adrogue, MD
9:00 a.m.
Clinical Use of Vaptans; Questions and Answers Joseph G. Verbalis, MD
10:00 a.m.
Break
10:30 a.m.
Illustrative Cases Horacio J. Adrogue, MD, Joseph G. Verbalis, MD
11:30 a.m.
Questions and Answers Jeffrey A. Kraut, MD
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Potassium Disorders in CKD; Questions and Answers Thomas D. DuBose, MD, FASN
2:00 p.m.
Treatment with Crystalloid Solutions: Benefits and Adverse Effects; Questions and Answers Biff F. Palmer, MD, FASN
3:00 p.m.
Break
3:30 p.m.
Electrolyte and Acid-Base Disorders in Parenteral Nutrition; Questions and Answers David S. Seres, MD
4:30 p.m.
Illustrative Cases Thomas D. DuBose, MD, FASN, Biff F. Palmer, MD, FASN, David S. Seres, MD
5:30 p.m. 6:00 p.m.
Questions and Answers Horacio J. Adrogue, MD
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
9
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Fundamentals of Renal Pathology Nothing more closely approaches the soul of nephrology than does the renal biopsy. The techniques and the interpretation of histopathology, however, receive inadequate attention in many training programs. This program is aimed at all who are interested in a basic introduction to renal pathology. The program authoritatively carries attendees through the classic renal pathologic changes seen in parenchymal nephropathies. The curriculum includes lectures and hands-on workshops. Enrollees are provided with microscopes and slides of key biopsies that are personally reviewed with the renal pathologists from the faculty. Attendance is limited to 50 people to maximize interactions with the faculty in workshop sessions. Upon completion of this program, the participant will be able to: 1) describe normal renal anatomy; 2) discuss key diagnostic lesions for selected, common renal parenchymal diseases; and 3) choose an overall approach to renal biopsy diagnosis and integrate all diagnostic information to arrive at a diagnosis. Program is subject to change.
PROGRAM CHAIRS Charles E. Alpers, MD, Agnes B. Fogo, MD, and J. Charles Jennette, MD
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
I. Anatomy, Histology, and Pathologic Evaluation of the Kidney 8:00 a.m.
Basic Concepts, Methods, Approaches, and Terminology in Renal Pathology J. Charles Jennette, MD
II. Glomerular Diseases with Nephrotic Syndrome Presentations 8:40 a.m.
Membranous Glomerulopathy Charles E. Alpers, MD
9:05 a.m.
Membranoproliferative Glomerulonephritis and C3 Glomerulopathy Mark Haas, MD, PhD
9:35 a.m.
Minimal Change Disease and FSGS Agnes B. Fogo, MD
10:05 a.m.
Questions and Answers
10:15 a.m.
Break
10:35 a.m.
Laboratory Session: Cases of Normal Kidney, Membranous Glomerulopathy, Membranoproliferative Glomerulonephritis, Minimal Change Disease, and FSGS— Evaluation of Case #1
11:30 a.m.
Review Session: Questions and Answers with Illustrations from Lab Cases— Discussion of Quiz Case #1 Charles E. Alpers, MD, Agnes B. Fogo, MD, Mark Haas, MD, PhD, J. Charles Jennette, MD
12:00 p.m.
Lunch (on your own)
1:00 p.m.
The Clinical Value of Renal Biopsies in Patients with Glomerular Diseases Venkataraman Ramanathan, MD, FASN
III. Glomerular Diseases with Nephritic Syndrome Presentations 1:20 p.m.
Postinfectious Glomerulonephritis Charles E. Alpers, MD
1:40 p.m.
IgA Nephropathy Mark Haas, MD, PhD
2:05 p.m.
Thin Basement Membranes and Alport Syndrome Agnes B. Fogo, MD
10
2:25 p.m.
Questions and Answers
2:30 p.m.
Break
IV. Systemic Diseases Affecting the Kidney 2:50 p.m.
Systemic Lupus Erythematosus Charles E. Alpers, MD
3:35 p.m.
Questions and Answers
3:40 p.m.
Crescentic Glomerulonephritis J. Charles Jennette, MD
4:10 p.m.
Vasculitides J. Charles Jennette, MD
4:35 p.m.
Questions and Answers
4:40 p.m.
Laboratory Session: Cases of Postinfectious Glomerulonephritis, Lupus Nephritis, IgA Nephropathy, and Granulomatosis with Polyangiitis (Wegener’s)—Evaluation of Case #2
5:30 p.m. 5:45 p.m.
Review Session: Questions and Answers with Illustrations from Lab Cases— Discussion of Quiz Case #2 Charles E. Alpers, MD, Agnes B. Fogo, MD, Mark Haas, MD, PhD, J. Charles Jennette, MD
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
V. Vascular Diseases 8:00 a.m.
Diabetic Nephropathy J. Charles Jennette, MD
8:30 a.m.
Nephrosclerosis and Hypertension Agnes B. Fogo, MD
8:50 a.m.
Thrombotic Microangiopathies Agnes B. Fogo, MD
9:15 a.m.
Questions and Answers
VI. Tubulointerstitial Diseases 9:25 a.m.
Acute and Chronic Tubulointerstitial Nephritis and Acute Tubular Injury Lynn D. Cornell, MD
10:05 a.m.
Break
10:25 a.m.
Renal Disease Caused by Monoclonal Immunoglobulins and Glomerular Diseases with Organized Deposits Lynn D. Cornell, MD
10:45 a.m.
Questions and Answers
10:55 a.m.
Laboratory Session: Cases of Hemolytic Uremic Syndrome, Acute Tubular Injury, Myeloma Kidney, Tubulointerstitial Nephritis, and Diabetic Nephropathy—Evaluation of Case #3
11:45 a.m.
Review Session: Questions and Answers with Illustrations from Lab Cases— Discussion of Quiz Case #3 Lynn D. Cornell, MD, Agnes B. Fogo, MD, J. Charles Jennette, MD
12:15 p.m.
Lunch (on your own)
1:15 p.m.
The Clinical Value of Renal Biopsies in Patients with Tubular and Tubulointerstitial Disease Venkataraman Ramanathan, MD, FASN
VII. The Renal Transplant 1:40 p.m.
Diseases of the Renal Transplant: Rejection Robert B. Colvin, MD
2:30 p.m.
Diseases of the Renal Transplant: Infection, Drug Toxicity, and Recurrent and De Novo Glomerular Disease Robert B. Colvin, MD
3:00 p.m.
Questions and Answers
3:10 p.m.
Break
11
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS 3:30 p.m.
Laboratory Session: Cases of Acute Cellular and Humoral Rejection, Chronic Rejection, and Calcineurin Inhibitor Toxicity—Evaluation of Case #4
4:20 p.m. 4:50 p.m.
Review Session: Questions and Answers with Illustrations from Lab Cases— Discussion of Quiz Case #4 Robert B. Colvin, MD
ASN designates this live activity for a maximum of 15.25 AMA PRA Category 1 CreditsTM.
12
Glomerulonephritis Update: Diagnosis and Therapy 2014 ASN thanks its Glomerular Diseases Advisory Group for assistance with this program.
The knowledge of the pathogenesis, diagnosis, and management of glomerular diseases is advancing rapidly. We assembled a panel of international experts in this rapidly growing field to discuss these advances. Using lectures, interactive case-based discussions, and self-assessment questions with audience response systems, the attendee is exposed to this wealth of information in an orderly and easily assimilable manner. At the conclusion of this program, the practitioner is able to utilize this information gainfully while taking care of challenging patients with glomerular disease, both common and uncommon. Upon completion of this program, the participant will be able to: 1) describe and integrate the pathology, diagnosis, and therapeutic options for glomerular diseases; 2) integrate information from current basic and clinical research studies and apply them to diagnosis and management of glomerular disorders; and 3) analyze nuances in the treatment of difficult patients with glomerular disease with experts in glomerular disease. Program is subject to change.
PROGRAM CHAIRS Jai Radhakrishnan, MD, FASN, Heather N. Reich, MD, PhD, and Brad H. Rovin, MD, FASN
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
8:00 a.m.
Complications of the Nephrotic Syndrome Jai Radhakrishnan, MD, FASN
8:45 a.m.
Pathology of Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, and Membranoproliferative Glomerulonephritis (MPGN) H. Terence Cook, MBBS
9:45 a.m.
Break
10:00 a.m.
Treatment of MCD and FSGS James A. Tumlin, MD, FASN
11:00 a.m.
Treatment of Membranous Nephropathy Daniel C. Cattran, MD
11:45 a.m.
Making Sense of Genetics in Glomerular Diseases Barry I. Freedman, MD
12:30 p.m.
Lunch (on your own)
1:30 p.m.
Viral Glomerulonephritides: HIV, Hepatitis B Virus, and Hepatitis C Virus Warren L. Kupin, MD
2:15 p.m.
MPGN and Dense Deposit Disease: A Clinical Approach Gerald B. Appel, MD, FASN
3:00 p.m.
Break
3:15 p.m.
Diabetic Kidney Disease Mark E. Williams, MD, FASN
4:00 p.m.
Thrombotic Microangiopathies William F. Clark, MD, FASN
4:45 p.m. 5:30 p.m.
Nephrotic Syndrome: Case Studies Jai Radhakrishnan, MD, FASN
13
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
8:00 a.m.
Pathology of the Dysproteinemias Glen S. Markowitz, MD
8:45 a.m.
Treatment of Dysproteinemic Renal Disease Nelson Leung, MD
9:30 a.m.
Pathology and Classification of Lupus Nephritis and IgA Nephropathy H. Terence Cook, MBBS
10:15 a.m.
Break
10:30 a.m.
Treatment of IgA Nephropathy Heather N. Reich, MD, PhD
11:15 a.m.
Current and New Treatments of Lupus Nephritis Brad H. Rovin, MD, FASN
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Pathology and Pathophysiology of Rapidly Progressive Glomerulonephritis H. Terence Cook, MBBS
1:30 p.m.
Diagnosis and Treatment of Small Vessel Vasculitis and Anti–Glomerular Basement Membrane Antibody Disease Patrick H. Nachman, MD, FASN
2:30 p.m.
Recurrent Glomerular Disease in Renal Transplants Karin A. True, MD, FASN
3:15 p.m.
Break
3:30 p.m.
Pregnancy and Glomerular Disease Michelle A. Hladunewich, MD, FASN
4:15 p.m. 5:30 p.m.
Nephritic Syndrome: Case Studies Glen S. Markowitz, MD, Patrick H. Nachman, MD, FASN, Heather N. Reich, MD, PhD, Brad H. Rovin, MD, FASN
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
14
Human Genetics in Nephrology: Clinical Fundamentals and Research Advances This program provides an introduction to key topics in human genetics and genomics, followed by indepth discussions of the full gamut of genetic diseases and syndromes. Leaders in the field discuss research advances in defining genes that contribute as high-penetrance, Mendelian causes of kidney disease and as susceptibility factors for kidney disease. Other topics include analytic approaches to renal transcriptomics that offer promise to define pathogenetic networks, the role for whole exome studies in identifying genetic variants, and ethical/legal/social issues pertaining to research and clinical practice. The program ends with practical advice for individuals who wish to become more involved in clinical genetic nephrology, including those who might wish to start a genetic nephrology clinic. Upon completion of this program, the participant will be able to: 1) describe the clinical science of human genetics and genomics; and 2) summarize current knowledge of genetic kidney diseases, including genes, phenotypes, and implications for diagnosis, counseling, and current management recommendations in presymptomatic and symptomatic phases. Program is subject to change.
PROGRAM CHAIRS Lisa M. Guay-Woodford, MD, and Jeffrey B. Kopp, MD, FASN
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
8:00 a.m.
Introduction to the Genome and Genomic Data Resources Lynn B. Jorde, PhD
8:45 a.m.
Methods for Finding Genetic Loci in Research and Genetic Variants in Practice Andrey S. Shaw, MD
9:30 a.m.
The Genomic Renal Biopsy and the Genomic Urinalysis Matthew Sampson, MD
10:00 a.m.
Break
10:30 a.m.
Pharmacogenomics: Focus on Nephrology, Hypertension, and Kidney Transplant Julie A. Johnson, PharmD
11:00 a.m.
Hypertension and Hypotension: Mendelian and Essential Forms Kevin O’Shaughnessy, MD, PhD
11:30 a.m.
C3 Glomerulopathy and Related Disorders Elena Bresin, MD
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Cases, Audience Response, Panel Discussion Kevin O’Shaughnessy, MD, PhD
2:00 p.m.
IgA Nephropathy Ali G. Gharavi, MD
2:30 p.m.
Molecular Mechanisms of Glomerular Proteinuria: Mendelian Forms of FSGS and MCD Rasheed A. Gbadegesin, MD
3:00 p.m.
Break
3:30 p.m.
APOL1 Nephropathies Martin R. Pollak, MD
4:00 p.m.
Bringing Susceptibility Genes into the Clinic: Approaches to Risk Profiling Barry I. Freedman, MD
4:30 p.m.
Diabetes: Metabolic Syndrome, Obesity, Diabetes, and Diabetic Nephropathy Jose C. Florez, MD, PhD
5:00 p.m.
NIDDK Resources for Genetic and Genomic Research Rebekah Sarah Rasooly, PhD
15
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS 5:15 p.m. 6:00 p.m.
Cases, Audience Response, Panel Discussion Rebekah Sarah Rasooly, PhD, Cheryl Ann Winkler, PhD
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
8:00 a.m.
Fabry Disease Robert J. Desnick, MD, PhD
8:30 a.m.
Alport and Thin Basement Membrane Diseases Clifford E. Kashtan, MD, FASN
9:00 a.m.
Polycystic Kidney Diseases Peter C. Harris, PhD
9:30 a.m.
Ciliopathies and CAKUT Friedhelm Hildebrandt, MD
10:00 a.m.
Break
10:30 a.m.
Tubular Diseases and Beyond Robert Kleta, MD, PhD, FASN
11:00 a.m.
Nephrolithiasis, Nephrocalcinosis, and Related Disorders John C. Lieske, MD, FASN
11:30 a.m.
Hereditary Renal Cancer Syndromes Laura S. Schmidt, PhD
12:00 p.m.
Lunch (on your own)
1:00 p.m.
Cases, Audience Response, Panel Discussion Robert Kleta, MD, PhD, FASN
2:00 p.m.
Present and Future Genome-Wide Analyses: Focus on Whole Exome for Research and Clinical Diagnosis David R. Adams, MD, PhD
2:30 p.m.
Gene Therapy for Cystinosis Stephanie Cherqui, PhD
3:00 p.m.
Salient Ethical, Legal, and Social Issues in Genetic Research and Genetic Practice Julie Sapp, ScM, CGC
3:30 p.m.
Break
4:00 p.m.
What Do I Need to Know to Start a Genetic Nephrology Clinic? Arlene B. Chapman, MD
4:30 p.m.
What Do I Ask and What Do I Say? Taking a Genetic History and Counseling Patients and Families Patrick E. Gipson, MD
5:00 p.m. 6:00 p.m.
Cases, Audience Response, Panel Discussion Arlene B. Chapman, MD
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
16
Innovation in Kidney Disease, Dialysis, and Vascular Access In cooperation with the American Society of Diagnostic and Interventional Nephrology.
This program describes novel approaches to the treatment of kidney disease by focusing on techniques, devices, and scientific methods that are in various stages of development. Examples of upcoming and current innovations highlight how they have developed into important clinical solutions, how they can be transformative for practice, and the challenges of sustainability in the current economic, social, and patient-care environments. Innovative ideas and technology touch on all aspects of nephrology from stem cells and cellular transplants to management of hypertension, AKI, and sepsis to new techniques to optimize hemodialysis and peritoneal dialysis (PD) care. This program also helps the new innovator to understand what is required to bring a creative basic scientific or clinical idea from “bench to beside and beyond.” There is a balanced combination of didactic lectures and clinical examples of how ideas are shaped to be favorable for funding, steps through the US regulatory process, clinical testing, and marketing strategies. Upon completion of this program, the participant will be able to: 1) describe the process of device or product development, from initial idea to regulatory approval and eventually marketing; 2) describe cellular innovations in the field of organ transplantation; 3) explain the roles of stenting and renal nerve denervation in the treatment of hypertension; 4) differentiate the concepts for potential new approaches to vascular access creation; 5) discuss potential novel techniques for extracorporeal therapy in sepsis and AKI; and 6) list recent innovations in wearable artificial kidneys and PD. Program is subject to change.
PROGRAM CHAIRS Charmaine E. Lok, MD, and Alexander S. Yevzlin, MD
Wednesday, November 12, 2014 7:00 a.m.
Registration and Continental Breakfast
I. Innovation: General 8:00 a.m.
Introduction Charmaine E. Lok, MD, Alexander S. Yevzlin, MD
8:10 a.m.
So…You Have an Idea—Now What? Insights and Examples Michael J. Kallok, PhD
8:35 a.m.
Fundraising: How, Who, When, and for What? Jim Hickey
9:00 a.m.
The Regulatory Process in the United States Miriam Provost, PhD
9:25 a.m.
From Clinical Testing to Marketing and Real-World Application Michael J. Kallok, PhD
9:50 a.m.
Break
II. Transplantation 10:10 a.m.
Innovation and Ethics of Maximizing Kidney Donation: Paired Exchange, O Donors, and Other Strategies John S. Gill, MD
10:35 a.m.
Kidney Structures from Stem Cells to Imprintable Kidneys: Are We There Yet? Albert Q. Lam, MD
11:00 a.m.
Repopulation of Kidney Scaffolds with Stem Cells Edward A. Ross, MD
17
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
III. Hypertension 11:25 a.m.
Renal Nerve Denervation: Does It Really Work? What Next? Alexander S. Yevzlin, MD
11:50 a.m.
Renal Artery Stenting: The CORAL Study and Lessons Learned Katherine R. Tuttle, MD, FASN
12:15 p.m.
Lunch (on your own)
IV. Vascular Access 1:15 p.m.
Inside-Out Catheter Placement Technique Micah R. Chan, MD
1:40 p.m.
Innovation in Hemodialysis AV Access Christi M. Terry, PhD
V. Advances in Renal Replacement Therapy 2:30 p.m.
Acute Care: Sepsis Therapy/Cell Deactivation with the Selective Cytopheresis Device H. David Humes, MD
2:55 p.m.
Polymixin B Cytokine Adsorption Alexander S. Yevzlin, MD
3:20 p.m.
Break
3:40 p.m.
Acute Care: PD in the ICU and New PD Solution Micah R. Chan, MD
VI. Updates in Novel Ongoing RRT Initiatives 4:05 p.m.
Wearable Hemodialysis Systems for Dialysis: Standard Sorbent, Nanofabricated Membranes William Fissell, MD
4:30 p.m.
Enhancements in Current Therapy Citrate Dialysis/CRRT Jerry Yee, MD, FASN
4:55 p.m. 5:00 p.m.
Closing Remarks
ASN designates this live activity for a maximum of 7.25 AMA PRA Category 1 CreditsTM.
18
Kidney Transplantation In cooperation with the American Society of Transplantation. ASN thanks its Transplant Advisory Group for assistance with this program. Supported by an independent educational grant from Astellas Scientific and Medical Affairs, Inc.
In recent years, there have been important advances in the field of kidney transplantation that will impact the care of the kidney transplant recipient. In particular, new allocation policies, changes in donor management (including living donor assessment and follow-up), novel immunosuppression strategies, and advances in the understanding of the causes of acute and chronic graft injury will directly influence nephrology practice both immediately and in the coming era. This program provides an interactive, case-based overview of these and other exciting advances in kidney transplantation, with a focus on specific populations, complications, and ethical issues. Nephrologists with an interest in transplantation, transplant physicians, and trainees in nephrology are encouraged to attend this program. Upon completion of this program, the participant will be able to: 1) describe the evaluation and management of the patient awaiting transplant; 2) discuss current diagnostic and treatment strategies for graft dysfunction; and 3) formulate management guidelines for common complications following transplant. Program is subject to change.
PROGRAM CHAIRS Roy D. Bloom, MD, Milagros D. Samaniego-Picota, MD, FASN, and Alexander C. Wiseman, MD
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
7:55 a.m.
Welcome and Introduction
I. Essentials of Transplantation Immunology and Allocation 8:00 a.m.
Immunobiology of Transplantation for the Clinician Leonardo V. Riella, MD, PhD, FASN
8:30 a.m.
Immunosuppression: Current and Future Therapies Roy D. Bloom, MD
9:00 a.m.
Immunological Assessment of the Transplant Recipient Douglas J. Norman, MD
9:30 a.m.
Organ Allocation within the United States John J. Friedewald, MD
10:00 a.m.
Break
II. Identifying Recipients and Donors 10:15 a.m.
Clinical Cases Roy D. Bloom, MD, Daniel C. Brennan, MD, Douglas J. Norman, MD
11:00 a.m.
Recipient Evaluation John S. Gill, MD
11:30 a.m.
Living Donor Evaluation and Outcomes Amit X. Garg, MD, PhD
12:00 p.m.
Expanding the Donor Pool Anil K. Chandraker, MBChB, FASN
12:30 p.m.
Lunch (on your own)
19
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
III. Acute Graft Dysfunction and Rejection: Case-Based Approach 1:30 p.m.
Discussants Douglas J. Norman, MD, Lorraine C. Racusen, MD, FASN, Milagros D. Samaniego-Picota, MD, FASN, Alexander C. Wiseman, MD
3:00 p.m.
Break
IV. Chronic Allograft Injury 3:30 p.m.
Multidisciplinary Case Presentations Roy D. Bloom, MD, Douglas J. Norman, MD, Lorraine C. Racusen, MD, FASN, Alexander C. Wiseman, MD
5:00 p.m.
Recurrent Disease in the Allograft Karin A. True, MD, FASN
5:30 p.m.
Management of a Recipient with a Failed Kidney Transplant Simin Goral, MD
6:00 p.m. 6:15 p.m.
Wrap-Up: Questions and Answers
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
V. Infection Issues in Kidney Transplantation 8:00 a.m.
BK, CMV, and EBV Daniel C. Brennan, MD
8:30 a.m.
HIV Deirdre L. Sawinski, MD
9:00 a.m.
Hepatitis B, C, and E Kimberly Brown, MD
9:30 a.m.
Infection Issues in Transplantation: Clinical Cases Daniel C. Brennan, MD, Milagros D. Samaniego-Picota, MD, FASN, Alexander C. Wiseman, MD
10:00 a.m.
Break
VI. Extrarenal Complications after Transplantation 10:30 a.m.
Metabolic Syndrome and Cardiovascular Disease in Kidney Recipients Donald E. Hricik, MD
11:00 a.m.
Post-Transplant Malignancy Milagros D. Samaniego-Picota, MD, FASN
11:30 a.m.
Post-Transplant Bone Disease Mary B. Leonard, MD
12:00 p.m.
Complications after Transplantation: Clinical Cases Donald E. Hricik, MD, Mary B. Leonard, MD, Milagros D. Samaniego-Picota, MD, FASN
12:30 p.m.
Lunch (on your own)
VII. Special Patient Populations 1:30 p.m.
Transplantation for Patients with Diabetic CKD Alexander C. Wiseman, MD
2:00 p.m.
Kidney Disease in Nonrenal Organ Recipients David J. Cohen, MD
2:30 p.m.
Women’s Health and Kidney Transplantation Michelle A. Hladunewich, MD, FASN
3:00 p.m.
The Adolescent and Transitioning Young Adult Sandra Amaral, MD
3:30 p.m.
Break
20
VIII. Ethics and Oversight: What It Means for Your Patients 4:00 p.m.
Registries in Transplantation Bertram L. Kasiske, MD
4:30 p.m.
Public Policy and Ethical Issues in Transplantation Peter P. Reese, MD
5:00 p.m. 5:30 p.m.
Panel Discussion Anil K. Chandraker, MBChB, FASN, John J. Friedewald, MD, Bertram L. Kasiske, MD, Peter P. Reese, MD
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
21
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Maintenance Dialysis ASN thanks its Dialysis Advisory Group for assistance with this program.
The treatment of patients with stage 5 kidney disease is always evolving. Research findings challenge old paradigms and introduce new concepts; technologic developments offer new opportunities and therapeutic options; and additional financial constraints constantly push us toward better efficiency and efficacy. This program critically reviews established norms and explores emerging concepts in dialysis care. It synthesizes new and old data to help physicians incorporate these findings into their daily clinical practice, with a focus on improving patient well-being and outcomes. Underlying physiology and pathophysiology are discussed, along with potential therapeutic interventions for patients treated with in-center or home hemodialysis (HD) and peritoneal dialysis (PD). Upon completion of this program, the participant will be able to: 1) describe the rationale and clinical role of recent advances in prescription management of PD and in-center and home HD; 2) apply recent evidence to better manage the dialysis access and complications of uremia; and 3) describe the current evidence to improve patient-reported outcomes and reduce cardiovascular risk in patients undergoing maintenance dialysis. Program is subject to change.
PROGRAM CHAIRS John M. Burkart, MD, Rajnish Mehrotra, MD, FASN, and Mark L. Unruh, MD
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
Session I Moderator:
Rajnish Mehrotra, MD, FASN
8:00 a.m.
Audience Response Questions Rajnish Mehrotra, MD, FASN
8:10 a.m.
Safe Transition from CKD to ESRD John M. Burkart, MD
8:50 a.m.
Urgent Start PD Arsh Jain, MD
9:20 a.m.
Reducing Risk for ESRD in Living Donors: Emerging Trends Barry I. Freedman, MD
10:00 a.m.
Break
Session II Moderator:
Peter G. Blake, MbChB
10:30 a.m.
Audience Response Questions Peter G. Blake, MbChB
10:40 a.m.
Potential Local and Systemic Benefits and Risk with Glucose in PD Rajnish Mehrotra, MD, FASN
11:20 a.m.
HD Dialysate Sodium, Ultrafiltration Rates, and Treatment Time: Maximizing Safety and Efficacy John T. Daugirdas, MD, FASN
12:00 p.m.
Lunch (on your own)
22
Session III Moderator:
John M. Burkart, MD
1:00 p.m.
Audience Response Questions John M. Burkart, MD
1:10 p.m.
Debate: Pro—Superiority of Arteriovenous Fistula over Central Venous Catheters Is Overrated: Focus on Cardiovascular and Infectious Risk Peter G. Blake, MbChB
1:30 p.m.
Debate: Con—Superiority of Arteriovenous Fistula over Central Venous Catheters Is Overrated: Focus on Cardiovascular and Infectious Risk Charmaine E. Lok, MD
1:50 p.m.
Debate: Rebuttal and Discussion
2:00 p.m.
Time to Abandon Routine Surveillance of Arteriovenous Access? Timmy C. Lee, MD, FASN
2:30 p.m.
Preventing and Managing PD Catheter-Related Peritonitis Sharon Nessim, MD
3:00 p.m.
Break
Session IV Moderator:
Mark L. Unruh, MD
3:30 p.m.
Case Studies: Clinical Problems with Hemodialysis Systems Scott D. Bieber, DO
4:15 p.m.
Exercise and the Health of a Dialysis Patient Kirsten L. Johansen, MD
4:45 p.m.
Case Studies: Common Medication Errors in Dialysis Patients Mitchell H. Rosner, MD, FASN
5:15 p.m. 6:00 p.m.
Normalizing the Vascular Physiology in ESRD? Raymond R. Townsend, MD
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
Session V Moderator:
Sarbjit Vanita Jassal, MD, PhD
8:00 a.m.
Audience Response Questions Sarbjit Vanita Jassal, MD, PhD
8:10 a.m.
Clinical Outcomes with Home HD: Better than In-Center HD? Christopher T. Chan, MD
8:45 a.m.
Home HD Prescriptions with Current and Emerging Platforms Joel D. Glickman, MD
9:15 a.m.
Case Studies: Catheter-Related and Other Noninfectious Complications of PD Joanne M. Bargman, MD
10:00 a.m.
Break
Session VI Moderator:
Joel D. Glickman, MD
10:30 a.m.
Audience Response Questions Joel D. Glickman, MD
10:40 a.m.
Lurking Risks with Intravenous Iron as ESA-Sparing Strategy Steven Fishbane, MD
11:10 a.m.
Novel Treatment Options for CKD-MBD on the Horizon Michel Chonchol, MD
11:35 a.m.
Insulin Resistance with ESRD: Relevant and Modifiable? T. Alp Ikizler, MD, FASN
12:00 p.m.
Lunch (on your own)
23
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Session VII Moderator:
Robert R. Quinn, MD, PhD
1:00 p.m.
Audience Response Questions Robert R. Quinn, MD, PhD
1:10 p.m.
Debate: Pro—Palliative Dialysis Is More Effective and Patient Centered for Frail Patients than Nondialytic Conservative Care or Full-Dose Dialysis Vanessa Grubbs, MD
1:30 p.m.
Debate: Con—Palliative Dialysis Is More Effective and Patient Centered for Frail Patients than Nondialytic Conservative Care or Full-Dose Dialysis Sarbjit Vanita Jassal, MD, PhD
1:50 p.m.
Debate: Rebuttal and Discussion
2:00 p.m.
Sleep Disorders in ESRD Mark L. Unruh, MD
2:30 p.m.
Interventions to Alleviate Symptom Burden in Dialysis Patients Steven D. Weisbord, MD, FASN
3:00 p.m.
Break
Session VIII Moderator:
Christopher T. Chan, MD
3:30 p.m.
Audience Response Questions Christopher T. Chan, MD
3:40 p.m.
Left Ventricular Hypertrophy: Relevant and Modifiable in HD and PD? David M. Charytan, MD
4:15 p.m.
Dialysate Composition: Modifiable Risk Factor for Sudden Death? Patrick H. Pun, MD
4:50 p.m.
Atrial Fibrillation in ESRD: Management Challenges Abhijit K. Kshirsagar, MD
5:25 p.m. 6:00 p.m.
Statins for Dialysis Patients: Ineffective and Wasteful? Robert R. Quinn, MD, PhD
ASN designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM.
24
Maintenance of Certification: NephSAP Review and ABIM Modules ASN thanks the American Board of Internal Medicine and the American College of Physicians for assistance with this program.
Maintenance of Certification (MOC) promotes lifelong learning and the enhancement of the clinical judgment essential for high-quality patient care. In 2014, in addition to reporting board certification, the American Board of Internal Medicine (ABIM) began reporting whether or not all ABIM Board-Certified physicians are “Meeting MOC Requirements” (i.e., continuously engaging in MOC activities). Certificates are contingent upon meeting the MOC requirements including the following: a) completing at least one MOC activity to earn ABIM MOC points by December 31, 2015 and every 2 years thereafter; b) earning a total of 100 ABIM MOC points, with at least 20 points in medical knowledge and 20 points in practice assessment by December 31, 2018 and every 5 years thereafter; c) fulfilling a patient safety and a patient voice requirement by December 31, 2018 and every 5 years thereafter; and d) passing the MOC exam every 10 years in each certification area the diplomate chooses to maintain. The points earned every 2 years count toward the diplomate’s 5-year requirement. MOC points apply to all certificates. For example, if 100 MOC points are earned by December 31, 2018, these points will meet the requirements for all certificates being maintained (e.g., both internal medicine and nephrology). This early program reviews two ASN NephSAP issues and three ABIM Medical Knowledge Modules. During the program, cases and questions are presented, and answer options are discussed with audience participation using an audience response system. The discussants review each question and pertaining literature. Following this program, participants can earn up to 50 ABIM MOC points in medical knowledge (10 points per issue/module) by taking the applicable exams on ASN’s and ABIM’s websites. All outlined policies and procedures for claiming the ABIM MOC points must be followed. Approximately 6–8 weeks after this program, slides used to illustrate key teaching points are made available to participants online, but answers are not provided. Upon completion of this program, the participant will be able to: 1) satisfy the criteria required to obtain CME credit toward MOC for completion of two ASN NephSAP issues and three ABIM Medical Knowledge Modules; 2) apply the approach to review key aspects of clinical nephrology and internal medicine under the auspices of experts in the field with whom they have had the opportunity to interact; and 3) provide a reasoned approach to diagnosis and therapy for a broad range of internal medicine and nephrology disorders. Program is subject to change.
PROGRAM CHAIRS Patrick C. Alguire, MD, and Gerald A. Hladik, MD, FASN
Tuesday, November 11, 2014 7:00 a.m.
Registration and Continental Breakfast
8:00 a.m.
Welcome and Introduction
I. ABIM Medical Knowledge Module—Internal Medicine: 2014 Update 8:05 a.m.
Cases and Questions 1–15 Patrick C. Alguire, MD
10:00 a.m.
Break
10:15 a.m.
Cases and Questions 16–30 Philip A. Masters, MD
25
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
II. ABIM Medical Knowledge Module—Hospital Medicine: 2014 Update 11:55 a.m.
Cases and Questions 1–5 Marc Shalaby, MD
12:30 p.m.
Lunch (on your own)
1:30 p.m.
Cases and Questions 6–15 Marc Shalaby, MD
2:30 p.m.
Cases and Questions 16–25 Richard Eisenstaedt, MD
3:30 p.m.
Break
3:45 p.m.
Cases and Questions 26–30 Richard Eisenstaedt, MD
III. ABIM Medical Knowledge Module—Nephrology: 2014 Update Part 1 4:15 p.m.
Cases and Questions 1–15 Anna Marie Burgner, MD
5:45 p.m. 6:00 p.m.
Questions and Answers
Wednesday, November 12, 2014 7:30 a.m.
Continental Breakfast
8:00 a.m.
Welcome and Introduction
IV. NephSAP, Volume 13, Number 1, January 2014: Vaso-Occlusive Diseases and the Kidney 8:05 a.m.
Cases and Questions 1–10 William F. Clark, MD, FASN
9:00 a.m.
Cases and Questions 11–15 Vimal K. Derebail, MD
10:00 a.m.
Break
10:15 a.m.
Cases and Questions 16–30 Vimal K. Derebail, MD
12:00 p.m.
Update from the ABIM Kevin Caviston, Stuart L. Linas, MD, FASN
12:30 p.m.
Lunch (on your own)
V. ABIM Medical Knowledge Module—Nephrology: 2014 Update Part 2 1:30 p.m.
Cases and Questions 16–30 Marc L. Weber, MD
3:00 p.m.
Break
VI. NephSAP, Volume 13, Number 4, November 2014: End-Stage Renal Disease and Dialysis 3:15 p.m.
Cases and Questions 1–15 Ruediger W. Lehrich, MD
4:30 p.m.
Cases and Questions 16–30 John Paul Middleton, MD
5:45 p.m. 6:00 p.m.
Questions and Answers
ASN designates this live activity for a maximum of 16.75 AMA PRA Category 1 CreditsTM.
26
Nephro-Pharmacology across the Spectrum of Kidney Diseases Knowledge of drug dosing based on pharmacology and pharmacokinetics is fundamentally important to clinicians caring for patients with kidney diseases. Additionally, emphasis on drug development for unmet medical needs in nephrology patients, as advocated by the Kidney Health Initiative, will require researchers to be well informed about renal pharmacology including drug disposition in subjects with kidney diseases. Changes in dialysis modalities and knowledge advancements in renal pharmacology require clinicians and researchers in nephrology to update their knowledge and skills in these areas. This program is designed as a comprehensive review of fundamental issues related to clinical pharmacology in kidney disease, using lectures, interactive case-based discussions, and self-assessment questions with an audience response system. At the conclusion of this program, nephrologists, pharmacists, nurses, trainees, and researchers gain up-to-date information on pharmacology and the kidneys, drug dosing, pharmacokinetics and pharmacology in acute kidney disease and CKD, and special topics in renal pharmacology. The primary audience target is clinicians and researchers that are interested in enhancing their knowledge and skills in the areas of drug dosing and pharmacology across the spectrum of kidney diseases, including acute kidney disease, CKD, and ESRD. Upon completion of this program, the participant will be able to: 1) apply the components of drug absorption, distribution, metabolism, and excretion (ADME), kidney function estimates, dialysis techniques, and drug properties to optimize treatment strategies across the spectrum of kidney diseases; and 2) assemble information from research and clinical cases and apply them to the design of optimal strategies for the treatment of patients with kidney diseases. Program is subject to change.
PROGRAM CHAIRS Melanie S. Joy, PharmD, PhD, FASN, Thomas D. Nolin, PhD, PharmD, FASN, and Wendy L. St. Peter, PharmD, FASN
Wednesday, November 12, 2014 7:00 a.m.
Registration and Continental Breakfast
I. Pharmacology and the Kidneys 8:00 a.m.
DAM! It’s Not All about Excretion (E): Distribution (D), Absorption (A), and Metabolism/Transport (M) Can Also Change in Kidney Diseases Thomas D. Nolin, PhD, PharmD, FASN
8:40 a.m.
Why Bother? Estimating Kidney Function for Purposes of Drug Dosing Wendy L. St. Peter, PharmD, FASN
9:20 a.m.
What Should the Clinical Researcher Know about Drug Development Tools for Developing Kidney Disease Therapeutics? Melanie S. Joy, PharmD, PhD, FASN
10:00 a.m.
Break
II. Pharmacology and Acute Kidney Disease 10:15 a.m.
Drug Disposition in AKI and CRRT George R. Aronoff, MD
11:00 a.m.
Extracorporeal Treatment in Drug Intoxication Brian S. Decker, MD, PharmD
11:40 a.m.
Clinical Case in AKI/CRRT (Audience Response) George R. Aronoff, MD, Brian S. Decker, MD, PharmD, Thomas D. Nolin, PhD, PharmD, FASN
12:00 p.m.
Lunch (on your own)
27
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
III. Pharmacology and CKD 1:00 p.m.
Turning the Titanic: Improving Data on Drug Disposition and Dosing in Intermittent Hemodialysis (IHD) Gary R. Matzke, PharmD, FASN
1:45 p.m.
Is It a House of Cards? Utilizing Anticoagulants across the Spectrum of Kidney Function and in Patients Receiving Dialysis William E. Dager, PharmD
2:30 p.m.
Clinical Case in IHD (Audience Response) William E. Dager, PharmD, Gary R. Matzke, PharmD, FASN, Wendy L. St. Peter, PharmD, FASN
3:00 p.m.
Break
IV. Special Topics in Renal Pharmacology 3:30 p.m.
Immunosuppressant Pharmacology in Kidney Transplant Patients: What Do We Need to Know about Glucocorticoids and Immune-Modulating Drugs? Kathleen M. Tornatore, PharmD
4:15 p.m.
Drug and Nutrient Interactions in Kidney Disease Therapeutics Mary F. Paine, PhD
5:00 p.m. 5:30 p.m.
Clinical Case (Audience Response) Melanie S. Joy, PharmD, PhD, FASN, Mary F. Paine, PhD, Kathleen M. Tornatore, PharmD
ASN designates this live activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM. This program provides up to 7.75 contact hours of continuing pharmacy education credit.
28
Professional Development Seminar In cooperation with the Women in Nephrology.
The Professional Development Seminar (PDS) organized by Women in Nephrology (WIN) is designed to provide trainees, junior faculty, and researchers in nephrology and renal physiology with the knowledge base and skills that enhances their professional growth and facilitates achievement of their career goals. PDS welcomes both men and women; minorities and disabled individuals are particularly encouraged to apply. Upon completion of this program, the participant will be able to: 1) apply the qualities, skills, and tools necessary to acquire career success, including better communication, motivating, and inspiring confidence and loyalty, as well as improving credibility, efficiency, and productivity; 2) identify potential barriers to accomplish career goals and to develop strategies to overcome the barriers; and 3) employ networking by bringing together junior and senior clinicians and scientists in the field of nephrology to discuss career issues of common interest. Program is subject to change.
PROGRAM CHAIRS Qi Qian, MD, and Kathryn Sandberg, PhD
Wednesday, November 12, 2014 7:00 a.m.
Registration and Continental Breakfast
8:00 a.m.
Remarks from Chair and ASN President: Goals and Objectives of PDS 2014 Sharon M. Moe, MD, FASN, Qi Qian, MD
8:15 a.m.
Career Choices and Opportunities in Nephrology Donald E. Kohan, MD, PhD, FASN
8:45 a.m.
Essentials of Leadership Sharon Anderson, MD, FASN
9:25 a.m.
Career Challenges: Work-Life Balance and Time Management Janis M. Orlowski, MD
10:00 a.m.
Break and 1:1 Mentoring
Roundtables 10:30 a.m.
Am I on the Right Track: Research, Clinic, or Education? Wendy Weinstock Brown, MD, Nuria M. Pastor-Soler, MD, PhD, FASN, Marsha Wolfson, MD How to Get Promoted Sharon Anderson, MD, FASN, Michelle A. Josephson, MD, Sandra P. Levison, MD Managing Your Lab and Grant Dollars Li-Li Hsiao, MD, PhD, Mariela Mendez, PhD, Sylvia E. Rosas, MD, FASN Medical Education Nancy Day Adams, MD, Ellie Kelepouris, MD Physician Leadership: Avoid Pitfalls Donald E. Kohan, MD, PhD, FASN, Janis M. Orlowski, MD, Amy W. Williams, MD Preparing for an Interview Susan H. Bray, MD, Lois Anne Katz, MD, Judith H. Veis, MD, FASN Private Practice and Industry Kelly E. Guglielmi, MD, Anne Pesenson, MD, FASN, Catherine O. Stehman-Breen, MD
12:00 p.m.
Crafting a Personal Five-Year Action Plan (lunch provided) Donald E. Kohan, MD, PhD, FASN, Sandra P. Levison, MD
29
EARLY PROGRAMS
EARLY PROGRAMS
EARLY PROGRAMS
Breakout Sessions 1:00 p.m.
Career in Private Practice: Nuts and Bolts Mary Tessie Behrens, MD, FASN, Kelly E. Guglielmi, MD Contract and Salary Negotiations: Academia Ellie Kelepouris, MD Key Elements in Preparing Your CV Wendy Weinstock Brown, MD, Maria E. Ferris, MD, PhD
1:45 p.m.
Career in Private Practice: Nuts and Bolts (repeat) Mary Tessie Behrens, MD, FASN, Kelly E. Guglielmi, MD Contract and Salary Negotiations: Academia (repeat) Ellie Kelepouris, MD Key Elements in Preparing Your CV (repeat) Wendy Weinstock Brown, MD, Maria E. Ferris, MD, PhD
2:30 p.m.
How to Manage Toxic Environments Christine K. Abrass, MD Preparing a Winning Presentation Li-Li Hsiao, MD, PhD Writing Papers Julie R. Ingelfinger, MD, Mariela Mendez, PhD
3:15 p.m.
Break and 1:1 Mentoring
Breakout Sessions 3:45 p.m.
How to Manage Toxic Environments (repeat) Christine K. Abrass, MD Preparing a Winning Presentation (repeat) Li-Li Hsiao, MD, PhD Shaking the Funding Tree Wendy Weinstock Brown, MD, Julie R. Ingelfinger, MD, Reshma Kewalramani, MD, FASN, Nuria M. Pastor-Soler, MD, PhD, FASN, Tracy L. Rankin, PhD
4:30 p.m.
Contract and Salary Negotiations: Private Practice Mary Tessie Behrens, MD, FASN, Kelly E. Guglielmi, MD Writing Grants Donald E. Kohan, MD, PhD, FASN
5:15 p.m.
Contract and Salary Negotiations: Private Practice (repeat) Kelly E. Guglielmi, MD Writing Grants (repeat) Donald E. Kohan, MD, PhD, FASN Writing Papers (repeat) Julie R. Ingelfinger, MD, Mariela Mendez, PhD
6:00 p.m. 7:00 p.m.
Networking Reception
ASN designates this live activity for a maximum of 9.0 AMA PRA Category 1 CreditsTM.
30
THURSDAY, NOVEMBER 13, 2014
AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2014 DAY-AT-A-GLANCE 8:00 a.m. – 9:30 a.m. Page 34
Opening Plenary Session
9:30 a.m. – 10:00 a.m.
Morning Break
Exhibit Halls A-C
9:30 a.m. – 2:30 p.m.
Scientific Exposition and Posters Open
Authors will be available at their posters 10:00 a.m. - 12:00 p.m. Exhibit Halls A-C
10:30 a.m. – 12:30 p.m. Page 35 Page 36
Page 37 Page 37 Page 38
Clinical Nephrology Conferences
Are We Missing the Achilles Heel in Hemodialysis Survival? Ballroom A “Do You Want the Good or Bad News?” Counseling Your Patient about the New National Kidney Allocation Policy Room 204-C Lupus Nephritis: The Wheels Are Turning, but Are We Moving? Ballroom B Moving from Science into Practice to Care for People with CKD Room 113 Nephrology Quiz and Questionnaire Room 103
10:30 a.m. – 12:30 p.m. Page 38 Page 39 Page 40
Special Sessions
The World Stage of Kidney Disease—ASN/ISN Joint Session Room 108 Tweets, Likes, and Blogs: How to Use Social Media for Your Patients and Your Benefit Room 201-C What’s New in KDIGO Guidelines and Conferences Room 114
12:30 p.m. – 2:00 p.m.
Lunch Break
12:45 p.m. – 1:45 p.m.
Educational Symposia
Please refer to the Guide to Educational Symposia for titles and locations. Doors will open at 12:30 p.m. Lunch will be provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants. Philadelphia Marriott Downtown
31
THURSDAY
President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture Hall D
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m. Page 41
Page 41 Page 42 Page 42 Page 43 Page 43 Page 44 Page 45
Page 46 Page 46 Page 47 Page 47 Page 48 Page 49 Page 49 Page 50 Page 51 Page 51
Basic and Clinical Science Symposia
A Glomerulus Potpourri: It’s All about the Podocyte, Including the Barry M. Brenner, MD, Endowed Lectureship Room 113 A Riddle Wrapped in a Mystery inside an Enigma: The Mitochondria in AKI Room 201-A Amyloidosis and the Kidney: Novel Discoveries and Therapies Room 115-C Belatacrolizumab XL: The Latest Potpourri of Emerging Immunosuppression Room 204-C Circadian Pacemakers in Health and Diseases Room 109 Dialysis in the Old World: Is It Time to Implement in the New World? Ballroom A Getting to the Action: Renal Microphages and Dendritic Cells in Homeostasis and Injury Room 108 Keeping the Tubule in Shape: Preventing Cyst Growth in PKD, Including the Robert W. Schrier, MD, Endowed Lectureship Room 119-B Residual Cardiovascular Disease Risk in CKD Ballroom B SGLT2 Inhibition: From Basic to Clinical Room 114 Stem Cells in Kidney Regeneration Room 103 Sweet Beginnings: New Targets for Diabetic Nephropathy Room 201-C The Brain behind the Bones: Osteocytes in Renal Osteodystrophy Room 119-A The Inflammasomes: Novel Players of the Intercellular Cross-Talk Room 118-C The Road Less Traveled: Evolving Therapeutic Pathways in AKI Room 202 Ubiquitin Meets Kidney Salt Transport and Blood Pressure Regulation Room 111 Unconfound It! Strategies in Comparative Effectiveness Research Room 118-B When Our Care System Fails to Care for Kidney Patients Room 105
2:00 p.m. – 4:00 p.m. Page 52
Page 53
Page 54
Special Sessions
Patient-Centric Clinical Trial and Regulatory Pathways: Patient-Reported Outcomes and Patient Preferences Room 107 The Dialysis Outcomes and Practice Patterns Study Program: Newest Findings and Expanded Scope Room 204-A The Future Direction of Nephrology: How Shall We Live Long and Prosper?, Including the Christopher R. Blagg, MD, Lectureship in Renal Disease and Public Policy Room 115-B
4:00 p.m. – 4:30 p.m.
Afternoon Break
Foyers of Room 108, Room 118, Room 201, and Ballroom
32
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m. Page 55 Page 55 Page 56 Page 56
4:30 p.m. – 6:30 p.m. Page 58 Page 59 Page 60 Page 61 Page 62 Page 63 Page 64 Page 65 Page 66 Page 67 Page 68 Page 69 Page 70 Page 71 Page 72 Page 73 Page 74 Page 75 Page 76
Oral Abstract Sessions
Advances in Understanding PKD Pathogenesis Room 118-C Advances in Vascular Biology Room 105 AKI: Cellular Responses to Injury and Repair - I Room 107 AKI: Interventions, Biomarkers, Genetics, and More Room 108 Bioengineering Advances for Next-Generation Renal Replacement Technologies Room 115-C CKD: Epidemiology and Outcomes Room 202 Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases Room 201-A Glomerular Biomarkers: Progress and Pitfalls Room 114 Hemodialysis for ESRD: Techniques and Vascular Access Room 204-A Hypertension: Novel Biomarkers and Target Organ Damage Room 111 Mineral Disease: Vitamin D, PTH, and FGF-23 Room 115-B Na+, K+, and Cl- Basic Room 203 New Mechanisms in Renal Injury Room 119-B New Perspectives on Permeability and the Glomerular Barrier Room 119-A Pathogenesis, Risk Factors, and Improving Cardiovascular Outcomes in Dialysis Patients Room 204-C Renal Epithelial Biology in Diabetes Room 118-B Renal Inflammation: Novel Mechanisms and Therapeutic Targets Room 109 Translational Transplantation Room 104 Transplantation: Basic and Experimental Room 112
33
THURSDAY
Page 57
Clinical Nephrology Conferences
Becoming the Biggest Loser: Obese Transplant Recipients Room 103 Blood Pressure in Dialysis: Striking a Balance between Highs and Lows Ballroom A High-Risk Groups for Diabetic Kidney Disease: Who Are They and What to Do? Room 113 Kidney–Liver Service 911 Ballroom B Pediatric Nephrology: 2014 Update Room 201-C
THURSDAY, NOVEMBER 13, 2014 8:00 a.m. – 9:30 a.m.
Opening Plenary Session
President’s Address, ASN Diamond Level Corporate Supporters Recognition, State-of-the-Art Lecture Hall D
Supported by an independent educational grant from Akebia Therapeutics.
Upon completion of this session, the participant will be able to describe the influence of stem cells in understanding and treating diabetes. 8:00 a.m.
President’s Address Sharon M. Moe, MD, FASN
8:35 a.m.
ASN Diamond Level Corporate Supporters Recognition
8:45 a.m.
State-of-the-Art Lecture “Stem Cells to Understand and Treat Diabetes” Douglas A. Melton, PhD
10:00 a.m. – 12:00 p.m.
Poster Presentations Exhibit Halls A-C
AKI: Risk Factors (001-028) Fellows Case Reports: AKI and Interstitial Nephritis (029-081) AKI: Biomarkers (082-129) AKI: Basic – Fresh Takes on Classic Models (130-179) AKI: Basic Repair (180-210) Cell Signaling/Oxidative Stress (211-248) Stem Cells and Regeneration (249-280) New Approaches to Genetic Kidney Diseases (281-319) Renal Immunology and Inflammation (320-369) Clinical/Diagnostic Renal Pathology: Glomerular Disorders and Diabetic Nephropathy (370-415) Glomerular and Tubulointerstitial Disease: Clinical Trials and Outcomes (416-460) Diabetes Mellitus and Obesity: Basic/Experimental - I (461-504) Hypertension: Renal Transport, Salt Sensitivity, RAAS, and Renal Nerves (505-534) Vascular Calcification - I (535-564) Mineral Disease: Vitamin D, PTH, and FGF-23 - I (565-590) Mineral Disease: CKD-Bone (591-622) CKD: Complications - I (623-672) CKD: Epidemiology and Outcomes - I (673-720) Novel Interventions and Screening Approaches to Prevent CKD (721-749) Fellows Case Reports: Dialysis (750-777) Hemodialysis for ESRD (778-813) Dialysis: Anemia and Iron Metabolism (814-860) Dialysis: Epi, Outcomes, Trials – Noncardiovascular - I (861-923) Peritoneal Dialysis - I (924-973) Patient Safety (974-995) Pediatric Nephrology (996-1031) Kidney Donor and Recipient Outcomes in Transplantation: Novel Risk Factors (1032-1081) Transplant Epidemiology and Health Services Research (1082-1131)
Please note that this book contains poster sessions but not individual abstract titles and authors. For abstract titles, authors, and more, please refer to the Kidney Week Mobile App, the “Locate Me” Kiosks for Posters and Exhibits in the exposition halls, or the Abstract Supplement pdf at www.asn-online.org/KidneyWeek.
34
THURSDAY, NOVEMBER 13, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Are We Missing the Achilles Heel in Hemodialysis Survival? Ballroom A
Upon completion of this session, the participant will be able to: 1) describe some of the main contributors to mortality in hemodialysis; 2) explain how to alter clinical practices and mitigate the effect of these factors; and 3) discuss the importance of residual kidney function in the survival of ESRD patients. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Systems-based Practice Moderators: Raymond M. Hakim, MD, PhD, and Nathan W. Levin, MD 10:30 a.m.
Get This Catheter Out! Jay B. Wish, MD
11:00 a.m.
It Is Good to the Last Drop: How to Preserve Residual Kidney Function in ESRD Patients Anthony J. Bleyer, MD, FASN
11:30 a.m.
PD First: Is It Possible? Jeffrey Perl, MD
12:00 p.m.
Should We Focus on “t” Regardless of the Kt/V? Jennifer E. Flythe, MD, FASN
35
THURSDAY
Despite monumental efforts, survival on hemodialysis has barely improved in the United States over the last decade. First-year mortality, particularly the initial 90 days, is still remarkably high. Initiating HD with central venous catheters still plagues the nephrology community. Are we focusing enough on critical factors that have the potential of paying large dividends? The experts in this session address this important topic.
THURSDAY, NOVEMBER 13, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
“Do You Want the Good or Bad News?” Counseling Your Patient about the New National Kidney Allocation Policy Room 204-C
After multiple failed amendment efforts, the national policy for allocation and utilization of deceased donor kidneys has recently been substantially revised. This session examines the new policy and the rationale for the change, considers its pros and cons, and provides guidance for nephrologists in counseling their patients. Upon completion of this session, the participant will be able to: 1) describe the new kidney allocation policy; 2) discuss the advantages and disadvantages of the new allocation policy; and 3) outline how to counsel patients that want, or are offered, a deceased donor kidney transplant. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Nicolae Leca, MD, FASN, and Titte Srinivas, MD 10:30 a.m.
What Are the New Kidney Allocation Rules and Why Were They Implemented? John J. Friedewald, MD
11:00 a.m.
The New Kidney Allocation System: Pros Alan B. Leichtman, MD
11:30 a.m.
The New Kidney Allocation System: Cons Lainie Friedman Ross, MD, PhD
12:00 p.m.
What Does the New Allocation System Mean for My Patient? Michelle A. Josephson, MD
36
THURSDAY, NOVEMBER 13, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Lupus Nephritis: The Wheels Are Turning, but Are We Moving? Ballroom B
Upon completion of this session, the participant will be able to: 1) identify new aspects of pathogenesis of lupus nephritis patients in your practice that may help guide therapy; 2) interpret the results of randomized lupus nephritis trials to determine optimal treatment for lupus nephritis patients in your practice; 3) examine the rationale for new therapies for lupus nephritis; and 4) identify measures to improve outcomes of pregnant lupus nephritis patients. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Gabriel Contreras, MD, and Michael P. Madaio, MD 10:30 a.m.
Role of Interstitial Inflammation in the Pathogenesis of Lupus Nephritis Marcus Clark, MD
11:00 a.m.
What Have We Learned from the Recent Randomized Trials in Lupus Nephritis? Brad H. Rovin, MD, FASN
11:30 a.m.
Novel Targets for the Basis of Biologic Therapies for Lupus Nephritis Jai Radhakrishnan, MD, FASN
12:00 p.m.
Optimizing Outcomes of Pregnancy in Patients with Lupus Nephritis Derek M. Fine, MD
10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Moving from Science into Practice to Care for People with CKD Room 113
This session describes recent studies designed to translate learnings from clinical trials to practical applications in the clinic and community. The focus is on a portfolio of studies aimed at creative methods for addressing high-risk groups and incorporating scientific knowledge into daily practice in the real world. Upon completion of this session, the participant will be able to: 1) discuss risks of hospitalization and potential safety indicators tailored to the CKD population; 2) describe a navigator program designed for people with CKD within a health care system; and 3) describe new approaches using “smart” technology to eliminate disparities and deliver high-quality CKD care to people in safety-net health care systems. Core Competency: Patient Care and Procedural Skills, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Neil R. Powe, MD, FASN, and Miguel A. Vazquez, MD, FASN 10:30 a.m.
Risks of Hospitalization in CKD: Do the Same Rules Apply for Patient Safety? Jeffrey C. Fink, MD, FASN
11:10 a.m.
How Navigators Facilitate Delivery of CKD Health Care in Complex Systems Joseph V. Nally, MD
11:50 a.m.
The “Smart” Way to Eliminate Disparities and Deliver High-Quality CKD Health Care in Safety-Net Systems Delphine S. Tuot, MD
37
THURSDAY
Lupus nephritis occurs in most patients with SLE, with 5–20% developing ESRD despite appropriate treatment. This session provides an update on the pathogenesis of lupus nephritis. The session also reviews recent randomized trials, as well as the rationale for new biologic treatments. Optimizing the outcome of pregnant patients with lupus nephritis is also discussed.
THURSDAY, NOVEMBER 13, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Nephrology Quiz and Questionnaire Room 103
The Nephrology Quiz and Questionnaire is an interactive session that begins with a case presented by an expert, followed by several quiz questions for the audience. The topics covered include electrolytes, glomerulonephritis, transplantation, and renal replacement therapy (RRT). Upon completion of this session, the participant will be able to: 1) describe the management of electrolyte disorders; 2) describe recent clinical advances in transplant; 3) discuss recent advances in glomerulonephritis; and 4) describe recent issues in RRT. Core Competency: Medical Knowledge Moderators: Michael J. Choi, MD, and Mark A. Perazella, MD, FASN 10:30 a.m.
Transplantation Cases Michelle A. Josephson, MD
11:00 a.m.
Electrolyte Cases Mitchell H. Rosner, MD, FASN
11:30 a.m.
Glomerulonephritis Cases Andrew S. Bomback, MD
12:00 p.m.
RRT Cases Rajnish Mehrotra, MD, FASN
10:30 a.m. – 12:30 p.m.
Special Session
The World Stage of Kidney Disease—ASN/ISN Joint Session Room 108
ASN thanks the International Society of Nephrology for assistance with this session.
This session aims to bring the global nephrology community together to save young lives. Lecture topics explore the “0 by 25” AKI initiative, which was developed to end all deaths in children and young adults from untreated AKI by the year 2025. Experts address leading major public health issues in less fortunate countries, providing invaluable insights to renal disease in the western hemisphere and allowing the development of action plans to reduce the burden of kidney disease. Upon completion of this session, the participant will be able to: 1) discuss the ISN’s “0 by 25” AKI initiative; 2) discuss the role of fetal and child health in the long-term risk of hypertension and kidney disease; and 3) examine the explosion of diabetes in the development world and discuss the causes and implications. Core Competency: Medical Knowledge; System-based Learning and Improvement Moderators: Thomas M. Coffman, MD, FASN, and Ricardo Correa-Rotter, MD 10:30 a.m.
The “0 by 25” AKI Initiative: Presidential Vision Giuseppe Remuzzi, MD
11:00 a.m.
The “0 by 25” AKI Initiative: Time to Make a Difference Ravindra L. Mehta, MD, FASN
11:30 a.m.
Healthy Babies for Healthy Kidneys Valerie A. Luyckx, MD
12:00 p.m.
Stopping Diabetic Nephropathy Worldwide Vivekanand Jha, MD
38
THURSDAY, NOVEMBER 13, 2014 10:30 a.m. – 12:30 p.m.
Special Session
Tweets, Likes, and Blogs: How to Use Social Media for Your Patients and Your Benefit Room 201-C
Upon completion of this session, the participant will be able to: 1) describe how social media is reshaping medical education, patient–physician relationships, and patient empowerment; 2) discuss the permanence and searchability of casual conversation on social media and the implications that violating privacy can have; 3) show how patients use social media to collaborate to route around roadblocks in medical care; 4) describe how social media opens new avenues for creative medical education; and 5) describe how to get started using social media. Core Competency: Medical Knowledge Moderators: Kenar D. Jhaveri, MD, FASN, and Matthew A. Sparks, MD, FASN 10:30 a.m.
The Public Physician: The Emerging Role of the Physician in a Connected, Always-On World Bryan S. Vartabedian, MD
11:00 a.m.
Social Media Challenges to Professionalism: Do the Rules Change or Do We Change Social Media? Margaret S. Chisolm, MD
11:30 a.m.
Patients Turning Likes and Retweets into Healing: Social Media and the Age of the Empowered ePatient Sarah E. Kucharski
12:00 p.m.
Social Media: How to Get Started Joel Topf, MD
39
THURSDAY
Social media is transforming medical education, physician–patient relationships, and the dissemination of medical information. There are more than 30 nephrology blogs and dozens of dialysis patient blogs. In this session, the use of social media in medical education and patient empowerment is discussed. The permanence of information on social media and related privacy issues are examined. In this session, leaders in the field of social media discuss the impact that social media is having in medical care and patient empowerment.
THURSDAY, NOVEMBER 13, 2014 10:30 a.m. – 12:30 p.m.
Special Session
What’s New in KDIGO Guidelines and Conferences Room 114
ASN thanks Kidney Disease Improving Global Outcomes for assistance with this session.
KDIGO has published nine guidelines and held 16 Controversies Conferences to date. In this session, KDIGO reports on its latest activities, presenting recommendations from the recent Controversies Conference on the Management of Iron Therapy in CKD, plans for an upcoming Controversies Conference on the Management of Diabetes in CKD Patients, and the status of two Guidelines under development on CKD-MBD and Living Kidney Donors. Upon completion of this session, the participant will be able to: 1) discuss plans on an upcoming KDIGO Conference on diabetes care in the CKD patients; 2) describe recommendations from the KDIGO Management of Iron Therapy Conference; 3) discuss the KDIGO Guideline update on CKDMBD; and 4) report on KDIGO’s next guideline on Living Donors. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Bertram L. Kasiske, MD, and David C. Wheeler, MD 10:30 a.m.
CKD-MBD Guideline Update Markus Ketteler, MD
11:00 a.m.
Guideline on Living Donors Amit X. Garg, MD, PhD, Krista L. Lentine, MD, PhD, FASN
11:30 a.m.
Management of Iron Therapy Conference Iain C. Macdougall, MD
12:00 p.m.
Diabetes in the CKD Patient Conference Vlado Perkovic, MBBS, FASN
40
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
A Glomerulus Potpourri: It’s All about the Podocyte, Including the Barry M. Brenner, MD, Endowed Lectureship Room 113
ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Barry M. Brenner, MD, Endowed Lectureship.
Upon completion of this session, the participant will be able to: 1) describe the significance of ApoL1 in kidney disease; 2) discuss the current understanding of ApoL1 in the podocyte; 3) describe the role of vesicular trafficking in podocyte function; 4) discuss the role of calcium channels in the podocyte; and 5) describe the rationale behind CTLA4 therapy in FSGS. Core Competency: Medical Knowledge Moderators: Lawrence B. Holzman, MD, and Stuart J. Shankland, MD, FASN 2:00 p.m.
Apol1 and Glomerular Disease—The Barry M. Brenner, MD, Endowed Lectureship Martin R. Pollak, MD
2:30 p.m.
Vesicular Trafficking in the Podocyte Shuta Ishibe, MD
3:00 p.m.
Calcium Channels in the Podocyte Anna Greka, MD, PhD
3:30 p.m.
The Role of Apol1 in Podocytes John R. Sedor, MD, FASN
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
A Riddle Wrapped in a Mystery inside an Enigma: The Mitochondria in AKI Room 201-A
The mitochondria play a central role in cellular energetics during both physiologic and pathologic states. This session highlights novel findings on the role of the mitochondria in the pathogenesis of AKI. Upon completion of this session, the participant will be able to: 1) describe the interplay of genetics and bioenergetics on mitochondrial function during injury; 2) integrate recent developments in mitochondrial dysfunction into the pathophysiology of AKI; and 3) identify therapeutic aspects of targeting the mitochondria in AKI. Core Competency: Medical Knowledge Moderators: Takashi Hato, MD, and Wilfred Lieberthal, MD 2:00 p.m.
Mitochondrial Bioenergetics during Injury and Disease Douglas C. Wallace, PhD
2:30 p.m.
Glycogen Synthase Kinase 3b and the Regulation of Mitochondrial Alterations in AKI Rujun Gong, MD, PhD
3:00 p.m.
Regulating Mitochondrial Biogenesis in AKI Rick G. Schnellmann, PhD
3:30 p.m.
Therapeutic Targeting of the Mitochondria during Injury Hazel H. Szeto, MD, PhD
41
THURSDAY
This session focuses on recent progress in glomerular research. Our current understanding of ApoL1 is covered, as is recent work on the cell biology of the podocyte. This progress may lead to new therapeutic strategies for diseases such as FSGS.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Amyloidosis and the Kidney: Novel Discoveries and Therapies Room 115-C
The introduction of proteomics as a diagnostic tool is not only leading to a more precise diagnosis of amyloidosis, but also to the discovery of novel types of amyloid. Furthermore, advances in understanding the molecular mechanisms of amyloid deposition are improving therapeutic possibilities. The session guides the audience through novel discoveries from molecular bases and animal/cellular models to novel therapies. Upon completion of this session, the participant will be able to: 1) describe amyloid deposition; 2) describe amyloidosis diagnosis; and 3) discuss novel and perspective therapies. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Maria M. Picken, MD, PhD, FASN, and Guy Touchard, MD 2:00 p.m.
The Formation of Amyloid: Amyloidogenic Properties of Different Proteins Vittorio Bellotti, MD, PhD
2:30 p.m.
Animal Models and Cell Culture Systems Ioannis Petrakis, MD
3:00 p.m.
Diagnosis and Typing: Histochemistry and Proteomics Samih H. Nasr, MD
3:30 p.m.
Design of Targeted Molecules and Innovative Drugs Merrill D. Benson, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Belatacrolizumab XL: The Latest Potpourri of Emerging Immunosuppression Room 204-C
Enhanced efficacy of currently used immunosuppression regimens has slowed the development of novel agents. This session examines emerging therapies, emphasizing the impact on improving adherence, targeting antibody-mediated injury, and finding achievable clinical end points to foster a future pipeline. Upon completion of this session, the participant will be able to: 1) describe the alloimmune response and the basis for selection of specific targets; 2) discuss the efficacy and safety of new and emerging T-cell therapies and their impact on adherence; 3) describe novel and emerging therapies to treat and prevent antibody-mediated injury; and 4) list issues related to the development of clinical trial end points for emerging immunosuppressive therapies. Core Competency: Medical Knowledge Moderators: Daniel C. Brennan, MD, and Karin A. True, MD, FASN 2:00 p.m.
Transplant Immunobiology for the Clinician: Identifying Potential Targets Milagros D. Samaniego-Picota, MD, FASN
2:30 p.m.
Emerging T-Cell Therapies in Transplantation Alexander C. Wiseman, MD
3:00 p.m.
Therapies for Preventing and Treating Antibody-Mediated Injury Arjang Djamali, MD, FASN
3:30 p.m.
Clinical Trial End Points for Emerging and Future Therapies Greg A. Knoll, MD
42
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Circadian Pacemakers in Health and Diseases Room 109
Supported by an independent educational grant from AbbVie.
Upon completion of this session, the participant will be able to: 1) describe the role of CLOCK genes in renal physiology; 2) discuss the role of CLOCK genes in inflammation; 3) describe the role of CLOCK genes in diabetes; and 4) discuss the role of CLOCK genes in cardiometabolic function. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Michelle L. Gumz, PhD, and David M. Pollock, PhD, FASN 2:00 p.m.
Control of Physiology and Behavior by Circadian Clocks Amita Sehgal, PhD
2:30 p.m.
CLOCK Genes in Renal Physiology Michelle L. Gumz, PhD
3:00 p.m.
Circadian Rhythm in Diabetes Joseph T. Bass, MD, PhD
3:30 p.m.
CLOCK Genes in Immune Cells John B. Hogenesch, PhD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Dialysis in the Old World: Is It Time to Implement in the New World? Ballroom A
This session updates the attendees regarding the application, benefits, and risks of different hemodialytic techniques including on-line hemodiafiltration and high-flux dialysis. Upon completion of this session, the participant will be able to: 1) describe the intricacies of different dialytic techniques; 2) discuss the potential benefits and limitations of high-flux dialysis and on-line hemodiafiltration; 3) identify ways to implement new dialytic techniques into clinical practice; and 4) discuss the economic considerations in dialysis modality selection. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Martin K. Kuhlmann, MD, and Jennifer M. MacRae, MD 2:00 p.m.
From High-Flux Dialysis to Hemodiafiltration Claudio Ronco, MD
2:30 p.m.
Online Hemodiafiltration: Efficacy on Clinical Outcomes Peter J. Blankestijn, MD, FASN
3:00 p.m.
Putting It Together: Should We, and How Can We, Implement New Dialytic Therapies into Clinical Practice Andrew Davenport, MD
3:30 p.m.
Economic Considerations in Dialysis Modality Selection Scott Klarenbach, MD
43
THURSDAY
This session summarizes the current understanding of the role of CLOCK genes and circadian rhythm in renal physiology, metabolism, and inflammation.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Getting to the Action: Renal Microphages and Dendritic Cells in Homeostasis and Injury Room 108
Infiltrating and resident leukocytes are central to kidney homeostasis and the way it senses and responds to injury. Recent data have revolutionized the understanding of these processes and have identified novel leukocyte subsets and characterized some of the interactions between them and intrinsic renal cells. This session summarizes this fast evolving field and emphasizes the implications of the new data for renal disease and its treatment. Upon completion of this session, the participant will be able to: 1) describe the mechanism of neutrophil glomerular recruitment; 2) discuss the distinct role of monocyte subsets in sensing and executing kidney injury; 3) describe the interactions between endothelium and leukocytes in controlling glomerular injury; and 4) describe the anatomical location of renal mononuclear cells influences their function. Core Competency: Medical Knowledge Moderators: Matthew D. Griffin, MbChB, and Peter J. Nelson, MD, FASN 2:00 p.m.
A New Paradigm for Recruiting Glomerular Neutrophils A. Richard Kitching, PhD, MBChB, FASN
2:30 p.m.
Patrolling Monocytes and Microvascular Injury in the Kidney Frederic Geissmann, MD, PhD
3:00 p.m.
TNF and the Control of Endothelial Signals Required for Glomerular Leukocyte Recruitment Tanya N. Mayadas, PhD
3:30 p.m.
Selective Leukocyte Recruitment by Functionally Distinct Renal Dendritic Cells Christian Kurts, PhD
44
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Keeping the Tubule in Shape: Preventing Cyst Growth in PKD, Including the Robert W. Schrier, MD, Endowed Lectureship Room 119-B
ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Robert W. Schrier, MD, Endowed Lectureship.
Upon completion of this session, the participant will be able to: 1) describe the role of cilia in cyst progression; 2) discuss the importance of tubule cell proliferation in cyst growth; and 3) report signaling pathways that are important for cyst growth. Core Competency: Medical Knowledge Moderators: Leonidas Tsiokas, PhD, and Jing Zhou, MD, PhD, FASN 2:00 p.m.
TNF Signaling in ADPKD Xiaogang Li, PhD
2:30 p.m.
Cilia as a Positive Signal for Cyst Growth Stefan Somlo, MD
3:00 p.m.
Proliferation and Cyst Growth in PKD Bradley K. Yoder, PhD
3:30 p.m.
MicroRNAs That Slow Cyst Progression—The Robert W. Schrier, MD, Endowed Lectureship Peter Igarashi, MD, FASN
45
THURSDAY
This session focuses on our current understanding of the forces that promote progressive growth of cysts in PKD and on novel approaches to slow cyst growth. The session covers novel roles of cilia signaling in activating cell growth pathways and the role of cell proliferation in the process of cyst enlargement. The signaling pathways involved in promoting cyst development and their epigenetic regulation are covered.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Residual Cardiovascular Disease Risk in CKD Ballroom B
This session aims to update the attendees regarding the most recent advances in cardiovascular (CV) disease risk and treatment in CKD patients. Upon completion of this session, the participant will be able to: 1) describe the most recent developments in HDL function in CKD/ESRD; 2) discuss the relevant importance of sudden death versus atherosclerosis in CKD/ESRD; 3) interpret the results of the SHARP study as they relate to CKD and ESRD patients; and 4) discuss the most recent advances in CV therapies and their implications in CKD patients. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Angela Yee Moon Wang, MD, PhD, and David C. Wheeler, MD 2:00 p.m.
HDL (Dys)Function in CKD Valentina Kon, MD
2:30 p.m.
EVOLVE Study and Implications for CVD in ESRD Patrick S. Parfrey, MD, FASN
3:00 p.m.
SHARP Study and Implications for CVD in CKD Andrzej Wiecek, MD, PhD
3:30 p.m.
Residual CVD Risk Reduction Initiative: What Is in the Horizon for CKD? Christoph Wanner, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium SGLT2 Inhibition: From Basic to Clinical Room 114
Supported by an independent educational grant from AbbVie.
This session reviews in a bench-to-bedside manner a new class of glucose-lowering drugs known as the SGLT inhibitors, which act primarily on renal glucose transport. Upon completion of this session, the participant will be able to: 1) describe the mechanism of action of these drugs and the safety issues that are relevant to this drug class; and 2) discuss the metabolic, renal, and cardiovascular effects of these drugs that are being monitored in ongoing major clinical trials. Core Competency: Medical Knowledge Moderators: Richard E. Gilbert, MD, PhD, and Carol A. Pollock, MD, PhD 2:00 p.m.
Overview of SGLT2 Inhibitors Ralph A. DeFronzo, MD
2:30 p.m.
Role of SGLT2 in Regulation of Renal Function in Diabetes David Cherney, MD, PhD
3:00 p.m.
Cardiovascular, Metabolic, and Renal Aspects of SGLT2 Inhibitors Ele Ferrannini, MD, PhD
3:30 p.m.
Safety Issues of These Agents Rajiv Agarwal, MD, MBBS, FASN
46
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Stem Cells in Kidney Regeneration Room 103
Upon completion of this session, the participant will be able to describe the recent advances in stem cell research as it relates to kidney regeneration. Core Competency: Medical Knowledge, Systems-based Practice Moderators: Laura Perin, PhD, and Takashi Yokoo, MD, PhD 2:00 p.m.
Renewable Nephron Progenitors from iPS Cells Juan Carlos Izpisua Belmonte, PhD
2:40 p.m.
Use of Silk Scaffolds to Engineer 3-D Tubules David Kaplan, PhD
3:20 p.m.
Repairing the Injured Heart through Reprogramming of Fibroblasts Eric Olson, PhD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Sweet Beginnings: New Targets for Diabetic Nephropathy Room 201-C
Supported by an independent educational grant from AbbVie.
This session reviews new treatments for diabetic renal disease that are currently in phase 2 and 3 clinical trials. Upon completion of this session, the participant will be able to describe new approaches for the treatment of subjects with moderate or advanced diabetic kidney disease. Core Competency: Medical Knowledge Moderators: Dick de Zeeuw, MD, PhD, and Masakazu Haneda, MD, PhD 2:00 p.m.
Incretin Pathway in Diabetes and Nephropathy Jean-Francois Yale, MD
2:30 p.m.
Vascular Protective Therapy for Diabetic Complications Kevin G. Peters, MD
3:00 p.m.
ET Antagonism in DN Donald E. Kohan, MD, PhD, FASN
3:30 p.m.
JAK Inhibitors in DN Frank C. Brosius, MD
47
THURSDAY
Stem cell research has assumed a breathtaking dynamic and allows for prospects unthinkable until very recently. This session discusses the emerging role of stem cells in the field of nephrology. In particular, it covers the role of stem cells in the development of renal disease models, kidney regeneration, and the development of complex three-dimensional organ structures.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
The Brain Behind the Bones: Osteocytes in Renal Osteodystrophy Room 119-A
Supported by an independent educational grant from OPKO Health Renal Division.
Osteocytes are a key regulator of bone formation and secrete fibroblast growth factor-23 (FGF23), a regulator of phosphate homeostasis and sclerostin, a Wnt antagonist. These bone-produced hormones regulate osteoblast activity, placing osteocytes in a central regulatory role of CKD-MBD. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) state the endocrine functions of the osteocyte; 2) describe how parathyroid hormone (PTH) regulates osteocyte and FGF23 synthesis; and 3) discuss the role of sclerostin as a marker of bone health and disease. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Renata C. Pereira, PhD, and Susan C. Schiavi, PhD 2:00 p.m.
Osteocyte: An Endocrine Organ Lynda Bonewald, PhD
2:30 p.m.
Osteocytes: Where PTH and Sclerostin Meet Robert L. Jilka
3:00 p.m.
Osteocyte Regulation in Renal Osteodystrophy Rosa M.A. Moyses, MD, PhD
3:30 p.m.
Circulating Sclerostin as a Marker of Bone Health and Disease Tamara Isakova, MD
48
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
The Inflammasomes: Novel Players of the Intercellular Cross-Talk Room 118-C
Upon completion of this session, the participant will be able to describe and discuss inflammation, immunology, and metabolic disorders. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Daniel A. Muruve, MD, and Masaomi Nangaku, MD, PhD 2:00 p.m.
The Inflammasomes: An Overview Daniel A. Muruve, MD
2:30 p.m.
The Inflammasome in Obesity and Diabetes Berend Heinrich Isermann, MD
3:00 p.m.
The Inflammasome in Autoimmunity Seth L. Masters, PhD
3:30 p.m.
The Inflammasome and the Kidney Hans J. Anders, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
The Road Less Traveled: Evolving Therapeutic Pathways in AKI Room 202
Integration of pathophysiologic pathways in AKI is an expanding area highlighting new therapeutic targets. This session highlights emerging concepts and pathways in the pathogenesis of AKI. Upon completion of this session, the participant will be able to: 1) describe the role of histone deacetylase in AKI; 2) discuss the importance of tubular cross-talk in AKI; and 3) identify mechanisms for necrosis and sensing energy flux at the cellular level. Core Competency: Medical Knowledge Moderators: Karl A. Nath, MD, and Babu J. Padanilam, PhD 2:00 p.m.
Tubular Cross-Talk in the Pathophysiology of AKI Tarek M. El-Achkar, MD, FASN
2:30 p.m.
Histone Deacetylase (HDAC) Inhibition as a Therapeutic Target in AKI Neil A. Hukriede, PhD
3:00 p.m.
Therapeutic Interference with Regulated Necrosis: Relative Contribution of Necroptosis, Ferroptosis, and Mitochondrial Permeability Transition Joel M. Weinberg, MD
3:30 p.m.
AMP Kinase and the Regulation of Cell Metabolism following Kidney Injury Kenneth R. Hallows, MD, PhD, FASN
49
THURSDAY
The inflammasomes are signaling platforms, which are assembled in response to pathogen-associated and damage-associated molecules and environmental stimuli. In particular, the NLRP3 inflammasome is able to sense stress signals coming from endogenous changes. This session explores recent findings on the involvement of inflammasomes in immunological and metabolic disorders, including diseases of the kidney.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Ubiquitin Meets Kidney Salt Transport and Blood Pressure Regulation Room 111
Recent studies revealed ubiquitin-mediated pathways for regulating the sodium-chloride cotransporter (NCC), the molecular target of the thiazide diuretics, and its WNK kinase regulators in health and hypertension. This session highlights recent exciting breakthrough studies. Upon completion of this session, the participant will be able to: 1) discuss the identification of new genes in pseudohypoaldosteronism type II, encoding a cullin ubiquitin complex; 2) describe a surprising new role for ubiquitin ligase NEDD4-2 in the controlling blood pressure through the regulation of NCC rather than ENaC; and 3) discuss how misfolded NCC proteins in Gitelman syndrome are processed by endoplasmic reticulum–associated degradation. Core Competency: Medical Knowledge Moderators: Sebastian Bachmann, PhD, and David H. Ellison, MD, FASN 2:00 p.m.
Mutations in the Kelch-Like 3/Cullin 3 Ubiquitin Ligase Complex Cause Hypertension and Electrolyte Abnormalities Richard P. Lifton, MD, PhD
2:30 p.m.
Impaired KLHL3-Mediated Ubiquitination of WNK4 Causes Human Hypertension Shinichi Uchida, MD, PhD
3:00 p.m.
NEDD4-2 Deficiency and NCC-Mediated Salt-Dependent Hypertension Olivier Staub, PhD
3:30 p.m.
Multichaperone Complexes Target NCC for Endoplasmic Reticulum-Associated Degradation Arohan R. Subramanya, MD, FASN
50
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Unconfound It! Strategies in Comparative Effectiveness Research Room 118-B
Upon completion of this session, the participant will be able to: 1) describe the rationale for conducting postmarketing comparative-effectiveness drug studies using health care utilization databases and the threats to validity with observational approaches; 2) discuss strategies and new approaches to reduce bias and improve validity of results in postmarketing comparative-effectiveness studies including propensity score methodologies, instrumental variables, and new user approaches; and 3) list specific examples of how each of these approaches has been used to reduce confounding in comparative-effectiveness and safety studies. Core Competency: Patient Care and Procedural Skills, Medical Knowledge Moderators: Brian D. Bradbury, DSc, and Wolfgang C. Winkelmayer, MD, ScD, FASN 2:00 p.m.
Propensity Score Approaches to Reduce Confounding: High-Dimensional Propensity Score, Multiple Groups Jeremy A. Rassen, ScD
2:40 p.m.
Finding the Right Instrument: Using an Instrumental Variable Approach in CER M. Alan Brookhart, PhD
3:20 p.m.
New User Designs and Other Methods to Reduce Misclassification Bias in Comparative Effectiveness and Safety Studies Adriana Hung, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
When Our Care System Fails to Care for Kidney Patients Room 105
This session discusses the social determinants of disparities in CKD. Upon completion of this session, the participant will be able to: 1) discuss how health care systems influence health status of people with CKD; 2) describe current evidence regarding health care systems impact on people with CKD/ESRD; and 3) explain health care system redesign as way to improve health status of people with CKD/ESRD. Core Competency: Medical Knowledge Moderators: William M. McClellan, MD, and Carmen A. Peralta, MD 2:00 p.m.
Special Lecture: What Does Social Science Tell Us about How Health Care Systems Affect Cardiovascular Health Lisa A. Cooper, MD
2:50 p.m.
Access to Health Care and Risk of CKD Carmen A. Peralta, MD
3:25 p.m.
Dialysis for Uninsured Immigrants: Care, Costs, and Controversies Rudolph A. Rodriguez, MD
51
THURSDAY
Comparative effectiveness research (CER) using health care utilization databases strives to provide head-to-head comparisons of drugs or other therapies on important clinical outcomes. However, confounding by selective prescribing based on indication for therapy, severity of illness, or disease prognosis often threatens the validity of results from these nonrandomized studies. This session uses recent examples to describe newer epidemiologic approaches that can reduce residual confounding and improve validity of findings.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Special Session
Patient-Centric Clinical Trial and Regulatory Pathways: Patient-Reported Outcomes and Patient Preferences Room 107
ASN thanks the Kidney Health Initiative for assistance with this session.
This session focuses on the optimization of clinical trial and regulatory pathways through the incorporation of patient-reported outcomes and patient preferences into this process. Topics include an initial overview of the use of patient-reported outcomes as a clinical trial end point, followed by the specific use of patient-reported outcomes in nephrology. The use of patient preferences to develop insight into the patient’s perspective on the sort of benefits that they truly want from novel therapies is then described. Finally, there is a discussion on the use of patient preferences to enhance the regulatory pathway for renal drugs and devices. Upon completion of this session, the participant will be able to: 1) describe the use of patient-reported outcomes as an important clinical trial end point; 2) illustrate effective and pragmatic patient-reported outcomes for kidney diseases; 3) report how patient preferences can be incorporated into regulatory guidelines; and 4) identify patient preferences for drugs and devices that will be used for kidney diseases. Core Competency: Patient Care and Procedural Skills, Medical Knowledge Moderators: Patrick Archdeacon, MD, and Prabir Roy-Chaudhury, MD, PhD, FASN 2:00 p.m.
Developing Patient-Reported Outcomes for the Kidney Space: Challenges and Opportunities Ronald D. Perrone, MD, FASN
2:30 p.m.
Patient-Reported Outcomes: A Patient’s Viewpoint Celeste Castillo Lee
3:00 p.m.
Incorporating Patient Preferences into the Regulatory Pathway: Using Patient Insights to Optimize Product Development Carolyn Y. Neuland, PhD
3:30 p.m.
Patient Preferences in Nephrology: Exploring New Territory Francesca Tentori, MD
52
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Special Session
The Dialysis Outcomes and Practice Patterns Study Program: Newest Findings and Expanded Scope Room 204-A
ASN thanks DOPPS for assistance with this session.
Upon completion of this session, the participant will be able to: 1) discuss the impact of recent policy changes on hemodialysis practices in the United States and compare with other DOPPS countries; 2) describe the newest results with regard to anemia management and vascular access use among hemodialysis patients and their potential impact on clinical outcomes; 3) discuss the preliminary findings from CKDopps regarding treatment of advanced CKD patients and international variability; and 4) describe early findings of PDOPPS, plans for future directions, and opportunities for research collaborations. Moderators: Friedrich K. Port, MD, and Bruce M. Robinson, MD, FASN 2:00 p.m.
What Makes the DOPPS Projects Unique? Nathan W. Levin, MD
2:10 p.m.
DOPPS Practice Monitor: Key Trends in U.S. Dialysis Practices and International Comparisons Raymond M. Hakim, MD, PhD
2:30 p.m.
CKDopps: A Study to Identify Optimal Practice in Advanced CKD—Preliminary Findings Roberto Pecoits-Filho, MD, PhD, FASN
2:50 p.m.
PDopps: Early Findings, Future Directions, and Research Opportunities Jeffrey Perl, MD
3:10 p.m.
Anemia: Potential Impact of Recent Practice Changes on Outcomes Christian Combe, MD, PhD
3:30 p.m.
Vascular Access Use and Outcomes: Latest International Findings Charmaine E. Lok, MD
3:50 p.m.
Panel Discussion
53
THURSDAY
The Dialysis Outcomes and Practice Patterns Study (DOPPS) is a prospective cohort study of hemodialysis practices in national samples of patients in multiple countries. The DOPPS program recently expanded its unique scientific approach to the study of patients on peritoneal dialysis (PDOPPS) and those with advanced CKD (CKDopps). In this session, an international panel of speakers presents the newest DOPPS findings and new directions. All lectures aim at providing a better understanding of how to improve patient care and outcomes, with a practical clinical focus.
THURSDAY, NOVEMBER 13, 2014 2:00 p.m. – 4:00 p.m.
Special Session
The Future Direction of Nephrology: How Shall We Live Long and Prosper?, Including the Christopher R. Blagg, MD, Lectureship in Renal Disease and Public Policy Room 115-B
ASN gratefully acknowledges the Northwest Kidney Centers and its contributors for support of the Christopher R. Blagg, MD, Lectureship in Renal Disease and Public Policy. ASN thanks its Public Policy Board and the Renal Physicians Association for assistance with this session.
Nephrologists are generally hard-working practitioners, caring for the chronically ill. Reimbursement models are changing, with new levels of complexity. Jobs are less plentiful, particularly for those searching in metropolitan areas. Numbers of applicants for fellowship have markedly decreased, possibly due to these factors. Given such concerns, how do we, as a profession, remain attractive and viable? This session discusses several issues. The first lecturer entertains how we can attract a young and diverse workforce to our profession, given the opportunities and challenges of the present juxtaposed with the needs for the future. The second lecturer discusses ongoing controversies regarding the current nephrology workforce, including the current supply of providers and increasing demands within the nephrology community. Finally, this session discusses trends among patients—entertaining reasons for changes in the ESRD and CKD population predictions, needs for inpatient care, such as AKI, and other areas where specialized expertise, such as transplantation, are required for patient well-being. Upon completion of this session, the participant will be able to: 1) discuss novel ways to attract a young and diverse provider population, given the current state of the profession; 2) describe the supply and the demand for our current and future nephrology workforce; and 3) discuss changes in specific kidney diseases that would result in changes in workforce needs. Moderators: Rebecca J. Schmidt, DO, FASN, and Suzanne Watnick, MD 2:00 p.m.
Opportunities and Challenges: Attracting the Next Generation— The Christopher R. Blagg, MD, Endowed Lectureship in Renal Disease and Public Policy Richard J. Baron, MD
2:40 p.m.
Supply and Demand: Our Current and Future Nephrology Workforce Mark G. Parker, MD
3:20 p.m.
Looking into the Crystal Ball: Changes in Kidney Disease and the Nephrology Workforce of Tomorrow Michael J. Fischer, MD, FASN
54
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Becoming the Biggest Loser: Obese Transplant Recipients Room 103
Upon completion of this session, the participant will be able to: 1) describe the pros and cons of pretransplant weight loss; 2) describe the strategies available to assist patients with weight loss prior to listing; and 3) discuss new surgical techniques used in transplanting obese recipients. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: John S. Gill, MD, and Karin A. True, MD, FASN 4:30 p.m.
Pretransplant Weight Loss: Yes Krista L. Lentine, MD, PhD, FASN
5:00 p.m.
Pretransplant Weight Loss: No Randal K. Detwiler, MD
5:30 p.m.
Pretransplant Bariatric Surgery Andrew Posselt, MD, PhD
6:00 p.m.
Mr. Roboto: Transplanting Obese Recipients Jose Oberholzer, MD
4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Blood Pressure in Dialysis: Striking a Balance between Highs and Lows Ballroom A
Hypertension remains a common problem in patients with ESRD, especially those receiving dialytic therapy. This session examines the role of volume and other mechanisms and suggests strategies for management of hypertension in this population. Upon completion of this session, the participant will be able to describe the evidence of potential mechanisms leading to hypertension in the dialysis population. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Rajiv Agarwal, MD, MBBS, FASN, and Jula K. Inrig, MD, FASN 4:30 p.m.
Measuring Blood Pressure in Hemodialysis: Pre, Post, Interval, Ambulatory, or All— So Many Choices, Not Enough Time Raven A. Voora, MD
5:00 p.m.
Chronic Volume Overload, Interdialytic Weight Gain, and Ultrafiltration Rates Jennifer E. Flythe, MD, FASN
5:30 p.m.
Dialysate Sodium Concentration and Its Relationship with Blood Pressure Brigitte Schiller, MD, FASN
6:00 p.m.
Hemodialysis-Associated Hypertension and Endothelial Dysfunction Peter N. Van Buren, MD
55
THURSDAY
Obesity is a common problem in our CKD and dialysis population and is often a barrier to transplantation. Many transplant programs have a BMI cutoff to be active on the kidney transplant waiting list, and as a consequence, most obese patients are status 7 (inactive). In this session, experts in the field discuss whether it is appropriate to require weight loss to list candidates for transplant, strategies for pretransplant weight loss (including bariatric surgery), and surgical techniques for transplanting obese patients.
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
High-Risk Groups for Diabetic Kidney Disease: Who Are They and What to Do? Room 113
Supported by an independent educational grant from AbbVie.
The purpose of this session is to highlight fresh insights into the status of high-risk groups for diabetic kidney disease (DKD) as defined by age, child-bearing, or race/ethnicity. A current look at multifactorial intervention to reduce risks rounds out the discussion. Upon completion of this session, the participant will be able to: 1) describe how youth-onset diabetes amplifies risk of DKD; 2) discuss effects of pregnancy on DKD and the reverse; 3) discuss risks of diabetes and kidney disease among indigenous people; and 4) summarize the current understanding of multifactorial intervention to reduce risks of DKD. Core Competency: Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills Moderators: Harold I. Feldman, MD, FASN, and Andrew S. Narva, MD, FASN 4:30 p.m.
Type 2 Diabetes in Youth: Gasoline on the Fire of Diabetic Kidney Disease Meda E. Pavkov, MD, PhD
5:00 p.m.
Best of Times and Worst of Times: Pregnancy and Diabetic Kidney Disease Elisabeth R. Mathiesen, MD
5:30 p.m.
Meet Them Where They Are: Diabetes and Kidney Disease among Indigenous Peoples Robert G. Nelson, MD, PhD
6:00 p.m.
Multifactorial Intervention: What Works and What Does Not? Peter Gaede
4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference Kidney–Liver Service 911 Ballroom B
This session reviews our current knowledge about hepatorenal syndrome. The newly described pathologic entity of bile cast nephropathy may have implications in the clinical management of patients in this unique setting. In addition, the decision to stratify these patients with chronic liver disease to those that will receive combined liver–kidney transplantation versus liver transplantation alone remains a clinical challenge. Upon completion of this session, the participant will be able to: 1) define the pathophysiology of hepatorenal syndrome; and 2) describe the pathologic characteristics of bile cast nephropathy. Core Competency: Medical Knowledge Moderators: Andrew Davenport, MD, and Seth B. Furgeson, MD 4:30 p.m.
Hepatorenal Syndrome Robert W. Schrier, MD
5:00 p.m.
Bile Cast Nephropathy: The Pathologic Correlate of Hepatorenal Syndrome? Anthony Chang, MD, FASN
5:30 p.m.
AKI and CKD in Chronic Liver Disease Patients Mitra K. Nadim, MD
6:00 p.m.
Liver Alone versus Liver-Kidney Transplantation: How to Choose? Alexander C. Wiseman, MD
56
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference Pediatric Nephrology: 2014 Update Room 201-C
Upon completion of this session, the participant will be able to: 1) identify the role of genetic mutations and genetic counseling in vesicoureteral reflux; 2) discuss the insights derived from the RIVUR study; 3) explain the role of ambulatory blood pressure monitoring in pediatric hypertension; and 4) describe the implications of preterm birth on future kidney health. Core Competency: Patient Care and Procedural Skills, Medical Knowledge Moderators: Coral D. Hanevold, MD, and Adam R. Weinstein, MD 4:30 p.m.
The Role of Genetic Mutations in the Development of VUR Rasheed A. Gbadegesin, MD
5:00 p.m.
Lessons Learned from the RIVUR Study Tej K. Mattoo, MD
5:30 p.m.
A Critical Role for the Use of ABP in Children Abanti Chaudhuri, MD
6:00 p.m.
Short-Term Gestation, Long-Term Risk Jennifer R. Charlton, MD
57
THURSDAY
Because of their roles in the early identification and treatment of kidney diseases in developing individuals, pediatric nephrologists have a unique opportunity to impact very-long-term outcomes in their patients. This session reviews the newest developments in the study of vesicoureteral reflux, in the assessment of the hypertensive child, and in the special burden of renal risk in the preterm and small-birth-weight infant.
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Sessions
Upon completion of the oral abstract sessions, the participant will be able to: 1) construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines; and 2) translate recent advances into new standards and approaches to clinical care of patients with kidney diseases and related disorders. Core Competency: Medical Knowledge
4:30 p.m. – 6:30 p.m.
Oral Abstract Session Advances in Understanding PKD Pathogenesis Room 118-C Moderators: E. Wolfgang Kuehn, MD, and Dorien J.M. Peters, PhD
4:30 p.m. TH-OR001
Cardiac Dysfunction in Pkd1-Deficient Mice and Phenotype Rescue by Galectin-3 Knockout — Bruno E. Balbo, Andressa Godoy Amaral, Jonathan Mackowiak Fonseca, Isac De Castro, Vera Mc Salemi, Leandro Eziquiel Souza, Fernando Santos, Maria Irigoyen, Feng Qian, Roger Chammas, Luiz F. Onuchic. São Paulo, Brazil.
4:42 p.m. TH-OR002
Deletion of Heart Pkd1 Promotes Cardiac Remodeling via Smyd2 and NF-κB Cross-Talk — Changlin Li, Lucy Fan, James P. Calvet, Xiaogang Li. Kansas City, KS.
4:54 p.m. TH-OR003
mTORC1 Regulates Polycystin-1 Expression Levels Possibly Explaining Renal Cystogenesis in Tsc1 Mutant Mice — Monika Pema, Marco Chiaravalli, Luca Drusian, Alessandra Boletta. Milan, Italy.
5:06 p.m. TH-OR004
Ciliary Polycystin Complex Traffics Through the Golgi Via a Rabep1/GGA1/Arl3-Dependent Mechanism — Feng Qian, Hyunho Kim, Hangxue Xu, Qin None Yao, Weizhe Li, Qiong Huang, Patricia Outeda, Marco Chiaravalli, Alessandra Boletta, Gregory G. Germino, Terry J. Watnick. Baltimore, MD.
5:18 p.m. TH-OR005
Arl13b and the Exocyst Are Necessary for Ciliogenesis and Interact Synergistically — Soo Young Choi, Cecília Seixas, Nicole L. Umberger, Xiaofeng Zuo, Tamara Caspary, Duarte C. Barral, Joshua H. Lipschutz. Philadelphia, PA.
5:30 p.m. TH-OR006
Ciliary Trafficking of Polycystin-1 Is Regulated by Polycystin-2 and Other Factors — Xuefeng Su, Gang Yao, Maoqing Wu, Azadeh Tabari, Jing Zhou. Boston, MA.
5:42 p.m. TH-OR007
Pkd2 Is Essential for Intraciliary Calcium Signaling In Vivo — Zhaoxia Sun, Shiaulou Yuan, Lu Zhao, Martina Brueckner. New Haven, CT.
5:54 p.m.
Invited Lecture: The Role of PKD1 in Lymphatic Development — Terry J. Watnick, MD
Presenting Authors Underlined
58
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Advances in Vascular Biology Room 105 Moderators: Rafael Kramann, MD, and Anton Jan Van Zonneveld, PhD
Pharmacology of a Novel, Highly Selective Aldosterone Synthase Inhibitor in Non-Human Primates — Steven M. Weldon, Nicholas F. Brown, Jeremy G. Richman, Matthew A. Cerny, Derek Cogan, Xin Guo, Glenn A. Reinhart. Ridgefield, CT.
4:42 p.m. TH-OR009
Heparanase-2 Is an Inhibitor of Heparanase-1, Stabilizes Endothelial Glycocalyx and Prevents Albuminuria in Zebrafish and Diabetic Mice — Hermann G. Haller, Anna Bertram, Putri Andina Agustian, Torsten Kirsch, Mario Schiffer, Jan Menne. Hannover, Germany.
4:54 p.m. TH-OR010
Activation of Aryl Hydrocarbon Receptor by Indoxyl Sulfate, a Uremic Toxin, Is Critically Involved in Vascular Inflammation — Shunsuke Ito, Takeo Edamatsu, Yoshiharu Itoh, Masayuki Yoshida. Tokyo, Japan.
5:06 p.m. TH-OR011
Low-Energy Shockwave Treatment Preserves the Kidney Microvasculature in Swine Renovascular Disease — Xin Zhang, James D. Krier, Carolina Amador Carrascal, James F. Greenleaf, Behzad Ebrahimi, Amir Lerman, Lilach O. Lerman. Rochester, MN.
5:18 p.m. TH-OR012
Glomerular Filtration Rate in the Contralateral Kidney Falls After Successful Revascularization of Stenotic Kidney — Sandra Herrmann, Ahmed Saad, Lilach O. Lerman, Stephen C. Textor. Rochester, MN.
5:30 p.m. TH-OR013
Serum FGF21 Is a Novel Biomarker Associated with Endothelial Dysfunction and Aortic Calcification in Chronic Kidney Disease — Masashi Kitagawa, Hitoshi Sugiyama, Hiroshi Morinaga, Ayu Akiyama, Toshio Yamanari, Akifumi Onishi, Keiko Tanaka, Yoko Kikumoto, Tatsuyuki Inoue, Yohei Maeshima, Jun Wada. Okayama, Japan.
5:42 p.m. TH-OR014
Enhancing Akt Signaling in the Endothelium Restores Defective Angiogenesis in Kidney After Injury — Takahide Aburatani, Giovanni Ligresti, Ying Zheng, Alfred Aplin, Roberto F. Nicosia, Jeremy Stuart Duffield. Seattle, WA.
5:54 p.m. TH-OR015
Effects of Linagliptin on Early Alterations of Renal Endothelial Function in Patients with Type-2 Diabetes — Roland E. Schmieder, Christian Ott, Iris Kistner, Stefanie Friedrich. Erlangen, Germany.
6:06 p.m. TH-OR016
Extracorporeal Removal of sFlt1 in Preeclampsia: A Pilot Trial — Ravi I. Thadhani, Henning Hagmann, Wiebke Schaarschmidt, Tuelay Kisner, S. Ananth Karumanchi, Tom H. Lindner, Alexander Fridman, Bernhard Roth, Peter Mallmann, Holger Stepan, Thomas Benzing. Boston, MA.
6:18 p.m. TH-OR017
Sphingosine-1-Phosphate Regulates Kidney Vascular Development — Yan Hu, Maria Luisa S. Sequeira Lopez. Charlottesville, VA.
59
THURSDAY
4:30 p.m. TH-OR008
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session AKI: Cellular Responses to Injury and Repair - I Room 107 Moderators: Erika I. Boesen, PhD, and Steven C. Borkan, MD
4:30 p.m. TH-OR018
Prior Ultrasound Reduces Murine Acute Kidney Injury by Modulating Splenocyte Function — Joseph C. Gigliotti, Liping Huang, Amandeep Bajwa, Eric Mace, Hong Ye, Diane L. Rosin, Kambiz Kalantari, John Hossack, Mark D. Okusa. Charlottesville, VA.
4:42 p.m. TH-OR019
Coupling Pulsed Focused Ultrasound with Mesenchymal Stem Cells Prevents and Rescues Established Acute Kidney Injury — Scott R. Burks, Saejeong Kim, Jonathan Street, Peter S.T. Yuen, Robert A. Star, Joseph Frank. Bethesda, MD.
4:54 p.m. TH-OR020
Glycogen Synthase Kinase 3β (GSK 3β) Inhibition Promotes Macrophage Polarization and Reduces Inflammation and Acute and Chronic Damage following Acute Kidney Injury (AKI) — Chunming Jiang, Evelyn Tolbert, Weiwei Xu, Hui Bao, Rujun Gong, Lance D. Dworkin. Providence, RI.
5:06 p.m. TH-OR021
KIM-1 Interacts with p85 and Modulates the Proximal Tubule Cell Inflammatory Response through Regulation of NFκB — Craig R. Brooks, Li Yang, Venkata Sabbisetti, Takaharu Ichimura, Li-Li Hsiao, Joseph V. Bonventre. Boston, MA.
5:18 p.m. TH-OR022
Fibroblast-Specific β-Catenin Signaling Dictates Tubular Injury and Repair After Acute Kidney Injury — Dong Zhou, Roderick J. Tan, Haiyan Fu, Youhua Liu. Pittsburgh, PA.
5:30 p.m. TH-OR023
mTOR Mediates Autophagy Impairment in Telomerase Deficient Mice and Leads to Delayed Renal Recovery after Ischemia Reperfusion (I/R) Injury — Huifang Cheng, Raymond C. Harris. Nashville, TN.
5:42 p.m. TH-OR024
Hepcidin Mediates Protection in Renal Ischemia Reperfusion Injury Through Modulation of Systemic Iron Homeostasis — Yogesh M. Scindia, Cindy N. Roy, Mark D. Okusa, Sundararaman Swaminathan. Charlottesville, VA.
5:54 p.m. TH-OR025
Tubular Repair following Acute Kidney Injury Occurs through Clonal Expansion of a Preexisting Population of Tubular Progenitors in Mouse — Anna Julie Peired, Elena Lazzeri, Duccio Lombardi, Elisa Ronconi, Maria Lucia Angelotti, Sara Nardi, Laura Lasagni, Paola Romagnani. Florence, Italy.
6:06 p.m. TH-OR026
Activated CD47 Contributes to Renal Ischemia Reperfusion Injury by Simultaneously Limiting Self-Renewal Genes and Autophagy — Natasha M. Rogers, Jeffrey S. Isenberg. Pittsburgh, PA.
6:18 p.m. TH-OR027
ADAM17 Promotes Kidney Fibrosis after Severe Ischemia-Reperfusion Injury — Eirini Kefalogianni, Jakob R. Kaeppler, Muthu Lakshmi Muthu, Benjamin D. Humphreys, Joseph V. Bonventre, Andreas Herrlich. Brighton, MA.
60
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
AKI: Interventions, Biomarkers, Genetics, and More Room 108 Moderators: Ashita J. Tolwani, MD, and Ron Wald, MD
A Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Conferring Risk for Acute Kidney Injury — Bixiao Zhao, Justin Miles Belcher, Edward D. Siew, T. Alp Ikizler, Amit X. Garg, Richard P. Lifton, Chirag R. Parikh. New Haven, CT.
4:42 p.m. TH-OR029
The Effect of Early Intervention with Renal Replacement Therapy Guiding by Plasma Neutrophil Gelatinase Associated Lipocalin and the Outcome of Acute Kidney Injury (the EARLYRRT Trial): A Randomized Controlled Trial — Nattachai Srisawat, Khajohn Tiranathanagul, Paweena Susantitaphong, Kearkiat Praditpornsilpa, Somchai Eiam-Ong, Kriang Tungsanga. Pittsburgh, PA.
4:54 p.m. TH-OR030
A Multi-Center, Randomized, Control Trial to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients with Acute Kidney Injury (AKI) — James A. Tumlin, Alexander S. Yevzlin, H.David Humes. Chattanooga, TN.
5:06 p.m. TH-OR031
Remote Ischemic Preconditioning May Reduce Acute Kidney and Myocardial Injury in Children Undergoing Cardiac Surgery — Christine W. Hsu, Matthew Toma, Ronit Katz, Cassianne Robinson-Cohen, Bryan R. Kestenbaum, Yuk M. Law, Jonathan Himmelfarb. Seattle, WA.
5:18 p.m. TH-OR032
Association between Urinary Kidney Injury Biomarker Concentrations and Urine Dipstick Findings — Steven G. Coca, Allison Meisner, Uptal D. Patel, Jay L. Koyner, Amit X. Garg, Charles L. Edelstein, Michael Shlipak, Chirag R. Parikh. New Haven, CT.
5:30 p.m. TH-OR033
Furosemide Stress Test Is Better Than Biochemical Biomarkers for the Prediction of AKI Severity, Progression and Mortality — Jay L. Koyner, Danielle Davison, Ermira Brasha-Mitchell, Divya M. Chalikonda, John M. Arthur, Andrew Shaw, James A. Tumlin, Sharon A. Trevino, Michael R. Bennett, Paul L. Kimmel, Michael Seneff, Lakhmir S. Chawla. Chicago, IL.
5:42 p.m. TH-OR034
Transient Tissue Hypoxia without Acute Kidney Injury Immediately and 3 Months after Complex CT Imaging and Renal Revascularization for Atherosclerotic Renovascular Disease — Ahmed Saad, Sandra Herrmann, James Glockner, Michael A. Mckusick, Lilach O. Lerman, Stephen C. Textor. Rochester, MN.
5:54 p.m. TH-OR035
Association between In-Hospital Furosemide Exposure and the Incidence of In-Hospital Acute Kidney Injury — Joshua Taylor Swan, Harlan Sparrow, Beverly A. Shirkey, Carol M. Ashton, Wadi N. Suki, David Putney, Nelda P. Wray, A. Osama Gaber. Houston, TX.
6:06 p.m. TH-OR036
Peri-Cardiac Surgery Levels of Plasma Neutrophil Gelatinase-Associated Lipocalin Are Not Associated with Long-Term Mortality Independent of Serum Creatinine Levels — Dennis Moledina, Chirag R. Parikh, Amit X. Garg, Heather Thiessen Philbrook, Jay L. Koyner, Uptal D. Patel, Prasad Devarajan, Michael Shlipak, Steven G. Coca. New Haven, CT.
6:18 p.m. TH-OR037
Intermittent Hemodialysis in Acute Kidney Injury: Results from the VA/NIH ATN Trial — Rowena B. Delos Santos, Tingting Li, Paul M. Palevsky, Anitha Vijayan. Saint Louis, MO.
61
THURSDAY
4:30 p.m. TH-OR028
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Bioengineering Advances for Next-Generation Renal Replacement Technologies Room 115-C Moderators: Paul R. Brakeman, MD, PhD, and H. David Humes, MD
4:30 p.m. TH-OR038
Recellularization of Vascular and Tubular Compartments of Rat Kidney Scaffolds with Embryonic Stem Cells — Andrea Remuzzi, Barbara Bonandrini, Marina Figliuzzi, Sara Silvani, Ariela Benigni, Giuseppe Remuzzi. Bergamo, Italy.
4:42 p.m. TH-OR039
Long-Term Water Transport and Barrier Function of Proximal Tubule Cells Cultured Under Apical Shear Flow Conditions — Paul R. Brakeman, Peter Soler, Nicholas J. Ferrell, William Fissell, Shuvo Roy. San Francisco, CA.
4:54 p.m. TH-OR040
Functional Organic Cation Transporters in Human Proximal Tubule Epithelial Cells Cultured on Hollow Fiber Membranes — Jitske Jansen, Ilaria Ester De Napoli, Carolien M.S. Schophuizen, Martijn J. Wilmer, Jack F. Wetzels, Lambertus P.W.J. Van den Heuvel, Joost Hoenderop, Dimitrios Stamatialis, Rosalinde Masereeuw. Nijmegen, Gelderland, Netherlands.
5:06 p.m. TH-OR041
A Microphysiological 3D Model of the Renal Proximal Tubule Demonstrates Reabsorptive Function — Else M. Frohlich, Hyoungshin Park, Jose L. Alonso, M. Amin Arnaout, Joseph L. Charest. Cambridge, MA.
5:18 p.m. TH-OR042
Development of a Bioengineered Human Kidney Microphysiological System for Assessment of Drug Transport and Toxicity — Alenka Jaklic, Elijah Weber, Danny D. Shen, Jonathan Himmelfarb, Edward J. Kelly. Seattle, WA.
5:30 p.m. TH-OR043
9 Day Filtration by an Implantable Hemofilter — Clark David Kensinger, Seth J. Karp, Joseph J. Groszek, Mark S. Goodin, Rishi Kant, Torin Yeager, Shuvo Roy, William Fissell. Nashville, TN.
5:42 p.m. TH-OR044
Evaluation of Next-Generation Silicon Nanopore Membranes Optimized for Diffusive Clearance — Steven Kim, Charles Blaha, Zohora Iqbal, Clarence Chow, Rishi Kant, Benjamin Chui, Jaehyun Park, Ken Goldman, Eun Jung Kim, William Fissell, Shuvo Roy. San Francisco, CA.
5:54 p.m. TH-OR045
Slit Nanotopography on Silicon Nanopore Membranes Resists Protein Deposition and Cell Attachment — Eun Jung Kim, William Fissell, Tejal Ashwin Desai, Shuvo Roy. San Francisco, CA.
6:06 p.m. TH-OR046
Water Permeable Nanoporous Membrane Device for Implantable Artificial Kidney — Yoshihiko Kanno, Naoya To, Shinya Morita, Ippei Sanada, Norihisa Miki, Hikaru Itoh. Tokyo, Japan.
6:18 p.m. TH-OR047
Extracorporeal Mesenchymal Stromal Cell Therapy for Acute Kidney Injury — Biju Parekkadan. Boston, MA.
62
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session CKD: Epidemiology and Outcomes Room 202 Moderators: Linda F. Fried, MD, FASN, and Ron T. Gansevoort, MD, PhD
eGFR Level and Its Past Trajectory for Risk of Progression to End-Stage Renal Disease: Meta-Analysis of 22 Cohorts in the CKD Prognosis Consortium — Csaba P. Kovesdy, Josef Coresh, Shoshana Ballew, Mark Woodward, David M. Naimark, Joseph V. Nally, Adeera Levin, Dietrich Rothenbacher, Benedicte Stengel, Kunitoshi Iseki, Kunihiro Matsushita, Andrew S. Levey. Memphis, TN.
4:42 p.m. TH-OR049
Prior Change in Estimated Glomerular Filtration Rate and the Subsequent Risk of All-Cause Mortality — David M. Naimark, M. Grams, Kunihiro Matsushita, Corri Black, Lesley Inker, Areef Ishani, Sun Ha Jee, Akihiko Kitamura, Janice P. Lea, Joseph V. Nally, Carmen A. Peralta, Dietrich Rothenbacher, Seungho Ryu, Marcello Tonelli, Hiroshi Yatsuya, Ron T. Gansevoort, David G. Warnock, Mark Woodward. North York, ON, Canada.
4:54 p.m. TH-OR050
Slope of Glomerular Filtration Rate Decline as Clinical Trial Endpoint — Misghina Tekeste Weldegiorgis, Dick de Zeeuw, Jamie P. Dwyer, Tom Greene, Hiddo Jan Lambers Heerspink. Groningen, Netherlands.
5:06 p.m. TH-OR051
The Association between Kidney Function and Major Bleeding in People with Atrial Fibrillation Initiating Warfarin Therapy — Min Jun, Matthew T. James, Braden J. Manns, Robert R. Quinn, Pietro Ravani, Marcello Tonelli, Vlado Perkovic, Wolfgang C. Winkelmayer, Zhihai Ma, Brenda Hemmelgarn. Calgary, AB, Canada.
5:18 p.m. TH-OR052
Association of Baseline Use of Niacin with Progression of Chronic Kidney Disease in over 3 Million US Veterans — Elani Streja, Kamyar Kalantar-Zadeh, Hamid Moradi, Miklos Zsolt Molnar, Jun Ling Lu, Csaba P. Kovesdy. Orange, CA.
5:30 p.m. TH-OR053
25-Year Kidney Function Trajectories Associated with APOL1 High-Risk Variants: The ARIC Study — M. Grams, Adrienne Tin, C. Rebholz, Yuan Chen, Wen Hong Linda Kao, Josef Coresh. Baltimore, MD.
5:42 p.m. TH-OR054
Different Biomarker Profiles Identify Chronic Kidney Disease Patients of Different Etiologies at the Highest Risk of Mortality before Progression to Dialysis Dependence — David Langsford, Ognjenka Djurdjev, Mila Tang, Adeera Levin. Vancouver, BC, Canada.
5:54 p.m. TH-OR055
Parathyroid Hormone and 25-Hydroxyvitamin D Concentrations and Risk of Incident Heart Failure: The MESA Study — Leila R. Zelnick, Ian H. de Boer, Cassianne Robinson-Cohen, Andrew N. Hoofnagle, Joachim H. Ix, Abigail Shoben, Carmen A. Peralta, David Siscovick, Bryan R. Kestenbaum, Nisha Bansal. Seattle, WA.
6:06 p.m. TH-OR056
Diet and Major Renal Outcomes: The NIH-AARP Diet and Health Study — Andrew Smyth, Michelle Canavan, Matthew D. Griffin, Martin O’donnell. Hamilton, ON, Canada.
6:18 p.m. TH-OR057
Sickle Cell Trait and Chronic Kidney Disease and Albuminuria in African-Americans — Vimal K. Derebail, R. Naik, M. Grams, Nora Franceschini, Bessie A. Young, A. V. Kshirsagar, James G. Wilson, Alex Reiner. Chapel Hill, NC.
63
THURSDAY
4:30 p.m. TH-OR048
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases Room 201-A Moderators: Robert Kleta, MD, PhD, FASN, and Jeffrey B. Kopp, MD, FASN
4:30 p.m. TH-OR058
The UMOD Locus Shows Signature of Pathogen Adaptation through Human Evolution — Olivier Devuyst, Linda Pattini, Guido Barbujani, Luca Rampoldi. Zurich, Switzerland.
4:42 p.m. TH-OR059
A Novel Locus for Blood Pressure Identified in GWAS of U.S. Hispanics — Nora Franceschini, Mariaelisa Graff, Christina Wassel, Myriam Fornage, Ran Tao, Cara Carty, Stephanie Rosse, Girish N. Nadkarni, Eli A. Stahl, Erwin P. Bottinger, Charles Kooperberg. Chapel Hill, NC.
4:54 p.m. TH-OR060
Functional Annotation of SNPs Associated with Chronic Kidney Disease — Yi-An Ko, Nora Ledo, Pazit Beckerman, Katalin Susztak. Philadelphia, PA.
5:06 p.m. TH-OR061
Rare Mutations Associating with Serum Creatinine and Chronic Kidney Disease — Runolfur Palsson, Olafur S. Indridason, Gardar Sveinbjornsson, Evgenia K. Mikaelsdottir, Hilma Hólm, Daniel Gudbjartsson. Reykjavik, Iceland.
5:18 p.m. TH-OR062
GWAS Results in the PediGFR Consortium Identifies Six Genomic Loci Associated with GFR and Proteinuria — Matthias Wuttke, Craig S. Wong, Elke Wuehl, Bradley A. Warady, Anke Doyon, Betul B.S. Sozeri, Daniela Kracht, Anette Melk, Uwe Querfeld, Tom D. Blydt-Hansen, Susan L. Furth, Franz S. Schaefer, Anna Kottgen. Freiburg, Germany.
5:30 p.m. TH-OR063
Characterization of HLA-DQA1 and PLA2R1 Risk Alleles across the Spectrum of Chronic Kidney Disease Etiologies — Peggy Sekula, Yong Li, Matthias Wuttke, Robert Kleta, Florian Kronenberg, Kai-Uwe Eckardt, Anna Kottgen. Freiburg, Germany.
5:42 p.m. TH-OR064
Genome Wide Exome Array Analysis Identifies HLA-DQA1 and PLCG2 as Risk Loci for Childhood Onset Steroid Sensitive Nephrotic Syndrome — Rasheed A. Gbadegesin, Adebowale A. Adeyemo, Nicholas J. Webb, Larry A. Greenbaum, Asiri S. Abeyagunawardena, Shenal Thalgahagoda, Debbie S. Gipson, Arundhati S. Kale, Tarak Srivastava, Jen-Jar Lin, Deepa H. Chand, Tracy E. Hunley, Patrick D. Brophy, Arvind Bagga, Michelle N. Rheault, Elizabeth C. Abraham, Halima S. Janjua, Abiodun A. Omoloja, Gina-Marie Barletta, William E. Smoyer, Gentzon Hall, Shashi K. Nagaraj, Delbert R. Wigfall, John W. Foreman, Michelle P. Winn. Durham, NC.
5:54 p.m. TH-OR065
Targeted Sequencing of MHC Region and Immune Related Genes in Han Chinese Identifies Independent Variants Associated with Lupus Nephritis — Ricong Xu, Qibin Li, Yingrui Li, Zhijian Li, Peiran Yin, Xueqing Yu. Guangzhou, China.
6:06 p.m. TH-OR066
Identification and Validation of New Risk Genes in European-American Population by Exome-Sequencing and RNAi-Based Mouse Model for Focal Segmental Glomerulosclerosis — Haiyang Yu, Cheryl Ann Winkler, Jeffrey B. Kopp, Andrey S. Shaw. Saint Louis, MO.
6:18 p.m. TH-OR067
Missense Mutation of the RhoGTPase Regulator FSGS11 Is a Cause of Autosomal Dominant FSGS — Gentzon Hall, Rasheed A. Gbadegesin, Andrew F. Malone, Paul J. Phelan, Alison Homstad, Guanghong Wu, Thomas Lindsey, Michelle P. Winn. Durham, NC.
64
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Glomerular Biomarkers: Progress and Pitfalls Room 114 Moderators: Sharon G. Adler, MD, FASN, and Zhihong Liu, MD
Complement Activation Patterns in Atypical Hemolytic Uremic Syndrome (aHUS) During Acute Phase and in Remission — Lambertus P.W.J. Van den Heuvel, Elena Volokhina, Thea J. Van der Velden, Dineke Westra, Nicole Van de Kar, Tom Eirik Mollnes. Nijmegen, Netherlands.
4:42 p.m. TH-OR069
Identification of Distinct Dominant and Subdominant Humoral Epitopes within PLA2R1 in Primary Membranous Nephropathy — Laurence H. Beck, Dana Sandor, Hong Ma, David J. Salant. Boston, MA.
4:54 p.m. TH-OR070
Phospholipase A2 Receptor Autoantibodies and Renal Function in Patients with Primary Membranous Nephropathy — Elion Hoxha, Sigrid Harendza, Hans O. Pinnschmidt, Ulf Panzer, Rolf A. Stahl. Hamburg, Germany.
5:06 p.m. TH-OR071
Identification of Thrombospondin Type 1 Domain Containing 7A as a Novel Antigen in Idiopathic Membranous Nephropathy — Nicola M. Tomas, Laurence H. Beck, Catherine Meyer-Schwesinger, Barbara Seitz-Polski, Hong Ma, Gunther Zahner, Guillaume Dolla, Elion Hoxha, Udo Martin Helmchen, Michael Merchant, Jon B. Klein, David J. Salant, Rolf A. Stahl, Gerard J. Lambeau. Hamburg, HB, Germany.
5:18 p.m. TH-OR072
Renal PLA2R in Hepatitis B Virus-Associated Membranous Nephropathy — Qionghong Xie, Yan Li, Chuanming Hao. Shanghai, China.
5:30 p.m. TH-OR073
Reassessment of suPAR in Kidney Disease — Joann M. Spinale, Laura H. Mariani, Robert J. Weyant, Peter X.K. Song, Deepak Nihalani, Lawrence B. Holzman. Philadelphia, PA.
5:42 p.m. TH-OR074
B7-1/CD80 Is Not a Reliable Immunophenotypical Marker of Focal Segmental Glomerulosclerosis, Membranous Glomerulonephritis and Diabetic Nephropathy — Zoltan G. Laszik, Dejan Dobi, Flavio Vincenti. San Francisco, CA.
5:54 p.m. TH-OR075
Biomarkers of Disease Pathobiology in Patients with Glomerulonephritis in the NEPTUNE Cohort — Heather N. Reich, Viji Nair, Wenjun Ju, David Cherney, Marie C. Hogan, John C. Lieske, Sharon G. Adler, Daniel C. Cattran, Michelle A. Hladunewich, James W. Scholey, Peter J. Nelson, Matthias Kretzler. Toronto, ON, Canada.
6:06 p.m. TH-OR076
TNFSF13 Has a Key Role in Both the Susceptibility and Progression of IgA Nephropathy — Seung Seok Han, Nara Shin, Seung Hee Yang, Hajeong Lee, Jung Pyo Lee, Jae Hyun Chang, Kwon Wook Joo, Yon Su Kim, Dong Ki Kim. Seoul, South Korea.
6:18 p.m. TH-OR077
Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis — Alan D. Salama, Ruth J. Pepper, Peter A. Merkel, Juliana Bordignon Draibe. London, United Kingdom.
65
THURSDAY
4:30 p.m. TH-OR068
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Hemodialysis for ESRD: Techniques and Vascular Access Room 204-A Moderators: Susan T. Crowley, MD, FASN, and Kevan Polkinghorne, PhD, MBChB
4:30 p.m. TH-OR078
Timing of Arrhythmias with Dialysis Schedule: Preliminary Results of the Monitoring in Dialysis (MiD) Study — Prabir Roy-Chaudhury, Alexandru Ionel Costea, James A. Tumlin, Amber S. Podoll, Don E. Williamson, Suresh Chandra Tiwari, Vikranth Reddy, David M. Charytan. Cincinnati, OH.
4:42 p.m. TH-OR079
Body Size and Gender Dependent Differences in Mortality Risks Associated with Ultrafiltration Rates — John W. Larkin, Sheetal Chaudhuri, Len A. Usvyat, Paul Balter, Peter Kotanko, Franklin W. Maddux, Eduardo K. Lacson. Caldwell, ID.
4:54 p.m. TH-OR080
Serum Filtration Markers to Estimate Native Kidney Urea Clearance (KrU) in Hemodialysis Patients — Tariq Shafi, Andrew S. Levey, Friedo W. Dekker, Lesley Inker, Raymond T. Krediet, Wieneke Michels, Tiny Hoekstra, Josef Coresh. Baltimore, MD.
5:06 p.m. TH-OR081
Low Predialysis Serum Sodium Modifies the Effect of Hemodialysis (HD) Frequency on Left Ventricular Mass: The Frequent Hemodialysis Network (FHN) Trial — Jochen G. Raimann, Christopher T. Chan, John T. Daugirdas, Thomas A. Depner, Frank A. Gotch, Tom Greene, George A. Kaysen, Alan S. Kliger, Peter Kotanko, Robert M. Lindsay, Michael V. Rocco, Glenn M. Chertow, Nathan W. Levin, The FHN Trial Group. New York, NY.
5:18 p.m. TH-OR082
FSP-1/ROCK1 Signaling Contributes to Diabetes-Induced Neointima Formation in Arteriovenous Graft — Jinlong Luo, Ming Liang, Farhad R. Danesh, William E. Mitch, Jizhong Cheng. Houston, TX.
5:30 p.m. TH-OR083
In Vivo Nanoparticle Imaging of Dysfunctional Endothelium Predicts the Development of Inflow Stenosis — Jie Cui, Chase Kessinger, Jason McCarthy, David E. Sosnovik, Ravi I. Thadhani, Farouc Amin Jaffer. Boston, MA.
5:42 p.m. TH-OR084
Validation of Criteria Diagnosing Catheter-Related Bloodstream Infections in Hemodialysis Patients — Friederike S. Quittnat Pelletier, Mohammad Z.H. Joarder, Alyssa Loughborough, Susan Poutanen, Charmaine E. Lok. Toronto, ON, Canada.
5:54 p.m. TH-OR085
International Differences in Bacteremia Rates in Hemodialysis Patients in the DOPPS: Strong Relationship with Catheter Use — Hugh C. Rayner, Lindsay Zepel, Michel Y. Jadoul, Charmaine E. Lok, David C. Mendelssohn, Jeffrey Perl, Richard J. Fluck, Lawrence M. Spergel, Brenda W. Gillespie, Ayman Karkar, Hideki Kawanishi, Brian Bieber, Friedrich K. Port, Bruce M. Robinson, Ronald L. Pisoni. Birmingham, West Midlands, United Kingdom.
6:06 p.m. TH-OR086
Preoperative and Postoperative Vascular Ultrasound in the Hemodialysis Fistula Maturation (HFM) Cohort Study — Michelle L. Robbin, Tom Greene, The HFM Study Group. Birmingham, AL.
6:18 p.m. TH-OR087
Demographic, Clinical, and Anatomic Factors Correlate with Physiologic Adaptation following Fistula Placement: The Hemodialysis Fistula Maturation (HFM) Cohort Study — Scott A. Berceli, Tom Greene, The HFM Study Group. Gainesville, FL.
66
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Hypertension: Novel Biomarkers and Target Organ Damage Room 111 Moderators: James M. Luther, MD, and Matthew R. Weir, MD
Effect of Dietary Sodium Restriction on Human Urinary Metabolomic Profiles — Kristen L. Jablonski, Jelena Klawitter, Michel Chonchol, Candace Bassett, Matt Racine, Douglas R. Seals. Aurora, CO.
4:42 p.m. TH-OR089
A Plasma Proteomic Classifier to Predict Transition of Albuminuria Stage in Subjects with Hypertension — Michelle Pena, Georg Heinze, Peter Rossing, Dick de Zeeuw, Hiddo Jan Lambers Heerspink, Joachim Jankowski. Groningen, Netherlands.
4:54 p.m. TH-OR090
Association of Plasma Renin with Subclinical Cardiovascular Disease in a PopulationBased Cohort: The Multi-Ethnic Study of Atherosclerosis — Dena E. Rifkin, Joseph A. Abdelmalek, Nancy Jenny, Robyn L. Mcclelland, Matthew Jay Budoff, Joachim H. Ix, Matthew Allison. La Jolla, CA.
5:06 p.m. TH-OR091
Association of Body Fluid Composition with Resistant Hypertension in Patients with Chronic Kidney Disease — Toshiyuki Aoki, Yasushi Ohashi, Reibin Tai, Sonoo Mizuiri, Yoshihide Tanaka, Atsushi Aikawa, Ken Sakai. Tokyo, Japan.
5:18 p.m. TH-OR092
Elevated Endogenous Ouabain and Reduced Excretion of Uric Acid after Acute Salt Load in Hypertensive Patients — Chiara Lanzani, Lorena Citterio, Elena Brioni, Marco Simonini, Chiara Maggioni, Elisabetta Messaggio, John Hamlyn, Paolo Manunta. Milan, Italy.
5:30 p.m. TH-OR093
Effect of Arteriolar Hyalinosis on the Blood Pressure-Dependent Proteinuria in NonNephrotic Chronic Kidney Disease — Ryo Zamami, Kentaro Kohagura, Yusuke Ohya, Kunitoshi Iseki. Nishihara-Cho, Japan.
5:42 p.m. TH-OR094
Long-Term Intake of Animal Flesh and Risk of Developing Hypertension in Three Prospective Cohorts — Lea Borgi, John P. Forman. Brookline, MA.
5:54 p.m. TH-OR095
Elevated Blood Pressure Index and Decreased Nocturnal Dip Are Risk Factors for Cognitive Dysfunction in Children and Young Adults — Nina Laney, Stephen R. Hooper, Jerilynn Radcliffe, Ji Young Kim, Rebecca Ruebner, Erum A. Hartung, Divya Ganeshmurthy Moodalbail, Susan L. Furth. Westampton, NJ.
6:06 p.m. TH-OR096
Examining Association of Medical Non-Adherence with All-Cause Mortality in Incident Hypertensive US Veterans — Elvira Gosmanova, Jun Ling Lu, Elani Streja, William C. Cushman, Miklos Zsolt Molnar, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy. Memphis, TN.
6:18 p.m. TH-OR097
Renal and Heart Function in Essential Hypertension — Vanessa E. Tzamou, Panagiota E. Giannou, Eva Karpanou, Dimitrios Petras, Gregory Vyssoulis. Athens, Greece.
67
THURSDAY
4:30 p.m. TH-OR088
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Mineral Disease: Vitamin D, PTH, and FGF-23 Room 115-B Moderators: Marta Christov, MD, PhD, and Orlando M. Gutierrez, MD
4:30 p.m. TH-OR098
Long Term Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation and Cardiac Parameters — Patrícia Matias, Cristina Jorge, Ana Azevedo, Ivo Laranjinha, David Navarro, Ana Carina Ferreira, Tiago Amaral, Marco Mendes, Ines Aires, Célia Gil, Manuel A. Ferreira. Vila Franca de Xira, Portugal.
4:42 p.m. TH-OR099
Proteinuria Increases Phosphatemia By Altering Tubular Handling of Phosphate — Pierre-Yves F. Martin, Sophie M. De Seigneux, Marie Courbebaisse, Joseph M. Rutkowski, Alexandra Wilhelm-Bals, Marie Metzger, Dominique Prie, Carsten A. Wagner, Benedicte Stengel, Philipp Scherer, Eric Feraille, Pascal Houillier. Geneva, Switzerland.
4:54 p.m. TH-OR100
PAI-1 Regulates FGF-23 Metabolism in Plasma — Aaron T. Place, Mesut Eren, Toshio Miyata, Douglas E. Vaughan. Chicago, IL.
5:06 p.m. TH-OR101
Rapid Minute-to-Minute Regulation of Plasma Fibroblast Growth Factor 23 – A Key Role of the Kidney — Maria Lerche Mace, Eva Gravesen, Jacob Hofman-Bang, Klaus Olgaard, Ewa Lewin. Copenhagen, Denmark.
5:18 p.m. TH-OR102
Inflammation and Iron Deficiency Stimulate FGF23 Production — Valentin David, Aline Martin, Kimberly Zumbrennen-Bullough, Chia Chi Sun, Herbert Y. Lin, Tamara Isakova, Jodie L. Babitt, Myles S. Wolf. Chicago, IL.
5:30 p.m. TH-OR103
FGF23 Targets the Heart by Activating FGFR4 — Ansel P. Amaral, Alexander Grabner, Saurav Singh, Karla J. Schramm, Alexis J. Sloan, Myles S. Wolf, Christian Faul. Miami, FL.
5:42 p.m. TH-OR104
Pharmacologic FGFR4 Blockade Attenuates LVH in a Rodent Model of CKD — Alexander Grabner, Ansel P. Amaral, Saurav Singh, Karla J. Schramm, Alexis J. Sloan, Dominik Kentrup, Stefan Reuter, Hermann Pavenstaedt, Giovana Seno Di Marco, Myles S. Wolf, Marcus Brand, Christian Faul. Miami, FL.
5:54 p.m. TH-OR105
Association of Bioavailable Vitamin D, Bone Mineral Density and Markers of Mineral Metabolism in Adults with Nephrotic Syndrome — Ashok Kumar Yadav, Abhinav Aggarwal, Vinod Sharma, Raja Ramachandran, Vivekanand Jha. Chandigarh, India.
6:06 p.m. TH-OR106
Association of Bone Turnover with Oxidized PTH, but Not ‘Intact’ PTH or Non-Oxidized PTH, in Patients Undergoing Hemodialysis (HD) Treatment — Berthold Hocher, Janaina Silva Martins, Tilman B. Drueke, Vanda Jorgetti. Potsdam, Germany.
6:18 p.m. TH-OR107
Increased Bone Density in Mice Lacking the Proton Receptor OGR1 Is due to Increased Osteoblast Activity — Nancy S. Krieger, Min Ho Kim, David A. Bushinsky. Rochester, NY.
68
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Na+, K+, and Cl- Basic Room 203 Moderators: Pablo A. Ortiz, PhD, and Arohan R. Subramanya, MD, FASN
Calcineurin Homologous Protein 1 Regulates the Renal Na-K-2Cl-Cotransporter — Kerim Mutig, Christin Dathe, Alexander Paliege, Vera Jankowski, Shigeo Wakabayashi, Takashi Hisamitsu, Sebastian Bachmann. Berlin, Germany.
4:42 p.m. TH-OR109
Identification of DNPEP, a Cytosolic Aminopeptidase That Cleaves SPAK in the Kidney — Nicolas Markadieu, Paul A. Welling, Eric J. Delpire. Nashville, TN.
4:54 p.m. TH-OR110
Functional Characterization of an Alternative Splice Variant of the Thiazide-Sensitive NaCl Cotransporter — Sabina K. Jelen, Omar Tutakhel, Marco Valdez Flores, Joost Hoenderop, René J. Bindels. Nijmegen, Netherlands.
5:06 p.m. TH-OR111
KCNJ10 (Kir4.1) Determines the Apical Na-Cl Expression in the Distal Convoluted Tubule (DCT) — WenHui Wang. Valhalla, NY.
5:18 p.m. TH-OR112
Increased Calcium-Binding Protein 39 (Cab39) Expression in Renal Tubule Recuses the Gitelman-Like Phenotype in Wnk4 Knockout Mice — Sung-Sen Yang, Shih-Hua P. Lin, Chih-Jen Cheng. Taipei, Taiwan.
5:30 p.m. TH-OR113
Renal Epithelial-Specific Disruption of Cullin 3 Causes Salt-Wasting, Polyuria, and Renal Fibrosis — Hae Jean Park, James A. McCormick. Portland, OR.
5:42 p.m. TH-OR114
Distal Nephron Remodeling Occurs in Response to a Loss of Thiazide-Sensitive SodiumChloride Channel Phosphorylation — P. Richard Grimm, Susan M. Wall, Eric J. Delpire, Paul A. Welling. Baltimore, MD.
5:54 p.m. TH-OR115
MicroRNA-27 Is Upregulated by Aldosterone in the Kidney Distal Nephron Where It Facilitates the Regulation of ENaC-Mediated Sodium Transport — Michael Butterworth, Christine Anne Klemens, Yu Leng Phua, Jacqueline Ho. Pittsburgh, PA.
6:06 p.m. TH-OR116
The PIM-3 Kinase as a New Player in the Aldosterone-Regulated Renal Salt Handling — Alessia Spirli, Caroline Ronzaud, Olivier Staub. Lausanne, Switzerland.
6:18 p.m. TH-OR117
The BKα/β1 Channel Localizes to Cilia of Principal Cells (PC) in Cortical Collecting Duct (CCD) — Rolando Carrisoza-Gaytan, Carlos Schreck, Lijun Wang, WenHui Wang, Lisa M. Satlin. New York, NY.
69
THURSDAY
4:30 p.m. TH-OR108
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session New Mechanisms in Renal Injury Room 119-B
Moderators: H. Terence Cook, MBBS, and Jeremy Stuart Duffield, MD, PhD
4:30 p.m. TH-OR118
In Vivo Measurement of Albumin Concentration Gradients within the Glomerular Capillary Wall — Bingshu Wang, Ruben M. Sandoval, Bruce A. Molitoris, Don Mitchell Wilkes, William Fissell. China.
4:42 p.m. TH-OR119
Genetic Deletion of Endothelial Hyaluronan Synthase 2 Results in Glomerular Injury and Albuminuria — Bernard van den Berg, Margien G.S. Boels, Cristina Avramut, Erik Jansen, Sascha Meldner, Martijn Dane, Johan Van der Vlag, Hans Vink, Abraham J. Koster, Anton Jan Van Zonneveld, Hermann-Josef Groene, Eelco de Koning, Ton J. Rabelink. Leiden, Netherlands.
4:54 p.m. TH-OR120
The Absence of Albumin Improves Kidney Disease in Alport Mice — George Jarad, Jeffrey H. Miner. St. Louis, MO.
5:06 p.m. TH-OR121
Tubule-Specific ß-Catenin Signaling Contributes to Glomerular Injuries — Roderick J. Tan, Dong Zhou, Liangxiang Xiao, Robert Powers, Youhua Liu. Pittsburgh, PA.
5:18 p.m. TH-OR122
Endoplasmic Reticulum Stress Is a New Therapeutic Target in Proteinuric Chronic Kidney Diseases — Khalil El Karoui, Amandine Viau, Clement Nguyen, Martine Burtin, Laurence Heidet, Geraldine Mollet, Frank Bienaime, Morgan Gallazzini, Fabiola Terzi. Paris, France.
5:30 p.m. TH-OR123
Injury to Glomerular Permeability Barrier by Cardiotrophin-Like Cytokine Factor 1 (CLCF1) or Focal Segmental Glomerulosclerosis (FSGS) Serum Is Mediated by JAK2 and STAT3 Activation — Mukut Sharma, Jianping Zhou, Tarak Srivastava, Ellen T. McCarthy, Ram Sharma, Virginia J. Savin, Jean-Francois Gauchat. Kansas City, MO.
5:42 p.m. TH-OR124
Neutrophil and Macrophage Extracellular Traps and Extracellular Myeloperoxidase Are Prominent in Human Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis — Kim M. O’Sullivan, Shaun A. Summers, Poh-Yi Gan, Sharon Lee Ford, A. Richard Kitching, Peter G. Kerr, Stephen R. Holdsworth. Melbourne, Australia.
5:54 p.m. TH-OR125
Neutrophil-Extracellular Traps Cause ANCA-Induced Glomerulonephritis in a ComplementDependent Mannor — Adrian Schreiber, Ralph Kettritz, Astrid Bergmann. Berlin, Germany.
6:06 p.m. TH-OR126
Fanconi Syndrome Associated Light Chains Trigger Aberrations of Endolysosomal Compartments and Apical Dedifferentiation in Proximal Tubule Cells — Alessandro Luciani, Claudia Raggi, Jenny A. Kuerth, Vincent Javaugue, Christophe Sirac, Olivier Devuyst. Zurich, Switzerland.
6:18 p.m. TH-OR127
Genetic Activation of Hypoxia-Signaling Restores Erythropoietin Synthesis in Renal Myofibroblasts — Tomokazu Souma, Masahiro Nezu, Sadayoshi Ito, Norio Suzuki, Masayuki Yamamoto. Chicago, IL.
70
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
New Perspectives on Permeability and the Glomerular Barrier Room 119-A Moderators: Christian Faul, PhD, and Marcus J. Moeller, MD
Pathogenic Form of suPAR in FSGS — Sanja Sever, Jochen Reiser. Charlestown, MA.
5:30 p.m. TH-OR129
Podocyte Autophagy Is Down Regulated by Cardiotrophin-Like Cytokine Factor-1 (CLCF1), a Permeability Factor in Focal Segmental Glomerulosclerosis (FSGS) — Mukut Sharma, Jianping Zhou, Alok De, Tarak Srivastava, Ellen T. McCarthy, Ram Sharma, Jean-Francois Gauchat, Virginia J. Savin. Kansas City, MO.
4:54 p.m. TH-OR130
Identification of Novel Gene Products that Regulate Glomerular Filtration Barrier Function — Davide Pietro Cina, Chengjin Li, Jason Moffat, Susan E. Quaggin. Chicago, IL.
5:06 p.m. TH-OR131
Regulation of Fluid-Phase Uptake in Podocytes by Albumin-Associated Lipids — Jun-Jae Chung, Tobias B. Huber, George Jarad, Bjorn Hartleben, Jeffrey H. Miner, Andrey S. Shaw. Saint Louis, MO.
5:18 p.m. TH-OR132
MiR-193a Regulates the Transdifferentiation of Human Parietal Epithelial Cells Towards a Podocyte Phenotype — Catherine Meyer-Schwesinger, Sebastian Guhr, Tobias N. Meyer, Marlies Sachs, Rolf A. Stahl, Moin Saleem, Dontscho Kerjaschki. Hamburg, Germany.
4:42 p.m. TH-OR133
The Role of Mesangial Cell-Derived CTGF in Anti-Glomerular Basement Membrane Nephritis — Naohiro Toda, Hideki Yokoi, Masato Kasahara, Kiyoshi Mori, Takashige Kuwabara, Hirotaka Imamaki, Akira Sugawara, Taiji Matsusaka, Kazuwa Nakao, Motoko Yanagita, Masashi Mukoyama. Kyoto, Japan.
5:42 p.m. TH-OR134
Crosstalk of mTOR Signaling and Autophagy — Tillmann Bork, Philipp Lee, Bjorn Hartleben, Tobias B. Huber. Freiburg, Germany.
5:54 p.m. TH-OR135
Investigating a Role for the ShcA Adaptor Protein in Kidney Podocytes — Claire E. Martin, Kelly A. Petersen, Vera Eremina, Susan E. Quaggin, Tomoko Takano, Nina Jones. Guelph, ON, Canada.
6:06 p.m. TH-OR136
Genetic Deletion of Myo1c in Podocytes Protects Them From Glomerular Injury Inducing Agents — Ehtesham Arif, Yogendra Singh Rathore, Lawrence B. Holzman, Deepak Nihalani. Philadelphia, PA.
6:18 p.m. TH-OR137
The Glomerular Filter as an Electrical Powerhouse: How Much Voltage Is Required to Prevent Proteinuria? — Turgay Saritas, Sandra Uhlig, Ralf Hausmann, Jürgen Floege, Marcus J. Moeller. Aachen, Germany.
71
THURSDAY
4:30 p.m. TH-OR128
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Pathogenesis, Risk Factors, and Improving Cardiovascular Outcomes in Dialysis Patients Room 204-C Moderators: Steven M. Brunelli, MD, and Sylvia E. Rosas, MD, FASN
4:30 p.m. TH-OR138
Lower Systolic Blood Pressures Are Consistently Associated with Poorer Outcomes in Incident Hemodialysis Patients in the First 8 Weeks of Treatment — Dugan Maddux, Len A. Usvyat, Jeroen Kooman, Frank van der Sande, Kevin Chan, Peter Kotanko, Franklin W. Maddux, John W. Larkin. Waltham, MA.
4:42 p.m. TH-OR139
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-Analysis — Kevin Quach, Lyubov O. Lytvyn, Colin Baigent, Joe A. Bueti, Amit X. Garg, Carmel M. Hawley, Richard Haynes, Braden J. Manns, Vlado Perkovic, Christian G. Rabbat, Ron Wald, Michael Walsh. Toronto, ON, Canada.
4:54 p.m. TH-OR140
Comparative Effectiveness of Renin-Angiotensin System Antagonists in Chronic Dialysis Patients — Theresa I. Shireman, James B. Wetmore, Edward F. Ellerbeck, Jonathan D. Mahnken, Milind A. Phadnis. Kansas City, KS.
5:06 p.m. TH-OR141
Comparative Effectiveness of Cardioselective and Non-Selective β-Adrenergic Blockers in Chronic Dialysis Patients — Theresa I. Shireman, James B. Wetmore, Edward F. Ellerbeck, Milind A. Phadnis, Jonathan D. Mahnken. Kansas City, KS.
5:18 p.m. TH-OR142
A Social Worker Initiated Program to Reduce Fluid Overload in Hemodialysis Patients — Stephanie Johnstone, Nien-Chen Li, Franklin W. Maddux, Amy R. Weissman-Hunt, Jessica Demaline, Eduardo K. Lacson. San Diego, CA.
5:30 p.m. TH-OR143
The Role of Cardiomyocyte Apoptosis in the Pathogenesis of Left Ventricular Hypertrophy (LVH): Results from the Frequent Hemodialysis Network (FHN) — Christopher T. Chan, Michael V. Rocco, Glenn M. Chertow, George A. Kaysen, Nathan W. Levin, Brett Larive, Gerald J. Beck, Alan S. Kliger. Toronto, ON, Canada.
5:42 p.m. TH-OR144
Frequency and Distribution of Dialysis-Associated Atrial Fibrillation: Results of MiD Study — James A. Tumlin, David M. Charytan, Don E. Williamson, Amber S. Podoll, Suresh Chandra Tiwari, Prabir Roy-Chaudhury, Vikranth Reddy. Chattanooga, TN.
5:54 p.m. TH-OR145
Greater Frequency of Clinically Significant Bradycardia Than Ventricular Tachycardia in Hemodialysis Patients: Preliminary Results of the Monitoring in Dialysis (MiD) Study — David M. Charytan, Bruce A. Koplan, Amber S. Podoll, Vikranth Reddy, Prabir Roy-Chaudhury, Suresh Chandra Tiwari, James A. Tumlin, Don E. Williamson. Brookline, MA.
6:06 p.m. TH-OR146
Remote Ischaemic Preconditioning in Haemodialysis: An Initial Randomised Controlled Trial — Lisa E. Crowley, Aghogho Odudu, Chris W. McIntyre. Derby, United Kingdom.
6:18 p.m. TH-OR147
Primary Prevention Implantable Cardioverter Defibrillators in Dialysis Patients: A Matched Cohort Study — Patrick H. Pun, Anne Hellkamp, Gillian Sanders, John Paul Middleton, Stephen Hammill, Hussein Al-Khalidi, Lesley H. Curtis, Gregg C. Fonarow, Sana M. Al-Khatib. Durham, NC.
72
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Renal Epithelial Biology in Diabetes Room 118-B
Moderators: Radko Komers, MD, PhD, and David J. Nikolic-Paterson, PhD, FASN
Effect of Maternal Obesity in Offspring Predisposition to Chronic Kidney Disease in Rats — Sarah J. Glastras, Hui Chen, Carol A. Pollock, Sonia Saad. St. Leonards, NSW, Australia.
4:42 p.m. TH-OR149
Tubular Dysfunction Results in Altered Nucleoside Metabolism in Diabetic Nephropathy — Anna V. Mathew, Farsad Afshinnia, Jaeman Byun, Pradeep Kayampilly, Frank C. Brosius, Subramaniam Pennathur. Ann Arbor, MI.
4:54 p.m. TH-OR150
G Protein Coupled Receptor TGR5 Agonist Prevents Kidney Disease in Mice with Diet Induced Obesity — Xiaoxin Wang, Yuhuan Luo, Cherelle Parker, Luciano Adorini, Michal Herman-Edelstein, Moshe Levi. Aurora, CO.
5:06 p.m. TH-OR151
Glomerular microRNA-26a Expression Correlates with eGFR in Diabetic Nephropathy and Its Regulation in Podocytes — Kenichi Koga, Hideki Yokoi, Kiyoshi Mori, Masato Kasahara, Takashige Kuwabara, Moin Saleem, Akira Sugawara, Kazuwa Nakao, Motoko Yanagita, Masashi Mukoyama. Kyoto, Japan.
5:18 p.m. TH-OR152
Overexpression of Transcription Factor FOXC2 Induces Dedifferentiation and Increased Motility of Cultured Human Podocytes — Sanna H. Lehtonen, Naoyuki Miura, Moin Saleem, Neeta Datta. Helsinki, Finland.
5:30 p.m. TH-OR153
Attenuated Cholesterol Efflux Causes Podocyte Cholesterol Accumulation and Apoptosis in Diabetic Kidney Disease — Christopher E. Pedigo, Farah Leclercq, Mayrin Correa-Medina, Alla Mitrofanova, Armando Mendez, Robert G. Nelson, George William Burke, Alessia Fornoni, Sandra M. Merscher. Miami, FL.
5:42 p.m. TH-OR154
Podocyte-Specific Nox4 Deletion Attenuates Albuminuria in Diabetic Nephropathy — Jay Chandra Jha, Stephen P. Gray, Mark E. Cooper, Harald H. Schmidt, Karin Jandeleit-Dahm. Cambellfield, Victoria, Australia.
5:54 p.m.
Invited Lecture: Podocyte Lipid Biology in Diabetic Nephropathy — Alessia Fornoni, MD, PhD, FASN
73
THURSDAY
4:30 p.m. TH-OR148
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Renal Inflammation: Novel Mechanisms and Therapeutic Targets Room 109 Moderators: Mark A. Little, MD, PhD, and Sundararaman Swaminathan, MD
4:30 p.m. TH-OR155
Unraveling the Mechanism of Action of Glucocorticoids in Glomerulonephritis — Christoph Kuppe, Claudia R.C. van Roeyen, Antonio Sechi, Tammo Ostendorf, Bart Smeets, Jürgen Floege, Hermann-Josef Groene, Marcus J. Moeller. Aachen, Germany.
4:42 p.m. TH-OR156
The Kidney Regulates Granulopoiesis and Neutrophil Homeostasis via Tamm-Horsfall Protein–Dependent Epithelial Activation of the IL-23/IL-17 Axis — Radmila Micanovic, Edward F. Srour, Pierre C. Dagher, Brahmananda Reddy Chitteti, Shehnaz Khan, Takashi Hato, Tarek M. El-Achkar. Indianapolis, IN.
4:54 p.m. TH-OR157
The Lymphotoxin β Receptor Is a Therapeutic Target in Renal Inflammation — Stephan Segerer, Gitta Seleznik, Harald Seeger, Kai Fu, Maja Lindenmeyer, Marcus J. Moeller, Judith Bauer, Mathias Heikenwaelder, Jeffrey L. Browning. Zürich, Switzerland.
5:06 p.m. TH-OR158
Milk Fat Globule-Epidermal Growth Factor-8 Limits Tissue Damage Through Inflammasome Inhibition in Renal Obstruction — Jean-Francois Cailhier, Marie-Joelle Brissette, Patrick Laplante. Montreal, QC, Canada.
5:18 p.m. TH-OR159
Myeloid-Derived tPA Promotes Macrophage Motility through FAK, Rac1 and NF-κB Pathway — Ling Lin, Kebin Hu. Hershey, PA.
5:30 p.m. TH-OR160
Lysosomal Transporter Cystinosin Alters Macrophage Activation and Promotes Renal Fibrosis — Daryl M. Okamura, Nadia Bahrami. Seattle, WA.
5:42 p.m. TH-OR161
A Small Molecule Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1) Reduces Key Pathological Processes Related to CKD — John T. Liles, Haichun Yang, Agnes B. Fogo, David G. Breckenridge. Foster City, CA.
5:54 p.m. TH-OR162
Loss of Sec63 and Xbp1 Caused Renal Interstitial Inflammation and Fibrosis — Yasunobu Ishikawa, Sorin V. Fedeles, Ming Ma, Rachel Gallagher, Stefan Somlo. East Haven, CT.
6:06 p.m. TH-OR163
De Novo Synthesis of Acetylcholine by Podocytes Is a Key Mechanism for Kidney SelfDefense against Progressive Kidney Injury — Gabriela E. Garcia, Luan D. Truong, Jessica Helen Trostel, Richard J. Johnson, Lili Feng. Greenwood Village, CO.
6:18 p.m. TH-OR164
Transcriptome-Based Cluster Analysis Identifies TNF-Subgroup in Focal and Segmental Glomerulosclerosis — Sebastian Martini, Viji Nair, Felix H. Eichinger, Heather N. Reich, Matthias Kretzler. Ann Arbor, MI.
74
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Translational Transplantation Room 104 Moderators: Ulf H. Beier, MD, and John J. Friedewald, MD
Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated with Renal Allograft Failure — Barry I. Freedman, Bruce A. Julian, Stephen O. Pastan, Ajay K. Israni, Allan D. Kirk, Robert S. Gaston, Robert J. Stratta, Sumit Mohan, Patricia L. Adams, Amudha Palanisamy, Amber M. Reeves-Daniel, Jasmin Divers. Winston-Salem, NC.
4:42 p.m. TH-OR166
Variation in the Multidrug Resistance Protein 1 Gene (ABCB1) in African American Deceased Organ Donors Is Associated with Renal Allograft Failure — Jun Ma, Jasmin Divers, Nicholette D. Palmer, Bruce A. Julian, Stephen O. Pastan, Ajay K. Israni, Robert S. Gaston, Lijun Ma, Robert J. Stratta, Amudha Palanisamy, Amber M. Reeves-Daniel, Barry I. Freedman. Winston-Salem, NC.
4:54 p.m. TH-OR167
Impact of Pre Transplant Donor Specific Antibodies in the Setting of a Negative Cell Based Flow Cytometry Cross Match on Graft Outcomes — Oluwafisayo O. Adebiyi, Jane Gralla, Alexander C. Wiseman, James E. Cooper. Aurora, CO.
5:06 p.m. TH-OR168
Persistence or De Novo Occurrence of C1q-Binding Donor Specific Antibodies Strongly Predict Future Graft Loss in Presensitized High-Risk Kidney Transplant Recipients — Sebastian Markus Schaefer, Caner Süsal, Gerhard Opelz, Luis Eduardo Becker, Stefanie Sickmüller, Ruediger Waldherr, Stephan Macher-Goeppinger, Martin G. Zeier, Christian Morath. Heidelberg, Germany.
5:18 p.m. TH-OR169
A Novel Multiplex Approach to Define Peripheral Blood HLA-Specific B-Cell Subsets in Clinical Transplantation — Ahmed Akl, Anat R. Tambur, Mohammed Javeed Ansari. Chicago, IL.
5:30 p.m. TH-OR170
Urine Kidney Injury Biomarkers and Risk of Cardiovascular Events, Death and End-Stage Renal Disease among Prevalent Kidney Transplant Recipients: The FAVORIT Trial — Nisha Bansal, Daniel E. Weiner, Myra A. Carpenter, Andrew S. Levey, Marc A. Pfeffer, Meyeon Park, Kathleen D. Liu, John W. Kusek, Chi-Yuan Hsu. Seattle, WA.
5:42 p.m. TH-OR171
Distinguishing Acute Antibody-Mediated Rejection (AMR) From T Cell-Mediated Acute Cellular Rejection (ACR) with the 3-Gene Urinary Cell Signature — Thangamani Muthukumar, Darshana Dadhania, Ruchuang Ding, Catherine Snopkowski, Carol Y. Li, John R. Lee, Hua Yang, Vijay K. Sharma, Manikkam Suthanthiran. New York, NY.
5:54 p.m. TH-OR172
Soluble CASK, a New Factor Implicated in the Recurrence of FSGS After Renal Transplantation — Séverine Beaudreuil, Xiaomeng Zhang, Ye Fan, H. Francois, L. Lecru, Jean Jacques Candelier, Bernard Charpentier, Aime Vazquez, Hans Kristian Lorenzo, A. Durrbach. Le Kremlin Bicêtre, France.
6:06 p.m. TH-OR173
The Double-Edged Sword of Therapeutic Tacrolimus Levels in African-American Kidney Transplant Recipients — David J. Taber, Titte Srinivas, Mulugeta Gebregziabher, Kenneth Chavin, Prabhakar Baliga, Leonard Egede. Charleston, SC.
6:18 p.m. TH-OR174
Epithelial to Mesenchymal Transition Markers in Kidney Transplantation Recipients: The CERTITEM Trial — Alexandre Hertig, Lionel Rostaing, Dany Anglicheau, Pierre Merville, Bruno Moulin, Marc Hazzan, Guy Touchard, Fabienne Di Giambattista, Eric Rondeau. Paris, France.
75
THURSDAY
4:30 p.m. TH-OR165
THURSDAY, NOVEMBER 13, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Transplantation: Basic and Experimental Room 112 Moderators: Arjang Djamali, MD, FASN, and Vineet Gupta, PhD
4:30 p.m. TH-OR175
Anti CD40 Autoantibodies Functionally Interact with suPAR to Predict and Cause FSGS Recurrence in Kidney Transplantation — Minnie Sarwal, Tara Sigdel, Changli Wei, Alessia Fornoni, Dany Anglicheau, Nada Alachkar, Jochen Reiser. San Francisco, CA.
4:42 p.m. TH-OR176
Salt Reduces Regulatory T Cells and Accelerates Allograft Rejection — Kassem Safa, Shunsuke Ohori, Ciara N. Magee, Anil K. Chandraker, Leonardo V. Riella. Boston, MA.
4:54 p.m. TH-OR177
Small Molecule Agonists of CD11b/CD18 Reduce Leukocyte Activation and Recruitment to Promote Kidney Allograft Survival — Samia Khan, Mohd Hafeez Faridi, Hatem A. Elshabrawy, James George, Anupam Agarwal, Vineet Gupta. Chicago, IL.
5:06 p.m. TH-OR178
MCMV Infection and Reactivation in Transplantation Tolerance — Lei Zhang, Xiaomin Zhang, Zheng Jenny Zhang, Mary Hummel, Xun-Rong Luo. Chicago, IL.
5:18 p.m. TH-OR179
Molecular and Immunological Phenotype of CNI Minimization Strategies Using an Investigational Proteasome Inhibitor, Ixazomib Citrate — Nancy A. Wilson, Shannon Reese, Gengwen Huang, Arjang Djamali. Madison, WI.
5:30 p.m. TH-OR180
Enhanced Engraftment of Hematopoietic Stem Cells for Solid Organ Transplant Tolerance — Reza Elahimehr, Sashi Kasimsetty, Alana Shigeoka, Dianne B. McKay. La Jolla, CA.
5:42 p.m. TH-OR181
Potent Beneficial Effects of HDAC11 Targeting on Foxp3+ Treg-Dependent Allograft Survival — Jianbing Huang, Liqing Wang, Rongxiang Han, Wayne W. Hancock. Philadelphia, PA.
5:54 p.m. TH-OR182
Inducible Knockdown of SHROOM3 Reduces Renal Fibrosis in Mice — Madhav C. Menon, Chengguo Wei, Ilana Greene, Ruijie Liu, Peter Y. Chuang, John C. He, Barbara T. Murphy. Forest Hills, NY.
6:06 p.m. TH-OR183
The H2S System during Cooling and Rewarming in the Kidney of Hibernators: From Hibernation to Kidney Transplantation — George Johnson Dugbartey, Leo E. Deelman. Groningen, Netherlands.
6:18 p.m. TH-OR184
Environment and Graft Interaction on Renocardiac Injury in Renal Transplantation — Diana A. Papazova, Jaap A. Joles, Marianne C. Verhaar. Utrecht, Netherlands.
76
FRIDAY, NOVEMBER 14, 2014
AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2014 DAY-AT-A-GLANCE 6:45 a.m. – 7:45 a.m.
Educational Symposia
Please refer to the Guide to Educational Symposia for titles and locations. Doors will open at 6:30 a.m. Breakfast will be provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants. Philadelphia Marriott Downtown
8:00 a.m. – 9:30 a.m. Page 80
Plenary Session
ASN Foundation for Kidney Research Founders Circle Recognition, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture Hall D
9:30 a.m. – 10:00 a.m.
Morning Break
9:30 a.m. – 2:30 p.m.
Scientific Exposition and Posters Open
Authors will be available at their posters 10:00 a.m. – 12:00 p.m. Exhibit Halls A-C
10:30 a.m. – 12:30 p.m. Page 81
Basic and Clinical Science Symposia
Clinical Trial End Points: Jumping the Barriers Room 114
10:30 a.m. – 12:30 p.m. Page 82 Page 82 Page 83 Page 83 Page 84 Page 84
Clinical Nephrology Conferences
Anemia Management Revisited Room 113 Antibody-Mediated Rejection: Under the Microscope Room 201-C Atrial Fibrillation: An Emerging Source of Morbidity and Mortality in CKD Room 103 Choosing Wisely When More Is Not Better Room 204-C Drugs, Devices, and Development of AKI Ballroom A Primary and Secondary Membranous Nephropathy Ballroom B
10:30 a.m. – 12:30 p.m. Page 85
Special Sessions
Lessons Learned about Renal Artery Stenosis from the CORAL Trial— ASN/AHA Joint Session Room 108
12:30 p.m. – 2:00 p.m.
Lunch Break
12:45 p.m. – 1:45 p.m.
Educational Symposia
Please refer to the Guide to Educational Symposia for titles and locations. Doors will open at 12:30 p.m. Lunch will be provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants. Philadelphia Marriott Downtown
77
FRIDAY
Exhibit Halls A-C
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m. Page 86 Page 86 Page 87 Page 87 Page 88 Page 89 Page 90 Page 90 Page 91 Page 92
Page 93 Page 93 Page 94
Page 94 Page 95
Page 96
Basic and Clinical Science Symposia
Breaking Bad: The New Chemistry and Metabolomics of Cardiovascular Disease Ballroom A Costimulation Blockade and Kidney: Two Sides to the Story Room 118-C Glutamate Signaling in the Kidney and Beyond Room 105 Gout Genes Identified Room 111 Hiding in Plain Sight: The Cellular Origin of Kidney Repair after AKI Room 201-A Immune Cells in CVD: Good, Bad, or Just Ugly? Room 204-A Metabolic Foundations of Kidney Disease Room 118-B Minimal Change and FSGS: So What’s the Difference? Ballroom B Novel Cellular Therapies for Transplantation Tolerance Room 103 Personalized Medicine: A Primer on Pharmacogenomics, Including the Michelle P. Winn, MD, Endowed Lectureship Room 119-B Regulation of Nephron Number Room 202 Seeing in a New Light: Recent Breakthroughs in Imaging the Kidney Room 114 Sorting It Out in Endosomes: An Emerging Concept in Renal Epithelial Cell Transport Regulation Room 115-C Sudden Cardiac Arrest: The Silent Killer Room 204-C The Moving and Hurting Together: The Muscle–Bone Unit in CKD, Including the Jack W. Coburn, MD, Endowed Lectureship Room 201-C Timely Topics in PD: From Membrane Physiology to Therapeutic Advances Room 109
2:00 p.m. – 4:00 p.m. Page 97 Page 98
Page 99 Page 99
Special Sessions
Boost Your Teaching Skills to Become a Contemporary Nephrology Educator Room 107 Diabetes and Advanced CKD: Diabetologists and Nephrologists on the Frontline— ASN/ADA Joint Session Room 113 Highlights from the ERA-EDTA Congress in Amsterdam Room 108 State of the Union of Federal Investment in Kidney Research Room 115-B
4:00 p.m. – 4:30 p.m.
Afternoon Break
Foyers of Room 108, Room 118, Room 201, and Ballroom
78
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m. Page 100 Page 100 Page 101 Page 101 Page 102
Clinical Nephrology Conferences
Cystic Kidney Disease in Children: Beyond Polycystic Room 103 Living on the Edge: Where Should We Draw the Line with Medically Complex Living Donors? Room 113 Obstetric Nephrology Ballroom A Perspectives on Volume, Fluids, and Urine: How They Impact AKI Ballroom B The Expanding Role of Interventional Nephrology Room 201-C
4:30 p.m. – 6:30 p.m. Page 103 Page 104 Page 105
Page 107 Page 108 Page 109 Page 110 Page 111 Page 112 Page 113 Page 114 Page 115 Page 116 Page 117 Page 118
79
FRIDAY
Page 106
Oral Abstract Sessions
AKI: Cellular Responses to Injury and Repair - II Room 107 Autophagy and Cellular Stress Mechanisms Room 104 CKD: Complications and Outcomes Room 204-C CKD: Estimating Equations, Incidence, Prevalence, and Special Populations Room 204-A Dialysis: Anemia and Iron Metabolism Room 115-C Dialysis: Identifying Risk Factors and Improving Noncardiovascular Outcomes Room 118-B Frailty and Sarcopenia: What’s in the Definition Room 118-C Glomerular Disease: Treatment and Outcomes Room 108 Hypertension: Understanding Immune Cells, Hormones, and Salt and Mineral Excretion Room 105 Immunopathogenesis of Glomerulonephritis Room 111 Innovation in Clinical Transplantation Room 201-A Mechanisms of Acid-Base Balance and Disease Room 203 Mineral Disease: Ca/Mg/PO4 Room 119-B Monitoring and Treatment of Diabetic Nephropathy Room 115-B New Molecular Pathways in Fibrosis Room 109 Oxidative Pathways to Cell Damage Room 112
FRIDAY, NOVEMBER 14, 2014 8:00 a.m. – 9:30 a.m.
Plenary Session
ASN Foundation for Kidney Research Founders Circle Recognition, Kidney News Recognition, Homer W. Smith Award Presentation and Address, State-of-the-Art Lecture Hall D
Supported by an independent educational grant from Akebia Therapeutics.
Upon completion of this session, the participant will be able to describe the influence of the genetic past. 8:00 a.m.
ASN Foundation for Kidney Research Founders Circle Recognition
8:05 a.m.
Kidney News Editor-in-Chief Recognition
8:10 a.m.
Homer W. Smith Award Presentation and Address “Single-Gene Defects Elucidate Mechanisms of CKD” Friedhelm Hildebrandt, MD
8:50 a.m.
State-of-the-Art Lecture “What We Can Learn from the Genetic Past?” Eske Willerslev, DSc
10:00 a.m. – 12:00 p.m.
Poster Presentations Exhibit Halls A-C
Renal Transport Mechanisms (001-050) AKI: Basic – Off the Beaten Path (052-092) AKI: Epidemiology and Outcomes (093-139) Cystic Kidney Diseases: Basic and Translational Science (140-188) Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases (189-227) Fellows Case Reports: Hereditary Kidney Diseases and Electrolytes (228-271) Inflammation, Biomarkers, and Outcomes (272-292) Renal Inflammation: Novel Mechanisms and Targets (293-331) Basic/Experimental Pathology - I (332-381) Transplantation: Basic and Experimental (382-400) Optimizing Graft Outcomes: Transplant Immunology, Therapeutics, and Adherence (401-450) Cell Biology: Glomerular - I (451-500) Extracellular Matrix Biology, Fibrosis, and Cell Adhesion - I (501-530) Glomerular and Tubulointerstitial Disease: Lupus Nephritis and IgA Nephropathy (531-581) Fellows Case Reports: Glomerulopathies and Vasculitis (582-657) Growth Factors, Chemokines, and Autacoids (658-670) Vascular and Lymphatic Development, Function, and Homeostasis (671-680) Apoptosis, Proliferation, Autophagy, Cell Senescence, and Cell Transformation (681-716) Developmental Biology (717-750) Diabetes Mellitus and Obesity: Clinical - I (751-794) CKD: Complications - II (795-814) Vascular Calcification - II (815-842) Mineral Disease: Vitamin D, PTH, and FGF-23 - II (843-882) CKD: Epidemiology and Outcomes - II (883-926) Dialysis for AKI: Hemodialysis, CRRT, SLED, and Others (927-948) Pharmacokinetics/Pharmacodynamics/Pharmacogenomics (949-969) Mechanisms of Vascular Access Function and Complications (970-1001) Dialysis: Epi, Outcomes, Trials – Cardiovascular - I (1002-1043) Dialysis: Palliative and End-of-Life Care (1044-1054) Geriatric Nephrology (1055-1074) Ethics in Transplant, CKD, and Dialysis (1075-1077) Multidisciplinary Team Approaches and Innovative Health Service Delivery Models (1078-1110) Bioengineering (1111-1122)
Please note that this book contains poster sessions but not individual abstract titles and authors. For abstract titles, authors, and more, please refer to the Kidney Week Mobile App, the “Locate Me” Kiosks for Posters and Exhibits in the exposition halls, or the Abstract Supplement pdf at www.asn-online.org/KidneyWeek.
80
FRIDAY, NOVEMBER 14, 2014 10:30 a.m. – 12:30 p.m.
Basic and Clinical Science Symposium Clinical Trial End Points: Jumping the Barriers Room 114
ASN thanks the Kidney Health Initiative for assistance with this session.
This session addresses the critically important issue of clinical trial end points for renal disease. An initial presentation focuses on why we need to innovate in order to choose the right set of end points, followed by a discussion on the need to develop a nephrocentric approach in this area. Then a presentation covers the benefits of early involvement of regulators, payers, and patients in this process. Finally, a panel discusses “Developing Innovative Real World Clinical Trial End Points for the Kidney Space.” Panelists include representatives from FDA, CMS, NIH, academia, industry, and patient groups. Upon completion of this session, the participant will be able to: 1) discuss the need for innovation in the development of the “right” clinical trial end points; 2) describe a nephrocentric approach to the development of these clinical trial end points; 3) discuss the importance of a multi-disciplinary approach to developing these clinical trial end points; and 4) identify pathways to do all of the above using a panel discussion format.
Moderators: Patrick Archdeacon, MD, and Ronald J. Falk, MD, FASN 10:30 a.m.
Innovating for the Right Clinical Trial End Points: Why It Matters Laura M. Dember, MD, FASN
11:00 a.m.
A Nephrocentric Approach to Clinical Trial End Points Reshma Kewalramani, MD, FASN
11:30 a.m.
Closing the Loop: Involving Regulators, Payers, and Patients Prabir Roy-Chaudhury, MD, PhD, FASN
12:00 p.m.
Panel Discussion: Developing Innovative Real World Clinical Trial End Points for the Kidney Space Paul T. Conway, Michael F. Flessner, MD, PhD, Louis Jacques, MD, James A. Sloand, MD, FASN
81
FRIDAY
Core Competency: Medical Knowledge, Practice-based Learning and Improvement
FRIDAY, NOVEMBER 14, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Anemia Management Revisited Room 113
Supported by an independent educational grant from Akebia Therapeutics.
This session provides the most up-to-date information regarding anemia management in CKD and ESRD patients. Upon completion of this session, the participant will be able to: 1) list the most recent advances in HIF activators as an option for treatment of CKD-related anemia; 2) describe the implications of experiences with peginesatide; 3) discuss the newest developments in treatment of iron deficiency in ESRD; and 4) examine the most updated information regarding erythropoietin dosing and hemoglobin targets in ESRD patients. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Steven Fishbane, MD, and Bruce M. Robinson, MD, FASN 10:30 a.m.
HIF Activators Volker H. Haase, MD
11:00 a.m.
Peginesatide: Lessons Learned Daniel W. Coyne, MD
11:30 a.m.
The New Ceiling and Floor in Anemia Management: Clinical Implications Jeffrey S. Berns, MD, FASN
12:00 p.m.
Iron and Anemia: What Is New in ESRD? Iain C. Macdougall, MD
10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Antibody-Mediated Rejection: Under the Microscope Room 201-C
Nephropathologists and the HLA Lab play a critical role in the diagnosis and management of AMR, both by interpreting biopsy findings and by identifying and categorizing antibodies. In this session, experts in the field review different elements that make up the diagnosis of AMR. Upon completion of this session, the participant will be able to: 1) describe the impact of de novo donor-specific antibodies on the graft; 2) discuss the role of antibodies that fix complement in graft injury; 3) identify the non-HLA antibodies that can participate in AMR; and 4) describe the natural history of graft injury from antibodies. Core Competency: Medical Knowledge Moderators: Robert B. Colvin, MD, and Lorraine C. Racusen, MD, FASN 10:30 a.m.
The Unwelcome Visitor: De Novo DSAs Michael Mengel, MD
11:00 a.m.
Complement Binding Antibodies Adriana Zeevi, PhD
11:30 a.m.
Out of the Ordinary: Non-HLA Antibodies Elaine F. Reed, PhD
12:00 p.m.
What It All Means for the Graft Peter W. Nickerson, MD
82
FRIDAY, NOVEMBER 14, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Atrial Fibrillation: An Emerging Source of Morbidity and Mortality in CKD Room 103
Recent data suggest that atrial fibrillation is common in the CKD population. This session examines how atrial fibrillation affects the CKD population and how the nephrologist can optimize management. Upon completion of this session, the participant will be able to: 1) report current data on morbidity of atrial fibrillation; and 2) discuss possible management strategies. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Alan S. Go, MD, and Wolfgang C. Winkelmayer, MD, ScD, FASN Atrial Fibrillation Morbidity in Vulnerable Populations Elsayed Z. Soliman, MD
11:00 a.m.
Can Atrial Fibrillation Hasten the Onset of ESRD? Nisha Bansal, MD
11:30 a.m.
To Treat or Not: ASA, Warfarin, Heparin, Direct Thrombin Inhibitors, or Nothing for Atrial Fibrillation? Anne-Lise Kamper, MD
12:00 p.m.
Targeting Therapy for Atrial Fibrillation Using Pharmacogenomics Melanie S. Joy, PharmD, PhD, FASN
10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Choosing Wisely When More Is Not Better Room 204-C
The pill burden in ESRD patients is of major concern. It is not uncommon to use high pharmacological doses in these patients to achieve a therapeutic goal. At what level will there be no returned benefit by escalating the dose or adding different agents? The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) describe the steps needed to be taken prior to escalating pharmacologic therapy; 2) discuss specific risk/benefit assessment in the management of hypertension in ESRD patients; 3) describe specific risk/benefit assessment in the management of hyperphosphatemia in ESRD patients; 4) discuss specific risk/benefit assessment in the management of hyperlipidemia in ESRD patients; and 5) describe specific risk/benefit assessment in the management of anemia in ESRD patients. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Systems-based Practice Moderators: Kamyar Kalantar-Zadeh, MD, PhD, FASN, and Mohamed A. Sekkarie, MD, FASN 10:30 a.m.
Hypertension Management in ESRD Patients: How Much and How Safe? Lionel U. Mailloux, MD
11:00 a.m.
Statin or No Statin? LDL 130, 100, 70, or Whatever? Suetonia Palmer, MD, PhD
11:30 a.m.
A Sliding Scale for Phosphate Binders: Is It Really Appropriate? Rajnish Mehrotra, MD, FASN
12:00 p.m.
ESA-Associated Mortality: Is It the Hemoglobin Level or ESA Dose? Lynda Szczech, MD, FASN
83
FRIDAY
10:30 a.m.
FRIDAY, NOVEMBER 14, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Drugs, Devices, and Development of AKI Ballroom A
New information regarding the role of drugs and devices in the development of AKI continues to accumulate. This session provides an overview of the use of cholesterol-lowering agents, RAAS blockers, or left ventricular assist devices (LVADs) and risk of developing AKI. Upon completion of this session, the participant will be able to: 1) describe the relationship between use of cholesterol-lowering agents or RAAS blockers and AKI risk; 2) discuss drug-induced tubulointerstitial diseases; and 3) outline the effect of LVADs on kidney function and AKI risk. Core Competency: Medical Knowledge Moderators: Jorge Cerda, MD, FASN, and Robert D. Toto, MD 10:30 a.m.
Do Drugs that Lower Cholesterol Influence the Risk of Developing AKI? Amit X. Garg, MD, PhD
11:00 a.m.
RAAS Blockade: Does It Cause or Worsen AKI? Rabi Yacoub, MD
11:30 a.m.
Drug-Induced Tubulointerstitial Diseases: What’s New? Chris Laing, MBChB
12:00 p.m.
AKI in Patients with Left Ventricular Assist Devices Ami Patel, MD
10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Primary and Secondary Membranous Nephropathy Ballroom B
It is difficult in some cases to distinguish primary from secondary membranous nephropathy. The role of anti–PLA-2R and other antibodies in distinguishing primary and secondary membranous is examined. Membranous nephropathy in the setting of hepatitis B infection and malignancy is discussed. Newer therapies for membranous nephropathy are discussed. Upon completion of this session, the participant will be able to: 1) describe the role of anti–PLA-2R and other autoantibodies in distinguishing primary versus secondary membranous nephropathy patients in your practice; 2) discuss therapy for hepatitis B–associated membranous nephropathy patients; 3) examine the relationship between malignancy and membranous nephropathy patients; and 4) examine newer therapies for membranous nephropathy for patients in your practice. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Laurence H. Beck, MD, PhD, and Meryl A. Waldman, MD 10:30 a.m.
Value of Anti–PLA-2R in Discerning “Primary” from “Secondary” Membranous Nephropathy Heather N. Reich, MD, PhD
11:00 a.m.
Membranous Nephropathy and Malignancy: When Are They Related? What Is the Approach? Richard J. Glassock, MD
11:30 a.m.
Beyond the Ponticelli Protocol: Success and Failures Michael J. Choi, MD
12:00 p.m.
Membranous Lupus Nephropathy Fernando C. Fervenza, MD, PhD, FASN
84
FRIDAY, NOVEMBER 14, 2014 10:30 a.m. – 12:30 p.m.
Special Session
Lessons Learned about Renal Artery Stenosis from the CORAL Trial— ASN/AHA Joint Session Room 108
ASN thanks the American Heart Association for assistance with this session.
This session to provide an in-depth look at the long-term randomized controlled clinical trial of optimal medical management alone or with renal artery stenting for treatment of people with renal artery stenosis, Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). This was the largest, most rigorously conducted study in renal artery stenosis to date. The primary results have been recently reported. Attendees will have an opportunity to hear a critical appraisal of the study from those who know it best, along with expert commentary and interactive discussion. Upon completion of this session, the participant will be able to: 1) discuss the main outcomes from the CORAL trial and implications for management of people with renal artery stenosis; 2) describe interventional strategies used in the CORAL trial and how the results apply in practice; and 3) discuss the optimal medical management regimen prescribed in the CORAL trial and its application in clinical care.
Moderators: George L. Bakris, MD, FASN, and Katherine R. Tuttle, MD, FASN 10:30 a.m.
The CORAL Trial: Major Findings and Implications for Treatment of People with Renal Artery Stenosis Lance D. Dworkin, MD, FASN
11:10 a.m.
How Do Interventional Strategies for Renal Artery Stenosis Apply after the CORAL Trial? Christopher J. Cooper, MD
11:50 a.m.
What Is Optimal Medical Management for Renal Artery Stenosis after the CORAL Trial? Kenneth A. Jamerson, MD
85
FRIDAY
Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Breaking Bad: The New Chemistry and Metabolomics of Cardiovascular Disease Ballroom A
Patients with CKD are more likely to die of cardiovascular (CV) causes than to survive long enough to progress to ESRD. Targeting traditional modifiable CV risk factors such as LDL-cholesterol has proven ineffective in ESRD, suggesting the possibility of novel metabolic and biochemical mechanisms of CV disease, which this provocative session explores. Upon completion of this session, the participant will be able to: 1) discuss emerging findings from large-scale genomics and metabolomics; 2) examine the evidence that directly links uremic metabolites to CV risk; and 3) interpret the relationship of bone–mineral metabolism to CV disease. Core Competency: Medical Knowledge Moderators: Thomas H. Hostetter, MD, and Steven Kim, MD 2:00 p.m.
The Human Microbiome: Scope and Potential Impact Lita M. Proctor, PhD
2:24 p.m.
Metabolomics and Genomics in the Framingham Cohort Eugene P. Rhee, MD
2:48 p.m.
Metabolic Mediators of Metabolic Syndrome Svati H. Shah, DrMed
3:12 p.m.
Mitochondria and Metabolomics in Diabetic Complications Kumar Sharma, MD
3:36 p.m.
Designing Better CV Trials in the CKD Population Vlado Perkovic, MBBS, FASN
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Costimulation Blockade and Kidney: Two Sides to the Story Room 118-C
This session reviews current thinking in the role of costimulation pathways in transplantation rejection and glomerulonephritis. Upon completion of this session, the participant will be able to: 1) describe the role of CD28:B7 in transplant rejection; 2) discuss the role of OX40:OX40L in transplant rejection; 3) describe the role of CD27:CD70 in immune regulation; and 4) discuss the role of costimulation in GNs. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Jonathan S. Maltzman, MD, PhD, and Nader Najafian, MD 2:00 p.m.
CD28:B7 in Transplant Immune Regulation Mandy L. Ford, PhD
2:30 p.m.
OX40:OX40L in Transplant Immune Regulation Xian C. Li, MD, PhD
3:00 p.m.
TIM Molecules Nader Najafian, MD
3:30 p.m.
Role of Costimulation in Podocyte Pathology and Nephrotic Syndrome Peter H. Mundel, MD
86
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Glutamate Signaling in the Kidney and Beyond Room 105
Glutamate is a major neurotransmitter in central and peripheral neurons. However, glutamate receptors are expressed by a variety of non-neuronal cells, where glutamate exerts a modulatory role. The session is designed to bring recent advances on the role of glutamate and its receptors in the kidney and in other cells/organs of relevance to kidney diseases, such as immune cells, bone, and pancreatic b cells. Upon completion of this session, the participant will be able to: 1) describe signaling; 2) discuss transmitters and receptors; and 3) describe glutamate. Core Competency: Professionalism, Medical Knowledge, Systems-based Practice Moderators: Thomas Benzing, MD, FASN, and Anna Greka, MD, PhD Glutamate and Glutamate Receptors in the Kidney Stuart E. Dryer, PhD, FASN
2:30 p.m.
Glutamate and the Immune System Francesca Fallarino, PhD
3:00 p.m.
Glutamate Signaling in Bone Yukio Yoneda, PhD
3:30 p.m.
Glutamate as a Modulator of Insulin Secretion Per-Olof Berggren
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Gout Genes Identified Room 111
Recent studies have revealed transporters responsible for the urate excretion. Variations in urate transport genes give form the genetic basis of hyperuricemia and gout. This session highlights these recent developments. Upon completion of this session, the participant will be able to: 1) describe the molecular genetic identity of the key urate transporters; 2) explain that common genetic variants in urate transporters cause hyperuricemia; and 3) describe new therapeutic opportunities for treating gout. Core Competency: Medical Knowledge Moderators: Michael Kottgen, MD, and David B. Mount, MD 2:00 p.m.
Overview of Urate Transport in the Kidney: Assigning Gene to Function Diana I. Jalal, MD
2:30 p.m.
Genetic Variants That Affect Serum Urate Levels and Gout Risk Anna Kottgen, MD
3:00 p.m.
Uncovering the Mechanisms of Genetic Dysfunction in ABCG2 Mediated Urate Secretion Owen M. Woodward, PhD
3:30 p.m.
Mechanisms of Urate Reabsorption by the URAT1 and SLC2A9 Transporters Hiroyuki Sakurai, MD, PhD
87
FRIDAY
2:00 p.m.
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Hiding in Plain Sight: The Cellular Origin of Kidney Repair after AKI Room 201-A
When epithelial cells in the proximal portion of the nephron are damaged, they rapidly proliferate to repair the damage to the kidney. Whether a stem cell is responsible for this proliferative response or not is highly controversial. Although a scattered population of cells can be found in the human proximal tubule that appears to have stem cell characteristics, they could also represent isolated damaged cells that have dedifferentiated and lost their epithelial characteristics. Recent findings have substantially clarified the cellular origin and mechanisms of proliferative proximal tubule repair after kidney injury. This session highlights very recent work in this rapidly developing area. Upon completion of this session, the participant will be able to: 1) describe the proximal tubule response to acute injury; 2) discuss the role of genetic lineage tracing in establishing cellular hierarchies in vivo; 3) state the role of heme-oxygenase-1 in the acute response to tissue damage; and 4) describe the evidence indicating that human proximal tubule may contain a scattered population of progenitors. Core Competency: Medical Knowledge Moderators: Zheng Dong, PhD, FASN, and Kai-Uwe Eckardt, MD 2:00 p.m.
Clonal Analysis Establishes That Differentiated Epithelial Cells Repair Injured Proximal Tubule Benjamin D. Humphreys, MD, PhD, FASN
2:30 p.m.
Evidence for Progenitor Cells in Human Proximal Tubule Paola Romagnani, MD
3:00 p.m.
Parietal and Proximal Tubule Epithelium and Regeneration Bart Smeets, PhD
3:30 p.m.
Heme-Oxygenase-1 and Adaptive Responses to Acute Injury Anupam Agarwal, MD, FASN
88
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Immune Cells in CVD: Good, Bad, or Just Ugly? Room 204-A
Accumulation of cholesterol metabolites in the arterial intima may lead to a proinflammatory response and promote atherosclerosis. Recent evidence suggests that the immune system might also play a protective role. Regulatory T cells may enhance cholesterol clearance from blood vessels. Besides cholesterol, immune cells are also sensitive to sodium. High interstitial sodium concentrations lead to IL-17 polarization of T cells and promote an autoimmune phenotype, which may link salt metabolism with cardiovascular disease (CVD). T cells are also important mediators of angiotensin (Ang)-induced hypertension. Ang II increases blood pressure only when T cells are present, linking the pathogenesis of the blood-pressure increase with a proinflammatory response. Immune cells may increase blood pressure by inducing proinflammatory responses in blood vessels, in the brain, or in the kidney. The experts in this session address this important topic.
Core Competency: Medical Knowledge Moderators: Thomas M. Coffman, MD, FASN, and Richard J. Johnson, MD 2:00 p.m.
Good or Bad? Proinflammatory versus Homeostatic Immune Cell Response in Arteries Roland Klingenberg, MD
2:30 p.m.
Salt as a Novel Immune Cell Activator: Salt Storage and Immune Cell Polarization Dominik N. Müller, PhD
3:00 p.m.
Immune Mechanisms of Angiotensin-Induced Hypertension David G. Harrison, MD
3:30 p.m.
How Renal Inflammation Increases Blood Pressure Bernardo Rodriguez-Iturbe, MD
89
FRIDAY
Upon completion of this session, the participant will be able to: 1) describe that immune cells are indispensable for blood-pressure regulation in most of the established animal models used to study arterial hypertension; 2) explain that immune cells are involved in inflammatory responses in cholesterol-driven arteriosclerosis; and 3) discuss that immune cells are actively regulate cholesterol levels in arteries.
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Metabolic Foundations of Kidney Disease Room 118-B
Cell metabolism has been recognized in recent years as a key regulator of cell survival and proliferative responses during periods of cell stress. This session provides an overview of the dependence of cell survival pathways on metabolic responses and provides descriptions of specific types of renal disease in which perturbations of cell metabolism result in abnormal end organ responses. Upon completion of this session, the participant will be able to: 1) describe the role of cell metabolism in cell survival; 2) list approaches to better study cell metabolism in specific disease states; and 3) discuss ways in which perturbations of cell metabolism result in disease progression in the kidney. Core Competency: Medical Knowledge Moderators: Patrick D. Brophy, MD, and Michael J. Caplan, MD, PhD 2:00 p.m.
Autophagic Cell Survival Muniswamy Madesh, PhD
2:30 p.m.
Glucose Metabolism in PKD Alessandra Boletta, PhD
3:00 p.m.
The Use of Metabolomics for Biomarker and Therapeutic Target Discovery Robert H. Weiss, MD
3:30 p.m.
Regulated Cell Necrosis after Ischemic Kidney Injury Stefan Krautwald, PhD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Minimal Change and FSGS: So What’s the Difference? Ballroom B
There has been confusion about relations between minimal change disease and FSGS almost since they were first defined by light microscopy. Originally, they were thought to have markedly contrasting prognoses, but the distinctions have been increasingly blurred and are likely to remain so in the absence of clear knowledge of pathogenesis. The introduction of molecular methods provides a much more precise way of analyzing these entities and provides the promise of more accurate diagnosis and targeted management. This session reviews the latest data on this fast moving area. Upon completion of this session, the participant will be able to: 1) describe what information can be gained from microscopy and what cannot; 2) discuss the extent to which analysis of gene expression amplifies what can be learned from microscopy; 3) report the latest information of permeability factors in FSGS; and 4) describe how the excretion of podocyte-specific mRNAs provides prognostic information. Core Competency: Medical Knowledge Moderators: Clemens D. Cohen, MD, and Vivette D. D’Agati, MD 2:00 p.m.
The Power and Limitations of the Microscope: It Looks like FSGS but Walks like MCD J. Charles Jennette, MD
2:30 p.m.
Comparative Transcriptomics of Minimal Change Disease and FSGS Matthias Kretzler, MD
3:00 p.m.
Podometrics in FSGS and Minimal Change Disease Roger C. Wiggins, MD
3:30 p.m.
Where Is the Permeability Factor? Lawrence B. Holzman, MD
90
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Novel Cellular Therapies for Transplantation Tolerance Room 103
This session summarizes current experimental tolerance strategies in clinical trials and the use of biomarkers for a tolerance signature. Upon completion of this session, the participant will be able to: 1) describe the role of mixed chimerism in tolerance induction; 2) discuss the role of donor-specific regulatory T cells in tolerance induction; and 3) describe the utility of biomarkers in establishing a tolerance signature. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Peter S. Heeger, MD, and Leonardo V. Riella, MD, PhD, FASN The Role of Facilitator Cells in Tolerance Induction for Kidney Transplantation Joseph Ross Leventhal, MD, PhD
2:30 p.m.
Ex Vivo Expanded Regulatory T Cells for Clinical Tolerance Induction Qizhi Tang, PhD
3:00 p.m.
Combined Kidney and HSC Transplant for Tolerance Induction John D. Scandling, MD
3:30 p.m.
Mesenchymal Stem Cells for Immunosuppression Minimization in Kidney Transplantation Camillo Ricordi, MD
91
FRIDAY
2:00 p.m.
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Personalized Medicine: A Primer on Pharmacogenomics, Including the Michelle P. Winn, MD, Endowed Lectureship Room 119-B
ASN gratefully acknowledges Duke University School of Medicine, the school’s Division of Nephrology, and several individuals for support of the Michelle P. Winn, MD, Endowed Lectureship.
Several risk models have been developed to predict kidney failure in patients with CKD. A recent review showed that there are several viable models that are ready for clinical testing. Proteinuria increases the risk for adverse outcomes in CKD patients. Recent evidence suggests that proteinuria correlates with the rate of GFR decline in CKD. Estimating the risk of progression based on trends in proteinuria may help clinicians determine which patients should be treated more aggressively. Rhabdomyolysis is a fairly common condition. Creatinine phosphokinase (CPK) levels are generally closely monitored. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) discuss predictive models that may aid clinicians in understanding individual patient risk for kidney failure, cardiovascular events, and mortality and making decisions regarding care of CKD patients; 2) describe new predictive models and risk assessment tools that may aid clinicians in determining the risk of AKI in patients with rhabdomyolysis; 3) discuss recent advances in whole genome sequencing; and 4) describe the use of whole genome sequencing for diagnosis. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice Moderators: Peter W. Mathieson, MD, PhD, MBBS, and Rulan S. Parekh, MD, FASN 2:00 p.m.
Genetics of Human FSGS—The Michelle P. Winn, MD, Endowed Lectureship Andrey S. Shaw, MD
2:30 p.m.
Rapid Diagnosis of Severe Pediatric Genetic Disorders Using Clinical Exome Sequencing Stephen F. Kingsmore, MD, PhD
3:00 p.m.
Use of Whole Genome Analysis in Undiagnosed Diseases Howard J. Jacob, PhD
3:30 p.m.
The NIH Undiagnosed Diseases Program William Gahl, MD, PhD
92
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Regulation of Nephron Number Room 202
The number of nephrons in a human kidney (nephron endowment) shows tremendous variation from individual to individual and can be affected by a variety of genetic and nongenetic factors. Historically, it has been thought that reduced nephron endowment has little impact on health as long as the number of functional nephrons did not drop below a critical threshold, frequently set at 200,000. However, growing evidence indicates that reduced nephron endowment may make individuals susceptible to hypertension and CKD. Final nephron endowment is ultimately determined by the timing of nephron progenitor cell exhaustion, which takes place during gestational week 36 in humans and within the first couple of days after birth in mice. Recent studies have shed light on the molecular processes that regulate the balance between progenitor cell renewal and differentiation and ultimately determine nephron number. This session covers our current understanding of the molecular pathways that determine nephron endowment and how this information can be exploited to improve renal function.
Core Competency: Medical Knowledge Moderators: Denise K. Marciano, MD, PhD, and Joo-Seop Park, PhD 2:00 p.m.
Molecular Regulation of Nephron Progenitor Renewal and Differentiation Leif Oxburgh, PhD
2:30 p.m.
Glomeruli and Podocytes: What Are the Numbers Telling Us? John F. Bertram, PhD
3:00 p.m.
Growing Renal Progenitors In Vitro Minoru Takasato, PhD
3:30 p.m.
Self-Renewal and Differentiation in the Nephron Stem Cell Niche: A Delicate Balance Michael I. Rauchman, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Seeing in a New Light: Recent Breakthroughs in Imaging the Kidney Room 114
New imaging technologies are transforming our understanding of the kidney. These methods allow for cells in the kidney to be monitored in the live mouse for periods up to days in length. Other new methods are allowing single molecule imaging at resolutions that break the diffraction barrier. Upon completion of this session, the participant will be able to: 1) describe new 2 photon microscopic methods in the kidney; 2) describe super-resolution methods of microscopy; and 3) discuss whole organ imaging by CLARITY. Moderators: Karlhans Endlich, MD, and Tobias B. Huber, MD 2:00 p.m.
The Origin and Fate of Podocytes and PECs Studied by Serial Two-Photon Microscopy Janos Peti-Peterdi, MD, PhD
2:30 p.m.
Live Imaging of Immune Complex Formation In Vivo Lai Guan Ng, PhD
3:00 p.m.
Using Clarity: Looking through the Kidney Alfred Hyoungju Kim, MD, PhD
3:30 p.m.
Super-Resolution Imaging of the Kidney Jeffrey H. Miner, PhD
93
FRIDAY
Upon completion of this session, the participant will be able to: 1) describe the key regulators of nephron progenitor renewal; 2) discuss the factors that determine nephron number; and 3) predict the feasibility of tissue engineering.
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Sorting It Out in Endosomes: An Emerging Concept in Renal Epithelial Cell Transport Regulation Room 115-C
Ion and water transport by the kidney is continually adjusted in response to physiologic cues. Selective endocytosis and endosomal trafficking is increasingly appreciated as a mechanism to acutely modulate renal function. This session highlights emerging paradigms in this new area of investigation. Upon completion of this session, the participant will be able to: 1) describe how adaptor molecules couple signal recognition to endocytic pit formation; 2) describe how the epithelial sodium channel and salt balance are controlled by a post-endocytosis routing mechanism; 3) discuss the role of clathrinmediated endocytosis in the podocyte and the filtration barrier; and 4) describe how endocytosis controls AQP2 for water balance. Core Competency: Medical Knowledge Moderators: Dennis Brown, PhD, and Chou-Long Huang, MD, PhD 2:00 p.m.
Endocytic Control of NKCC2 Traffic in the Thick Limb Pablo A. Ortiz, PhD
2:30 p.m.
ESCRTing ENaC for Degradation Peter M. Snyder, MD
3:00 p.m.
Flow-Stimulated Endocytosis in the PT Ora A. Weisz, PhD
3:30 p.m.
Preserving Water, Preventing AQP2 Endocytosis Robert A. Fenton, PhD, FASN
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Sudden Cardiac Arrest: The Silent Killer Room 204-C
Sudden cardiac arrest is a common cause of death in ESRD patients. This session reviews the mechanistic basis for dysrhythmias, identifies risk factors in ESRD that render this population vulnerable to cardiac arrest, and surveys the state-of-the-art research being conducted in this field to identify novel underlying causes and prevent death in the dialysis population. Upon completion of this session, the participant will be able to: 1) enumerate the pathogenesis of dysrhythmias to understand why ESRD is a high-risk condition; 2) discuss emerging research aimed at discovering the interaction between clinical risk factors and genetic predisposition; and 3) describe how sudden cardiac arrest in ESRD patients may be treated in the future. Core Competency: Professionalism, Medical Knowledge Moderators: Raymond M. Hakim, MD, PhD, and Sahir Kalim, MD 2:00 p.m.
Pathogenesis of Dysrhythmias: A Primer for the Nephrologist Peter Zimetbaum, MD
2:30 p.m.
Modifiable Risk Factors for Sudden Cardiac Death in ESRD Patrick H. Pun, MD
3:00 p.m.
Exome Sequencing for Discovery of Novel Sudden Cardiac Arrest Genes Alfred L. George, MD
3:30 p.m.
An Innovation Gap in ESRD Care: Seeking New Therapies for Dysrhythmias Charles A. Herzog, MD
94
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
The Moving and Hurting Together: The Muscle–Bone Unit in CKD, Including the Jack W. Coburn, MD, Endowed Lectureship Room 201-C
Supported by an independent educational grant from OPKO Health Renal Division. ASN gratefully acknowledges Amgen for support of the Jack W. Coburn, MD, Endowed Lectureship. ASN thanks the American Society for Bone and Mineral Research for assistance with this program.
In patients with CKD, the loss of muscle mass is much more intensive. It is associated with the wholebody protein-energy deficiency. It seems to be one of the major factors limiting patient’s autonomy and decreasing the quality of life. If it cannot be treated with simple methods requiring some knowledge and devotion, we will fail to save patients who die due to cardiovascular disease and infection, despite proper conduction of renal replacement therapy. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) describe the interactions between the bone and muscle in CKD; 2) discuss muscle and bone biomechanics; and 3) measure physical performance in kidney disease patients.
Moderators: Jessica B. Kendrick, MD, and Ranjani N. Moorthi, MD, MBBS 2:00 p.m.
Frailty, Fractures, and the Bone-Muscle Connection in CKD— The Jack W. Coburn, MD, Endowed Lectureship Mary B. Leonard, MD
2:30 p.m.
Muscle and Bone Interactions: Myostatin and Aging Mark W. Hamrick, PhD
3:00 p.m.
Muscle Structure and Function in CKD: Relevance of Mitochondrial Function Jorge Gamboa
3:30 p.m.
Molecular and Physiological Aspects of Protein Catabolism in CKD William E. Mitch, MD, FASN
95
FRIDAY
Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Timely Topics in PD: From Membrane Physiology to Therapeutic Advances Room 109
This session updates the attendees regarding the most recent advances in understanding the peritoneal membrane physiology and therapeutic maneuvers to maintain its function. It reviews and updates on the use of acute PD. Upon completion of this session, the participant will be able to: 1) discuss the relevance of systemic and local inflammation and peritoneal membrane structure and function; 2) describe the potential therapies aimed at maintaining peritoneal membrane integrity; 3) define the use of different dialysate compositions; and 4) describe the indications and applicability of acute peritoneal dialysis. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Bernard G. Jaar, MD, FASN, and Jeffrey Perl, MD 2:00 p.m.
Cells and Membrane Function Michael F. Flessner, MD, PhD
2:30 p.m.
Use of Glucose Sparing Dialysate in PD: Is the Verdict in Yet? Cheuk-Chun Szeto, MD
3:00 p.m.
High Bicarbonate Dialysate David W. Johnson, MD, PhD, FASN
3:30 p.m.
Urgent Start PD: How and For Whom? Arshia Ghaffari, DO
96
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Special Session
Boost Your Teaching Skills to Become a Contemporary Nephrology Educator Room 107
Medical education culture is rapidly evolving; nephrologists need to keep abreast of trends. Proficiency with modern teaching and assessment formats is essential for the contemporary nephrology educator, as is the ability to illustrate topics in new ways. In this session, the Master Class segment highlights fresh approaches to teaching glomerular disease. Next, expert educators explore efficiency for observation in the ambulatory setting and innovative techniques to enhance learners’ communication skills. Finally, novel methods to expose residents to the full spectrum of nephrology are addressed. Upon completion of this session, the participant will be able to: 1) illustrate novel strategies to teach glomerular disease; 2) apply effective observation and learner feedback in the ambulatory setting; 3) describe techniques to enhance learner communication skills; and 4) discuss mechanisms to enhance resident exposure to and interest in nephrology. Core Competency: Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice
2:00 p.m.
Master Class: Teaching the Glomerular Diseases Andrew S. Bomback, MD
2:30 p.m.
Practical Tips to Enhance Learners’ Communication Skills Robert A. Cohen, MD, Jane O. Schell, MD
3:00 p.m.
Integrating the Next Accreditation System into Clinic: Efficient Observation John D. Mahan, MD
3:30 p.m.
There’s More to Nephrology than Acute Consults: Redesigning Resident Exposure to Improve Nephrology Interest Karen M. Warburton, MD
97
FRIDAY
Moderators: Kenar D. Jhaveri, MD, FASN, and Laura J. Maursetter, DO
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Special Session
Diabetes and Advanced CKD: Diabetologists and Nephrologists on the Frontline— ASN/ADA Joint Session Room 113
ASN thanks the American Diabetes Association for assistance with this session.
This session focuses on quality of life and delivery of optimal care for people with diabetes and advanced CKD. It emphasizes the cooperative roles of diabetologists and nephrologists in clinical management. Upon completion of this session, the participant will be able to: 1) list the major risks and complications for people with diabetes and CKD as they transition to ESRD; 2) discuss how other diabetic complications should be evaluated and managed in those with diabetes and advanced CKD; 3) describe cognitive decline influences quality of life and choices of care in those with diabetes and advanced CKD; and 4) describe a collaborative care model involving experts in diabetes and nephrology in management for diabetes and advanced CKD. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Ian H. de Boer, MD, and Robert G. Nelson, MD, PhD 2:00 p.m.
What Does CRIC Tell Us about CKD and the Transition to ESRD in Diabetes? Chi-Yuan Hsu, MD
2:30 p.m.
Diabetes Means Multiple Complications: Care of the Eyes and Feet in CKD Patients Amy K. Mottl, MD
3:00 p.m.
Thinking Straight about Cognitive Impairment in Patients with Diabetes and CKD Mark L. Unruh, MD
3:30 p.m.
Collaborative Care for Patients with Diabetes and Advanced CKD: The Diabetologist and the Nephrologist Mark E. Molitch, MD
98
FRIDAY, NOVEMBER 14, 2014 2:00 p.m. – 4:00 p.m.
Special Session
Highlights from the ERA-EDTA Congress in Amsterdam Room 108
ASN thanks the European Renal Association – European Dialysis and Transplant Association for assistance with this session.
This session provides the most interesting aspects of AKI, hypertension, clinical nephrology, and mineral and bone metabolism in CKD presented during the ERA-EDTA Congress in Amsterdam, June 2014. Upon completion of this session, the participant will be able to discuss the latest aspects of AKI, hypertension, clinical nephrology, and mineral and bone metabolism in CKD. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderator: Raymond C. Vanholder, MD, PhD Acute Kidney Injury Norbert H. Lameire, MD, PhD
2:30 p.m.
Hypertension Andrzej Wiecek, MD, PhD
3:00 p.m.
Clinical Nephrology Vladimir Tesar, MD, PhD, FASN
3:30 p.m.
Mineral and Bone Metabolism in CKD Markus Ketteler, MD
FRIDAY
2:00 p.m.
2:00 p.m. – 4:00 p.m.
Special Session
State of the Union of Federal Investment in Kidney Research Room 115-B
ASN thanks its Public Policy Board for assistance with this session.
ASN is increasingly engaged in advocacy and collaborative efforts with federal research funding agencies. Although recognition of issues and investigation related to kidney disease is on the rise within these agencies, their activities remain opaque to many within the nephrology community. This session educates the kidney research community about the myriad research opportunities that exist to advance knowledge within our field. The largest federal funding agencies are represented to increase transparency and raise awareness in the community regarding resources and scope, which will raise the likelihood that more investigators can access the programs that are available to them. Upon completion of this session, the participant will be able to: 1) classify funding opportunities at the NIH; 2) discuss the VA funding programs, including the VA Merit grants and Cooperative Studies Program for large scale clinical projects to advance the study of patients with kidney disease; and 3) apply resources at AHRQ and PCORI regarding current activities to support patient-centered outcomes research and comparative effectiveness research. Core Competency: Medical Knowledge; System-based Learning and Improvement Moderators: Crystal A. Gadegbeku, MD, and John F. O’Toole, MD 2:00 p.m.
Resources for Kidney-Related Research at NIH: Truth and Transparency Mark L. Zeidel, MD, FASN
2:40 p.m.
VA and Kidney Disease: What Have We Done and What Will We Do— From Basic Science to Large Clinical Trials Linda F. Fried, MD, FASN
3:20 p.m.
Overlooked Opportunities: Projects and Programs at AHRQ and PCORI L. Ebony Boulware, MD
99
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Cystic Kidney Disease in Children: Beyond Polycystic Room 103
ASN thanks the Renal Pathology Society for assistance with this session.
Cystic kidney disease in children is often difficult to diagnose accurately, particularly outside the spectrum of ADPKD/ARPKD. There is a considerable phenotypic overlap, and diagnosis often depends on genetics. The pathogenesis of cyst formation as the common denominator of different genetic abnormalities continues to be fascinating and puzzling at the same time. This session makes science simple for the general nephrologist. Upon completion of this session, the participant will be able to: 1) describe the new entities classified under nephronophthisis as these are defined by molecular genetics; 2) discuss the genetic findings and clinical presentation in patients with Bardet–Biedl syndrome (BBS); 3) describe the pathology of cystic kidney disease; and 4) discuss the pathogenesis of cyst formation in the kidney. Core Competency: Medical Knowledge Moderators: Stephen M. Bonsib, MD, and Lisa M. Guay-Woodford, MD 4:30 p.m.
Nephronophthisis with Overlapping Phenotypes John J. Bissler, MD
5:00 p.m.
BBS: From Discovery to Mechanisms to Candidate Therapeutics Matthias Wolf, MD
5:30 p.m.
Pathology of Renal Cysts in Children Nicholas Katsanis, PhD
6:00 p.m.
Mechanisms of Cystogenesis Stephen M. Bonsib, MD
4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Living on the Edge: Where Should We Draw the Line with Medically Complex Living Donors? Room 113
The chronic organ shortage has led to expanded use of medically complex living donors by transplant centers, as well as increasingly novel methods by which transplant candidates recruit donors. This session examines the long-term outcomes and the ethical and medical implications of these practices. Upon completion of this session, the participant will be able to: 1) describe the emerging data regarding long-term outcomes for live kidney donors; 2) discuss the diverse methods used by transplant candidates to find potential donors and their ethical and medical implications; and 3) restate the ethical implications of donor autonomy. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Didier A. Mandelbrot, MD, and Robert W. Steiner, MD 4:30 p.m.
Longer-Term Outcomes for Live Kidney Donors: What Have Recent Studies Taught Us? Amit X. Garg, MD, PhD
5:00 p.m.
Donors without Borders: Access via the World Wide Web and Transplant Tourism Gabriel M. Danovitch, MD
5:30 p.m.
Whose Decision Is It Anyway? Ethical Issues with Donor Autonomy Peter P. Reese, MD
6:00 p.m.
Future Considerations in Living Donor Kidney Transplantation Hassan N. Ibrahim, MD, FASN
100
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference Obstetric Nephrology Ballroom A
In this session, an update on new developments in the pathogenesis of preeclampsia is presented. The obstetric issues that are critical in assessing in any pregnant woman with hypertension or kidney problems are reviewed. Some of the newer biomarkers for preeclampsia are presented. The complexities of the microangiopathic syndromes in pregnancy are discussed. Upon completion of this session, the participant will be able to: 1) describe the pathogenesis of preeclampsia; 2) discuss the obstetric tests and terminology relevant to pregnant women with hypertension and/or kidney disease; 3) describe the development and clinical utility of newer biomarkers for diagnosis and treatment of preeclampsia; and 4) discuss the natural history, diagnosis, and management of primary aldosteronism in pregnancy. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement
4:30 p.m.
Preclampsia: A Fetal-Placental-Renal Syndrome Vesna D. Garovic, MD
5:00 p.m.
Obstetrics for the Nephrologists: NSTs, EFWs, AFIs, etc. Daniel W. Skupski, MD
5:30 p.m.
New Biomarkers for Preeclampsia: “Flting” from the Placenta to the Podocyte Belinda Bun Jim, MD
6:00 p.m.
Primary Aldo in Pregnancy: Not So Simple! Tiina Podymow, MD
4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Perspectives on Volume, Fluids, and Urine: How They Impact AKI Ballroom B
This session describes the management of fluids and volume in patients with AKI. Upon completion of this session, the participant will be able to: 1) describe the role of fluid balance and type of fluid used and the risk of AKI; 2) describe the use of diuretics in patients with AKI; and 3) manage volume status in acutely ill patients to prevent AKI. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Ravindra L. Mehta, MD, FASN, and Raymond R. Townsend, MD 4:30 p.m.
Fluid Balance in Patients with AKI Melanie Godin
5:00 p.m.
Does Chloride Influence the Development of AKI? Nor Azim Mohd Yunos, MBBS
5:30 p.m.
Diuretics for the Prevention and Treatment of AKI Josee Bouchard, MD
6:00 p.m.
Optimal Timing and Choice of Renal Replacement Modality in the Setting of AKI Martin P. Gallagher, MBBS, PhD
101
FRIDAY
Moderators: Ayub Akbari, MD, and S. Ananth Karumanchi, MD
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference The Expanding Role of Interventional Nephrology Room 201-C
Interventional nephrology is not a new subspecialty anymore, but new and exciting things are happening! What started as a dialysis access specialty has been evolving into a procedural discipline that covers many different aspects of care. The purpose of this session is to introduce the general nephrologist and other health care professionals to these exciting new directions. Upon completion of this session, the participant will be able to: 1) describe the role of renal nerve denervation in the management of hypertension; 2) state the role of the nephrologist in the management of peripheral vascular disease in the ESRD population; 3) examine the new scientific evidence for renal artery stenosis intervention; and 4) describe the importance of surgical skill and experience in the creation of AV access. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Timothy A. Pflederer, MD, and Aris Q. Urbanes, MD 4:30 p.m.
An Update on Renal Nerve Denervation and Its Impact on the Management of Hypertension: The Simplicity HTN-4 Trial Alexander S. Yevzlin, MD
5:00 p.m.
Peripheral Vascular Disease Management in the ESRD Population: Principles and Practice Peter Mason, MD
5:30 p.m.
The CORAL Renal Artery Stenosis Intervention Study: A Critical Review and Application to the Nephrology Patient Stephen C. Textor, MD
6:00 p.m.
The Elephant in the Room: Does Surgical Skill and Experience Matter for Vascular Access Outcomes? Gerald A. Beathard, MD, PhD, FASN
102
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Sessions
Upon completion of the oral abstract sessions, the participant will be able to: 1) construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines; and 2) translate recent advances into new standards and approaches to clinical care of patients with kidney diseases and related disorders. Core Competency: Medical Knowledge
4:30 p.m. – 6:30 p.m.
Oral Abstract Session AKI: Cellular Responses to Injury and Repair - II Room 107 Moderators: Jerrold S. Levine, MD, and Aaron J. Polichnowski, PhD
Heme Oxygenase-1 (HO-1) Expression Regulates Trafficking of Myeloid Cells in Acute Kidney Injury (AKI) — Ahmed I. Kamal, Travis D. Hull, Ravindra Boddu, Subhashini Bolisetty, Sunil Rangarajan, Lingling Guo, Lisa M. Curtis, James George, Anupam Agarwal. Birmingham, AL.
4:42 p.m. FR-OR002
Retinoic Acid Signaling Promotes Repair by Altering Renal Macrophage Responses after Acute Kidney Injury — Mark P. De Caestecker, Nataliya Skrypnyk, Lauren Brilli, Ming-Zhi Zhang, Raymond C. Harris, Neil A. Hukriede, Takuto Chiba. Nashville, TN.
4:54 p.m. FR-OR003
The Sentinel Role of Renal Dendritic Cells in Systemic Infection — Karim Yatim, Martin H. Oberbarnscheidt. Pittsburgh, PA.
5:06 p.m. FR-OR004
Transcriptional Regulation of Th17 Cell Differentiation in Ischemia-Reperfusion Injury — Hajeong Lee, Seung Hee Yang, Ji In Park, Kyung Don Yoo, Seung Seok Han, Dong Ki Kim, Yon Su Kim. Seoul, South Korea.
5:18 p.m. FR-OR005
Th-17 Cell Activation in Response to High Salt following Acute Kidney Injury Is Associated with Progressive Fibrosis and Attenuated By AT-1 Antagonism — Purvi Mehrotra, David P. Basile, Jaymin B. Patel, Carlie M. Ivancic. Indianapolis, IN.
5:30 p.m. FR-OR006
T Lymphocyte Specific Nuclear Factor Erythroid-Derived 2-Like 2 (Nrf2) Activation Protects from Acute Kidney Injury in Mice — Sanjeev Noel, Maria Noel Martina Lingua, Samatha Bandapalle, Sekhar P. Reddy, Lorraine C. Racusen, Abdel Hamad, Hamid Rabb. Baltimore, MD.
5:42 p.m. FR-OR007
Role of IKK2 Mediated NF-kappa B Activation in CD4 Positive Lymphocytes in Ischemia Reperfusion Injury Model — Linlin Guo, Hannah Heejung Lee, Hans-Joachim Paust, Gunther Zahner, Friedrich Thaiss. Hamburg, Germany.
5:54 p.m. FR-OR008
IL-233 Fusion Cytokine - A Novel Therapeutic Approach for Acute Kidney Injury — Marta Stremska, Liping Huang, Amandeep Bajwa, Diane L. Rosin, Mark D. Okusa, Rahul Sharma. Charlottesville, VA.
6:06 p.m. FR-OR009
Kidney Derived Endothelial Progenitors Play a Critical Role during Development and Kidney Injury — Sunder Sims-Lucas, Natasha M. Rogers, Christopher Cain Rymer. Pittsburgh, PA.
6:18 p.m. FR-OR010
Human Endothelial Progenitor Cells Protect against Acute Kidney Injury: Role of Exosomes and miR-486 — Jose L. Vinas, Dylan Burger, Alex Gutsol, Pearl Ann Campbell, David Allan, Kevin D. Burns. Ottawa, ON, Canada.
Presenting Authors Underlined
103
FRIDAY
4:30 p.m. FR-OR001
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Autophagy and Cellular Stress Mechanisms Room 104 Moderators: Jeremy S. Leventhal, MD, and Man J. Livingston, MD, PhD
4:30 p.m. FR-OR011
Exploring the Pathophysiological Functions of Resident Fibroblasts in the Kidney — Jin Nakamura, Akiko Oguchi, Ryo Yamada, Motoko Yanagita. Kyoto, Japan.
4:42 p.m. FR-OR012
Cell Autonomous and Non-Cell Autonomous Responses Mediated By Angiogenin During Kidney Injury — Nicolas Pallet, Iadh Mami, Eric Thervet. Paris, France.
4:54 p.m. FR-OR013
Podocytes Proliferation Is Detected in Rat and Human Nephoritis — Zhigang Zhang, Ruimin Hu, Xing Mao, Huijuan Wu. Shanghai, China.
5:06 p.m. FR-OR014
Krüppel-Like Factor 6 Protects the Podocyte from Mitochondrial Injury under Cell Stress — Sandeep K. Mallipattu, Sylvia Horne, John C. He. Stony Brook, NY.
5:18 p.m. FR-OR015
Suppression of Acetyl-CoA Carboxylase 2 Rescues Kidney Proximal Tubule Epithelial Cells from Palmitic Acid-Induced Lipotoxicity via Autophagy — Wei Xin, Xu Zhao, Liyong Chen, Lei Liu, Ying Xu, Qiang Wan. Jinan, China.
5:30 p.m. FR-OR016
Long-Chain Saturated Fatty Acid-Induced Endoplasmic Reticulum Stress Suppresses Erythropoietin Production in Kidney — Thitinun Anusornvongchai, Chih-Kang Chiang, Yu Ishimoto, Norio Suzuki, Masayuki Yamamoto, Masaomi Nangaku, Reiko Inagi. Tokyo, Japan.
5:42 p.m. FR-OR017
Altered Autophagy Flux Contributes to Kidney Aging via Mitochondrial Dysfunction — Takeshi Yamamoto, Yoshitsugu Takabatake, Tomonori Kimura, Atsushi Takahashi, Tomoko Namba, Jun Matsuda, Fumio Niimura, Taiji Matsusaka, Motoko Yanagita, Hiromi Rakugi, Yoshitaka Isaka. Suita, Osaka, Japan. Autophagy, Renal Function, and Immune Function in Aging — Tobias B. Huber, MD
5:54 p.m.
104
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session CKD: Complications and Outcomes Room 204-C Moderators: Catherine M. Clase, MbChB, FASN, and Adeera Levin, MD
A Lifetime Health Outcomes Model in Moderate to Severe Chronic Kidney Disease Based on the Study of Heart and Renal Protection (SHARP) — Borislava N. Mihaylova, Iryna Schlackow. Oxford, United Kingdom.
4:42 p.m. FR-OR019
Early GFR Decline as a Predictor of Cardiovascular Mortality in Non-CKD Diabetics — Srini Beddhu, G. Wei, E. Constantz, Xiaorui Chen, R. Boucher, Ajay Giri, Debra Lynn Simmons, Molly B. Conroy, Jane J. Lee, Tom Greene. Salt Lake City, UT.
4:54 p.m. FR-OR020
Risk of Complications in Hospitalized Patients with Chronic Kidney Disease — Babak Bohlouli, Terri Jurgens Jackson, Marcello Tonelli, Scott Klarenbach. Edmonton, AB, Canada.
5:06 p.m. FR-OR021
Infection Is a Risk Factor for Faster Progression to Renal Replacement Therapy and Death in Chronic Kidney Disease — Hicham I. Cheikh Hassan, Mila Tang, Ognjenka Djurdjev, Adeera Levin. Vancouver, BC, Canada.
5:18 p.m. FR-OR022
Incident Atrial Fibrillation and Risk of End-Stage Renal Disease in Chronic Kidney Disease: The CRIC Study — Nisha Bansal, Dawei Xie, Elsayed Z. Soliman, Kelvin Tao, Jing Chen, Rajat Deo, Edward J. Horwitz, Chi-Yuan Hsu, Claudia M. Lora, Dominic S. Raj, Myles S. Wolf, Alan S. Go. Seattle, WA.
5:30 p.m. FR-OR023
Chronic Kidney Disease and 10-Year Risk of Cardiovascular Death: An Evaluation of European Cardiovascular Prevention Guidelines in a Community-Based Cohort — Martin Holzmann, Axel C. Carlsson, Per Erik Wändell, Johan Arnlov. Stockholm, Sweden.
5:42 p.m. FR-OR024
Weight Loss after Bariatric Surgery Is Associated with Increased eGFR and Decreased Albuminuria — Alex R. Chang, Robert M. Perkins, G. Craig Wood, M. Grams. Danville, PA.
5:54 p.m. FR-OR025
Uromodulin Excretion Predicts Renal Disease Progression in Children with Chronic Kidney Disease — Elke Wuehl, Anke Doyon, Aysun Karabay Bayazit, Nur Canpolat, Ali Duzova, Daniela Kracht, Betul B.S. Sozeri, Mieczyslaw Litwin, Matthias Wuttke, Anna Kottgen, Marietta Kirchner, Olivier Devuyst, Franz S. Schaefer. Heidelberg, Germany.
6:06 p.m. FR-OR026
Children and Young Adults with Chronic Kidney Disease Have Neurocognitive Deficits Compared to Healthy Controls — Rebecca Ruebner, Nina Laney, Ji Young Kim, Stephen R. Hooper, Jerilynn Radcliffe, Susan L. Furth. Philadelphia, PA.
6:18 p.m. FR-OR027
Association between Body Mass Index and ESRD Outcomes in US Children — Elaine Ku, David V. Glidden, Barbara A. Grimes, Chi-Yuan Hsu, Anthony A. Portale, Kirsten L. Johansen. San Francisco, CA.
105
FRIDAY
4:30 p.m. FR-OR018
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
CKD: Estimating Equations, Incidence, Prevalence, and Special Populations Room 204-A Moderators: Brad C. Astor, PhD, and Lesley Inker, MD
4:30 p.m. FR-OR028
Does Tubular Secretion of Creatinine Increase Proportionally as Renal Function Declines? — Xuehan Zhang, Yen Chung Lin, Charles E. McCulloch, Isabel Elaine Allen, Nisha Bansal, Alan S. Go, Chi-Yuan Hsu. Beijing, China.
4:42 p.m. FR-OR029
Serum Filtration Markers to Estimate Residual Kidney Function (RKF) without Urine Collection in Dialysis Patients — Tariq Shafi, Andrew S. Levey, Friedo W. Dekker, Lesley Inker, Raymond T. Krediet, George J. Schwartz, Wieneke Michels, Tiny Hoekstra, Josef Coresh. Baltimore, MD.
4:54 p.m. FR-OR030
Independent Predictors of Uromodulin Excretion in a Large Population Survey: The CARTaGENE Study — Catherine Delmas-Frenette, Stephan Troyanov, Philip Awadalla, Olivier Devuyst, Francois Madore. Montreal, QC, Canada.
5:06 p.m. FR-OR031
Precise Estimation of Glomerular Filtration Rate from Multiple Blood Biomarkers — Josef Coresh, Lesley Inker, Andrew S. Levey. Baltimore, MD.
5:18 p.m. FR-OR032
Estimated GFR Is Biased by Non-Traditional Cardiovascular Risk Factors — Toralf Melsom, Jørgen Schei, Trond G. Jenssen, Harald Strand, Bjorn Odvar Eriksen. Tromso, Norway.
5:30 p.m. FR-OR033
Change in Measured GFR Does Not Outperform Change in Estimated GFR in Predicting Adverse Outcomes in CKD: Results from the CRIC Study — Elaine Ku, Dawei Xie, Michael Shlipak, Amanda Hyre Anderson, Jing Chen, Alan S. Go, Jiang He, Edward J. Horwitz, Mahboob Rahman, Ana C. Ricardo, James H. Sondheimer, Raymond R. Townsend, Chi-Yuan Hsu. San Francisco, CA.
5:42 p.m. FR-OR034
The Association of Maternal Obesity with Infant Congenital Abnormalities of the Kidney and Urinary Tract in Washington State — Ian R. Macumber, Nicolae Leca. Seattle, WA.
5:54 p.m.
Invited Lecture: GFR Estimation, CKD Staging and Risk: Recent Developments and Future Needs — Andrew S. Levey, MD
106
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Dialysis: Anemia and Iron Metabolism Room 115-C Moderators: Hitesh H. Shah, MD, FASN, and Jay B. Wish, MD
Payer Impact of Anemia Management Among Medicare Insured Dialysis Patients During the Implementation of the ESRD Prospective Payment System (PPS) — James B. Wetmore, Craig Solid, Spyridon Tzivelekis. Minneapolis, MN.
4:42 p.m. FR-OR036
Evaluation of the Annual Red Blood Cell Transfusion Rate in Patients on Dialysis before and after the Implementation of the New Prospective Payment System (PPS) — Allan J. Collins, Scott Jackson, Yi Peng, Anne C. Beaubrun, Keri Monda, Brian D. Bradbury, David T. Gilbertson. Minneapolis, MN.
4:54 p.m. FR-OR037
Changes in Hemoglobin under the Dialysis Prospective Payment System (PPS) by Facility Payer Mix — Marc Turenne, Purna Mukhopadhyay, Jeffrey Pearson, Elizabeth L. Cope, Chad M. Cogan, Brenda W. Gillespie. Ann Arbor, MI.
5:06 p.m. FR-OR038
Decreasing the Cost of Anemia Treatment, in Hemodialysis Patients, Through Splitting of Iron and Darbepoetin Doses — Marco Oliveira Mendes, David Navarro, Ana Azevedo, Cristina Jorge, Patrícia Matias, Ana Carina Ferreira, Bruno Costa Pinto, Fernanda Gomes, Célia Gil, Manuel A. Ferreira, Ines Aires. Lisboa, Portugal.
5:18 p.m. FR-OR039
Understanding the Recent Increase in Ferritin Levels in US Dialysis Patients — Angelo Karaboyas, Hal Morgenstern, Jacqueline G. Nolen, Raymond M. Hakim, Kamyar Kalantar-Zadeh, Philip Zager, Ronald L. Pisoni, Friedrich K. Port, Bruce M. Robinson. Ann Arbor, MI.
5:30 p.m. FR-OR040
Longitudinal Changes in Serum Ferritin over 5 Years in 134,090 Incident Dialysis Patients — Sepideh Rezakhani, Elani Streja, Vanessa A. Ravel, Connie Rhee, Miklos Zsolt Molnar, Csaba P. Kovesdy, Rajnish Mehrotra, Kamyar Kalantar-Zadeh. Orange, CA.
5:42 p.m. FR-OR041
Association between Intravenous Iron Receipt during Infection-Related Hospitalization and Clinical Outcomes among Hemodialysis Patients — Julie H. Ishida, Ben Marafino, Charles E. McCulloch, Lorien S. Dalrymple, R. Adams Dudley, Barbara A. Grimes, Kirsten L. Johansen. San Francisco, CA.
5:54 p.m. FR-OR042
Robust Treatment for Renal Anemia Increase Frataxin Level in Parallel with the Improved Mitochondria Metabolism and Oxidative Stress in ESA-Hyporesponsive Anemic Patients on Maintenance Hemodialysis (MHD) — Yukiko Hasuike, Wataru Fukao, Kazuhiro Toyoda, Satoko Masachika, Yuki Morikami, Tomoko Kimura, Kiyoko Yamamoto, Sayuri Kawada, Kosuke Mizusaki, Soshi Yorifuji, Mai Oue, Shoji Kaibe, Mana Yahiro, Aritoshi Kida, Masayoshi Nanami, Takeshi Nakanishi. Nishinomiya City, Hyogo, Japan.
6:06 p.m. FR-OR043
Is Erythropoietin Resistance Index (ERI) Merely a Proxy for Inflammation? — Anirudh Rao, Julie A. Gilg, Fergus J. Caskey. Avon, Lanarkshire, United Kingdom.
6:18 p.m. FR-OR044
ESA Hyporesponsiveness Is Associated with Adverse Event in Maintenance Hemodialysis (MHD) Patients, but Not with Iron Storage — Takahiro Kuragano, Takeshi Nakanishi. Nishinomiya, Japan.
107
FRIDAY
4:30 p.m. FR-OR035
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Dialysis: Identifying Risk Factors and Improving Noncardiovascular Outcomes Room 118-B Moderators: Elvira Gosmanova, MD, FASN, and Bernard G. Jaar, MD, FASN
4:30 p.m. FR-OR045
Phosphorus Binding with Ferric Citrate Is Associated with Reduced Hospitalizations and Costs for Cardiac, Gastrointestinal, and Infection-Related Causes — Roger A. Rodby, Robert M. Niecestro, T. Christopher Bond, Mohammed Sika, Jamie P. Dwyer, Julia Lewis, Kausik Umanath. Chicago, IL.
4:42 p.m. FR-OR046
Reduced Hemodialysis Patient Hospital Admissions and Readmissions Associated with Right TraC (RT) Transitions of Care Program — Andrew D. Howard, Rebecca L. Wingard, Kathryn A. McDougall, Billie Axley, Cathleen Okeefe, Janice B. Sitzlar, Sharon Deluca, Fern Parlier, John W. Larkin, Len A. Usvyat, Franklin W. Maddux. Clinton, MD.
4:54 p.m. FR-OR047
Hyperthyrotropinemia and Mortality in a National Incident Hemodialysis Cohort — Connie Rhee, Steven B. Kim, Bahattin T. Oztan, Jiaxi Wang, Daniel L. Gillen, Rajnish Mehrotra, Steven M. Brunelli, Csaba P. Kovesdy, Gregory Brent, Kamyar Kalantar-Zadeh. Orange, CA.
5:06 p.m. FR-OR048
The BMI / Survival “Paradox” among HD Patients Is Explained By Differential Followup — Stephen P. McDonald, Mark R. Marshall, Kevan Polkinghorne. Adelaide, South Australia, Australia.
5:18 p.m. FR-OR049
A Personalized, Low-Intensity, Easy to Implement, Home Exercise Program Improves Physical Performance in Dialysis Patients: The Exercise Introduction to Enhance Performance in Dialysis (EXCITE ) Trial — Francesca Mallamaci, Fabio Manfredini, Davide Bolignano, Silvio Bertoli, Piergiorgio Messa, Alessandro Zuccalà, Pasquale Fatuzzo, Francesco Rapisarda, Luigi Lombardi, Adamasco Cupisti, Giorgio Fuiano, Claudia Torino, Rossella Baggetta, Giovanni Tripepi, Luigi Catizone, Carmine Zoccali. Reggio Calabria, Italy.
5:30 p.m. FR-OR050
Upper Urinary Tract Cancer, but Not Kidney Cancer, Is Significantly Associated with Chinese Herbal Medicines Containing Aristolochic Acid in Dialysis ESRD Patient — Sheng-Wen Niu, Ming-Yen Lin, Huei-Lan Lee, Shu-An Yang, Li-Tzong Chen, Shang-Jyh Hwang. Kaohsiung, Taiwan.
5:42 p.m. FR-OR051
Influenza Vaccination Reduced Pneumococcal Disease in Incident Dialysis Patients — Jordan T. Powner, Thomas Ryan Gallaher, Rhonda E. Colombo, Stephanie L. Baer, Lulu Huber, Mufaddal F. Kheda, N. Stanley Nahman, Kristina Weis Kintziger. Augusta, GA.
5:54 p.m. FR-OR052
Perceived Facilitators of and Barriers to Home Dialysis Use: A Canadian National Survey of Nephrologists — Gihad E. Nesrallah, Lianne Barnieh, Braden J. Manns, Andreas Pierratos, David C. Mendelssohn, Catherine M. Clase, Gordon Guyatt. Toronto, ON, Canada.
6:06 p.m. FR-OR053
Lower Risk of Death in Daily Home Hemodialysis versus Peritoneal Dialysis Patients — Eric D. Weinhandl, David T. Gilbertson, Allan J. Collins. Minneapolis, MN.
6:18 p.m. FR-OR054
Declines in Hemodialysis Patients’ Physical and Mental Component Scores before Death — Stephanie Johnstone, Lisa Dombro, Greg S. Garza, Krister Cromm, John W. Larkin, Len A. Usvyat, Eduardo K. Lacson, Peter Kotanko, Jeffrey L. Hymes, Franklin W. Maddux. San Diego, CA.
108
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Frailty and Sarcopenia: What’s in the Definition Room 118-C Moderators: Branko Braam, MD, PhD, FASN, and Harold A. Franch, MD
Skeletal Muscle Cytokine Gene Expression after Resistance Exercise in Chronic Kidney Disease — Joao L. Viana, Emma L. Watson, Neil J. Greening, Jonathan Barratt, Alice C. Smith. Loughborough, United Kingdom.
4:42 p.m. FR-OR056
Muscle Mass and Function following Renal Transplantation — Thomas Dienemann, Shaun Bender, Francis Perry Wilson, Peter P. Reese, Jin Long, Mary B. Leonard. Philadelphia, PA.
4:54 p.m. FR-OR057
N-Terminal pro-B-Type Natriuretic Peptide as a Biomarker for Sarcopenia in Prevalent Hemodialysis Patients — Misa Ikeda, Hirokazu Honda, Hiroaki Ogata, Fumihiko Koiwa, Eriko Kinugasa, Kanji Shishido, Takanori Shibata. Tokyo, Japan.
5:06 p.m. FR-OR058
Association between Fibroblast Growth Factor-23 and Frailty in Elderly Community-Living Adults: The Cardiovascular Health Study — Tomasz Beben, Michel Chonchol, Linda F. Fried, Bryan R. Kestenbaum, Mark J. Sarnak, Michael Shlipak, Ian H. de Boer, Joachim H. Ix, Dena E. Rifkin. La Jolla, CA.
5:18 p.m. FR-OR059
Insulin Resistance in CKD-A New Role for the Ubiquitin System in Muscle — Molly Colleen Tokaz, Yanlan Dong, Liping Zhang, William E. Mitch. Houston, TX.
5:30 p.m. FR-OR060
Prevalence, Body Composition and Mortality Associations of Protein-Energy Wasting in Non-CKD and CKD in the US — Srini Beddhu, G. Wei, R. Boucher, E. Constantz, Xiaorui Chen, Tom Greene. Salt Lake City, UT.
5:42 p.m. FR-OR061
Creatinine Index Dynamics before Death in Chronic Hemodialysis Patients – Results of an International Study — Daniele Marcelli, Len A. Usvyat, Peter Kotanko, Michael Etter, Gero D. von Gersdorff, Aileen Grassmann, Cristina Marelli, Adrian M. Guinsburg, Laura Scatizzi, Inga Bayh, Yuedong Wang, Frank van der Sande, Jeroen Kooman, Bernard J. Canaud. Bad Homburg, Germany.
5:54 p.m.
Invited Lecture: Frailty, Sacropenia: What’s in the Definition — Kirsten L. Johansen, MD
109
FRIDAY
4:30 p.m. FR-OR055
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Glomerular Disease: Treatment and Outcomes Room 108
Moderators: Michelle A. Hladunewich, MD, FASN, and Vivekanand Jha, MD
4:30 p.m. FR-OR062
Histologic versus Clinical Remission in Lupus Nephritis (LN) — Ana Malvar, Valeria Gabriela Alberton, Cecilia Recalde, Bernarda Fazzini, Bruno Jorge Lococo, Paola Pirruccio, Brad H. Rovin. Buenos Aires, Argentina.
4:42 p.m. FR-OR063
Repeat Renal Biopsies Help to Tailor Immunosuppression in Lupus Nephritis — Angela Pakozdi, Dev Pyne, Michael Sheaff, Ravindra Rajakariar. London, United Kingdom.
4:54 p.m. FR-OR064
Outcomes of Maintenance Therapy in Patients with Less Severe Lupus Nephritis Previously Randomized to Receive Either Low Dose Cyclophosphamide versus Oral Mycophenolate Mofetil — Manish Rathi, Krishan L. Gupta, Ajay Jaryal, Aman Sharma. Chandigarh, India.
5:06 p.m. FR-OR065
Long Term Follow Up of the Rituxilup Steroid Sparing Regimen in Lupus Nephritis — Andrew Porter, Marie B. Condon, Anne Frances Doyle, Megan Griffith, H. Terence Cook, Tom Cairns, Liz Lightstone. London, United Kingdom.
5:18 p.m. FR-OR066
Tacrolimus Combined with Corticosteroids versus Modified Ponticelli Regimen in Treatment of Idiopathic Membranous Nephropathy: Randomized Control Trial — Raja Ramachandran, Harsha Kumar Hn, Vinod Sharma, Ashwani Kumar, Ashok Kumar Yadav, Ritambhra Nada, Harbir Singh Kohli, Vivekanand Jha, Krishan L. Gupta. Chandigarh, India.
5:30 p.m. FR-OR067
The Risk of Cardiovascular Events (CVE) Is Greater in Membranous Nephropathy (MN) Than Focal Segmental Glomerulosclerosis (FSGS) — Taewoo Lee, Vimal K. Derebail, A. V. Kshirsagar, Caroline J. Poulton, Susan L. Hogan, Sophia Lionaki, Ronald J. Falk, Heather N. Reich, Patrick H. Nachman. Chapel Hill, NC.
5:42 p.m. FR-OR068
Extended NIH Cyclophosphamide Regime Is Associated with Improved Patient Outcomes in ANCA Associated Vasculitis — Valeed Ghafoor, Laura Chadwick, Ajay Prabhakar Dhaygude, Michael Venning. Manchester, United Kingdom.
5:54 p.m. FR-OR069
Can Autologous Stem Cell Transplantation Improve the Prognosis of Primary AL Amyloidosis via Cardiac Effects? — Masahiro Kawada, Yoshifumi Ubara, Junichi Hoshino, Koki Mise, Kenmei Takaichi. Minato-Ku, Tokyo, Japan.
6:06 p.m. FR-OR070
Outcomes in Anti-Complement Factor H Antibody Associated Hemolytic Uremic Syndrome: Nationwide Data — Arvind Bagga, Aditi Sinha, Indian Hemolytic Uremic Syndrome Registry. New Delhi, India.
6:18 p.m. FR-OR071
Mycophenolate Mofetil in C3 Glomerulonephritis — Cristina Rabasco, Manuel Praga. Madrid, Spain.
110
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Hypertension: Understanding Immune Cells, Hormones, and Salt and Mineral Excretion Room 105 Moderators: Steven D. Crowley, MD, and Susan B. Gurley, MD, PhD
Ablation of Dendritic Cells Prevents Hypertension in Mice Infused with Angiotensin II plus High Salt Diet — Daniel E. Hevia, Carolina E. Prado, Eugenia L. Fuentes, Rodrigo Pacheco, Luis F. Michea. Santiago, Chile.
4:42 p.m. FR-OR073
IL-1 Potentiates Sodium Retention in Angiotensin II-Dependent Hypertension Through Nitric-Oxide-Mediated Regulation of Na+-K+-2Cl- Cotransporter — Jiandong Zhang, Matthew A. Sparks, Steven D. Crowley. Durham, NC.
4:54 p.m. FR-OR074
Kidney Specific FKBP12 Knockout Mice Are Protected From Tacrolimus Induced Hypomagnesemia and Hypercalciuria — Rebecca A. Lazelle, Belinda H. McCully, Chao-Ling Yang, David H. Ellison. Portland, OR.
5:06 p.m. FR-OR075
Increased Susceptibility to Angiotensin II-Induced Renal Injury and Glomerular Filtration Rate Reduction in Mice with Vascular-Specific EP4 Receptor Deletion — Jean-Francois Thibodeau, Chet E. Holterman, Chris R. Kennedy. Ottawa, Canada.
5:18 p.m. FR-OR076
Cardiac Hypertrophy in Angiotensin II-Dependent Hypertension: Dominant Effect of Blood Pressure — Matthew A. Sparks, Johannes Stegbauer, Steven D. Crowley, Subramaniam Pennathur, Susan B. Gurley, Thomas M. Coffman. Durham, NC.
5:30 p.m. FR-OR077
Kidney Androgen Regulated Protein Controls Baseline Blood Pressure — Kamyar A. Zahedi, Saeed Alshahrani, Marybeth Brooks, Sharon L. Barone, Jie Xu, Manoocher Soleimani. Cincinnati, OH.
5:42 p.m. FR-OR078
Role of the Natriuretic Peptide GC-A Receptor on Podocytes in Aldosterone-Induced Glomerular Injury — Yukiko Kato, Hideki Yokoi, Kiyoshi Mori, Masato Kasahara, Yoshihisa Ogawa, Takashige Kuwabara, Takeshi Tokudome, Ichiro Kishimoto, Akira Sugawara, Taiji Matsusaka, Kazuwa Nakao, Motoko Yanagita, Masashi Mukoyama. Kyoto, Japan.
5:54 p.m.
Invited Lecture: Role of Immune Cells in Salt-Sensitive Hypertension — David L. Mattson, PhD
111
FRIDAY
4:30 p.m. FR-OR072
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Immunopathogenesis of Glomerulonephritis Room 111 Moderators: Laurence H. Beck, MD, PhD, and Ulf Panzer, MD
4:30 p.m. FR-OR079
B Cell Derived IL-4 Induces Proteinuria and Foot Process Effacement — Alfred Hyoungju Kim, Shreeram Akilesh, Ania B. Koziell, Sanjay Jain, Jeffrey B. Hodgin, Jeffrey H. Miner, Andrey S. Shaw. Saint Louis, MO.
4:42 p.m. FR-OR080
Pathogenic RORt+ Regulatory T Cells Aggravate Crescentic Glomerulonephritis — Malte A. Kluger, Matthias C. Meyer, Michael Luig, Boeren Goerke, Anna Nosko, Claudia Wegscheid, Rolf A. Stahl, Ulf Panzer, Oliver M. Steinmetz. Hamburg, Germany.
4:54 p.m. FR-OR081
Micromanging Autoimmune Nephritis: Role of miR-17 in Modulating Regulatory T Cell Activity by Targeting Foxp3 Co-Regulators — Huang-Yu Yang, Chih-Wei Yang. Taoyuan, Taiwan.
5:06 p.m. FR-OR082
Myeloperoxidase Peptide Based Nasal Tolerance as Treatment for Anti-Neutrophil Cytoplasmic Antibody Associated Glomerulonephritis — Stephen R. Holdsworth, Poh-Yi Gan, A. Richard Kitching. Clayton, Victoria, Australia.
5:18 p.m. FR-OR083
TLR9 Ligation Enhances Anti-Myeloperoxidase Autoimmunity and Glomerulonephritis Through Dendritic Cell Activation — Sharon Lee Ford, Irina Caminschi, A. Richard Kitching, Stephen R. Holdsworth. East Burwood, Victoria, Australia.
5:30 p.m. FR-OR084
CXCR3 Guides the Exit of CD4+ Renal T Cells to the Draining Lymph Node in Crescentic GN — Christian Franz Krebs, Tobias Koyro, Hans-Joachim Paust, Anna Kaffke, Jan-Eric Turner, Rolf A. Stahl, Ulf Panzer. Hamburg, Germany.
5:42 p.m. FR-OR085
Development, and Morphologic Characteriziation of a Mouse Model of Membranous Nephropathy Involving the Human Phospholipase A2 Receptor — Gunther Zahner, Catherine Meyer-Schwesinger, Nicola M. Tomas, Elion Hoxha, Thorsten Wiech, Rolf A. Stahl. Hamburg, Germany.
5:54 p.m. FR-OR086
The Immunodominant Epitope in PLA2R Mediating Idiopathic Membranous Nephropathy Is Located in the CysR-FnII-CTLD1 Region — Quansheng Zhu, Liyo Kao, Vinson Lam, Meryl A. Waldman, Richard J. Glassock. Los Angeles, CA.
6:06 p.m. FR-OR087
Alternative Pathway Amplifies Complement Activation by Human Anti-PLA2R Antibodies in Membranous Nephropathy — Dorin-Bogdan Borza, Tanu Rana, Florina Olaru, Joshua M. Thurman, Stephen Tomlinson, Laurence H. Beck, David J. Salant. Nashville, TN.
6:18 p.m. FR-OR088
Glomerular Deposition of Food Antigens in Adult Patients with Membranous Nephropathy — Hequn Zou. Guangzhou, China.
112
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Innovation in Clinical Transplantation Room 201-A Moderators: Krista L. Lentine, MD, PhD, FASN, and Rachel E. Patzer, PhD
A Population-Based Study of the U.S. Population Shows the Majority of Persons Cannot Donate due to Preventable Diseases and Socio-Economic Conditions — Anthony J. Bleyer, Amber M. Reeves-Daniel, Anthony J. Bleyer. Winston-Salem, NC.
4:42 p.m. FR-OR090
Kidney Function Evaluation in Prospective Kidney Donors – Performance of Creatinine Clearance versus GFR as Measured by Iothalamate Clearance — Grace Snyder, Jesse D. Schold, Didier A. Mandelbrot, Stuart M. Flechner, Emilio D. Poggio. Cleveland, OH.
4:54 p.m. FR-OR091
Long Term Survival in Kidney Donors with Pre Existing Hypertension — Geir Mjøen, Hallvard Holdaas. Oslo, Norway.
5:06 p.m. FR-OR092
Gout in Living Kidney Donors — Ngan Lam, Eric Mcarthur, Joseph Kim, G.V. Ramesh Prasad, Krista L. Lentine, Peter P. Reese, Bertram L. Kasiske, Charmaine E. Lok, Amit X. Garg. London, ON, Canada.
5:18 p.m. FR-OR093
Number of Glomeruli Estimated from Renal Biopsy and CT Scan of Living Donors — Aleksandar Denic, Harini A. Chakkera, Emilio D. Poggio, Prince Singh, Walter Park, Mariam P. Alexander, Walter K. Kremers, Andrew D. Rule. Rochester, MN.
5:30 p.m. FR-OR094
The Effects of Recipient-Donor Gender Combinations and Body Size on Kidney Allograft Survival — Valarie B. Ashby, Alan B. Leichtman, Michael A. Rees, Peter X.K. Song, Mathieu Bray, Richard Eikstadt, Audrey J. Goulding, Wen Wang, John Kalbfleisch. Ann Arbor, MI.
5:42 p.m. FR-OR095
HLA Match/Mismatch Profiles and Impact on 10 Year Graft Survival: An Analysis of OPTN/ UNOS Registry Data — Rabi Yacoub, Madhav C. Menon, Girish N. Nadkarni, Etti Deborah Zeldis, Ioannis Konstantinidis, John C. He, Barbara T. Murphy. New York, NY.
5:54 p.m. FR-OR096
Better Human Leukocyte Antigen Matching Is Associated with Graft Outcomes Among Pediatric Kidney Transplant Recipients — Meera Gupta, Peter Abt, Matthew H. Levine. Philadelphia, PA.
6:06 p.m. FR-OR097
Frailty as a Novel Predictor of Mortality in Kidney Transplant Recipients of All Ages — Mara Mcadams-DeMarco, Andrew Law, Elizabeth King, Babak Orandi, Megan Salter, Nada Alachkar, Niraj Desai, Ravi Varadhan, Jeremy Walston, Dorry L. Segev. Baltimore, MD.
6:18 p.m. FR-OR098
The Histologic Staging of Polyoma-BK-Virus Nephropathy: Results from a Multicenter Study — Volker Nickeleit, Surya V. Seshan, A. Gasim, Harsharan Kaur Singh. Chapel Hill, NC.
113
FRIDAY
4:30 p.m. FR-OR089
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Mechanisms of Acid-Base Balance and Disease Room 203
Moderators: Nuria M. Pastor-Soler, MD, PhD, FASN, and Michael F. Romero, PhD
4:30 p.m. FR-OR099
Sirtuin 7 Modulates Renal Acid-Base Homeostasis through Deacetylation of the K+:ClCotransporter, KCC4 — Zesergio Melo, Armando R. Tovar, Silvia Cruz-Rangel, Adriana P. Mercado, Dongryeol Ryu, Nimbe Torres, Gerardo Gamba, Lilia G. Noriega. Mexico, Mexico.
4:42 p.m. FR-OR100
The Function of ATP6AP2/PRR in Endosomal Trafficking in the Proximal Tubules of the Mouse Kidney — Simon Daniel Gerber, Florian Grahammer, Tobias B. Huber, Matias Simons. Paris, France.
4:54 p.m. FR-OR101
Renal Peroxiredoxin 6 Interacts with Anion Exchanger 1 and Plays a Novel Role in pH Homeostasis — Sara Lynn Sorrell, Zoe J. Golder, D. B. Johnstone, Fiona E. Karet. New Castle, IN.
5:06 p.m. FR-OR102
High Mobility Group Box 1 (HMGB1) Inhibits HCO3- Absorption in Medullary Thick Ascending Limb (MTAL) through a Receptor for Advanced Glycation End Products (RAGE)Dependent Pathway — David W. Good, Thampi George, Bruns A. Watts. Galveston, TX.
5:18 p.m. FR-OR103
Furosemide Stimulates Pronounced H+ Secretion in the Thick Ascending Limb — Pauline I.A. de Bruijn, Nina Himmerkus, Helle A. Praetorius, Markus Bleich, Jens G. Leipziger. Aarhus, Denmark.
5:30 p.m. FR-OR104
Axial Flow Stimulates Acid Secretion in the Distal Convoluted Tubule — Tong Wang, Lawrence G. Palmer, Alan Mark Weinstein. New Haven, CT.
5:42 p.m. FR-OR105
Targeted NBCe1A Deletion Causes Proximal RTA: Whole nbce1 (sh_nbce1) KO versus nbce1A KO Mice — An-Ping Chen, Heather L. Holmes, Minhwang Chang, Lena Carleton, Michael F. Romero. Rochester, MN.
5:54 p.m.
Invited Lecture: Mapping the V-ATPase Interactome — Dennis Brown, PhD
114
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Mineral Disease: Ca/Mg/PO4 Room 119-B Moderators: Judith Blaine, MD, PhD, and Anthony A. Portale, MD
Dietary Phosphate Is a Novel Regulator of Glucose and Lipid Metabolism — Maerjianghan Abuduli, Yutaka Taketani, Hirokazu Ohminami, Haruka Ueda, Eiji Takeda. Tokushima, Japan.
4:42 p.m. FR-OR107
Metabolic Effects of Different Sources of Dietary Phosphorus — Anuja P. Shah, Joel D. Kopple, Rachelle Bross, Rajnish Mehrotra. Torrance, CA.
4:54 p.m. FR-OR108
Intracellular Pi Evolution in Pig Muscle during Hemodialysis: An In-Vivo Phosphate MR Spectroscopy Study — Sandrine Lemoine, Thomas Fournier, Gabriel Kocevar, Danielle Ibarrola, Dominic Sappey-Marinier, Laurent Juillard. Lyon, France.
5:06 p.m. FR-OR109
Inorganic Phosphate Inhibits Osteoclastogenesis by Modulating miR-223. Implications for Chronic Kidney Disease-Mineral and Bone Disorder — Laurent Metzinger, Eleonore Ourouda Mbaya, Loïc Louvet, Valérie Metzinger-Le Meuth, Ziad Massy. Amiens, France.
5:18 p.m. FR-OR110
Down-Regulation of Renal Type IIa Sodium-Dependent Phosphate Co-Transporter During Lipopolysaccharide-Induced Acute Inflammation — Hironori Yamamoto, Shoko Ikeda, Otoki Nakahashi, Yutaka Taketani, Masayuki Iwano, Ken-Ichi Miyamoto, Eiji Takeda. Echizen City, Fukui, Japan.
5:30 p.m. FR-OR111
Tenapanor Inhibits Phosphorous Absorption, and Protects against Vascular Calcification in Nephrectomized Rats — Dominique Charmot, Andrew G. Spencer, Marc Navre, Jason G. Lewis, Christopher Carreras, Jeffrey Jacobs, Noah Bell, Limin He, Desiree Deshpande, Kenji Kozuka, Samantha Koo-Mccoy, Ingrid Langsetmo, Edward E. Dy, Michael R. Leadbetter, Jill N. Kohler, Ziyang Zhong, Eric Daniel Labonte. Fremont, CA.
5:42 p.m. FR-OR112
Tenapanor, a Minimally Absorbed NHE3 Inhibitor, Reduces Dietary Phosphorus Absorption in Healthy Volunteers — David P. Rosenbaum, Susanne Johansson, Bjorn Carlsson, Andrew G. Spencer, Bergur V. Stefansson, Mikael Knutsson, Jeffrey Jacobs, Dominique Charmot. Fremont, CA.
5:54 p.m. FR-OR113
Uromodulin Upregulates the Epithelial Magnesium Channel TRPM6 by Impairing Dynamin II-Dependent Endocytosis — Matthias Wolf, Mingzhu Nie, Joost Hoenderop, René J. Bindels, Manjot S. Bal. Dallas, TX.
6:06 p.m. FR-OR114
Mutations in CNNM2 Cause Hypomagnesemia and Seizures in Patients due to Impaired Renal Magnesium Handling — Joost Hoenderop, Francisco J. Arjona, Jeroen H.F. De Baaij, Karl P. Schlingmann, Martin Konrad, René J. Bindels. Nijmegen, Netherlands.
6:18 p.m. FR-OR115
Effect of Intravenous Bisphosphonates (IVBP) on Bone Mineral Density (BMD) and Bone Turnover Markers (BTM) Is Reversible in Children — Tarak Srivastava, Naziya Tahseen, Hongying Dai, Uri S. Alon. Kansas City, MO.
115
FRIDAY
4:30 p.m. FR-OR106
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Monitoring and Treatment of Diabetic Nephropathy Room 115-B Moderators: Hanna E. Abboud, MD, and Luigi Gnudi, MD, FASN
4:30 p.m. FR-OR116
miRNome Expression Profiling Identifies Circulating MicroRNAs That Are Differentially Expressed among Type 1 Diabetic Patients with Proteinuria and at Increased Risk of Rapid Renal Function Decline — Marcus G. Pezzolesi, Eiichiro Satake, Kevin P. Mcdonnell, Adam Smiles, Andrzej S. Krolewski. Boston, MA.
4:42 p.m. FR-OR117
Identification of New Predictors of Declining Renal Function in Patients with Type 2 Diabetes by Metabolomics — Ele Ferrannini, Anna Solini, Giuseppe Penno, Giuseppe Pugliese, Jeff E. Cobb, Regis Perichon. Pisa, Italy.
4:54 p.m. FR-OR118
Plasma Concentrations of Midregional Pro-Atrial Natriuretic Peptide Are Associated with Cardiorenal Function and Predicts All-Cause Mortality and End Stage Renal Disease in Type 1 Diabetes — Simone Theilade, Tine Hansen, Jens Peter Goetze, Peter Rossing. Hellerup, Denmark.
5:06 p.m. FR-OR119
Circulating Tumor Necrosis Factor Receptors 1 and 2 Correlate with Glomerular Structure in Type 2 Diabetes — Gudeta D. Fufaa, Robert G. Nelson, E. Jennifer Weil, William Knowler, Monika A. Niewczas, Andrzej S. Krolewski. Phoenix, AZ.
5:18 p.m. FR-OR120
Anti-inflammatory and Renoprotective Effects of CCL2 Inhibition with Emapticap Pegol (NOX-E36) in Type 2 Diabetic Patients with Albuminuria — Hermann G. Haller, Jan Menne, Dirk Eulberg, Matthias Baumann. Hannover, Germany.
5:30 p.m. FR-OR121
Selective Inhibition of Phosphodiesterase Type 5 Reduces Macroalbuminuria in Subjects with Type 2 Diabetes, and Overt Nephropathy — Willem H. Scheele, Susan Diamond, Jeremy D. Gale, Valerie Clerin, Nihad Tamimi, Vu Le, Rosalind Jane Walley, Fernando Grover Páez, Meguid El Nahas. Cambridge, MA.
5:42 p.m. FR-OR122
Efficacy and Safety of Liraglutide versus Placebo by eGFR Subgroup in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Trial — David Scott, Guillermo Umpierrez, Stephen Atkin, Stephen Bain, Peter Rossing, Minara Shamkhalova, Heidrun Bosch-Traberg, Annika Syrèn, Melanie Davies. Jamaica, NY.
5:54 p.m. FR-OR123
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Once-Daily ZS-9 for Treatment of Hyperkalemia: Achievement and Maintenance of K+ in Subgroup Analysis of Patients with Significant Renal Impairment and Diabetes — Bhupinder Singh, Henrik S. Rasmussen, Philip T. Lavin, Alex Yang, Wajeh Y. Qunibi. Paradise Valley, AZ.
6:06 p.m. FR-OR124
The Risk Pattern for CV Events Differ Between Coronary Heart Disease (CHD) and Stroke in Patients with Type 2 Diabetes and Renal Impairment — Hanri Afghahi, Mirnabi Pirouzi Fard, Bjorn Eliasson, Maria Svensson. Skövde, Västra Götaland, Sweden.
6:18 p.m. FR-OR125
Metformin Therapy at Different Stages of Chronic Kidney Disease — Farshad Kajbaf, Jean-Daniel Lalau, Mohamed Azzoug, Anne-Sophie Lemaire-Hurtel, Marc E. De Broe. Amiens, France.
116
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session New Molecular Pathways in Fibrosis Room 109 Moderators: Shiguang Liu, MD, PhD, and Ambra Pozzi, PhD
Epithelial-Derived Wnt Ligand Drives Interstitial Fibrosis Through Paracrine Signaling — Omar H. Maarouf, Deepika Rangarajan, Jeremy Welborn, Benjamin D. Humphreys. Boston, MA.
4:42 p.m. FR-OR127
Tubule-Derived Wnts Are Indispensable for Fibroblast Activation and Kidney Fibrosis — Dong Zhou, Roderick J. Tan, Haiyan Fu, Liangxiang Xiao, Youhua Liu. Pittsburgh, PA.
4:54 p.m. FR-OR128
Loss of Angiopoietin-1 Increases Kidney Fibrosis — Krishnapriya Loganathan, Marie Jeansson. Uppsala, Sweden.
5:06 p.m. FR-OR129
FGFR2 Signaling Promotes Kidney Fibroblast Activation and Kidney Fibrosis — Zhuo Xu, Weichun He, Junwei Yang, Chunsun Dai. Nanjing, China.
5:18 p.m. FR-OR130
Role of Platelet-Derived Growth Factor DD in Healthy Kidneys and Renal Fibrosis — Eva Miriam Buhl, Sonja Djudjaj, Barbara Mara Klinkhammer, Janka Babickova, Jürgen Floege, Peter Boor. Aachen, Germany.
5:30 p.m. FR-OR131
Blocking SIRT 1/2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy — Shougang Zhuang. Providence, RI.
5:42 p.m. FR-OR132
Tenascin-C Plays an Important Role in Kidney Fibrosis — Qionghong Xie, Min Zhang, Shaojun Liu, Chuanming Hao. Shanghai, China.
5:54 p.m. FR-OR133
Role for Rictor/mTORC2 Signaling in Mediating TGFb1-Induced Fibroblast Activation and Kidney Fibrosis — Jianzhong Li, Weichun He, Junwei Yang, Chunsun Dai. Nanjing, China.
6:06 p.m. FR-OR134
GLI2 Antagonism Is a Novel Antifibrotic Strategy by Inducing Myofibroblast-Specific Cell Cycle Arrest — Rafael Kramann, Susanne V. Fleig, Benjamin D. Humphreys. Boston, MA.
6:18 p.m. FR-OR135
Notch1, but Not Notch2, Regulates Podocyte Dedifferentiation in Glomerulosclerosis via Snail1 — Mariya T. Sweetwyne, Katalin Susztak. Philadelphia, PA.
117
FRIDAY
4:30 p.m. FR-OR126
FRIDAY, NOVEMBER 14, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Oxidative Pathways to Cell Damage Room 112 Moderators: Farhad R. Danesh, MD, FASN, and Jeffrey R. Schelling, MD
4:30 p.m. FR-OR136
Acute Kidney Injury Progresses to Chronic Kidney Disease via Persistent Metabolic Alterations and Oxidative Stress — David M. Small, Washington Yamandu Sanchez, Sandrine F. Roy, Christudas Morais, David W. Johnson, Glenda C. Gobe. Brisbane, Queensland, Australia.
4:42 p.m. FR-OR137
Defective Fatty Acid Oxidation in Renal Tubular Epithelial Cells Plays Key Role in Kidney Fibrosis Development — Hyun Mi Kang, Seon-Ho Ahn, Yi-An Ko, Ae Seo Deok Park, Jianling Tao, Frank S. Chinga, James M. Pullman, Erwin P. Bottinger, Katalin Susztak. Philadelphia, PA.
4:54 p.m. FR-OR138
Sphingosine 1-Phosphate Receptor-1 Modulates Mitochondrial Dynamics in Proximal Tubule Cells — Heather M. Perry, Amandeep Bajwa, Diane L. Rosin, Mark D. Okusa. Charlottesville, VA.
5:06 p.m. FR-OR139
Renal Tubular-Specific Lkb1 Deletion Results in Severe Kidney Damage via Altered Metabolic Reprogramming — Seung Hyeok Han, Laura Malaga-Dieguez, Frank S. Chinga, Katalin Susztak. Seoul, South Korea.
5:18 p.m. FR-OR140
Mechanisms Involved in AMPK-Regulated Tight Junction Assembly — Jingshing Wu, Michael J. Caplan. New Haven, CT.
5:30 p.m. FR-OR141
Transcriptome-Based Network Analysis Reveals Renal Cell Type-Specific Dysregulation of Hypoxia-Associated Transcripts — Maja Lindenmeyer, Natallia Shved, Gregor Warsow, David Hoogewijs, Clemens D. Cohen. Zurich, ZH, Switzerland.
5:42 p.m. FR-OR142
Renal Protective Effect of Proximal Tubules-Specific Ghrelin/GHSR System Through the Regulation of Oxidative Stress Levels — Keiko Fujimura, Shu Wakino, Kazuhiro Hasegawa, Koichi Hayashi, Motoko Yanagita, Hiroshi Itoh. Tokyo, Japan.
5:54 p.m. FR-OR143
Nox2 as a Modulator of Ischemia-Reperfusion-Induced Renal Fibrosis — Aos S. Karim, Shannon Reese, Nancy A. Wilson, Arjang Djamali. Madison, WI.
6:06 p.m. FR-OR144
Endothelial Dysfunction and Injury Control Podocyte Defects in Diabetic Nephropathy Susceptible Mice — Ilse S. Daehn, Gabriella Casalena, Liping Yu, Erwin P. Bottinger. New York, NY.
6:18 p.m. FR-OR145
The Polycomb Repressor Complex and Smad3 Constitute a Switch Enhancing Complex that Interprets TGF- Signaling to Control Cell Fate in Diabetic Microvascular Complications — Letizia De Chiara, Hayley Beaton, Catherine Godson, John Crean. Dublin, Ireland.
118
SATURDAY, NOVEMBER 15, 2014
AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2014 DAY-AT-A-GLANCE 8:00 a.m. – 9:30 a.m. Page 122
Plenary Session
President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State-of-the-Art Lecture Hall D
9:30 a.m. – 10:00 a.m.
Morning Break
Exhibit Halls A-C
9:30 a.m. – 2:30 p.m.
Scientific Exposition and Posters Open
Authors will be available at their posters 10:00 a.m. – 12:00 p.m. Exhibit Halls A-C
10:30 a.m. – 12:30 p.m. Page 123 Page 123 Page 124
Page 125
Page 126
10:30 a.m. – 12:30 p.m. Page 127
SATURDAY
Page 125
Clinical Nephrology Conferences
Big Brother Watching You: Regulation in Kidney Transplantation Room 201-C Bug Off: Surviving AKI with Sepsis Ballroom A Controversies in Nephrology: Debate 1—Bicarbonate in Dialysis, Debate 2—Phosphorus Binders in NDD-CKD Ballroom B Getting the Word Out: Education and CKD Room 204-C Hepatitis C and the Kidney Room 113 Recognizing Disparities in CKD Care Room 103
Oral Abstract Session
High-Impact Clinical Trials Hall D
12:30 p.m. – 2:00 p.m.
Lunch Break
12:45 p.m. – 1:45 p.m.
Educational Symposia
Please refer to the Guide to Educational Symposia for titles and locations. Doors will open at 12:30 p.m. Lunch will be provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants. Philadelphia Marriott Downtown
119
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m. Page 128 Page 129 Page 130 Page 131 Page 131 Page 132 Page 132 Page 133 Page 134 Page 134 Page 135 Page 135 Page 136 Page 136
Basic and Clinical Science Symposia
ANCA-Associated Vasculitis: Beyond ANCA Ballroom A Blood Pressure Is Only Skin Deep Room 118-B Clearance beyond Tubular Function: Lymph Vessels in Renal and Cardiovascular Disease Room 105 Finding the Way Home: Recent Discoveries in Polarized Trafficking Room 118-C I’m Hot and Bothered: Kidney Inflammation in AKI Room 201-A Intensive Dialysis: The Good, the Bad, and the Unnoticed Room 119-B Live Imaging and Cell Movements during Kidney Development Room 109 Mapping the Alignment of the Spheres of Phosphate, FGF23, and Klotho Ballroom B Novel GPCR Signaling in Electrolyte Balance and Hypertension Room 115-C The Good and Bad Bugs in Kidney Diseases and Transplantation Room 202 The Path to CKD: Fibrosis to Sclerosis Room 204-C The Renal Tissue Can Tell You More Room 204-A Update in the Genetics and Epigenetics of Diabetic Nephropathy Room 201-C Urine Proteomics to Diagnose Renal Disease Room 107
2:00 p.m. – 4:00 p.m. Page 137 Page 138
Page 139 Page 140 Page 141 Page 142
Special Sessions
ClinicoPathologic Conference Room 108 ESRD Innovation Pathway: Breaking Ground in Collaborations between FDA, Industry, and Academia Room 111 Government Policy for ESRD Care: The Year in Review as the Dust Is Settling Room 115-B New Hypertension Guidelines and Consensus Recommendations—ASN/ASH Joint Session Room 103 The Older Patient with CKD: Optimizing Patient-Centered Care Room 119-A USRDS: New Perspectives on ESRD and Its Management in the United States Room 114
4:00 p.m. – 4:30 p.m.
Afternoon Break
Foyers of Room 108, Room 118, Room 201, and Ballroom
120
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m. Page 143 Page 144 Page 144 Page 145 Page 146 Page 147
Clinical Nephrology Conferences
Alport Syndrome: From Genetics to Genomics and Back to Basics Room 201-C Doctor, Your Patient Is Getting Worse! Are You Sure the Drug Dose Is Right? Room 204-C Hypertension: Kidney Is King Ballroom B Matters of the Mind in CKD Room 103 Renal Biopsy: Clinical Correlations Room 113 The ABCs of Kidney Disease in HIV Ballroom A
4:30 p.m. – 6:30 p.m. Page 148 Page 149 Page 150 Page 151 Page 152 Page 153 Page 154
Page 156 Page 157 Page 158 Page 159
AKI: Risk, Epidemiology, and Outcomes of Clinical AKI Room 111 Biomarkers in CKD Room 105 Developmental Biology Room 109 Diabetic Nephropathy: Experimental Room 114 Diagnostic and Therapeutic Advances in Cystic Kidney Diseases Room 201-A Mechanisms of Glomerular Cell Function and Disease Room 108 Mechanisms of Vascular Calcification Room 203 New Genetic Approaches to Glomerular Disease Room 107 No Borders: Globalizing CKD Prevention Strategies Room 104 Stones and Bones: Pathogenesis and Treatment Room 204-A Water/Urea/Vasopressin, and Organic Solutes Room 112 What’s New in Peritoneal Dialysis? Updates from the Bench and the Bedside Room 202
121
SATURDAY
Page 155
Oral Abstract Sessions
SATURDAY, NOVEMBER 15, 2014 8:00 a.m. – 9:30 a.m.
Plenary Session
President’s Medal, Robert G. Narins Award Presentation, John P. Peters Award Presentation, Belding H. Scribner Award Presentation, Passing of the Gavel, State-of-the-Art Lecture Hall D
Supported by an independent educational grant from Akebia Therapeutics.
Upon completion of this session, the participant will be able to describe the influence of nanomedicine. 8:00 a.m.
President's Medal Presentation The Honorable Tom Marino (R-PA) The Honarable Jim McDermott, MD (D-WA)
8:05 a.m.
Robert G. Narins Award Presentation Stuart L. Linas, MD, FASN
8:15 a.m.
John P. Peters Award Presentation Josephine P. Briggs, MD
8:25 a.m.
Belding H. Scribner Award Presentation Allan J. Collins, MD
8:35 a.m.
Passing the Gavel Jonathan Himmelfarb, MD, FASN, Sharon M. Moe, MD, FASN
8:50 a.m.
State-of-the-Art Lecture “Realizing the Promise of Nanomedicine” Chad A. Mirkin, PhD
10:00 a.m. – 12:00 p.m.
Poster Presentations Exhibit Halls A-C
AKI: Meta-Analysis, Nephrotoxins, and Special Populations (001-034) Mineral Disease: Ca/Mg/PO4 (035-058) Mineral Disease: Nephrolithiasis (059-081) Water/Urea/Vasopressin and Organic Solutes (082-109) Fluid, Electrolyte, and Acid-Base Disorders (110-155) Hypertension: Clinical (156-205) Effect of Diet on Outcomes and Metabolism (206-237) Diabetes Mellitus and Obesity: Clinical - II (238-278) Diabetes Mellitus and Obesity: Basic/Experimental - II (279-320) Vascular Biology: Atherosclerosis, Inflammation, and Endothelium (321-359) Basic/Experimental Pathology - II (360-396) Extracellular Matrix Biology, Fibrosis, and Cell Adhesion - II (397-427) Cell Biology: Glomerular - II (428-470) Clinical/Diagnostic Renal Pathology: Tubulointerstitial Disorders and Novel Techniques (471-495) Glomerular and Tubulointerstitial Disease: Biomarkers (496-549) Cystic Kidney Diseases: Clinical Studies and Promising Therapeutics in Animal Models (550-598) Fellows Case Reports: Myeloma, Thrombotic Microangiopathy, and More (599-643) Educational Research (644-670) Advances in Clinical and Translational Transplantation (671-720) Fellows Case Reports: Transplantation (721-772) CKD: Estimating Equations, Incidence, Prevalence, and Special Populations (773-822) CKD: Health Disparities (823-863) CKD: Epidemiology and Outcomes - III (864-895) Home and Frequent Dialysis (896-916) Peritoneal Dialysis - II (917-957) Standard Hemodialysis for ESRD (958-981) Dialysis: Epi, Outcomes, Trials – Cardiovascular - II (982-1010) Dialysis: Epi, Outcomes, Trials – Noncardiovascular - II (1011-1065) Clinical Science of Vascular Access Function and Complications (1066-1090) Late-Breaking Abstracts (1091-1110)
Please note that this book contains poster sessions but not individual abstract titles and authors. For abstract titles, authors, and more, please refer to the Kidney Week Mobile App, the “Locate Me” Kiosks for Posters and Exhibits in the exposition halls, or the Abstract Supplement pdf at www.asn-online.org/KidneyWeek.
122
SATURDAY, NOVEMBER 15, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Big Brother Watching You: Regulation in Kidney Transplantation Room 201-C
An increasing number of regulations have been put in place to hold transplant centers more accountable for optimizing patient survival and ensuring safety. This session explores the impact of the increased regulatory environment on patient outcomes, as well as transplant center volumes and resource utilization. Upon completion of this session, the participant will be able to: 1) describe the role of SRTR in providing program-specific reports; 2) discuss what we have learned thus far from Transplant Center Reports; 3) list the barriers to compliance with living donor regulatory requirements; and 4) describe the resources required and costs incurred in maintaining compliance in the era of increased regulation. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Anil K. Chandraker, MBChB, FASN, and John S. Gill, MD 10:30 a.m.
Regulation of Kidney Transplantation 101: Fitting All the Pieces Together Dorry L. Segev, MD, PhD
11:10 a.m.
The SRTR Annual Report: Current Uses and Future Needs Bertram L. Kasiske, MD
11:50 a.m.
What Have We Learned from Transplant Center Report Cards Jesse D. Schold, PhD
Clinical Nephrology Conference Bug Off: Surviving AKI with Sepsis Ballroom A
Nephrologists commonly see patients with sepsis, because it is the most common cause of AKI in the ICU. This session provides updates regarding the pathophysiology and pathology of septic AKI, the general medical management of sepsis, and CRRT management of septic AKI. Upon completion of this session, the participant will be able to: 1) describe the pathophysiology and pathology of septic AKI; 2) discuss the general medical management of patients with sepsis, including the surviving sepsis guidelines; and 3) report the approach to CRRT management of sepsis. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Rajit K. Basu, MD, and Jay L. Koyner, MD 10:30 a.m.
Pathophysiology of Septic AKI Philip R. Mayeux, PhD
11:00 a.m.
Medical Management of Sepsis Lakhmir S. Chawla, MD
11:30 a.m.
CRRT Management of Septic AKI John A. Kellum, MD
12:00 p.m.
Pathology of Septic AKI Joseph Gaut, MD, PhD
123
SATURDAY
10:30 a.m. – 12:30 p.m.
SATURDAY, NOVEMBER 15, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference
Controversies in Nephrology: Debate 1—Bicarbonate in Dialysis, Debate 2—Phosphorus Binders in NDD-CKD Ballroom B
Supported by an independent educational grant from OPKO Health Renal Division.
Nephrology guidelines suggest to avoid acidemia in dialysis patients and to keep serum phosphorus within normal range across all CKD stages including in those not yet on dialysis. This session examines two ongoing controversies: first, the role of serum bicarbonate and added bicarbonate into dialysate in dialysis patients; and second, the potential role of phosphorus binders in the management of hyperphosphatemia of individuals with nondialysis dependent CKD (NDD-CKD). During these two debates, critical questions are addressed including 1) whether or nor not serum bicarbonate should be higher or lower than normal range in the care of dialysis patients; and 2) whether a phosphate binder should be given early on to CKD patients prior to ESRD. Upon completion of this session, the participant will be able to: 1) state the benefits of serum bicarbonate monitoring and modulation in dialysis patients; 2) discuss emerging controversies about added bicarbonate to dialysate bath; 3) discuss ongoing controversies related to serum phosphorus measurements in NDD-CKD; and 4) describe the role of phosphate binders in NDD-CKD. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Manjula Kurella Tamura, MD, and Hamid Moradi, MD, FASN 10:30 a.m.
Higher Serum Bicarbonate in Dialysis Patients Is Good Rajnish Mehrotra, MD, FASN
11:00 a.m.
Higher Serum Bicarbonate in Dialysis Patients Is Bad Francesca Tentori, MD
11:30 a.m.
Using Phosphate Binders in CKD Stage III-IV Is Good News Geoffrey A. Block, MD, FASN
12:00 p.m.
Using Phosphate Binders in CKD Stage III-IV Is Bad News Bryan R. Kestenbaum, MD
124
SATURDAY, NOVEMBER 15, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Getting the Word Out: Education and CKD Room 204-C
Awareness of CKD is low among patients and primary care providers (PCPs). Patient understanding and self-management are key to slowing progression of CKD. Early identification by PCPs is important for risk stratification and initiation of risk reduction therapies. This session aims to describe available tools and strategies for nephrologists to educate their patients and colleagues about CKD. Upon completion of this session, the participant will be able to: 1) describe the ASN educational portal and other tools available to optimize CKD education and patient self-management; 2) identify the core components of optimal pre-ESRD education; 3) discuss how to overcome barriers created by limited health literacy; and 4) identify strategies to educate primary care colleagues about CKD. Core Competency: Professionalism, Interpersonal and Communication Skills, Systems-based Practice Moderators: Uptal D. Patel, MD, and Caroline J. Poulton What Is the Toolkit Available to Optimize Patient CKD Education and Self-Management? Kerri L. Cavanaugh, MD
11:00 a.m.
What Does Optimal Pre-ESRD Education Look Like? Vanessa Grubbs, MD
11:30 a.m.
Overcoming Limited Health Literacy in the Clinic Encounter Julie A. Wright Nunes, MD
12:00 p.m.
The Nephrology–PCP Interface: Communicating about CKD to Colleagues Raquel Charles Greer, MD
10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Hepatitis C and the Kidney Room 113
Hepatitis C virus (HCV) can lead to immune complex syndromes of cryoglobulinemia and membranoproliferative glomerulonephritis. This session discusses management of different HCVrelated kidney and systemic disease, including treatment options for those with impaired GFR, and possible future therapies. The management of HCV-positive transplant patients is also discussed. Upon completion of this session, the participant will be able to: 1) describe the spectrum of hepatitis C virus that may be seen in practice; 2) assess treatment options for those with HCV-related kidney disease, including those with impaired GFR, and future therapies; and 3) discuss the management of HCV-positive transplant patients. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Richard J. Johnson, MD, and Meghan E. Sise, MD 10:30 a.m.
The Spectrum of Hepatitis C–Related Kidney Disease Jai Radhakrishnan, MD, FASN
11:00 a.m.
Treatment of HCV-Related Kidney Disease with Normal and Impaired GFR Fabrizio Fabrizi, MD
11:30 a.m.
Future Therapies for Hepatitis C Marc G. Ghany, MD
12:00 p.m.
What Are the Implications for Transplantation in HCV Patients? Roy D. Bloom, MD
125
SATURDAY
10:30 a.m.
SATURDAY, NOVEMBER 15, 2014 10:30 a.m. – 12:30 p.m.
Clinical Nephrology Conference Recognizing Disparities in CKD Care Room 103
This session provides an overview of the disparities in CKD among U.S. under-represented minorities and strategies to eliminate disparities. Upon completion of this session, the participant will be able to: 1) discuss health disparities in the CKD population; 2) illustrate the role of social networks in racial and ethnic minorities with CKD; and 3) identify specific interventions aimed at eliminating health disparities in the CKD population. Core Competency: Medical Knowledge Moderators: Deidra C. Crews, MD, FASN, and Neil R. Powe, MD, FASN 10:30 a.m.
The Magnitude of Health Disparities in the CKD Population Claudia M. Lora, MD
11:00 a.m.
Role of Social Networks Teri Browne, PhD
11:30 a.m.
Cultural Adaptation of CKD Programs and Interventions Bessie A. Young, MD, FASN
12:00 p.m.
Dietary Counseling in Underserved Populations Deidra C. Crews, MD, FASN
126
SATURDAY, NOVEMBER 15, 2014 10:30 a.m. – 12:30 p.m.
Oral Abstract Session High-Impact Clinical Trials Hall D Moderators: Michel Chonchol, MD, and T. Alp Ikizler, MD, FASN
HALT Progression of Polycystic Kidney Disease (HALT PKD) Trials: Primary Results of a 2x2 Factorial Trial in Early Stage CKD — Arlene B. Chapman, Kaleab Z. Abebe, Ronald D. Perrone, Vicente E. Torres, William E. Braun, Theodore I. Steinman, Franz Winklhofer, Godela M. Brosnahan, Peter G. Czarnecki, Marie C. Hogan, Dana Miskulin, Frederic F. Rahbari-Oskoui, Jared J. Grantham, Peter C. Harris, Michael F. Flessner, Kyongtae Ty Bae, Charity G. Moore, Robert W. Schrier. Atlanta, GA.
10:37 a.m.
HALT Progression of Polycystic Kidney Disease Trials: Primary Results of a Randomized Trial in Moderately Advanced Stage CKD — Vicente E. Torres, Kaleab Z. Abebe, Arlene B. Chapman, Robert W. Schrier, William E. Braun, Theodore I. Steinman, Franz Winklhofer, Godela M. Brosnahan, Peter G. Czarnecki, Marie C. Hogan, D. Miskulin, Frederic F. Rahbari-Oskoui, Jared J. Grantham, Peter C. Harris, Michael F. Flessner, Charity G. Moore, Ronald D. Perrone. Rochester, MN.
10:44 a.m.
Questions and Answers
10:50 a.m.
ADVANCE-ON: Long-Term Benefits of Intensive Glucose Control for End-Stage Kidney Disease — Vlado Perkovic, Mark E. Cooper, Mark Woodward, John P. Chalmers, Michel Marre, Sophia Zoungas. Sydney, Australia.
11:00 a.m.
Questions and Answers
11:04 a.m.
Renal Efficacy and Safety of Anti-TGF-β1 Therapy in Patients with Diabetic Nephropathy — James R. Voelker, Paul H. Berg, Matthew Sheetz, Kevin L. Duffin, Julia Lewis, Tom Greene, Philippe Zaoui. Carmel, IN.
11:14 a.m.
Questions and Answers
11:18 a.m.
Randomized Clinical Trial of Ergocalciferol Supplementation in 25 Vitamin D Deficient Hemodialysis Patients — Dana Miskulin, Hocine Tighiouart, Karen M. Majchrzak, Richard S. Muther, Toros Kapoian, Doug Johnson, Daniel E. Weiner. Sommerville, MA.
10:44 a.m.
Questions and A\nswers
11:32 a.m.
Effect of Perioperative Aspirin and Clonidine on Acute Kidney Injury — Amit X. Garg for the POISE-2 Investigators. London, Canada.
11:42 a.m.
Questions and Answers
11:46 a.m.
Six-Month Results of the RESCUE Trial: Fluency® Plus Endovascular Stent Graft versus PTA for In-Stent Restenosis — Alexander S. Yevzlin, Ivan D. Maya, Abigail Falk. Madison, WI.
11:56 a.m.
Questions and Answers
12:00 p.m.
Impact of Extended Weekly Hemodialysis Hours on Quality of Life and Clinical Outcomes: The ACTIVE Dialysis Multinational Trial — Meg J. Jardine, Li Zuo, Nicholas A. Gray, Janak Rashme de Zoysa, Christopher T. Chan, Martin P. Gallagher, Alan Cass, Vlado Perkovic. Campertown, Australia.
12:10 p.m.
Questions and Answers
12:14 p.m.
ACT-AKI: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects — Madhav Swaminathan, David Mazer, Glenn M. Chertow, David G. Warnock, Viken Paragamian, Robert M. Brenner. Durham, NC.
12:24 p.m.
Questions and Answers
127
SATURDAY
10:30 a.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium ANCA-Associated Vasculitis: Beyond ANCA Ballroom A
Despite the overwhelming evidence that ANCA is a major cause of injury in ANCA-associated vasculitis, recent studies emphasize they have a more complex relation to injury than previously thought. Randomized controlled trials and meta-analyses show ANCA correlates poorly with disease activity and relapse; ANCA-negative patients are well recognized. This session analyses possible explanations for these anomalies. It summarizes current knowledge of T cells, nonclassical autoantibodies, and inflammatory pathways to the pathogenesis, and reviews novel therapeutic approaches to control them. Upon completion of this session, the participant will be able to: 1) describe the potential pathogenetic role of T cells and ANCA-associated vasculitis; 2) discuss the possible causes of injury in ANCA-negative pauci-immune focal necrotizing glomerulonephritis (FNGN); 3) stratify patients with ANCA-associated vasculitis according to risk of relapse; and 4) summarize potential novel therapies. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Fernando C. Fervenza, MD, PhD, FASN, and Mark Alan Little, MD, PhD 2:00 p.m.
Effector-Memory T Cells in Patients with ANCA-Associated Vasculitis Cees G.M. Kallenberg, MD, PhD
2:30 p.m.
Potential Pathogenetic Mechanisms in ANCA-Negative Pauci-Immune Focal Necrotizing Glomerulonephritis Renate Kain, MD, PhD
3:00 p.m.
Transcriptomic Signatures that Identify Frequently Relapsing Patients with ANCA-Associated Vasculitis Paul Anthony Lyons
3:30 p.m.
Potential New Therapies for ANCA-Associated Vasculitis Ronald J. Falk, MD, FASN
128
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Blood Pressure Is Only Skin Deep Room 118-B
Control of extracellular fluid space composition is generally considered as extracellular volume control. We generally believe that renal excretion of electrolyte and water is sufficient to control extracellular volume and thereby regulate blood pressure. Besides skeletal muscle, the skin is the largest extracellular organ. Emerging evidence suggests that the internal environmental composition of the skin is relevant for systemic blood pressure control. This local regulation does not directly rely on renal blood purification mechanisms. Additional local skin-specific extrarenal regulatory components are involved in maintenance of the microenvironment of the skin, which are tightly coupled to systemic blood pressure control. Disruption of these extrarenal regulatory components results in arterial hypertension. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) describe that nitric oxide (NO) production in the skin is relevant for skin blood perfusion and is regulated by hypoxia-inducible factors generated by keratinocytes; 2) explain that ultraviolet (UV) irradiation releases NO from skin stores and lowers blood pressure; and 3) discuss that large amounts of sodium are stored in the skin. The experts in this session address this important topic. Core Competency: Medical Knowledge Moderators: Nathan W. Levin, MD, and Detlef O. Schlondorff, MD Hypoxia Inducible Factors and Circulation: Is Blood Pressure Regulated in the Skin? Randall S. Johnson, PhD
2:30 p.m.
The Sunny Side of Blood Pressure Regulation: Skin UV Exposition and NO Release Richard Beresford Weller, MD
3:00 p.m.
Psoriasis: When Autoimmune Skin Inflammation Meets Hypertension Susanne Helena Karbach, MD
3:30 p.m.
Skin Sodium Storage Links Electrolyte Homeostasis with Essential Hypertension Friedrich C. Luft, MD, FASN
129
SATURDAY
2:00 p.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Clearance beyond Tubular Function: Lymph Vessels in Renal and Cardiovascular Disease Room 105
Do the kidneys really solely control the extracellular volume? There is little doubt that the kidneys control the blood volume; however, whether or not blood purification alone is sufficient for interstitial volume and electrolyte homeostasis has become controversial. Recent advances in understanding the molecular control of the lymph-capillary system provides novel insights into how the interstitial space is regulated. The interstitium seems to be a fluid compartment, which relies on separate, tissue-specific immune cell and lymph capillary-driven local clearance mechanisms. These processes regulate immune-cell trafficking, cholesterol transport, local fluid/electrolyte relationships, and blood pressure homeostasis. Upon completion of this session, the participant will be able to: 1) describe the biology of the lymph capillary system; 2) discuss the role of lymph capillaries for interstitial fat clearance; and 3) describe the role of lymph capillaries for interstitial electrolyte clearance. Core Competency: Professionalism, Medical Knowledge Moderators: Barbara J. Ballermann, MD, and Ambra Pozzi, PhD 2:00 p.m.
The Biology of the Lymph Capillary System in Health and Disease Taija Mäkinen
2:30 p.m.
Lymphatics in the Kidney Dontscho Kerjaschki, MD
3:00 p.m.
Lymphatic Cholesterol Clearance and Atherosclerosis Gwendalyn Randolph, PhD
3:30 p.m.
Lymphatic Regulation of the Interstitial Space Helge Wiig, MD, PhD
130
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Finding the Way Home: Recent Discoveries in Polarized Trafficking Room 118-C
Polarized distribution of membrane proteins on apical and basolateral membrane domains is a central underpinning of epithelial transport and development. In recent years, remarkable progress has been made in identifying intracellular trafficking machineries that sort, send, retain, and recycle membrane proteins to the correct membrane domain. This session highlights recent breakthroughs in the field. Upon completion of this session, the participant will be able to: 1) describe new concepts about polarized trafficking of apical and basolateral membrane-destined proteins from the trans-Golgi; 2) describe the vesicular tethering machinery that defines apical polarity and tubule lumen formation; 3) discuss the role of clathrin-adaptor molecules in basolateral polarity; and 4) describe the function of the Crumbs complex in apical-basolateral polarity. Core Competency: Medical Knowledge Moderators: Judith Blaine, MD, PhD, and Joshua H. Lipschutz, MD ARH as a Basolateral Membrane Targeting Machine Heike Folsch, PhD
2:30 p.m.
Polarity in Epithelial Morphogenesis Keith Mostov, MD, PhD
3:00 p.m.
Clathrin Adaptors in Basolateral Polarity Enrique Rodriguez-Boulan, MD
3:30 p.m.
Crumbs3 Is Crucial for Apical Membrane Morphogenesis Benjamin L. Margolis, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium I’m Hot and Bothered: Kidney Inflammation in AKI Room 201-A
The inflammatory response is a key contributor to injury and repair in AKI. This session examines emerging themes associated with the inflammatory response in AKI. Upon completion of this session, the participant will be able to: 1) describe the inflammatory response to injury in human AKI; 2) discuss the emerging role of IL-22 in AKI; 3) examine the mechanisms of macrophage activation in AKI; and 4) describe the contribution of dendritic cells to AKI. Core Competency: Medical Knowledge Moderators: Patrick Cunningham, MD, FASN, and William Brian Reeves, MD, FASN 2:00 p.m.
Macrophage Activation in AKI Sarah C. Huen, MD
2:30 p.m.
Inflammatory Markers of AKI in Septic Shock Didier M. Payen, MD, PhD
3:00 p.m.
IL-22–Mediated Protection in AKI Bin Gao, MD, PhD
3:30 p.m.
Dendritic Cells in the Innate Immune Response Mark D. Okusa, MD, FASN
131
SATURDAY
2:00 p.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Intensive Dialysis: The Good, the Bad, and the Unnoticed Room 119-B
This session updates the attendees regarding the benefits and risks of frequent dialysis, primarily based on the most recent data published by the FHN group. Upon completion of this session, the participant will be able to: 1) discuss the benefits of frequent dialysis; 2) describe the potential risks and complications of frequent hemodialysis; 3) state the lack of effect of frequent dialysis on certain patient-related outcomes; and 4) describe ways to improve patient–physician communication when discussing dialysis options with the patients. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Interpersonal and Communication Skills Moderators: Glenn M. Chertow, MD, FASN, and Rachel B. Fissell, MD 2:00 p.m.
More Is Better: How to Communicate to the Patient? Kerri L. Cavanaugh, MD
2:30 p.m.
Effects of Frequent Dialysis on LVH/CVD Michael V. Rocco, MD
3:00 p.m.
Effects of Frequent Dialysis on Physical and Cognitive Function Mark L. Unruh, MD
3:30 p.m.
Effects of Frequent Dialysis on Vascular Access Outcomes: Practical Applications Arif Asif, MD, FASN
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Live Imaging and Cell Movements during Kidney Development Room 109
To achieve proper function, renal tubules must achieve the proper length and diameter. Several recent studies have shown that cells within the tubule are not locked in place. Instead, directional cell movement appears essential for establishing and maintaining tubule diameter. In this session, several distinct examples of how cell movement regulates tubule diameter are presented. Upon completion of this session, the participant will be able to: 1) discuss various mechanisms involved in tubule elongation during normal development; 2) describe mechanisms involved in tubular repair; and 3) discuss molecular mechanisms underlying directed cell movement. Core Competency: Medical Knowledge Moderators: Robert L. Bacallao, MD, and Alessandra Boletta, PhD 2:00 p.m.
Live Imaging Mammary Epithelium Morphogenesis Andrew J. Ewald, PhD
2:30 p.m.
Vertebrate Kidney Tubules Elongate Using a Planar Cell Polarity-Dependent, Rosette-Based Mechanism of Convergent Extension Soeren S. Lienkamp, MD
3:00 p.m.
Collective Cell Migration Regulates Kidney Tubule Elongation Aleksandr Vasilyev, MD, PhD
3:30 p.m.
Cell Movement during Ureteric Bud Branching Morphogenesis Frank Costantini, PhD
132
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Mapping the Alignment of the Spheres of Phosphate, FGF23, and Klotho Ballroom B
Supported by an independent educational grant from OPKO Health Renal Division.
Hyperphosphatemia is one of the more prevalent metabolic disturbances in kidney failure. Phosphate can be considered a uremic toxin based on the accumulation of phosphate during CKD, the effects of phosphate on biological systems, and the adverse effects of hyperphosphatemia. The renal clearance of phosphate is maintained until later stages of CKD, when the remaining nephrons are no longer able to excrete sufficient phosphate to offset dietary phosphate absorption. Elevated phosphorus is associated with arterial and valvular calcification, arteriosclerosis, and an increased risk of cardiovascular death. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) describe the phosphate regulation at the kidney; 2) discuss the consequences of hyperphosphatemia at the vasculature; and 3) describe the role of the intestine on phosphate absorption. Core Competency: Medical Knowledge Moderators: Cynthia Delgado, MD, and Makoto Miyazaki, PhD Phosphorus, FGF23, and Klotho Regulation at the Kidney: Who Is in Charge? Tobias E. Larsson, MD, PhD
2:30 p.m.
Vascular Consequences of Elevated Phosphate Cecilia M. Giachelli, PhD
3:00 p.m.
Intestinal Phosphate Absorption: From Animals to Humans John Scott Radcliffe, PhD
3:30 p.m.
Controlling Phosphate at the Food Source Myles S. Wolf, MD
133
SATURDAY
2:00 p.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Novel GPCR Signaling in Electrolyte Balance and Hypertension Room 115-C
Novel G-protein–coupled receptors (GPCRs) have recently been identified in the kidney, illuminating completely new signaling systems that regulate electrolyte balance and control blood pressure. A new paradigm of GPCRs in intrarenal paracrine signaling and metabolism coupling has emerged. This session highlights these new developments. Upon completion of this session, the participant will be able to: 1) describe paracrine regulation of ENaC; 2) discuss how Krebs cycle intermediates as paracrine regulators in the kidney; and 3) describe how microbiota-derived signals regulate renin secretion and blood pressure. Core Competency: Medical Knowledge Moderators: Donald E. Kohan, MD, PhD, FASN, and Volker Vallon, MD 2:00 p.m.
Purinergic/Endothelin Regulation of the Epithelial Na(+) Channel as a Model of Intrinsic Paracrine/Autocrine GPCR Regulation James D. Stockand, PhD
2:30 p.m.
α-Ketoglutarate Regulates Acid-Base Balance through an Intrarenal Paracrine Mechanism Dmitri Firsov, PhD
3:00 p.m.
Emerging Paradigms in V2-Vasopressin Receptor Trafficking and Signaling in Health and Disease Michel Bouvier, PhD
3:30 p.m.
Olfactory Receptor in Kidney Links Gut Microbiota-Derived Signals to Renin Secretion and Blood Pressure Regulation Jennifer L. Pluznick, PhD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
The Good and Bad Bugs in Kidney Diseases and Transplantation Room 202
This session provides an update on the frontier of microbiota research in kidney diseases. Upon completion of this session, the participant will be able to: 1) describe the role of microbiota in kidney inflammation; 2) discuss the role of microbiota in salt and blood pressure regulation; 3) describe the role of microbiota in chronic rejection of kidney allografts; and 4) discuss the role of microbiota in transplantation tolerance. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Dominic S. Raj, MD, FASN, and Nosratola D. Vaziri, MD 2:00 p.m.
Microbiome in Inflammatory Diseases Dan R. Littman, MD, PhD
2:30 p.m.
Microbiota in Transplantation Tolerance Maria-Luisa Alegre, MD, PhD
3:00 p.m.
Infection and Chronic Rejection of Kidney Allografts Daniel R. Salomon, MD
3:00 p.m.
Inflammasomes and Metabolic Diseases Jorge Henao-Mejia, MD, PhD
134
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium The Path to CKD: Fibrosis to Sclerosis Room 204-C
Despite its complex pathogenesis, renal fibrosis is the single common pathway downstream of most renal injuries that contributes to progressive CKD and represents an important diagnostic and therapeutic target. This session highlights the cellular and molecular mechanisms of fibrosis in the progression of kidney disease and describes lessons learned from pulmonary fibrosis. Upon completion of this session, the participant will be able to: 1) examine the role of fibrosis in progressive kidney disease; 2) describe its relationship to glomerular sclerosis; 3) describe the cellular origin of myofibroblasts and molecular mechanisms of fibrosis; and 4) discuss pulmonary fibrosis and lessons learned in related research. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Youhua Liu, PhD, and Daniel A. Muruve, MD Is It a Matter of the Tail Wagging the Dog? Does Proximal Tubular Injury Trigger Interstitial Fibrosis and Glomerulosclerosis? Joseph V. Bonventre, MD, PhD, FASN
2:30 p.m.
Myofibroblasts: Cellular Origins of Kidney Fibrosis Michael Zeisberg, MD
3:00 p.m.
Hypoxic HIF, Fibrosis, and CKD Masaomi Nangaku, MD, PhD
3:30 p.m.
Putting It All Together: Lessons Learned from Liver Fibrosis Scott L. Friedman, MD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium The Renal Tissue Can Tell You More Room 204-A
Recent discoveries are establishing the importance of metabolic and signaling pathways and are highlighting the relevance of molecules to the pathogenesis of renal diseases. However, in sharp contrast to other fields such as oncology and immunology, diagnosis remains based on traditional microscopy findings. This session helps the attendees make better utilization of the renal biopsy by adding information that can be relevant to diagnosis, therapy, and prognosis of the patient. Upon completion of this session, the participant will be able to: 1) describe markers of kidney damage; 2) discuss immunostaining; and 3) describe human renal biopsies. Core Competency: Professionalism, Medical Knowledge Moderators: Agnes B. Fogo, MD, and Zhihong Liu, MD 2:00 p.m.
Human Tissue Banking and Expression Studies: The Neptune Example Matthias Kretzler, MD
2:30 p.m.
IgG Subclasses, Antigens, and Complement Components to Improve Diagnosis of Membranous Nephropathy Pierre M. Ronco, MD, PhD
3:00 p.m.
From Steroids to Rituximab: Renal Expression of Drug Targets Alessia Fornoni, MD, PhD, FASN
3:30 p.m.
Markers of Inflammation and Fibrosis in Native and Transplant Biopsies Hermann-Josef Groene, MD
135
SATURDAY
2:00 p.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium
Update in the Genetics and Epigenetics of Diabetic Nephropathy Room 201-C
Supported by an independent educational grant from AbbVie.
The session reviews the latest results in identifying genes implicated in susceptibility to diabetic nephropathy and characterizing the human epigenome in subjects with and without diabetic nephropathy. Upon completion of this session, the participant will be able to: 1) describe more about new approaches to identify genes in health and disease such as exome sequencing; and 2) discuss epigenetic pathways that are currently being investigated in human diseases including diabetes and its complications. Core Competency: Medical Knowledge Moderators: Rama Natarajan, PhD, FASN, and Katalin Susztak, MD, PhD 2:00 p.m.
Advances in the Understanding of the Genetics of Diabetic Nephropathy: Findings from the Summit Consortium Leif Groop, MD, PhD
2:00 p.m.
Current Status Genetics of Diabetic Nephropathy Jose C. Florez, MD, PhD
2:30 p.m.
Overview of Epigenetic Mechanisms: Relevance to Chronic Diseases Francine Einstein, MD
3:00 p.m.
Characterizing the Human Epigenome in Diabetic Nephropathy Assam El-Osta, MD, PhD
2:00 p.m. – 4:00 p.m.
Basic and Clinical Science Symposium Urine Proteomics to Diagnose Renal Disease Room 107
This session highlights the technical advances in proteomics to identify and quantify urinary proteins for diagnosis of kidney diseases. Upon completion of this session, the participant will be able to: 1) describe the capabilities of mass spectroscopy in identifying and quantifying urinary proteins; and 2) discuss the use of mass spectroscopy for the identification and prediction of kidney diseases. Core Competency: Medical Knowledge Moderators: Deepika Jain, MD, and Chirag R. Parikh, MD, PhD, FASN 2:00 p.m.
Challenges in the Use of Urine Proteomics for Biomarker Discovery John M. Arthur, MD, PhD
2:30 p.m.
Urine Proteomics and the Progression of PKD Arlene B. Chapman, MD
3:00 p.m.
Defining Presymptomatic Kidney Disease by Urine Proteomics Kevin Mills, PhD
3:30 p.m.
Using Proteomics to Predict Kidney Function Joost Schanstra
136
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Special Session ClinicoPathologic Conference Room 108
This session provides a case presentation in clinicopathologic conference format. The clinical discussant is provided a case by the pathologist 6–8 weeks prior to the meeting and presents a discussion of the case with differential and final diagnoses. This presentation is followed by review of the biopsy/ pathology materials from the case by the pathology discussant. The clinical discussant then follows up on the case discussion, and both presenters answer questions from the audience. Upon completion of this session, the participant will be able to: 1) discuss the differential diagnosis based on the clinical presentation of the case; 2) describe key pathologic features in establishing a diagnosis; and 3) outline the benefits of clinical pathologic correlation. Core Competency: Medical Knowledge Moderator: Kevin E.C. Meyers, MD, FASN 2:00 p.m.
Clinical Discussant Milagros D. Samaniego-Picota, MD, FASN
3:00 p.m.
Pathology Discussant Joseph Gaut, MD, PhD
SATURDAY
137
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Special Session
ESRD Innovation Pathway: Breaking Ground in Collaborations between FDA, Industry, and Academia Room 111
ASN thanks the Food and Drug Administration for assistance with this session.
The FDA Innovation Pathway was developed to help safe, breakthrough medical products reach patients in a timely manner. Its ultimate goals are to shorten the overall time and cost it takes for the development, assessment, and review of medical devices, and to improve or transform how FDA staff and innovators work together. The session provides an update on the ESRD Innovation Pathway, including a description of the program, the collaborations between the FDA, industry, and academia, and its outcomes. Upon completion of this session, the participant will be able to: 1) describe stakeholder awareness of the FDA’s Innovation Pathway; 2) describe potential mechanisms of collaboration between the FDA, industry, academia, and other stakeholders (payers, professional medical societies, etc); 3) discuss outcomes of current collaborations; and 4) discuss how to apply lessons learned from the Innovation Pathway to future innovative device development and collaboration between the FDA, industry, and academia. Core Competency: Medical Knowledge, Systems-based Practice Moderators: Alan S. Kliger, MD, and Murray Sheldon, MD 2:00 p.m.
Introduction to Innovation Pathway Murray Sheldon, MD
2:18 p.m.
Project 1: Implantable Renal Assist Device (iRAD) Shuvo Roy, PhD
2:36 p.m.
Project 2: Wearable Artificial Kidney (WAK) Victor Gura, MD, FASN
2:54 p.m.
Project 3: HemoAccess Valve System Steve Johnson
3:12 p.m.
Outcomes and Future Considerations Carolyn Y. Neuland, PhD
3:30 p.m.
Panel: Discussion Q & A Gema Gonzalez, PhD, Frank P. Hurst, MD, FASN, Carolyn Y. Neuland, PhD, Douglas M. Silverstein, MD
138
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Special Session
Government Policy for ESRD Care: The Year in Review as the Dust Is Settling Room 115-B
ASN thanks its Public Policy Board for assistance with this session.
Federal programs for patients with ESRD continue to provide examples of new models of health care to the general medical community. This session reviews the successes and challenges from the policies put into action over the past year. First, the current status of the ESCO program is described, including perceived opportunities and challenges regarding ESCO program financial viability, quality measures, and community participation in the ESCO program over the last year, with perspectives from large and small organizations. Then, the progress of the credible measure development for the Quality Incentive Program (QIP) with examination of the CMS Technical panels (TEPs) is discussed, as well as data generated from the QIP of prior years. Here, the innovative products that are being considered for inclusion in “the bundle” are discussed, including bundled payments from other realms, such as technologies added to the hospital “bundle.” How can the nephrology community learn from the opportunities and pitfalls that others have experienced? Upon completion of this session, the participant will be able to: 1) describe the current state of the ESCO model and explain the benefits and challenges that patients and providers are experiencing; 2) discuss the current mechanism for QIP measure development; 3) discuss other bundled payment systems, such as the hospital arena, and lessons learned that can be applied to nephrology; and 4) describe the status of the changes to the ESRD prospective payment system over the last year. Core Competency: Medical Knowledge, Systems-based Practice Moderators: Amy W. Williams, MD, and Leslie P. Wong, MD, FASN The Current State of the ESCO Model: Benefits and Challenges for Patients and Providers Thomas H. Hostetter, MD
2:40 p.m.
The Nephrologist Trapped: How to Care for Dialysis Patients in a World of Population Quality Metrics Daniel E. Weiner, MD, FASN
3:20 p.m.
Non-ESRD Bundled Payment Systems: Lessons Learned for ESRD Care Janis M. Orlowski, MD
139
SATURDAY
2:00 p.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Special Session
New Hypertension Guidelines and Consensus Recommendations— ASN/ASH Joint Session Room 103
Supported by an independent educational grant from Relypsa. ASN thanks the American Society of Hypertension for assistance with this session.
Hypertension remains a major contributor to morbidity and mortality in the adult population. This session examines the recently published national and international guidelines for the treatment of hypertension in adults and in patients with CKD. The faculty discuss the different criteria used to build those guidelines and how to integrate the guidelines into clinical practice. Upon completion of this session, the participant will be able to: 1) report current national and international guidelines on treatment of hypertension; 2) appraise the management and treatment of hypertension in the general population and patients with CKD; and 3) describe how to integrate guidelines into practice. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice Moderators: Efrain Reisin, MD, and Raymond R. Townsend, MD 2:00 p.m.
European Guidelines for Hypertension Management Luis M. Ruilope, MD, PhD
2:30 p.m.
KDIGO Clinical Practice Guidelines George L. Bakris, MD, FASN
3:00 p.m.
JNC 8 and ASH-ISH Guidelines Sandra J. Taler, MD
3:30 p.m.
Making Sense of It All: How Does the Clinician Integrate Guidelines into Practice? Matthew R. Weir, MD
140
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Special Session
The Older Patient with CKD: Optimizing Patient-Centered Care Room 119-A
ASN thanks the National Institutes of Health’s National Institute on Aging for assistance with this session.
Most CKD patients, especially older patients, carry the burden of multiple additional chronic conditions (MCCs) including hypertension, diabetes, cardiovascular disease, and others. These comorbidities further complicate the ability to predict kidney function trajectories, as well as ESRD, suitability for renal replacement therapy, and mortality. Using the American Geriatric Society’s Stepwise Approach to Multiple Chronic Conditions, this session proposes a clinically useful format to provide patient-centered care by incorporating CKD patients’ values and comorbidities to better predict and optimize renal and clinical outcomes. It also addresses the MCC impact on older kidney donors and transplant recipients. Upon completion of this session, the participant will be able to: 1) describe a clinically useful method to incorporate comorbidities and patients’ views for estimating renal function risk and trajectories; 2) demonstrate communication skills to elicit and incorporate patient preference and prognosis into discussions of care strategies in older CKD patients; 3) discuss clinically useful methods to assess and communicate the candidacy of older potential kidney donors and recipients; and 4) identify specific strategies to manage older renal transplant patients to preserve their function and quality of life. Moderators: C. Barrett Bowling, MD, and Susan J. Zieman, MD, PhD My Older ESRD Patient Has Been Transplanted…Now What? Christopher D. Blosser, MD
2:30 p.m.
Clinical Prediction Tools in CKD Navdeep Tangri, MD
3:00 p.m.
Optimizing Treatment of the Elderly with ESRD and Other Comorbidities Manjula Kurella Tamura, MD
3:30 p.m.
Renal Transplant for Older Patients with Comorbidities Dorry L. Segev, MD, PhD
141
SATURDAY
2:00 p.m.
SATURDAY, NOVEMBER 15, 2014 2:00 p.m. – 4:00 p.m.
Special Session
USRDS: New Perspectives on ESRD and Its Management in the United States Room 114
ASN thanks the United States Renal Data System for assistance with this session.
In the last decade, the incidence rates of ESRD seem to have reached a plateau, but the prevalence rate has continued to increase. This session explores the new trends in ESRD incidence, the management and outcomes, including the current level of fistula use, and the influence of the timing of the start of dialysis. The need for future studies to explore factors influencing transition from CKD to renal replacement therapy and palliative care of patients with advanced CKD is also discussed. Upon completion of this session, the participant will be able to: 1) describe the reasons for the increasing ESRD prevalence rate despite the stable incidence rates; 2) discuss some of the factors influencing initiation of first dialysis and the related outcome; 3) describe the need for investigating factors that influence transition of care from advanced stage of CKD to renal replacement therapy; and 4) discuss the rationale for the proposed investigations into palliative care for patients with advanced CKD and end-of-life care in ESRD. Core Competency: Medical Knowledge Moderators: Kevin C. Abbott, MD, and Lawrence Agodoa, MD 2:00 p.m.
Introduction of the New USRDS Team Lawrence Agodoa, MD
2:05 p.m.
Trends and Outcomes in the United States Rajiv Saran, MD
2:25 p.m.
Examining Facility-Level Data for the USRDS Yi Li, PhD
2:45 p.m.
Predictors of Timing of Dialysis Start in the United States Bruce M. Robinson, MD, FASN
3:05 p.m.
Transition of Care from Advanced CKD to Renal Replacement Therapy Kamyar Kalantar-Zadeh, MD, PhD, FASN
3:25 p.m.
Palliative and End-of-Life Care in Patients with Kidney Disease Ann M. O’Hare, MD
3:45 p.m.
Questions and Answers
142
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Alport Syndrome: From Genetics to Genomics and Back to Basics Room 201-C
ASN thanks the Renal Pathology Society for assistance with this session.
Diagnosis, management, and treatment of patients with Alport syndrome (AS) are not infrequently a challenge because there is considerable variability in disease presentation, pathology, and multisystem involvement. This is particularly the case in autosomal recessive AS heterozygous parent carriers who may have subclinical disease, and disease in children has atypical clinical symptoms and or pathology. Genotyping patients for mutations in COL4 a chains has aided in accurately diagnosing AS and additionally helped in understanding disease severity; therefore, it is considered the gold standard for diagnosis of AS. This session focuses on the impact of known Alport mutations in assessing disease severity, limitations of the current genetic approaches, and implications for patient prognosis and management. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) differentiate pathologic from “nonpathologic” Alport mutations in X-L, AR, and AD Alport; 2) describe advantages and limitations of linkage analysis and whole genome sequencing; 3) describe focal segmental glomerulosclerosis as a histopathologic variant of Alport nephritis; and 4) apply this knowledge in patient management. Core Competency: Medical Knowledge Moderators: Dorin-Bogdan Borza, PhD, and Jeffrey H. Miner, PhD Pathologic and Nonpathologic Mutations: How to Deal with Unknown Ones Frances Anne Flinter, MD
5:00 p.m.
AR-Alport Presenting as FSGS Constantinos Deltas, PhD
5:30 p.m.
Genomic Analysis for Alport Nephritis: Challenges and Opportunities Sanjay Jain, MD, PhD
6:00 p.m.
Current Guidelines for Patient Management Oliver Gross, DrMed
143
SATURDAY
4:30 p.m.
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference
Doctor, Your Patient Is Getting Worse! Are You Sure the Drug Dose Is Right? Room 204-C
The safe and effective use of drugs in patients with kidney disease is contingent on optimal drug selection and dosing. This session provides an overview of the fundamental pharmacokinetic and dynamic principles necessary when making pharmacotherapeutic decisions in patients across the spectrum of kidney function with a focus on patients receiving intermittent and continuous dialytic techniques. Upon completion of this session, the participant will be able to: 1) describe basic pharmacokinetic and pharmacodynamic principles and corresponding alterations observed in CKD; and 2) discuss drug clearance and dosing considerations in patients receiving various dialytic techniques. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: George R. Aronoff, MD, and Mark A. Perazella, MD, FASN 4:30 p.m.
Pharmacokinetic and Pharmacodynamic Principles across the CKD Spectrum Brian S. Decker, MD, PharmD
5:10 p.m.
Comparison of Drug Clearance and Dosing during Intermittent and Continuous Renal Replacement Therapy Rachel F. Eyler, PharmD
5:50 p.m.
Drug Clearance and Dosing in Patients Receiving Peritoneal Dialysis Katie E. Cardone, PharmD
4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference Hypertension: Kidney Is King Ballroom B
This session focuses on hypertension associated with vascular disease, CKD and end-stage kidney disease, and essential hypertension, with an emphasis on renal mechanisms. Upon completion of this session, the participant will be able to: 1) describe the pathogenesis of renovascular hypertension and ischemic nephropathy; 2) discuss appropriate treatment of renovascular hypertension; 3) describe the pathogenesis of hypertension in patients with reduced GFR; 4) discuss the appropriate treatment of hypertension in patients with chronic and end-stage kidney disease; and 5) describe the important role of the kidney in the pathogenesis of essential hypertension. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement Moderators: Rajiv Agarwal, MD, MBBS, FASN, and Raymond R. Townsend, MD 4:30 p.m.
The Genetics of Hypertension: From Rare Phenotypes to Common Pathways Richard P. Lifton, MD, PhD
5:00 p.m.
The Essentials of Hypertension Richard J. Johnson, MD
5:30 p.m.
Hypertension Associated with CKD Piero Luigi Ruggenenti, MD
6:00 p.m.
Atherosclerotic Renovascular Hypertension: Who, Where, What, and When Stephen C. Textor, MD
144
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference Matters of the Mind in CKD Room 103
Depression and cognitive impairment are under-recognized and undertreated in patients with CKD. Early identification is important for decision making and improving quality of life. This session describes the state of the art regarding diagnosis and therapy for patients with either depression or cognitive impairment and CKD. Upon completion of this session, the participant will be able to: 1) describe tools that can be used for depression screening; 2) discuss medication and behavioral strategies to treat depression in CKD; 3) identify the relationships between CKD, cognitive impairment, and decisional capacity; and 4) discuss evidence-based strategies for adults with CKD and diminished decisional capacity. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Manjula Kurella Tamura, MD, and Suzanne Watnick, MD Screening for Depression and Associated Outcomes for Patients with CKD Susan Hedayati, MD, FASN
5:00 p.m.
Identifying Cognitive Impairment and Decisional Capacity in CKD Patients Rute C. Paixao, MD
5:30 p.m.
Strategies to Address Cognitive Impairment and Diminished Decisional Capacity in CKD Patients Dianne T. Sandy, MD
6:00 p.m.
Medications and Behavioral Therapy for CKD Patients with Depression Daniel Cukor, PhD
145
SATURDAY
4:30 p.m.
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference Renal Biopsy: Clinical Correlations Room 113
This session includes a case presentation, presented in a mini-CPC format with a clinical discussant. Case histories and biopsy images are posted on the ASN website prior to the meeting. Glass slides and case materials can be reviewed and discussed with renal pathology faculty onsite in the Microscope Room prior to this session. The Microscope Room is located in Room 110 and is open on Thursday– Friday, 9:30 a.m.–4:30 p.m. and Saturday, 9:30 a.m.–12:00 p.m. Diagnoses are distributed and available on the ASN website after the session. Upon completion of this session, the participant will be able to: 1) analyze clinical and renal biopsy findings; 2) describe main diagnostic features of presented cases; and 3) discuss histologic findings in specific diseases. Core Competency: Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice Moderators: Ingeborg M. Bajema, MD, PhD, and Michael Mengel, MD 4:30 p.m.
Introduction
4:35 p.m.
Clinical Discussant: Case History I and Differential Diagnosis Liz Lightstone, MD, PhD
4:40 p.m.
Pathology Discussant: Biopsy Findings Harsharan Kaur Singh, MD
4:50 p.m.
Clinical Discussant: Response; Audience Q&A Liz Lightstone, MD, PhD
4:58 p.m.
Clinical Discussant: Case History II and Differential Diagnosis Liz Lightstone, MD, PhD
5:03 p.m.
Pathology Discussant: Biopsy Findings Kerstin U. Amann, MD
5:13 p.m.
Clinical Discussant: Response; Audience Q&A Liz Lightstone, MD, PhD
5:21 p.m.
Clinical Discussant: Case History III and Differential Diagnosis Liz Lightstone, MD, PhD
5:26 p.m.
Pathology Discussant: Biopsy Findings Mark Haas, MD, PhD
5:36 p.m.
Clinical Discussant: Response; Audience Q&A Liz Lightstone, MD, PhD
5:44 p.m.
Clinical Discussant: Case History IV and Differential Diagnosis Liz Lightstone, MD, PhD
5:49 p.m.
Pathology Discussant: Biopsy Findings Samih H. Nasr, MD
5:59 p.m.
Clinical Discussant: Response; Audience Q&A Liz Lightstone, MD, PhD
6:07 p.m.
Clinical Discussant: Case History V and Differential Diagnosis Liz Lightstone, MD, PhD
6:12 p.m.
Pathology Discussant: Biopsy Findings Erika R. Bracamonte, MD
6:22 p.m.
Clinical Discussant: Response; Audience Q&A Liz Lightstone, MD, PhD
146
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Clinical Nephrology Conference The ABCs of Kidney Disease in HIV Ballroom A
This session describes how kidney disease in HIV patients has evolved with the advent of antiretroviral treatment. Genetic predisposition, various glomerular diseases associated with HIV, the common cause of AKI in the setting of HIV infection, and the renal consequences of combination ART are discussed. Upon completion of this session, the participant will be able to: 1) discuss genetic factors that predispose HIV patients to kidney disease; 2) describe how HIV infection causes various glomerular diseases; 3) explain how combination ART may cause kidney disease; and 4) describe the causes and consequences of AKI in HIV. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Ravinder K. Wali, MD, and Jonathan A. Winston, MD Genetics and HIV-Kidney Disease: A Tale of Two Races Jeffrey B. Kopp, MD, FASN
5:00 p.m.
AKI in the Setting of HIV: Common Causes and Consequences Christina M. Wyatt, MD
5:30 p.m.
Combination ART Nephrotoxicity in HIV: How Big a Problem? Michael J. Ross, MD, FASN
6:00 p.m.
HIV-Associated Glomerular Disease: More than HIVAN Derek M. Fine, MD
147
SATURDAY
4:30 p.m.
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Sessions
Upon completion of the oral abstract sessions, the participant will be able to: 1) construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines; and 2) translate recent advances into new standards and approaches to clinical care of patients with kidney diseases and related disorders. Core Competency: Medical Knowledge
4:30 p.m. – 6:30 p.m.
Oral Abstract Session
AKI: Risk, Epidemiology, and Outcomes of Clinical AKI Room 111 Moderators: Steven G. Coca, DO, and Michael Heung, MD
4:30 p.m. SA-OR001
Laboratory and Biological Variation in Serum Creatinine Measurement Results in High False Positive Rate of Acute Kidney Injury — Jennie Lin, Hilda E. Fernandez, Dan Negoianu, Jeffrey S. Berns, Michael G. Shashaty, Francis Perry Wilson. Philadelphia, PA.
4:42 p.m. SA-OR002
Patterns of Recovery from Acute Kidney Injury (AKI) and Risk of Kidney Disease Progression in the Irish Population — Austin G. Stack, Els H. Gillis, Mohamed Elsayed, Hoang Thanh Nguyen, Ailish Hannigan, Patrick T. Murray, Howard Johnson, Liam F. Casserly, John P. Ferguson. Limerick, Ireland.
4:54 p.m. SA-OR003
Development and Validation of a Risk Score for Predicting Acute Kidney Injury in Intensive Care Unit Patients — Rakesh Malhotra, Etienne Macedo, Josee Bouchard, Kianoush Banaei-Kashani, Ravindra L. Mehta. Nashville, TN.
5:06 p.m. SA-OR004
Synergistic Effects of Acute Kidney Injury and Chronic Kidney Disease on the Mortality After Coronary Artery Bypass Graft — Seung Seok Han, Seon Ha Baek, Dong Ki Kim, Sejoong Kim, Ho Jun Chin, Dong-Wan Chae, Ki Young Na. Seoul, South Korea.
5:18 p.m. SA-OR005
Obesity, Weight Distribution, and the Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities Study — Keiko I. Greenberg, Josef Coresh, M. Grams. Baltimore, MD.
5:30 p.m. SA-OR006
Associations of eGFR and Albuminuria with Acute Kidney Injury in Individuals with and without Diabetes and Hypertension: A Collaborative Meta-Analysis — Matthew T. James, M. Grams, Mark Woodward, Carolyn Raina Elley, Jamie Alton Green, David C. Wheeler, Ron T. Gansevoort, Andrew S. Levey, David G. Warnock, Mark J. Sarnak. Calgary, AB, Canada.
5:42 p.m. SA-OR007
The Association of Age, Sex, Race, and Kidney Measures with Acute Kidney Injury: CKD Prognosis Consortium Analysis of 1,364,568 Participants in 13 Cohorts — M. Grams, Yingying Sang, Shoshana Ballew, Ron T. Gansevoort, Csaba P. Kovesdy, David M. Naimark, Cecilia Montgomery Øien, David Smith, Josef Coresh, Mark J. Sarnak, Benedicte Stengel, Marcello Tonelli. Baltimore, MD.
5:54 p.m. SA-OR008
Volatile Anesthetics in Preventing Acute Kidney Injury following Cardiac Surgery — Jieru Cai, Rende Xu, Xiaofang Yu, Yi Fang, Xiaoqiang Ding. Shanghai, China.
6:06 p.m. SA-OR009
Increased Risk of Elevated Blood Pressure (BP) after Acute Kidney Injury (AKI) — Chi-Yuan Hsu, Raymond K. Hsu, Jingrong Yang, Juan Daniel Ordonez, Sijie Zheng, Alan S. Go. San Francisco, CA.
6:18 p.m. SA-OR010
Impact of Acute Kidney Injury on Mortality Diminishes with Greater Severity of Illness — Andrew Moore, Jean-Sebastien Rachoin, Lawrence S. Weisberg. Cambridge, MA.
Presenting Authors Underlined
148
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Biomarkers in CKD Room 105 Moderators: Harold I. Feldman, MD, FASN, and Linda F. Fried, MD, FASN
Association of Urine KIM-1 and NAG with CKD Progression: Results from the CRIC Study — Chi-Yuan Hsu, Dawei Xie, Xiaoming Zhang, Sushrut S. Waikar, Venkata Sabbisetti, Joseph V. Bonventre, Josef Coresh, Robert G. Nelson, Clarissa Jonas Diamantidis, Claudia M. Lora, Francis Perry Wilson, Edgar R. Miller, Jiang He, Jeffrey R. Schelling, Mahboob Rahman, Akinlolu O. Ojo, Paul L. Kimmel, Harold I. Feldman, Vasan S. Ramachandran, Kathleen D. Liu. San Francisco, CA.
4:42 p.m. SA-OR012
Serum -Trace Protein and -2 Microglobulin as Predictors End-Stage Renal Disease in Adults with Chronic Kidney Disease — Meredith C. Foster, Josef Coresh, Chi-Yuan Hsu, Andrew S. Levey, Robert G. Nelson, John H. Eckfeldt, Vasan S. Ramachandran, Paul L. Kimmel, Jeffrey R. Schelling, Michael S. Simonson, James H. Sondheimer, Amanda Hyre Anderson, Sanjeev Akkina, Harold I. Feldman, John W. Kusek, Akinlolu O. Ojo, Lesley Inker. Roslindale, MA.
4:54 p.m. SA-OR013
Novel and Traditional Factors Associated with Kidney Function Decline Over Time: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study — Amanda Hyre Anderson, Dawei Xie, Jason Roy, Lawrence J. Appel, Laura M. Dember, Jiang He, John W. Kusek, James P. Lash, Sankar D. Navaneethan, Akinlolu O. Ojo, Mahboob Rahman, Julia J. Scialla, James H. Sondheimer, Susan P. Steigerwalt, Francis Perry Wilson, Myles S. Wolf, Harold I. Feldman. Philadelphia, PA.
5:06 p.m. SA-OR014
Urine Collagen Fragments Predict CKD Progression: The Cardiovascular Health Study — Joachim H. Ix, Mary L. Biggs, Kenneth J. Mukamal, David Siscovick, Ronit Katz, Joseph Delaney, Dena E. Rifkin, Jan M. Hughes-Austin, Pranav S. Garimella, Mark J. Sarnak, Michael Shlipak, Jorge R. Kizer. San Diego, CA.
5:18 p.m. SA-OR015
Association of Serum Erythropoietin with Cardiovascular Events, Kidney Function Decline and Mortality: The Health ABC — Pranav S. Garimella, Ronit Katz, Kushang V. Patel, Stephen Kritchevsky, Joachim H. Ix, Chirag R. Parikh, Linda F. Fried, Michael Shlipak, Mark J. Sarnak. Boston, MA.
5:30 p.m. SA-OR016
Fractional Phosphate Excretion Predicts CKD Progression Independently of FGF23 — Carmine Zoccali, Patrizia Pizzini, Anna Pisano, Daniela Leonardis, Vincenzo Panuccio, Giovanni Tripepi, Francesca Mallamaci. Reggio Calabria, Italy.
5:42 p.m. SA-OR017
Renal Tubular Secretion in Chronic Kidney Disease — Astrid Suchy-Dicey, Thomas J. Laha, Andrew N. Hoofnagle, Cassianne Robinson-Cohen, Ernest Ayers, Tammy L. Sirich, Timothy W. Meyer, Jonathan Himmelfarb, N. David Yanez, Noel Weiss, Bryan R. Kestenbaum. Seattle, WA.
5:54 p.m.
Invited Lecture: Biomarkers in CKD: What Can We Learn from AKI Biomarker Development — Chirag R. Parikh, MD, PhD, FASN
149
SATURDAY
4:30 p.m. SA-OR011
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Developmental Biology Room 109 Moderators: Zubaida R. Saifudeen, PhD, and Rebecca A. Wingert, PhD
4:30 p.m. SA-OR018
WT1 Promotes Fgf Signaling in Nephron Progenitor Cells by Transcriptional Control of Gas1 — Martin Kann, Maximilian Otto Lenz, Valerie A. Schumacher, Bernhard Schermer, Chen-Ming Fan, Thomas Benzing, Jordan A. Kreidberg. Cologne, Germany.
4:42 p.m. SA-OR019
Histone Deacetylases 1 and 2 Repress Wnt4 During Kidney Development — Shaowei Chen, Xiao Yao, Samir S. El-Dahr. New Orleans, LA.
4:54 p.m. SA-OR020
Nephron Lumen Formation During Kidney Development — Denise K. Marciano, Zhufeng Yang, Lei Gao, Paul R. Brakeman, Keith Mostov, Xinchao Pan, Ulrike Schnell, Thomas J. Carroll, Susan E. Zimmerman. Dallas, TX.
5:06 p.m. SA-OR021
A Novel Mechanism of Glomerular Cyst Formation in Hepatocyte Nuclear Factor 1 Beta (Hnf1b)-Deficiency — Armelle Jm Christophorou, Filippo Massa, Arianna Fiorentino, Serge Garbay, Evelyne Fischer, Marco Pontoglio. Paris, France.
5:18 p.m. SA-OR022
The Hippo Pathway Functions in Kidney Branching Morphogenesis — Antoine Reginensi, Masato Hoshi, Marco Giovannini, Sanjay Jain, Helen McNeill. Toronto, ON, Canada.
5:30 p.m. SA-OR023
Patterning of the Renal Stroma Does Not Require Input from the Nephron Progenitors, the Ureteric Bud or Their Derivatives — Amrita Das, Thomas J. Carroll. Dallas, TX.
5:42 p.m. SA-OR024
Role of Transcription Factor Cp2l1 in Differentiation and Patterning of the Collecting Duct— Max Werth, Kai M. Schmidt-Ott, Christian Hinze, Andong Qiu, Jonathan M. Barasch. New York, NY.
5:54 p.m. SA-OR025
Cell Fate Patterning along the Kidney Collecting Ducts Is Dependent on Notch/Rbpj Signaling, with Ectopic Activation of Notch1 Capable of Turning on Elf5 and the Principal Cell Program — Kameswaran Surendran, Justin J. Grassmeyer, Casey Hettinger, Malini Mukherjee, Monica R. Bailey, Satrajit Sinha. Sioux Falls, SD.
6:06 p.m. SA-OR026
The Transcription Factor etv5a Is Essential for Multiciliated Cell Development During Zebrafish Nephrogenesis — Amanda N. Marra, Rebecca A. Wingert. Notre Dame, IN.
6:18 p.m. SA-OR027
Injury to the Developing Kidney Leads to Impaired Maturation but Not Inflammation or Fibrosis — Scott R. Manson, Julio J. Geminiani, Gino J. Vricella, Qiusha Guo, Paul F. Austin. Saint Louis, MO.
150
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Diabetic Nephropathy: Experimental Room 114 Moderators: Denis Feliers, PhD, and Josephine M. Forbes, PhD
Restoring Mitochondrial Superoxide Levels with BendaviaTM Protects against Progression of Diabetic Kidney Disease in db/db Mice — Satoshi Miyamoto, Manjula Darshi, Larkin B. Slater, Tai Nguyen, Peter J. Oates, Kumar Sharma. La Jolla, CA.
4:42 p.m. SA-OR029
Minichromosome Maintenance Protein 3 Associates with and Regulates Nrf2 in Proximal Tubules — Michelle T. Barati, Eric Poulos, Whitney L. Ward, Susan M. Isaacs, Madhavi J. Rane, Jon B. Klein, Michael Merchant. Louisville, KY.
4:54 p.m. SA-OR030
Progression of Tubular Damage in Diabetic Nephropathy (DN) Is Linked to an Altered Ubiquitination of the Cytoskeleton — Paola Pontrelli, Francesca Conserva, Massimo Papale, Matteo Accetturo, Margherita Gigante, Grazia Vocino, Anna Maria Di Palma, G. Grandaliano, Salvatore Di Paolo, Loreto Gesualdo. Bari, Italy.
5:06 p.m. SA-OR031
Proximal Tubular Activated Sirt3 and Proliferated Mitochondrial Ribosomes Compensated for Decreased Sirt1 and Mitochondrial Dysfunction at Very Early stage of Diabetic Nephropathy — Kazuhiro Hasegawa, Shu Wakino, Koichi Hayashi, Hiroshi Itoh. Tokyo, Japan.
5:18 p.m. SA-OR032
Urinary Semaphorin 3A Correlates with Diabetic Proteinuria and Mediates Diabetic Nephropathy and Associated Inflammation in Mice — Riyaz Mohamed, Punithavathi Vilapakkam Ranganathan, Calpurnia Jayakumar, Ganesan Ramesh. Augusta, GA.
5:30 p.m. SA-OR033
Overexpression of Heterogeneous Nuclear Ribonucleoprotein F Attenuates Tubular Apoptosis and Tubulointerstitial Fibrosis in Type 2 Diabetic Mice — Chao-Sheng Lo, Yixuan Shi, Isabelle Chenier, Janos G. Filep, Julie R. Ingelfinger, Shao-Ling Zhang, John S.D. Chan. Montreal, QC, Canada.
5:42 p.m. SA-OR034
Deletion of UNC5B Receptor in Kidney Epithelium Exacerbates Diabetic Nephropathy in Mice — Punithavathi Vilapakkam Ranganathan, Riyaz Mohamed, Calpurnia Jayakumar, Ganesan Ramesh. Augusta, GA.
5:54 p.m. SA-OR035
The CCR2 Antagonist CCX140 Improves Renal Function in a Human Transgenic CCR2 Diabetic Mouse Model — Zhenhua Miao, Linda Ertl, Jeffrey P. Mcmahon, Shichang Miao, James J. Campbell, Thomas J. Schall. Mt View, CA.
6:06 p.m. SA-OR036
Inhibition of EGFR Activity Protects against Diabetic Nephropathy in Type II Diabetes By Multiple Mechanisms — Ming-Zhi Zhang, Raymond C. Harris. Nashville, TN.
6:18 p.m. SA-OR037
Reduction in Albuminuria in Diabetic Nephropathy by Atrasentan Is Associated with Restoration of the Glomerular Endothelial Glycocalyx — Margien G.S. Boels, Cristina Avramut, Angela Koudijs, Martijn Dane, Dae Hyun Lee, Johan Van der Vlag, Abraham J. Koster, Anton Jan Van Zonneveld, Hermann-Josef Groene, Bernard van den Berg, Ton J. Rabelink. Leiden, Netherlands.
151
SATURDAY
4:30 p.m. SA-OR028
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Diagnostic and Therapeutic Advances in Cystic Kidney Diseases Room 201-A Moderators: Reena Rao, PhD, and Terry J. Watnick, MD
4:30 p.m. SA-OR038
Tolvptan-Treatment of ADPKD Confers Persistent eGFR Improvement: Results from the TEMPO 4:4 Extension Trial — Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Eiji Higashihara, Ronald D. Perrone, John Ouyang, Susan E. Shoaf, Jaime Blais, Frank S. Czerwiec. Rochester, MN.
4:42 p.m. SA-OR039
Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Toronto Genetic Epidemiology Study of PKD (TGESP) — Young-Hwan Hwang, John Conklin, Ning He, Kairong Wang, Jamie L. Sundsbak, Christina M. Heyer, Masoom Haider, Peter C. Harris, York P. Pei. Seoul, South Korea.
4:54 p.m. SA-OR040
Enhanced Diagnostics and Gene Discovery in ARPKD-Like and Meckel Syndrome (MKS) Pedigrees Using a Next Generation Sequencing (NGS) Ciliopathy Panel — Katharina Hopp, Sarah J. Koon, Christina M. Heyer, Vicente E. Torres, Peter C. Harris. Rochester, MN.
5:06 p.m. SA-OR041
Mutations in DCDC2 Cause Nephronophthisis with Hepatic Fibrosis in Humans — Daniela A. Braun, Markus Schueler, Gayathri Chandrasekar, Heon Yung Gee, Isabel Tapia Paez, Andrea Bieder, Jan Halbritter, Jonathan Porath, Rannar Airik, Detlef Bockenhauer, Tomas Honzik, Richard P. Lifton, Juha Kere, Friedhelm Hildebrandt. Boston, MA.
5:18 p.m. SA-OR042
High Prevalence of Sleep-Disordered Breathing and Its Association with Liver and Kidney Volume in Patients with Autosomal Dominant Polycystic Kidney Disease — Keiichi Sumida, Junichi Hoshino, Tatsuya Suwabe, Koki Mise, Kenmei Takaichi, Yoshifumi Ubara. Tokyo, Japan.
5:30 p.m. SA-OR043
Using Human Pluripotent Stem Cells to Model Kidney Disease Pathophysiology and Therapy — Benjamin S. Freedman, Albert Q. Lam, Theodore I. Steinman, Peter C. Harris, Jing Zhou, Joseph V. Bonventre. Boston, MA.
5:42 p.m. SA-OR044
miR-17~92 microRNA Cluster Promotes Disease Progression in Genetic Models of ADPKD — Vishal Patel, Darren Williams, Ronak Lakhia, Sachin S. Hajarnis. Dallas, TX.
5:54 p.m. SA-OR045
Angiotensinogen Inhibition Slows Polycystic Kidney Disease in Mice with a Targeted Mutation in Pkd2 — Kameswaran Ravichandran, Abdullah Ozkok, Qian Wang, Adam E. Mullick, Charles L. Edelstein. Aurora, CO.
6:06 p.m. SA-OR046
Vascular Endothelial Growth Factor C Therapy for Polycystic Kidney Diseases — Jennifer L. Huang, Adrian S. Woolf, Maria K. Joannou, Richard N. Sandford, Dorien J.M. Peters, Karen Price, Paul Winyard, David A. Long. London, United Kingdom.
6:18 p.m. SA-OR047
Magnetization Transfer Imaging for Tissue Remodeling Analysis in a Murine Model of ADPKD — Timothy L. Kline, Maria V. Irazabal, Behzad Ebrahimi, Katharina Hopp, Joshua D. Warner, Lilach O. Lerman, Peter C. Harris, Bernard F. King, Vicente E. Torres, Bradley J. Erickson. Rochester, MN.
152
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
Mechanisms of Glomerular Cell Function and Disease Room 108 Moderators: Kirk N. Campbell, MD, and Nina Jones, PhD
Podocyte Specific Expression of Mutant APOL1 Induces Albuminuria and Global Sclerosis in Mice — Ae Seo Deok Park, Jeffrey B. Kopp, Cheryl Ann Winkler, James M. Pullman, Jeffrey H. Miner, Katalin Susztak. Philadelphia, PA.
4:42 p.m. SA-OR049
Identification of Small Molecule Integrin 1 Agonist as a Podocyte Protective Agent Using a Novel Podocyte High Content Screening Assay — Ha Won Lee, Mehmet M. Altintas, Mohd Hafeez Faridi, Hatem A. Elshabrawy, Jochen Reiser, Vineet Gupta. Chicago, IL.
4:54 p.m. SA-OR050
In Vivo Serial Multiphoton Imaging of the Early Changes in Glomerular Structure and Function in Nephrotic NEP25/Podocin-Confetti Mice — Kengo Kidokoro, James L. Burford, Taiji Matsusaka, Naoki Kashihara, Janos Peti-Peterdi. Los Angeles, CA.
5:06 p.m. SA-OR051
Microtubule Stabilization By Taxol Promotes Podocyte Process Elongation and Enhances Compensatory Glomerular Adaptation to Podocyte Depletion — Weiwei Xu, Yan Ge, Zhihong Liu, Rujun Gong. Providence, RI.
5:18 p.m. SA-OR052
Protamine Sulfate-Induced Degradation of Synaptopodin and Loss of Stress Fibers Are Mediated by EGF Receptor-Dependent Activation of Src — Lisa Maria Buvall, Hanna Ilse Wallentin, Jonas Sieber, Hoon Young Choi, Anna Greka, Peter H. Mundel. Charlestown, MA.
5:30 p.m. SA-OR053
Identification of Podocytopathy-Associated Genes by Translational Profiling of Podocytes — Ivica Grgic, Andreas Hofmeister, Hua Sun, Omar H. Maarouf, Vanesa Bijol, Martin R. Pollak, Benjamin D. Humphreys. Marburg, Germany.
5:42 p.m. SA-OR054
Characterization of WT1-Directed Transcription in Podocytes In Vivo by ChIPseq — Martin Kann, Sandrine S. Ettou, Maximilian Otto Lenz, Bernhard Schermer, Thomas Benzing, Jordan A. Kreidberg. Cologne, NW, Germany.
5:54 p.m. SA-OR055
Tankyrase Inhibition Reduces Elevated Total PARsylation in CD2AP Deficient Podocytes but Aggravates Kidney Injury — Sanna H. Lehtonen, Hong Wang, Hani Suleiman, Andrey S. Shaw, Sara Kuusela. Helsinki, Finland.
6:06 p.m. SA-OR056
Regulatory Genomics of the Glomerular Podocyte — Shreeram Akilesh. Seattle, WA.
6:18 p.m. SA-OR057
Glomerular Endothelial Cells Form a Functional Syncytium for Calcium Signals Upon Injury – A Multiphoton In Vivo Study — Julia Binz, Matthias Hackl, Bernhard Schermer, Thomas Benzing. Cologne, Germany.
153
SATURDAY
4:30 p.m. SA-OR048
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Mechanisms of Vascular Calcification Room 203 Moderators: Ming Chang Hu, MD, PhD, and Wei Ling Lau, MD
4:30 p.m. SA-OR058
PiT-1 Signaling through ERK1/2 Promotes Smooth Muscle Cell Osteochondrogenic Phenotype Change and Calcification — Nicholas W. Chavkin, Cecilia M. Giachelli. Seattle, WA.
4:42 p.m. SA-OR059
Chronic Kidney Disease Results in Deficiency of ABCC6, the Novel Inhibitor of Vascular Calcification — Shuman Liu, Wei Ling Lau, Nosratola D. Vaziri. Irvine, CA.
4:54 p.m. SA-OR060
Dietary Protein Restriction Induces Inflammation and Malnutrition, and Exacerbates Vascular Calcification in Uremic Rats with Hyperphosphatemia — Shunsuke Yamada, Masanori Tokumoto, Narihito Tatsumoto, Hiroaki Ooboshi, Takanari Kitazono, Kazuhiko Tsuruya. Fukuoka, Japan.
5:06 p.m. SA-OR061
Angiopoietin-2 Accelerates Vascular Calcification in Children with Chronic Kidney Disease Undergoing Dialysis — Alexandra F. Todd, Karen Price, Maria K. Joannou, Lesley Rees, Rukshana Shroff, David A. Long. London, United Kingdom.
5:18 p.m. SA-OR062
Matrix Metalloproteinases Promote Uremic Vascular Calcification — Uwe Querfeld, Eva Hecht, Christian Freise, Karoline Websky, Berthold Hocher. Berlin, Germany.
5:30 p.m. SA-OR063
Chronic Kidney Disease (CKD) Stimulates Activin and Endothelial to Mesenchymal Transition (EnMT) which Causes Vascular Calcification and Is Inhibited by an Activin Ligand Trap — Keith A. Hruska, Olga A. Agapova, Yifu Fang, Toshifumi Sugatani, Michael E. Seifert, Victoria Sung. St. Louis, MO.
5:42 p.m. SA-OR064
Warfarin Promotes Medial Vascular Calcification in Humans — Ekamol Tantisattamo, Kum Hyun Han, W. Charles O’Neill. Atlanta, GA.
5:54 p.m. SA-OR065
Blood Calcification Propensity and Cardiovascular Events in Hemodialysis Patients in the EVOLVE Trial — Andreas Pasch, Matthias Bachtler, Edward Robert Smith, Willi Jahnen-Dechent, Spyridon Arampatzis, Glenn M. Chertow, Patrick S. Parfrey, Yumi Kubo, Jürgen Floege. Bern, Switzerland.
6:06 p.m. SA-OR066
Sodium Thiosulfate and Co-Treatments for Calcific Uremic Arteriolopathy — Sagar U. Nigwekar, Ann Mooney, Jeffrey L. Hymes, Debra Meade, Cindy A. Premo, Kevin Chan, Franklin W. Maddux, Ravi I. Thadhani. Boston, MA.
6:18 p.m. SA-OR067
Vascular Protective Effect of Spironolactone on Arterial Medial Calcification in AdenineInduced Chronic Kidney Disease Rats — Narihito Tatsumoto, Shunsuke Yamada, Masanori Tokumoto, Kazuhiko Tsuruya, Takanari Kitazono. Fukuoka, Japan.
154
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session New Genetic Approaches to Glomerular Disease Room 107 Moderators: Lorenzo G. Gallon, MD, and Rasheed A. Gbadegesin, MD
Focal Segmental Glomerulosclerosis Exomes Reveal Candidate Variants Highly Enriched in Cell Movement and Cell Adhesion-Related Genes — Jung Hee Suh, Giulio Genovese, Victoria Charoonratana, Andrea Knob, Martin R. Pollak. Boston, MA.
4:42 p.m. SA-OR069
KANK Deficiency Leads to Defective Podocyte Function — Heon Yung Gee, Fujian Zhang, Shazia Ashraf, Stefan Kohl, Carolin Sadowski, Svjetlana Lovric, Zhe Han, Friedhelm Hildebrandt. Boston, MA.
4:54 p.m. SA-OR070
NUP93 and NUP205, which Encode for Nuclear Pore Complex Proteins, Are Mutated in Individuals with Nephrotic Syndrome — Stefan Kohl, Carolin Sadowski, Svjetlana Lovric, Shazia Ashraf, Werner Pabst, Heon Yung Gee, Daniela A. Braun, Wolfram Antonin, Friedhelm Hildebrandt. Boston, MA.
5:06 p.m. SA-OR071
Addition of Genome-Wide Linkage Analysis Is Superior to Whole-Exome Sequencing Alone for Identification of Novel Genetic Causes of Hereditary Kidney Diseases — Paul J. Phelan, Gentzon Hall, Andrew F. Malone, Alison Homstad, Thomas Lindsey, Guanghong Wu, Rasheed A. Gbadegesin, Michelle P. Winn. Durham, NC.
5:18 p.m. SA-OR072
Identification of the First Gene Mutated in Galloway-Mowat Syndrome, an Association of Early-Onset Nephrotic Syndrome and Post-Natal Microcephaly — Evelyne Huynh Cong, Estelle Colin, Geraldine Mollet, Olivier Gribouval, Christelle Arrondel, Olivia Boyer, Laurent Daniel, Marie-Claire Gubler, Zelal Ekinci, Michel Tsimaratos, Anne Moncla, Dominique Bonneau, Corinne Antignac. Paris, France.
5:30 p.m. SA-OR073
Integrative Genomics Identifies Novel Associations of APOL1 Risk Genotype in AfricanAmerican NEPTUNE Subjects — Matthew Sampson, Laura H. Mariani, Sebastian Martini, Kevin V. Lemley, C. Gillies, Peter X.K. Song, J. Troost, Matthias Kretzler, John R. Sedor. Ann Arbor, MI.
5:42 p.m. SA-OR074
Mutations of the SLIT2-ROBO2 Pathway Genes SLIT2 and SRGAP1 Cause Congenital Anomalies of the Kidney and Urinary Tract — Daw-Yang Hwang, Stefan Kohl, Xueping Fan, Asaf Vivante, Stefanie Chan, Gabriel C. Dworschak, Heon Yung Gee, Christoph Schell, Tobias B. Huber, Heiko M. Reutter, Neveen Soliman, Radovan Bogdanovic, Elijah O. Kehinde, Richard P. Lifton, Velibor Tasic, Weining Lu, Friedhelm Hildebrandt. Boston, MA.
5:54 p.m. SA-OR075
Anti-miR-21 as a Potential Novel Therapy for Both Early and Late Stages of Alport Syndrome — Joseph H. Boulanger, Wenping Song, Shweta Pandya, Kelly A. Rogers, Lucy A. Phillips, Deidre Mackenna, Rachel Yabkowitz, Oxana Beskrovnaya, Steven R. Ledbetter, Shiguang Liu. Framingham, MA.
6:06 p.m. SA-OR076
Endothelin A Receptor Blockade Prevents Mesangial Filopodial Invasion of Glomerular Capillaries and Delays Alport Glomerular and Interstitial Disease Onset — Dominic E. Cosgrove, Brianna Johnson, Daniel T. Meehan, Linda Cheung, Duane C. Delimont. Omaha, NE.
6:18 p.m. SA-OR077
Podocyte-Specific Fat1 Deletion Leads to Focal Segmental Glomerulosclerosis in Mice — Alda Tufro, Pardeep Kumar Aggarwal, Sherene Mason, Gilbert W. Moeckel. New Haven, CT.
155
SATURDAY
4:30 p.m. SA-OR068
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
No Borders: Globalizing CKD Prevention Strategies Room 104 Moderators: Andrew S. Narva, MD, FASN, and David C. Wheeler, MD
4:30 p.m. SA-OR078
Research Priorities in Chronic Kidney Disease: A Partnership among Patients, Caregivers, Clinicians, Researchers and Policy Makers — Allison Tong, Sally Crowe, Shingisai Alice Chando, Jonathan C. Craig. Sydney, New South Wales, Australia.
4:42 p.m. SA-OR079
A Sustained Dietary Sodium Reduction Program Reduces Albuminuria: A Large Cluster Randomised Trial — Meg J. Jardine, Nicole Yan Li, Toshiharu Ninomiya, Xiangxian Feng, Jianxin Zhang, Jingpu Shi, Yuhong Zhang, Rui Zhang, Vlado Perkovic, Hiddo Jan Lambers Heerspink, Yangfeng Wu, Lijing Yan, Bruce C. Neal. Camperdown, NSW, Australia.
4:54 p.m. SA-OR080
Promoting Awareness and Screening Indian Youth for CKD Risk Factors: Pilot Program Results — Panduranga S. Rao, Ravichandran Rajan, Rachel Perlman, Julie A. Wright Nunes. Ann Arbor, MI.
5:06 p.m. SA-OR081
Challenges and Opportunities for Effective Chronic Kidney Disease Care Delivery: A Synthesis of Health Systems and Policies from 19 Countries — Aminu K. Bello, Adeera Levin, Braden J. Manns, Tilman B. Drueke, Brenda Hemmelgarn, Scott Klarenbach, Giuseppe Remuzzi, Marcello Tonelli. Edmonton, AB, Canada.
5:18 p.m. SA-OR082
Patients That Utilise a Patient Facing Health Record Have Better Health Outcomes — Anirudh Rao, David Pitcher, Richard G. Phelps. Avon, Lanarkshire, United Kingdom.
5:30 p.m. SA-OR083
Evaluating Risk of End-Stage Renal Disease in Public Health Settings — Yoshio N. Hall, Marlena Maziarz, Glenn M. Chertow, Jonathan Himmelfarb. Seattle, WA.
5:42 p.m. SA-OR084
Low Awareness and Comprehension of Chronic Kidney Disease Among Japanese HealthCheck Subjects — Yoshinari Yasuda, Mayumi Kamiya, Yohei Maeshima, Tadao Akizawa, Seiichi Matsuo, Shoichi Maruyama. Nagoya, Japan.
5:54 p.m.
Invited Lecture: Imagine All the People: Globalizing Prevention Strategies for CKD — Donal J. O’Donoghue
156
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Stones and Bones: Pathogenesis and Treatment Room 204-A Moderators: Lada Beara Lasic, MD, and Stuart M. Sprague, DO, FASN
An Oral Enzyme (ALLN-177) Reduces Dietary Hyperoxaluria — Craig B. Langman, Danica Grujic, Rita Pease, Alexey Margolin, Lee Brettman. Chicago, IL.
4:42 p.m. SA-OR086
Oxalobacter Formigenes Colonization Normalizes Oxalate Excretion in a Gastric Bypass Model of Hyperoxaluria — Benjamin Canales, Marguerite Hatch. Gainesville, FL.
4:54 p.m. SA-OR087
Urinary Hydroxy-Oxo-Glutarate (HOG) as Diagnostic Factor for Primary Hyperoxaluria Type 3 — Markus Feldkötter, Andrew Z. Wei, Craig B. Langman, Ada Ventzke, Bernd Hoppe. Bonn, Germany.
5:06 p.m. SA-OR088
Characterization of the Urine Proteome in Calcium Oxalate Stone Formers — Jeffrey Wesson, Ann M. Kolbach, Neil S. Mandel. Milwaukee, WI.
5:18 p.m. SA-OR089
Dedifferentiation of Renal Epithelial Cells into Osteogenic Cells and Formation of Randall’s Plaque — Saeed R. Khan, Sunil Joshi, Wei Wang. Gainesville, FL.
5:30 p.m. SA-OR090
Mechanism for Elevated Urine pH in Patients Who Form Calcium Phosphate Renal Stones — Kristin J. Bergsland, Elaine M. Worcester, Fredric L. Coe. Chicago, IL.
5:42 p.m. SA-OR091
Influence of Hydroxyproline Plasma Concentration on the Metabolism of Oxalate — Sonia Fargue, John Knight, Dawn S. Milliner, W. Todd Lowther, Ross P. Holmes. Birmingham, AL.
5:54 p.m. SA-OR092
Distinct Impact of Dabigatran and Warfarin Treatment on Bone Volume and Structure in Rats — Maria Fusaro, Luca Dalle Carbonare, Adriana S. Dusso, M. Vittoria Arcidiacono, Sabina Pasho, Giovanni Tripepi, Claudia Torino, Maurizio Gallieni. Padua, Italy.
6:06 p.m. SA-OR093
Raloxifene, but Not Calcitriol, Improves the Structural and Mechanical Properties of Bone in an Animal Model of Chronic Kidney Disease — Christopher Newman, Drew M. Brown, Neal X. Chen, Sharon M. Moe, Matthew R. Allen. Indianapolis, IN.
6:18 p.m. SA-OR094
Identification of a Bone Defect in ADPKD — Berenice Y. Gitomer, Renata C. Pereira, Mikaela R. Malaczewski, Myles S. Wolf, Isidro B. Salusky, Jason W. Stoneback, Michel Chonchol. Aurora, CO.
157
SATURDAY
4:30 p.m. SA-OR085
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session Water/Urea/Vasopressin, and Organic Solutes Room 112 Moderators: Mitsi A. Blount, PhD, and Robert A. Fenton, PhD, FASN
4:30 p.m. SA-OR095
A Renal Olfactory Receptor Aids in Glucose Handling in the Proximal Tubule — Blythe D. Shepard, Lydie Cheval, Alain Doucet, Jennifer L. Pluznick. Baltimore, MD.
4:42 p.m. SA-OR096
Nanomolar-Potency, UT-A-Selective Inhibitors of Kidney Tubule Urea Transporters Produce Salt-Sparing Diuresis in Rats — Cristina Esteva-Font, Onur Cil, Puay Wah Phuan, Tao Su, Sujin Lee, Marc O. Anderson, Alan S. Verkman. San Francisco, CA.
4:54 p.m. SA-OR097
Vasopressin-Responsive miRNAs and AQP2-Targeting miRNAs in Kidney Collecting Duct Cells — Jae-Eun Kim, Hyun Jun Jung, Tae-Hwan Kwon. Jung-Gu, Daegu, South Korea.
5:06 p.m. SA-OR098
MiR-132 Regulates Diuresis Through Vasopressin and Prostaglandin-Dependent Alteration of Aquaporin-2 Localization — Roel Bijkerk, Christiane Trimpert, Ruben de Bruin, Coen van Solingen, Ton J. Rabelink, Benjamin D. Humphreys, Peter M.T. Deen, Anton Jan Van Zonneveld. Leiden, South (Zuid) Holland, Netherlands.
5:18 p.m. SA-OR099
Inhibition of Mitochondrial Complex-1 Restores the Downregulation of Aquaporins in Obstructed Kidney Independently of COX-2/PGE2 Pathway — Zhanjun Jia, Ying Sun, Yue Zhang, Guixia Ding, Songming Huang, Aihua Zhang. Salt Lake City, UT.
5:30 p.m. SA-OR100
Cholesterol Depletion of mpkCCD Cells Is Associated with Increased Ubiquitylation of Aquaporin-2 — Cecilie Noehr Pedersen, Robert A. Fenton, Hanne Moeller. Aarhus C, Denmark.
5:42 p.m. SA-OR101
NDFIP1: the missing Adaptor for Ubiquitination and Degradation of the Aquaporin-2 Water Channel by NEDD4 and NEDD4L — Peter M.T. Deen, Christiane Trimpert, Theun de Groot, Martha Pimentel Rodriguez. Nijmegen, Netherlands.
5:54 p.m. SA-OR102
Luminal pH Affects Phosphorylation (Serine 256) and Intracellular Trafficking of AQP2 in Inner Medullary Collecting Duct Cells — Hyo-Jung Choi, Tae-Hwan Kwon. Daegu, South Korea.
6:06 p.m. SA-OR103
CaSR Signaling Prevents Forskolin-Induced pS256-AQP2 in Isolated Mouse Collecting Duct Tubules and Impairs Osmotic Water Permeability in Renal Cells — Marianna Ranieri, Grazia Tamma, Annarita Di Mise, Mariangela Centrone, Maria Svelto, Giovanna Valenti. Bari, Italy.
6:18 p.m. SA-OR104
Glutathionylation of the Aquaporin-2 Water Channel: A Novel Post-Translational Modification Modulated By the Oxidative Stress — Grazia Tamma, Marianna Ranieri, Annarita Di Mise, Mariangela Centrone, Maria Svelto, Giovanna Valenti. Bari, Italy.
158
SATURDAY, NOVEMBER 15, 2014 4:30 p.m. – 6:30 p.m.
Oral Abstract Session
What’s New in Peritoneal Dialysis? Updates from the Bench and the Bedside Room 202 Moderators: Jeffrey Perl, MD, and Beth M. Piraino, MD
Peritonitis as a Risk Factor for Long-Term Cardiovascular Mortality in Peritoneal Dialysis Patients — Roberto Pecoits-Filho, Ludimila Guedim de Campos, Thyago Proença de Moraes. Curitiba, Paraná, Brazil.
4:42 p.m. SA-OR106
Association of Race with Risk of Mortality and Transfer to In-Center Hemodialysis in Peritoneal Dialysis Patients — Melissa Soohoo, Vanessa A. Ravel, Elani Streja, Sooraj Kuttykrishnan, Miklos Zsolt Molnar, Kamyar Kalantar-Zadeh, Rajnish Mehrotra. Orange, CA.
4:54 p.m. SA-OR107
Circulating Bacterial-Derived DNA Fragment Level Is a Strong Predictor of Cardiovascular Disease in Peritoneal Dialysis Patients — Cheuk-Chun Szeto. Shatin, Hong Kong, China.
5:06 p.m. SA-OR108
Icodextrin Reduces Insulin Resistance in Incident Non-Diabetic Patients on Peritoneal Dialysis: Results of a Randomized Controlled Trial (STARCH) — Thyago Proença de Moraes, Maria Eugenia F. Canziani, Marcia Olandoski, Jose C. Divino-Filho, Roberto Pecoits-Filho. Curitiba, Brazil.
5:18 p.m. SA-OR109
Longitudinal Effect of Biocompatible Solutions on Peritoneal Solute Transport: Results from the Global Fluid Study — Emma H. Elphick, Mark Lambie, Lucy Riley, James A. Chess, Yong-Lim Kim, Marc Dorval, Simon J. Davies. Stoke on Trent, United Kingdom.
5:30 p.m. SA-OR110
Maintenance of Volume Status Supported by Bioimpedance Leads to Better Preservation of Cardiac Function — Boon Kay Tan, Zanzhe Yu, Simon J. Davies, Frauke Wilma Gisela Wenzelburger. Stoke on Trent, United Kingdom.
5:42 p.m. SA-OR111
Anti-Fibrotic Effect of Valproic Acid in Experimental Peritoneal Fibrosis in Rats — Elerson Costalonga, Deise S.J. Pimentel, Filipe M. Silva, Irene L. Noronha. São Paulo, Brazil.
5:54 p.m. SA-OR112
Inter-State Variability in Home Dialysis Utilization among Minorities in the US — Eric L. Wallace, Janice P. Lea, Eric Hammelman, Joshua F. Cohen, James A. Sloand. Birmingham, AL.
6:06 p.m. SA-OR113
Time from Onset of Symptoms and Administration of Initial Antibiotic Therapy Predicts Peritonitis Outcomes and Hospitalizations — Kalindu Muthucumarana, Prue E. Howson, Ramyasuda Swaminathan, Douglas Patrick Crawford, Samantha Chua, Sally A. Burrows, Ashley B. Irish. Innaloo, Australia.
6:18 p.m. SA-OR114
Klotho Overexpression Attenuates Peritoneal Fibrosis via Suppression of Wnt/-Catenin Signaling Pathway in Mice — Hiroyuki Kadoya, Minoru Satoh, Seiji Itano, Atsushi Uchida, Tamaki Sasaki, Naoki Kashihara. Kurashiki, Okayama, Japan.
159
SATURDAY
4:30 p.m. SA-OR105
NOTES
______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________
SUNDAY, NOVEMBER 16, 2014
AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2014 DAY-AT-A-GLANCE 8:00 a.m. – 9:30 a.m. Page 160
Plenary Session
In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture Hall D
9:30 a.m. - 10:00 a.m. Page 160
Special Session
ASN Business Meeting Hall D
10:00 a.m. – 12:00 p.m. Page 160 Page 161 Page 162 Page 162 Page 163 Page 163 Page 164 Page 165
Basic and Clinical Science Symposia
B Cells Behaving Badly Room 202 Complement and Kidney Disease: Entering a New Era? Room 108 RAAS Action inside and outside the Kidney Room 204-A Role of Reactive Oxygen Species in Diabetic Nephropathy Room 203 Salt and Hypertension: How Does Potassium and Chloride Flip the Switch? Room 104 Targeting the Microvascular Environment in AKI during Injury and Repair Room 201-A The Gut–Kidney Connection Room 105 Vascular Calcification: Molecular Mechanism and Clinical Implications Room 201-C
10:00 a.m. – 12:00 p.m. Page 166 Page 167 Page 168
Emerging Fronts in Endo-Nephrology Room 107 Extracorporeal Therapies for Intoxications and Drug Overdoses Room 103 HD Infection Update Ballroom A Update on Evaluation and Management of Kidney Stones Room 204-C
161
SUNDAY
Page 169
Clinical Nephrology Conferences
SUNDAY, NOVEMBER 16, 2014 8:00 a.m. – 9:30 a.m.
Opening Plenary Session
In Memoriam, ASN/AHA Young Investigator Award Presentation and Address, State-of-the-Art Lecture Hall D
Supported by an independent educational grant from Akebia Therapeutics. ASN thanks the American Heart Association’s Council of the Kidney for co-sponsorship of the Young Investigator Award.
Upon completion of this session, the participant will be able to discuss the influence of autophagy and metabolic diseases. 8:00 a.m.
In Memoriam
8:05 a.m.
ASN/AHA Young Investigator Award Presentation and Address “Mineral (Mal) Adaptation to Kidney Disease” Myles S. Wolf, MD
8:45 a.m.
State-of-the-Art Lecture “Autophagy and Metabolic Diseases” Beth C. Levine, MD
9:30 a.m. – 10:00 a.m.
Special Session ASN Business Meeting Hall D
10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium B Cells Behaving Badly Room 202
B cells have a major role in kidney transplant alloimmunity. Unfortunately, that role is often a destructive one. In this session, experts in the field review B cells that are present in the graft, how they behave (both pathologically and nonpathologically), and therapies available that target B cells. Upon completion of this session, the participant will be able to: 1) describe the role of B cells present in a kidney transplant; 2) discuss how B and T cells communicate; 3) identify B cells that may be beneficial to a kidney graft; and 4) describe therapies that target B cells. Core Competency: Medical Knowledge Moderators: Roy D. Bloom, MD, and Milagros D. Samaniego-Picota, MD, FASN 10:00 a.m.
B Cells in the Graft Emmanuel Zorn, PhD
10:30 a.m.
B-Cell and T-Cell Cross-Talk Jeffrey L. Platt, MD
11:00 a.m.
B Cells: Not All Bad! Kenneth A. Newell, MD, PhD
11:30 a.m.
B-Cell Therapies Denis Glotz, MD, PhD
162
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium
Complement and Kidney Disease: Entering a New Era? Room 108
New insights into the relevance of defects in the complement system and their implication for kidney disease have opened doors for a new understanding of an increasing number of kidney diseases. In addition, the advent of specific therapies for complement-mediated diseases has allowed for breakthroughs in the treatment of thus far only poorly managed conditions. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) describe the growing spectrum of complement-mediated kidney diseases; 2) discuss pathomechanisms involved in complementmediated kidney diseases; and 3) discuss related new treatment strategies in complement-mediated kidney diseases. Core Competency: Patient Care and Procedural Skills, Medical Knowledge, Systems-based Practice Moderators: Craig B. Langman, MD, and Joshua M. Thurman, MD 10:00 a.m.
Complement and ADAMTS13 in TTP: Not So Distinct after All Giuseppe Remuzzi, MD
10:30 a.m.
A Role for Complement in ANCA-Vasculitis Peter Heeringa, PhD
11:00 a.m.
A Role for Complement in Post-BMT Thrombotic Microangiopathy Sonata Jodele, MD
11:30 a.m.
From the Horseshoe Crab to Eculizumab: Translational Research Online Matthew C. Pickering, MD
SUNDAY
163
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium RAAS Action inside and outside the Kidney Room 204-A
Supported by an independent educational grant from ZS Pharma.
The renin-angiotensin-aldosterone system (RAAS) is one of the major salt and volume regulatory systems. The salt-retaining effect of renal RAAS action has been linked with the pathogenesis of arterial hypertension. Recent findings suggest that the RAAS may also modulate blood pressure via direct vascular effects and is an important mediator of systemic inflammation. As a matter of fact, a renal sense of smell contributes to renin release and therefore blood pressure. RAAS-induced anti-inflammatory responses may prevent cardiovascular disease, especially in hemodialysis (HD) patients. Because hyperkalemia is a major adverse effect of mineralocorticoid receptor (MR) blockade, MR antagonists such as spironolactone are rarely used in HD patients. A new study suggests that MR antagonists could reduce mortality in HD patients. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) describe aldosterone antagonism and renal protection; 2) discuss vascular aldosterone actions and hypertension; and 3) describe aldosterone blockade in the management of CKD. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge Moderators: Friedrich C. Luft, MD, FASN, and Timothy W. Meyer, MD 10:00 a.m.
The Renin-Angiotensin System in Blood Pressure Regulation: A Renal Affair? Steven D. Crowley, MD
10:30 a.m.
Blood Pressure Goes with Mineralocorticoid Receptors Celso E. Gomez-Sanchez, MD
11:00 a.m.
Aldosterone in Vascular Inflammation and Diabetes James M. Luther, MD
11:30 a.m.
Aldosterone Blockade in HD Patients: Does Spironolactone Reduce Mortality? Yoshihiro Matsumoto, MD, PhD
164
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium
Role of Reactive Oxygen Species in Diabetic Nephropathy Room 203
Supported by an independent educational grant from AbbVie.
This session reviews different sources of reactive oxygen species (ROS) that lead to enhanced oxidative stress in the diabetic kidney. It addresses different therapeutic strategies to target and specifically inhibit the disparate sources of ROS in diabetic nephropathy. Upon completion of this session, the participant will be able to: 1) report that there are multiple sources of ROS in diabetes; and 2) describe potential new renoprotective therapies in diabetes that act primarily by targeting ROS generation and accumulation. Core Competency: Medical Knowledge Moderators: Chris R. Kennedy, PhD, and Kumar Sharma, MD 10:00 a.m.
Inhibiting Mitochondrial ROS in Diabetic Complications Michael A. Brownlee, MD
10:30 a.m.
NADPH Oxidase in Diabetic Complications Harald H. Schmidt, MD, PhD
11:00 a.m.
Baroxolone and Related Derivatives: Role in Renoprotection Merlin C. Thomas, MD, PhD
11:30 a.m.
Targeting Uric Acid to Inhibit ROS in Renal Diseases Radko Komers, MD, PhD
10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium
Salt and Hypertension: How Does Potassium and Chloride Flip the Switch? Room 104
Upon completion of this session, the participant will be able to: 1) describe the role of pedrin in regulation of salt balance; 2) discuss the mechanism of chloride-sensitive hypertension; 3) describe how WNK1 controls the balance between sodium and potassium excretion; and 4) describe the mechanism by which dietary potassium shuts off the NCC. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Ewout J. Hoorn, MD, PhD, and Alicia A. McDonough, PhD 10:00 a.m.
Pendrin in Renal Salt Handling Susan M. Wall, MD
10:30 a.m.
Pendrin Overexpression in Intercalated Cells Produces Chloride-Sensitive Hypertension Dominique Eladari, MD, PhD
11:00 a.m.
WNK1 Switches Sodium and Potassium Balance Juliette Hadchouel, PhD
11:30 a.m.
Dietary Potassium Rapidly Shuts Off Thiazide-Sensitive Sodium Transport Johannes Loffing, MD
165
SUNDAY
Alternations in renal sodium handling are well appreciated to contribute to the development of hypertension, but the precise role of dietary salt remains hotly debated. Recent studies have begun to resolve the paradox as important roles of dietary chloride and potassium have been identified. This session highlights recent breakthrough studies revealing mechanisms by which potassium and chloride separately control renal salt handling.
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium
Targeting the Microvascular Environment in AKI during Injury and Repair Room 201-A
A mounting body of evidence has underscored the importance of the renal microvasculature in the pathophysiology of AKI. This session highlights the recent advances in how the microvasculature and endothelium contribute to the pathogenesis of AKI. Upon completion of this session, the participant will be able to: 1) discuss the tissue-specific heterogeneity of the endothelium and how it contributes to organ pathophysiology; 2) identify novel pathways involved in endothelial signaling and microvascular-circulating cell interactions; and 3) describe new insights into the microvascular transcriptional response following injury. Core Competency: Medical Knowledge Moderators: David P. Basile, PhD, and Michael S. Goligorsky, MD, PhD 10:00 a.m.
Endothelial Heterogeneity: Novel Insight into Lung Physiology and Pathophysiology Troy Stevens, PhD
10:30 a.m.
Endothelial HIF and Kidney Microvascular Alterations following Injury Pinelopi P. Kapitsinou, MD
11:00 a.m.
Slit2-Robo Signaling in the Kidney Microvasculature Lisa Robinson, MD
11:30 a.m.
Characterization of the Microvascular Translational Response in Acute Kidney Injury Jing Liu
10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium The Gut–Kidney Connection Room 105
This session updates the attendees on the most recent advances regarding uremic toxins, their metabolic and clinical relevance, and strategies to ameliorate their accumulation and adverse effects with specific emphasis on the recent developments on gut microbiome and its effects in advanced kidney disease. Upon completion of this session, the participant will be able to: 1) discuss the most recent abnormalities in uremic toxins and their origin; 2) describe the molecular and physiological aspects of uremic toxin identification; 3) report the relevant gut microbiome, especially in advanced kidney disease; and 4) discuss the effects of various interventions aimed at improving uremic toxicity in CKD patients including strategies targeted at changing the gut microbiome. Core Competency: Medical Knowledge, Practice-based Learning and Improvement Moderators: Thomas H. Hostetter, MD, and Ziad Massy, MD, PhD 10:00 a.m.
Uremic Toxins: What Is New in 2014? Raymond C. Vanholder, MD, PhD
10:30 a.m.
Gut Microbiome and Kidney Disease Dominic S. Raj, MD, FASN
11:00 a.m.
Gut Microbiota and Uremic Toxins Pieter Evenepoel, MD, PhD
11:30 a.m.
Protein and Amino Acid Carbamylation in CKD Anders H. Berg, MD, PhD
166
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Basic and Clinical Science Symposium
Vascular Calcification: Molecular Mechanism and Clinical Implications Room 201-C
Supported by an independent educational grant from OPKO Health Renal Division.
Vascular calcification, an independent and strong predictor of cardiovascular risk, is often found in CKD patients. The degree of vascular calcification is providing incremental prognostic value over traditional risk markers. There is interest in improving our understanding of mechanisms and establishing diagnostic methods and effective prevention and treatment modalities. The abnormal mineral metabolism of CKD is known to facilitate the progression of vascular calcification, in concert with altered activities of vascular calcification inhibitors. The experts in this session address this important topic. Upon completion of this session, the participant will be able to: 1) discuss the role of matrix gla protein in vascular calcification; 2) describe novel signaling mechanism of vascular calcification; and 3) describe the role of endothelial dysfunction on vascular calcification. Core Competency: Medical Knowledge Moderators: Kristen L. Jablonski, PhD, and Rukshana Shroff, MD, PhD 10:00 a.m.
Matrix Gla Protein: From Genes to Patients Georg Schlieper, MD
10:30 a.m.
Wnt Signaling and Vascular Health and Disease Keith A. Hruska, MD
11:00 a.m.
The Role of the Renin-Angiotensin System on Vascular Calcification Florian C. Lang, MD
11:30 a.m.
MicroRNA and Vascular Phenotype and Calcification Neal X. Chen, PhD
SUNDAY
167
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Clinical Nephrology Conference Emerging Fronts in Endo-Nephrology Room 107
A variety of endocrine derangements (hypothyroidism, insulin resistance, testosterone deficiency) are disproportionately prevalent in the CKD population. These disorders have been shown to negatively impact morbidity and mortality in the general population, but have received comparatively less attention from nephrology community. During this session, presenters discuss the epidemiology and pathophysiology on hypothyroidism, insulin resistance, and testosterone deficiency in CKD, as well as emerging evidence on their links with adverse cardiovascular outcomes in this population. Upon completion of this session, the participant will be able to: 1) describe the incidence and prevalence of endocrine disorders in CKD; 2) discuss potential risk factors and prognostic implications in endocrine disorders and their impact on CKD outcomes; and 3) describe management of these under-recognized endocrine derangements in CKD. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Joel D. Kopple, MD, FASN, and Carmine Zoccali, MD, FASN 10:00 a.m.
Beyond Masculinity: Testosterone Deficiency and the Cardiometabolic Complications of CKD Juan Jesus Carrero, PhD
10:30 a.m.
Hypothyroidism in CKD: Physiologic Adaptation or Pathologic Entity? Connie Rhee, MD
11:00 a.m.
Insulin Resistance of CKD: Is It a Potential Target for Interventions to Improve Outcomes Adriana Hung, MD
11:30 a.m.
Obesity in ESRD Kirsten L. Johansen, MD
168
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Clinical Nephrology Conference
Extracorporeal Therapies for Intoxications and Drug Overdoses Room 103
This session evaluates the utility of extracorporeal therapies for certain drug overdoses. Dabigatran toxicity is associated with serious bleeding. Hemodialysis as a therapy to remove the drug is reviewed along with other management approaches. The utility of the newly available drug, glucarbidase, is examined as a potentially more effective therapy for methotrexate intoxication compared with hemodialysis. The dialytic approach to metformin-associated lactic acidosis and AKI is also reviewed. Finally, the role for albumin-based dialysis in certain drug intoxications is explored. Upon completion of this session, the participant will be able to: 1) describe the dialytic and supportive approach to Dabigatran overdose; 2) discuss the role of hemodialysis and glucarpidase in treatment of methotrexate intoxication; 3) describe the dialytic approach to patients with metformin overdose complicated by AKI and lactic acidosis; and 4) discuss the utility of albumin-based dialytic therapies for drug intoxications. Core Competency: Professionalism, Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Systems-based Practice Moderators: Thomas D. Nolin, PhD, PharmD, FASN, and Mark A. Perazella, MD, FASN 10:00 a.m.
Dialytic Approach to Patients with Serious Bleeding Complications from Dabigatran Felix Knauf, MD
10:30 a.m.
What Is the Best Therapy for Methotrexate-Associated AKI: HF-HD or Glucarpidase? Anushree C. Shirali, MD
11:00 a.m.
Use of RRT for Metformin Toxicity and Associated Lactic Acidosis Roger A. Rodby, MD, FASN
11:30 a.m.
Is There a Role for Albumin-Based ECT (MARS) for Intoxications? Andrew Davenport, MD
SUNDAY
169
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Clinical Nephrology Conference HD Infection Update Ballroom A
This session provides an update on reporting requirements and prevention strategies for infection control in the dialysis unit. Upon completion of this session, the participant will be able to: 1) describe the reasons for and the impact of the NHSN Dialysis Event Reporting requirements; 2) determine what are the common multidrug resistant organisms in dialysis units, the trends in organism resistance and effective treatments, the impact of these organisms to hemodialysis (HD) patients, and the clinical outcomes and how they can be prevented; and 3) discuss how infection is transmitted in the HD unit and how it can be effectively prevented. Core Competency: Medical Knowledge Moderators: Michael Allon, MD, and Charmaine E. Lok, MD 10:00 a.m.
NHSN Dialysis Event Reporting Update Priti R. Patel, MD
10:40 a.m.
Multidrug Resistance Organisms in the Dialysis Unit: Their Impact and Effective Strategies for Eradication Erika M.C. D’Agata, MD
11:20 a.m.
Infection Transmission in HD: Who, What, When...and How to Make It Stop! Matthew J. Arduino, PhD
170
SUNDAY, NOVEMBER 16, 2014 10:00 a.m. – 12:00 p.m.
Clinical Nephrology Conference
Update on Evaluation and Management of Kidney Stones Room 204-C
Supported by an independent educational grant from OPKO Health Renal Division.
Nephrologists are often called on to evaluate and manage patients with recurrent kidney stones. This session reviews the current state of the art with respect to evaluation and management of all forms of stone disease. Case-based discussions are used to facilitate discussions centered around interpretation of 24-hour urine chemistries used to diagnose and treat stone patients. A patient-centered approach to the risks and benefits of pharmacologic (thiazides, citrate, and allopurinol) and diet therapies for calcium oxalate stones is presented. Therapies for recurrent calcium phosphate stones are also reviewed. This session discusses new data about the links between diabetes, obesity, CKD, and hypertension with stones in general and uric acid stones in particular. When to consider rare genetic forms of stones such as Dent disease and primary hyperoxaluria is addressed, as well as the management of cystinuria and enteric hyperoxaluria. The role of stone imaging modalities is reviewed, including considerations regarding radiation risk. Finally, the indications, risks, and benefits of various surgical approaches for stone removal are presented. Upon completion of this session, the participant will be able to: 1) analyze interpretation of 24-hour urine collections and assessment of kidney stone risk factors; 2) describe the risks and benefits of stone imaging modalities; 3) describe the relative merits and risks of dietary and pharmacologic management of recurrent stone disease; 4) list clues to rare causes of kidney stones and the appropriate next diagnostic steps; and 5) describe potential kidney stone surgical procedures and relative indications, risk, and benefits for each. Core Competency: Medical Knowledge Moderators: David A. Bushinsky, MD, and Wei Ling Lau, MD Epidemiology of Kidney Stones Gary C. Curhan, MD, ScD, FASN
10:30 a.m.
Interpretation of 24-Hour Urine Chemistries John R. Asplin, MD, FASN
11:00 a.m.
Approach to Calcium Phosphate Stones and Staghorn Calculi David S. Goldfarb, MD, FASN
11:30 a.m.
Calcium Oxalate Stones, Urate Stone, and Other Nephrolithiases John C. Lieske, MD, FASN
171
SUNDAY
10:00 a.m.
NOTES
______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________
FACULTY INDEX 142 116 30 115 59 16 29 75 65 8, 9 116 7, 88 46, 55, 144 142 101 153 75 134 25 170 10, 11 146 68 20 49, 166 149 29 104 67 13 52, 81 170 132 71 27, 144 136 113 132 7 171 106 132 50 110 146 140, 85 58 130 75, 83, 105 151 23 54 166 43 2 123 157 116 75 109
Beck, Laurence H. Beddhu, Srini Behrens, Mary Tessie Beier, Ulf H. Bello, Aminu K. Bellotti, Vittorio Benson, Merrill D. Benzing, Thomas Berceli, Scott A. Berg, Anders H. Berggren, Per-Olof Bergsland, Kristin J. Berns, Jeffrey S. Bertram, John F. Bieber, Scott D. Bijkerk, Roel Binz, Julia Bissler, John J. Blaine, Judith Blake, Peter G. Blankestijn, Peter J. Bleyer, Anthony J. Block, Geoffrey A. Bloom, Roy D. Blosser, Christopher D. Blount, Mitsi A. Boels, Margien G.S. Boesen, Erika I. Bohlouli, Babak Boletta, Alessandra Bomback, Andrew S. Bonewald, Lynda Bonsib, Stephen M. Bonventre, Joseph V. Borgi, Lea Bork, Tillmann Borkan, Steven C. Borza, Dorin-Bogdan Bouchard, Josee Boulanger, Joseph H. Boulware, L. Ebony Bouvier, Michel Bowling, C. Barrett Braam, Branko Bracamonte, Erika R. Bradbury, Brian D. Brakeman, Paul R. Braun, Daniela A. Bray, Susan H. Brennan, Daniel C. Brenner, Robert M. Bresin, Elena Briggs, Josephine P. Brookhart, M. Alan Brooks, Craig R. Brophy, Patrick D. Brosius, Frank C. Brower, Roy G. Brown, Dennis Brown, Kimberly
173
65, 84, 112 105, 109 30 75 156 42 42 87 66 70, 166 87 157 82 93 23 158 153 100 115, 131 22, 23 43 35, 113 124 19, 20, 125, 162 141 158 151 60 105 90, 132 38, 97 48 100 3, 135 67 71 60 112, 143 101 155 4, 99 134 141 109 146 51 62 152 29 19, 20, 42 3 15 122 51 60 90 47, 73 6 3, 94, 114 20
FACULTY INDEX
Abbott, Kevin C. Abboud, Hanna E. Abrass, Christine K. Abuduli, Maerjianghan Aburatani, Takahide Adams, David R. Adams, Nancy Day Adebiyi, Oluwafisayo O. Adler, Sharon G. Adrogue, Horacio J. Afghahi, Hanri Agarwal, Anupam Agarwal, Rajiv Agodoa, Lawrence Akbari, Ayub Akilesh, Shreeram Akl, Ahmed Alegre, Maria-Luisa Alguire, Patrick C. Allon, Michael Alpers, Charles E. Amann, Kerstin U. Amaral, Ansel P. Amaral, Sandra Anders, Hans J. Anderson, Amanda Hyre Anderson, Sharon Anusornvongchai, Thitinun Aoki, Toshiyuki Appel, Gerald B. Archdeacon, Patrick Arduino, Matthew J. Arif, Asif Arif, Ehtesham Aronoff, George R. Arthur, John M. Ashby, Valarie B. Asif, Arif Askenazi, David J. Asplin, John R. Astor, Brad C. Bacallao, Robert L. Bachmann, Sebastian Bagga, Arvind Bajema, Ingeborg M. Bakris, George L. Balbo, Bruno E. Ballermann, Barbara J. Bansal, Nisha Barati, Michelle T. Bargman, Joanne M. Baron, Richard J. Basile, David P. Bass, Joseph T. Basu, Joydeep Basu, Rajit K. Beara Lasic, Lada Beathard, Gerald A. Beaudreuil, Séverine Beben, Tomasz
FACULTY INDEX Brown, Wendy Weinstock Browne, Teri Brownlee, Michael A. Brunelli, Steven M. Buhl, Eva Miriam Burgner, Anna Marie Burkart, John M. Burks, Scott R. Bushinsky, David A. Butterworth, Michael Buvall, Lisa Maria Cai, Jieru Cailhier, Jean-Francois Campbell, Kirk N. Canales, Benjamin Caplan, Arnold I. Caplan, Michael J. Cardone, Katie E. Carrero, Juan Jesus Carrisoza-Gaytan, Rolando Carroll, Thomas J. Cattran, Daniel C. Cavanaugh, Kerri L. Caviston, Kevin Cerda, Jorge Chan, Christopher T. Chan, Micah R. Chandraker, Anil K. Chang, Alex R. Chang, Anthony Chapman, Arlene B. Charlton, Jennifer R. Charmot, Dominique Charytan, David M. Chaudhuri, Abanti Chavkin, Nicholas W. Chawla, Lakhmir S. Cheikh Hassan, Hicham I. Chen, An-Ping Chen, Neal X. Chen, Shaowei Cheng, Huifang Cherney, David Cherqui, Stephanie Chertow, Glenn M. Cheung, Alfred K. Chisolm, Margaret S. Choi, Hyo-Jung Choi, Michael J. Choi, Soo Young Chonchol, Michel Christophorou, Armelle Jm Christov, Marta Chung, Jun-Jae Cina, Davide Pietro Clark, Marcus Clark, William F. Clase, Catherine M. Coca, Steven G. Coffman, Thomas M.
29, 30 126 165 4, 72 117 26 22, 23 60 171 69 153 148 74 153 157 3 90 144 168 69 2 13 125, 132 26 84 23, 24, 72 18 19, 21, 123 105 56 16, 127, 136 57 115 24, 72 57 154 6, 123 105 114 167 150 60 46 16 132 4 39 158 38, 84 58 23 150 68 71 71 37 13, 26 105 61, 148 38, 89
Cohen, Clemens D. Cohen, David J. Cohen, Robert A. Collins, Allan J. Colvin, Robert B. Combe, Christian Contreras, Gabriel Conway, Paul T. Cook, H. Terence Cooper, Christopher J. Cooper, Lisa A. Coresh, Josef Cornell, Lynn D. Correa-Rotter, Ricardo Cosgrove, Dominic E. Costalonga, Elerson Costantini, Frank Coyne, Daniel W. Crews, Deidra C. Crowley, Lisa E. Crowley, Steven D. Crowley, Susan T. Cui, Jie Cukor, Daniel Cunningham, Patrick Curhan, Gary C. D’Agata, Erika M.C. D’Agati, Vivette D. Daehn, Ilse S. Dager, William E. Daley, George Danesh, Farhad R. Danovitch, Gabriel M. Das, Amrita Dathe, Christin Daugirdas, John T. Davenport, Andrew David, Valentin Davidson, Alan J. de Boer, Ian H. de Bruijn, Pauline I.A. De Caestecker, Mark P. De Chiara, Letizia de Zeeuw, Dick Decker, Brian S. Deen, Peter M.T. DeFronzo, Ralph A. Dekel, Benjamin Delgado, Cynthia Delmas-Frenette, Catherine Delos Santos, Rowena B. Deltas, Constantinos Dember, Laura M. Denic, Aleksandar Derebail, Vimal K. Desnick, Robert J. Detwiler, Randal K. Devuyst, Olivier Dienemann, Thomas Djamali, Arjang
174
90 20 97 107, 122 11, 12, 82 53 37 81 13, 14, 70 85 51 106 11 38 155 159 2, 132 82 126 72 111, 164 66 66 145 131 171 170 90 118 28 3 118 100 150 76 5, 22 43, 56, 169 68 3 98 114 103 118 47 27, 144 158 46 3 133 106 61 143 4, 5, 81 113 26, 63 16 55 64 109 42, 76
FACULTY INDEX 88 87 9 70 76 85 88 136 26 70 49 165 76 9, 50 136 159 9 93 158 166 132 144 125 81, 128 87 157 71 157 56, 149 151 94, 158 46, 116 30 93, 144 40, 165 40 134 54 23, 82 132 18 5, 81, 96 143 15, 136 35, 55 10, 11, 74, 135 131 151 86 112 73, 135 149 64 109 13, 15, 22, 75 152 63, 99, 149 19, 21, 36, 75 135 62
Fufaa, Gudeta D. 116 Fujimura, Keiko 118 Furgeson, Seth B. 56 Fusaro, Maria 157 Gadegbeku, Crystal A. 99 Gaede, Peter 56 Gahl, William 92 Gallagher, Martin P. 101 Gallon, Lorenzo G. 155 Gamboa, Jorge 95 Gansevoort, Ron T. 63 Gao, Bin 131 Garcia, Gabriela E. 74 Garg, Amit X. 19, 40, 84, 100, 127 Garimella, Pranav S. 149 Garovic, Vesna D. 101 Gaut, Joseph 123, 137 Gbadegesin, Rasheed A. 15, 57, 64, 155 Gee, Heon Yung 155 Geissmann, Frederic 44 Gennari, F. John 9 George, Alfred L. 94 Gerber, Simon Daniel 114 Ghaffari, Arshia 96 Ghafoor, Valeed 110 Ghany, Marc G. 125 Gharavi, Ali G. 15 Giachelli, Cecilia M. 133 Gigliotti, Joseph C. 60 Gilbert, Richard E. 46 Gill, John S. 17, 19, 55, 123 Gipson, Patrick E. 16 Gitomer, Berenice Y. 157 Glassock, Richard J. 84 Glastras, Sarah J. 73 Glickman, Joel D. 23 Glotz, Denis 162 Gnudi, Luigi 116 Go, Alan S. 83 Godin, Melanie 101 Goldfarb, David S. 7, 171 Goligorsky, Michael S. 166 Gomez-Sanchez, Celso E. 164 Gong, Rujun 41 Gonzalez, Gema 138 Good, David W. 114 Goral, Simin 20 Gosmanova, Elvira 67, 108 Grabner, Alexander 68 Grams, M. 63, 148 Greenberg, Keiko I. 148 Greene, Tom 4 Greer, Raquel Charles 125 Greka, Anna 41, 87 Grgic, Ivica 153 Griffin, Matthew D. 44 Grimm, P. Richard 69 Groene, Hermann-Josef 135 Groop, Leif 136 Gross, Oliver 143
175
FACULTY INDEX
Dong, Zheng Dryer, Stuart E. DuBose, Thomas D. Duffield, Jeremy Stuart Dugbartey, George Johnson Dworkin, Lance D. Eckardt, Kai-Uwe Einstein, Francine Eisenstaedt, Richard El Karoui, Khalil El-Achkar, Tarek M. Eladari, Dominique Elahimehr, Reza Ellison, David H. El-Osta, Assam Elphick, Emma H. Emmett, Michael Endlich, Karlhans Esteva-Font, Cristina Evenepoel, Pieter Ewald, Andrew J. Eyler, Rachel F. Fabrizi, Fabrizio Falk, Ronald J. Fallarino, Francesca Fargue, Sonia Faul, Christian Feldkötter, Markus Feldman, Harold I. Feliers, Denis Fenton, Robert A. Ferrannini, Ele Ferris, Maria E. Fervenza, Fernando C. Fine, Derek M. Fink, Jeffrey C. Firsov, Dmitri Fischer, Michael J. Fishbane, Steven Fissell, Rachel B. Fissell, William Flessner, Michael F. Flinter, Frances Anne Florez, Jose C. Flythe, Jennifer E. Fogo, Agnes B. Folsch, Heike Forbes, Josephine M. Ford, Mandy L. Ford, Sharon Lee Fornoni, Alessia Foster, Meredith C. Franceschini, Nora Franch, Harold A. Freedman, Barry I. Freedman, Benjamin S. Fried, Linda F. Friedewald, John J. Friedman, Scott L. Frohlich, Else M.
FACULTY INDEX Grubbs, Vanessa Guay-Woodford, Lisa M. Guglielmi, Kelly E. Gumz, Michelle L. Guo, Linlin Gupta, Meera Gupta, Vineet Gura, Victor Gurley, Susan B. Gutierrez, Orlando M. Haas, Mark Haase, Volker H. Hadchouel, Juliette Hakim, Raymond M. Hall, Gentzon Hall, Yoshio N. Haller, Hermann G. Hallows, Kenneth R. Hamrick, Mark W. Han, Seung Hyeok Han, Seung Seok Haneda, Masakazu Hanevold, Coral D. Harris, Peter C. Harrison, David G. Hasegawa, Kazuhiro Hasuike, Yukiko Hato, Takashi Hedayati, Susan Heeger, Peter S. Heeringa, Peter Henao-Mejia, Jorge Herrmann, Sandra Hertig, Alexandre Herzlinger, Doris A. Herzog, Charles A. Heung, Michael Hevia, Daniel E. Hickey, Jim Hildebrandt, Friedhelm Himmelfarb, Jonathan Hladik, Gerald A. Hladunewich, Michelle A. Hocher, Berthold Hoenderop, Joost Hogenesch, John B. Holdsworth, Stephen R. Holzman, Lawrence B. Holzmann, Martin Hoorn, Ewout J. Hopp, Katharina Hoshizaki, Deborah Hostetter, Thomas H. Hough, Catherine (Terri) L. Howard, Andrew D. Hoxha, Elion Hricik, Donald E. Hruska, Keith A. Hsiao, Li-Li Hsu, Chi-Yuan
24, 125 15, 100 29, 30 43 103 113 76 138 111 68 10, 11, 146 82 165 35, 53, 94 64 156 59, 116 49 95 118 65, 148 47 57 16 89 151 107 41 145 91 163 134 59 75 2 94 148 111 17 16, 80 122 25 14, 20, 110 68 115 43 112 41, 90 105 165 152 3 86, 139, 166 6 108 65 20 154, 167 29, 30 98, 148, 149
Hsu, Christine W. Hu, Ming Chang Hu, Yan Huang, Chou-Long Huang, Jennifer L. Huang, Jianbing Huber, Tobias B. Huen, Sarah C. Hukriede, Neil A. Humes, H. David Humphreys, Benjamin D. Hung, Adriana Hurst, Frank P. Huynh Cong, Evelyne Hwang, Daw-Yang Hwang, Young-Hwan Ibrahim, Hassan N. Igarashi, Peter Ikeda, Misa Ikizler, T. Alp Ingelfinger, Julie R. Inker, Lesley Inrig, Jula K. Isakova, Tamara Isermann, Berend Heinrich Ishibe, Shuta Ishida, Julie H. Ishikawa, Yasunobu Ito, Shunsuke Ix, Joachim H. Izpisua Belmonte, Juan Carlos Jaar, Bernard G. Jablonski, Kristen L. Jacob, Howard J. Jacques, Louis Jain, Arsh Jain, Deepika Jain, Sanjay Jaklic, Alenka Jalal, Diana I. Jamerson, Kenneth A. James, Matthew T. Jansen, Jitske Jarad, George Jardine, Meg J. Jassal, Sarbjit Vanita Jelen, Sabina K. Jennette, J. Charles Jha, Jay Chandra Jha, Vivekanand Jhaveri, Kenar D. Jiang, Chunming Jilka, Robert L. Jim, Belinda Bun Jodele, Sonata Joffe, Steven Johansen, Kirsten L. Johnson, David W. Johnson, Julie A. Johnson, Randall S.
176
61 154 59 94 152 76 93, 104 131 49 18, 62 3, 7, 88 51, 168 138 155 155 152 100 45 109 23 30 106 55 48 49 41 107 74 59 149 2, 47 96, 108 67, 167 92 81 22 136 143 62 87 85 148 62 70 127, 156 23, 24 69 10, 11, 90 73 38, 110 39, 97 60 48 101 163 4 23, 109, 168 96 15 129
FACULTY INDEX 89, 125, 144 138 72, 108 153 15 29, 36, 38 27, 28, 83 63 159 128 116 83, 142 94 128 17 103 83 118 150, 153 62 166 3, 47 107 129 118 101 16 21, 40, 123 111 100 29 110 60 29, 30 6, 7, 123 95 165 62 130 124 40, 99 30, 81 157 76 153 93, 112 62 158 62, 86 5 92 59 44 43 16, 64 138 152 89 112 169
Knoll, Greg A. Ko, Yi-An Koga, Kenichi Kohan, Donald E. Kohl, Stefan Komers, Radko Kon, Valentina Kopan, Raphael Kopp, Jeffrey B. Kopple, Joel D. Kottgen, Anna Kottgen, Michael Kovesdy, Csaba P. Koyner, Jay L. Kramann, Rafael Kraut, Jeffrey A. Krautwald, Stefan Krebs, Christian Franz Kretzler, Matthias Krieger, Nancy S. Kshirsagar, Abhijit K. Ku, Elaine Kucharski, Sarah E. Kuehn, E. Wolfgang Kuhlmann, Martin K. Kupin, Warren L. Kuppe, Christoph Kuragano, Takahiro Kurella Tamura, Manjula Kurts, Christian Lacson, Eduardo K. Laing, Chris Lam, Albert Q. Lam, Ngan Lameire, Norbert H. Laney, Nina Lang, Florian C. Langman, Craig B. Langsford, David Lanzani, Chiara Larkin, John W. Larsson, Tobias E. Laszik, Zoltan G. Lau, Wei Ling Lazelle, Rebecca A. Leca, Nicolae Lee, Celeste Castillo Lee, Ha Won Lee, Hajeong Lee, Taewoo Lee, Timmy C. Lehrich, Ruediger W. Lehtonen, Sanna H. Leichtman, Alan B. Lemoine, Sandrine Lentine, Krista L. Leonard, Mary B. Leung, Nelson Leventhal, Jeremy S. Leventhal, Joseph Ross
177
42 64 73 29, 30, 47, 134 155 73, 165 46 2 15, 64, 147 168 87 87 63 6, 7, 61, 123 59, 117 8, 9 90 112 90, 135 68 24 105, 106 39 58 43 13 74 107 124, 141, 145 44 5 84 17 113 99 67 167 157, 163 63 67 66 133 65 154, 171 111 36 52 153 103 110 23 26 73, 153 36 115 40, 55, 113 20, 95 14 104 91
FACULTY INDEX
Johnson, Richard J. Johnson, Steve Johnstone, Stephanie Jones, Nina Jorde, Lynn B. Josephson, Michelle A. Joy, Melanie S. Jun, Min Kadoya, Hiroyuki Kain, Renate Kajbaf, Farshad Kalantar-Zadeh, Kamyar Kalim, Sahir Kallenberg, Cees G.M. Kallok, Michael J. Kamal, Ahmed I. Kamper, Anne-Lise Kang, Hyun Mi Kann, Martin Kanno, Yoshihiko Kapitsinou, Pinelopi P. Kaplan, David Karaboyas, Angelo Karbach, Susanne Helena Karim, Aos S. Karumanchi, S. Ananth Kashtan, Clifford E. Kasiske, Bertram L. Kato, Yukiko Katsanis, Nicholas Katz, Lois Anne Kawada, Masahiro Kefalogianni, Eirini Kelepouris, Ellie Kellum, John A. Kendrick, Jessica B. Kennedy, Chris R. Kensinger, Clark David Kerjaschki, Dontscho Kestenbaum, Bryan R. Ketteler, Markus Kewalramani, Reshma Khan, Saeed R. Khan, Samia Kidokoro, Kengo Kim, Alfred Hyoungju Kim, Eun Jung Kim, Jae-Eun Kim, Steven Kimmel, Paul L. Kingsmore, Stephen F. Kitagawa, Masashi Kitching, A. Richard Klarenbach, Scott Kleta, Robert Kliger, Alan S. Kline, Timothy L. Klingenberg, Roland Kluger, Malte A. Knauf, Felix
FACULTY INDEX Levey, Andrew S. Levin, Adeera Levin, Nathan W. Levine, Beth C. Levine, Jerrold S. Levison, Sandra P. Li, Changlin Li, Jianzhong Li, Joan Li, Xian C. Li, Xiaogang Li, Yi Lieberthal, Wilfred Lienkamp, Soeren S. Lieske, John C. Lifton, Richard P. Lightstone, Liz Liles, John T. Lin, Fangming Lin, Jennie Lin, Ling Linas, Stuart L. Lindenmeyer, Maja Lipschutz, Joshua H. Little, Mark Alan Littman, Dan R. Liu, Jing Liu, Kathleen D. Liu, Shiguang Liu, Shuman Liu, Youhua Liu, Zhihong Livingston, Man J. Lo, Chao-Sheng Loffing, Johannes Loganathan, Krishnapriya Lok, Charmaine E. Lora, Claudia M. Luciani, Alessandro Luft, Friedrich C. Luo, Jinlong Luther, James M. Luyckx, Valerie A. Lyons, Paul Anthony Ma, Jun Maarouf, Omar H. Macdougall, Iain C. Mace, Maria Lerche MacRae, Jennifer M. Macumber, Ian R. Madaio, Michael P. Maddux, Dugan Madesh, Muniswamy Madias, Nicolaos E. Mahan, John D. Mailloux, Lionel U. Mäkinen, Taija Malhotra, Rakesh Mallamaci, Francesca Mallipattu, Sandeep K.
106 105 35, 53, 129 162 103 29 58 117 3 86 45 142 41 132 16, 171 50, 144 146 74 3 148 74 26, 122 118 131 128 134 166 6, 7 117 154 135 65, 135 104 151 165 117 17, 23, 53, 170 126 70 129, 164 66 67, 164 38 128 75 117 40, 82 68 43 106 37 72 90 8 97 83 130 148 108 104
Maltzman, Jonathan S. 86 Malvar, Ana 110 Mandelbrot, Didier A. 100 Manson, Scott R. 150 Marcelli, Daniele 109 Marciano, Denise K. 93, 150 Margolis, Benjamin L. 131 Markadieu, Nicolas 69 Markowitz, Glen S. 14 Marra, Amanda N. 150 Marshall, Mark R. 7 Martin, Claire E. 71 Martin, Pierre-Yves F. 68 Martini, Sebastian 74 Mason, Peter 102 Massy, Ziad 166 Masters, Philip A. 25 Masters, Seth L. 49 Mathew, Anna V. 73 Mathiesen, Elisabeth R. 56 Mathieson, Peter W. 92 Matias, Patrícia 68 Matsumoto, Yoshihiro 164 Matthay, Michael 3 Mattoo, Tej K. 57 Mattson, David L. 111 Matzke, Gary R. 28 Maursetter, Laura J. 97 Mayadas, Tanya N. 44 Mayeux, Philip R. 123 Mcadams-DeMarco, Mara 113 McClellan, William M. 51 McDonald, Stephen P. 108 McDonough, Alicia A. 165 McMahon, Andrew P. 2 Mehrotra, Purvi 103 Mehrotra, Rajnish 22, 38, 83, 124 Mehta, Ravindra L. 38, 101 Melo, Zesergio 114 Melsom, Toralf 106 Melton, Douglas A. 34 Mendes, Marco Oliveira 107 Mendez, Mariela 29, 30 Mengel, Michael 82, 146 Menon, Madhav C. 76 Metzinger, Laurent 115 Meulemans, Jeroen 3 Meyer, Timothy W. 164 Meyer-Schwesinger, Catherine 71 Meyers, Kevin E.C. 137 Miao, Zhenhua 151 Micanovic, Radmila 74 Middleton, John Paul 26 Mihayalova, Borislava N. 105 Mills, Kevin 136 Miner, Jeffrey H. 93, 143 Mirkin, Chad A. 122 Miskulin, Dana 127 Mitch, William E. 95 Miyamoto, Satoshi 151
178
FACULTY INDEX 133 113 29, 34, 122 71 151 61 98 148 95 124 159 6 131 98 87 48 7 89 86 49, 135 159 75 69 14 56 63 86 104 37 49, 135 56, 156 42, 146 136 49 44 56, 98 108 23 52, 138 162 157 93 113 82 154 73 108 103 27, 169 19, 20 156 142 15 70 99 55 74 131 3, 47 29, 139
Ortiz, Pablo A. Osafune, Kenji Oxburgh, Leif Padanilam, Babu J. Paine, Mary F. Paixao, Rute C. Pakozdi, Angela Palevsky, Paul M. Pallet, Nicolas Palmer, Biff F. Palmer, Suetonia Palsson, Runolfur Panzer, Ulf Papazova, Diana A. Parekh, Rulan S. Parekkadan, Biju Parfrey, Patrick S. Parikh, Chirag R. Park, Ae Seo Deok Park, Hae Jean Park, Joo-Seop Parker, Mark G. Pasch, Andreas Pastor-Soler, Nuria M. Patel, Ami Patel, Priti R. Patel, Uptal D. Patel, Vishal Patzer, Rachel E. Pavkov, Meda E. Payen, Didier M. Pecoits-Filho, Roberto Pedersen, Cecilie Noehr Pedigo, Christopher E. Peired, Anna Julie Pema, Monika Pena, Michelle Peralta, Carmen A. Perazella, Mark A. Pereira, Renata C. Perin, Laura Perkovic, Vlado Perl, Jeffrey Perrone, Ronald D. Perry, Heather M. Pesenson, Anne Peters, Dorien J.M. Peters, Kevin G. Peti-Peterdi, Janos Petrakis, Ioannis Pezzolesi, Marcus G. Pflederer, Timothy A. Phelan, Paul J. Picken, Maria M. Pickering, Matthew C. Piraino, Beth M. Place, Aaron T. Platt, Jeffrey L. Pluznick, Jennifer L. Podymow, Tiina
179
69, 94 2 2, 93 49 28 145 110 6, 7 104 9 83 64 112 76 92 62 46 136, 149 153 69 93 54 154 29, 30, 114 84 170 125 152 113 56 131 53, 159 158 73 60 58 67 51 38, 144, 169 48 47 40, 86, 127 35, 53, 96, 159 52 118 29 58 47 93 42 116 102 155 42 163 159 68 162 134 101
FACULTY INDEX
Miyazaki, Makoto Mjøen, Geir Moe, Sharon M. Moeller, Marcus J. Mohamed, Riyaz Moledina, Dennis Molitch, Mark E. Moore, Andrew Moorthi, Ranjani N. Moradi, Hamid Moraes, Thyago Proença de Moss, Alvin H. Mostov, Keith Mottl, Amy K. Mount, David B. Moyses, Rosa M.A. Mueller, Bruce A. Müller, Dominik N. Mundel, Peter H. Muruve, Daniel A. Muthucumarana, Kalindu Muthukumar, Thangamani Mutig, Kerim Nachman, Patrick H. Nadim, Mitra K. Naimark, David M. Najafian, Nader Nakamura, Jin Nally, Joseph V. Nangaku, Masaomi Narva, Andrew S. Nasr, Samih H. Natarajan, Rama Nath, Karl A. Nelson, Peter J. Nelson, Robert G. Nesrallah, Gihad E. Nessim, Sharon Neuland, Carolyn Y. Newell, Kenneth A. Newman, Christopher Ng, Lai Guan Nickeleit, Volker Nickerson, Peter W. Nigwekar, Sagar U. Nikolic-Paterson, David J. Niu, Sheng-Wen Noel, Sanjeev Nolin, Thomas D. Norman, Douglas J. O’Donoghue, Donal J. O’Hare, Ann M. O’Shaughnessy, Kevin O’Sullivan, Kim M. O’Toole, John F. Oberholzer, Jose Okamura, Daryl M. Okusa, Mark D. Olson, Eric Orlowski, Janis M.
FACULTY INDEX Polichnowski, Aaron J. 103 Polkinghorne, Kevan 66 Pollak, Martin R. 15, 41 Pollock, Carol A. 46 Pollock, David M. 43 Pontrelli, Paola 151 Port, Friedrich K. 53 Portale, Anthony A. 115 Porter, Andrew 110 Posselt, Andrew 55 Poulton, Caroline J. 125 Powe, Neil R. 37, 126 Powner, Jordan T. 108 Pozzi, Ambra 117, 130 Proctor, Lita M. 86 Provost, Miriam 17 Pun, Patrick H. 24, 72, 94 Qian, Feng 58 Qian, Qi 29 Quach, Kevin 72 Querfeld, Uwe 154 Quinn, Robert R. 24 Quittnat Pelletier, Friederike S. 66 Rabasco, Cristina 110 Racusen, Lorraine C. 20, 82 Radcliffe, John Scott 133 Radhakrishnan, Jai 13, 37, 125 Raimann, Jochen G. 66 Raj, Dominic S. 134, 166 Ramachandran, Raja 110 Ramanathan, Venkataraman 10, 11 Rame, Jesus Eduardo 6 Randolph, Gwendalyn 130 Ranieri, Marianna 158 Rankin, Tracy L. 30 Rao, Anirudh 107, 156 Rao, Panduranga S. 156 Rao, Reena 152 Rasooly, Rebekah Sarah 15, 16 Rassen, Jeremy A. 51 Rathi, Manish 110 Rauchman, Michael I. 93 Ravichandran, Kameswaran 152 Rayner, Hugh C. 66 Reed, Elaine F. 82 Reese, Peter P. 21, 100 Reeves, William Brian 131 Reginensi, Antoine 150 Reich, Heather N. 13, 14, 65, 84 Reisin, Efrain 156 Remuzzi, Andrea 62 Remuzzi, Giuseppe 38, 163 Rezakhani, Sepideh 107 Rhee, Connie 108, 168 Rhee, Eugene P. 86 Ricordi, Camillo 91 Riella, Leonardo V. 19, 91 Rifkin, Dena E. 67 Robbin, Michelle L. 66 Robinson, Bruce M. 53, 82, 142
Robinson, Lisa Rocco, Michael V. Rodby, Roger A. Rodriguez, Rudolph A. Rodriguez-Boulan, Enrique Rodriguez-Iturbe, Bernardo Rogers, Natasha M. Romagnani, Paola Romero, Michael F. Ronco, Claudio Ronco, Pierre M. Rosas, Sylvia E. Rosenbaum, David P. Rosner, Mitchell H. Ross, Edward A. Ross, Lainie Friedman Ross, Michael J. Rovin, Brad H. Roy, Shuvo Roy-Chaudhury, Prabir Ruebner, Rebecca Ruggenenti, Piero Luigi Ruilope, Luis M. Saad, Ahmed Safa, Kassem Saifudeen, Zubaida R. Sakurai, Hiroyuki Salama, Alan D. Salomon, Daniel R. Samaniego-Picota, Milagros D. Sampson, Matthew Sandberg, Kathryn Sandy, Dianne T. Sapp, Julie Saran, Rajiv Saritas, Turgay Sarwal, Minnie Sawinski, Deirdre L. Scandling, John D. Schaefer, Sebastian Markus Schanstra, Joost Scheele, Willem H. Schell, Jane O. Schelling, Jeffrey R. Schiavi, Susan C. Schiller, Brigitte Schlieper, Georg Schlondorff, Detlef O. Schmidt, Harald H. Schmidt, Laura S. Schmidt, Rebecca J. Schnellmann, Rick G. Schold, Jesse D. Schreiber, Adrian Schrier, Robert W. Schultheiss, Thomas M. Scindia, Yogesh M. Scott, David Sedor, John R.
180
166 132 108, 169 51 131 89 60 88 114 43 135 29, 72 115 7, 23, 38 17 36 147 13, 14, 37 138 52, 66, 81 105 144 140 61 76 150 87 65 134 19, 20, 42, 137, 162 15, 155 29 145 16 142 71 76 20 91 75 136 116 97 118 48 55 167 129 165 16 54 41 123 70 56 2 60 116 41
FACULTY INDEX 74 123, 141 43 83 64 9 71 66, 106 115 107 86 26 3, 41 86, 165 70, 71 15, 92 4 138 158 72 167 138 103 116 146 125 101 81 118 3, 88 63 113 94 83 45 159 114 70 39, 111 2 65 69 157 36 61 115 27, 28 148 50 29 100 166 134 63 103 58 50, 69 149 4 155
Sumida, Keiichi 152 Sun, Zhaoxia 58 Surendran, Kameswaran 150 Susztak, Katalin 136 Swaminathan, Madhav 127 Swaminathan, Sundararaman 74 Swan, Joshua Taylor 61 Sweetwyne, Mariya T. 117 Szczech, Lynda 83 Szeto, Cheuk-Chun 96, 159 Szeto, Hazel H. 41 Taber, David J. 75 Takasato, Minoru 93 Taler, Sandra J. 140 Tamma, Grazia 158 Tan, Boon Kay 159 Tan, Roderick J. 70 Tang, Qizhi 91 Tangri, Navdeep 141 Tantisattamo, Ekamol 154 Tatsumoto, Narihito 154 Tentori, Francesca 52, 124 Terry, Christi M. 18 Tesar, Vladimir 99 Textor, Stephen C. 102, 144 Thadhani, Ravi I. 59 Theilade, Simone 116 Thibodeau, Jean-Francois 111 Thomas, Merlin C. 165 Thurman, Joshua M. 163 Toda, Naohiro 71 Todd, Alexandra F. 154 Tokaz, Molly Colleen 109 Tolwani, Ashita J. 7, 61 Tomas, Nicola M. 65 Tong, Allison 156 Topf, Joel 39 Tornatore, Kathleen M. 28 Torres, Vicente E. 127, 152 Toto, Robert D. 84 Touchard, Guy 42 Townsend, Raymond R. 23, 101, 140, 144 True, Karin A. 14, 20, 42, 55 Tsiokas, Leonidas 45 Tufro, Alda 155 Tumlin, James A. 13, 61, 72 Tuot, Delphine S. 37 Turenne, Marc 107 Tuttle, Katherine R. 18, 85 Tzamou, Vanessa E. 67 Uchida, Shinichi 50 Unruh, Mark L. 22, 23, 24, 98, 132 Urbanes, Aris Q. 102 Vallon, Volker 134 Van Buren, Peter N. 55 van den Berg, Bernard 70 Van den Heuvel, Lambertus P.W.J. 65 Van Zonneveld, Anton Jan 59 Vanholder, Raymond C. 99, 166 Vartabedian, Bryan S. 39
181
FACULTY INDEX
Segerer, Stephan Segev, Dorry L. Sehgal, Amita Sekkarie, Mohamed A. Sekula, Peggy Seres, David S. Sever, Sanja Shafi, Tariq Shah, Anuja P. Shah, Hitesh H. Shah, Svati H. Shalaby, Marc Shankland, Stuart J. Sharma, Kumar Sharma, Mukut Shaw, Andrey S. Sheffer, Emily Sheldon, Murray Shepard, Blythe D. Shireman, Theresa I. Shroff, Rukshana Silverstein, Douglas M. Sims-Lucas, Sunder Singh, Bhupinder Singh, Harsharan Kaur Sise, Meghan E. Skupski, Daniel W. Sloand, James A. Small, David M. Smeets, Bart Smyth, Andrew Snyder, Grace Snyder, Peter M. Soliman, Elsayed Z. Somlo, Stefan Soohoo, Melissa Sorrell, Sara Lynn Souma, Tomokazu Sparks, Matthew A. Spence, Jason R. Spinale, Joann M. Spirli, Alessia Sprague, Stuart M. Srinivas, Titte Srisawat, Nattachai Srivastava, Tarak St. Peter, Wendy L. Stack, Austin G. Staub, Olivier Stehman-Breen, Catherine O. Steiner, Robert W. Stevens, Troy Stockand, James D. Streja, Elani Stremska, Marta Su, Xuefeng Subramanya, Arohan R. Suchy-Dicey, Astrid Sugarman, Jeremy Suh, Jung Hee
FACULTY INDEX Vasilyev, Aleksandr 132 Vaziri, Nosratola D. 134 Vazquez, Miguel A. 37 Veis, Judith H. 29 Verbalis, Joseph G. 9 Viana, Joao L. 109 Vilapakkam Ranganathan, Punithavathi 151 Vinas, Jose L. 103 Voelker, James R. 127 Voora, Raven A. 55 Wald, Ron 7, 61 Waldman, Meryl A. 84 Wali, Ravinder K. 147 Wall, Susan M. 165 Wallace, Douglas C. 41 Wallace, Eric L. 159 Wang, Angela Yee Moon 46 Wang, Bingshu 70 Wang, Tong 114 Wang, WenHui 69 Wang, Xiaoxin 73 Wanner, Christoph 46 Warburton, Karen M. 97 Watnick, Suzanne 54, 145 Watnick, Terry J. 58, 152 Weber, Marc L. 26 Weinberg, Joel M. 49 Weiner, Daniel E. 139 Weinhandl, Eric D. 108 Weinstein, Adam R. 57 Weir, Matthew R. 67, 140 Weisbord, Steven D. 6, 7, 24 Weiss, Robert H. 90 Weisz, Ora A. 94 Weldegiorgis, Misghina Tekeste 63 Weldon, Steven M. 59 Weller, Richard Beresford 129 Werth, Max 150 Wertheim, Jason 3 Wesson, Jeffrey 157 Wetmore, James B. 107 Wheeler, David C. 40, 46, 156 Wiecek, Andrzej 46, 99 Wiggins, Roger C. 90 Wiig, Helge 130 Willerslev, Eske 80 Williams, Amy W. 29, 139 Williams, Mark E. 13 Wilson, Nancy A. 76 Wingert, Rebecca A. 150 Winkelmayer, Wolfgang C. 4, 5, 51, 83 Winkler, Cheryl Ann 16 Winston, Jonathan A. 147 Wiseman, Alexander C. 19, 20, 42, 56 Wish, Jay B. 35, 107 Wolf, Matthias 100, 115 Wolf, Myles S. 133, 162 Wolfson, Marsha 29 Wong, Florence 7 Wong, Leslie P. 139
Woodward, Owen M. Wright Nunes, Julie A. Wu, Jingshing Wuehl, Elke Wuttke, Matthias Wyatt, Christina M. Xie, Qionghong Xin, Wei Xu, Ricong Xu, Weiwei Xu, Zhuo Yacoub, Rabi Yadav, Ashok Kumar Yale, Jean-Francois Yamada, Shunsuke Yamamoto, Hironori Yamamoto, Takeshi Yang, Huang-Yu Yang, Sung-Sen Yasuda, Yoshinari Yatim, Karim Yee, Jerry Yevzlin, Alexander S. Yoder, Bradley K. Yokoo, Takashi Yoneda, Yukio Young, Bessie A. Yu, Haiyang Yu, Jing Yunos, Nor Azim Mohd Zahedi, Kamyar A. Zahner, Gunther Zamami, Ryo Zeevi, Adriana Zeidel, Mark L. Zeisberg, Michael Zelnick, Leila R. Zhang, Jiandong Zhang, Lei Zhang, Ming-Zhi Zhang, Xin Zhang, Xuehan Zhang, Zhigang Zhao, Bixiao Zhou, Dong Zhou, Jing Zhu, Hao Zhu, Quansheng Zhuang, Shougang Zieman, Susan J. Zimetbaum, Peter Zoccali, Carmine Zorn, Emmanuel Zou, Hequn
182
87 125 118 105 64 147 65, 117 104 64 153 117 84, 113 68 47 154 115 104 112 69 156 103 18 17, 18, 102, 127 45 47 87 126 64 2 101 111 112 67 82 99 135 63 111 76 151 59 106 104 60, 61 117 45 3 112 117 141 94 149, 168 162 112
NOTES
_______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________
NOTES
_______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________
Scientific Exposition A vital part of the Kidney Week® educational experience is found on the scientific exposition floor, Halls A–C of the Pennsylvania Convention Center. This unparalleled international venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care. On the exposition hall floor, you can engage in peer-to-peer interactions with representatives and businesses that form an integral part of your day-to-day fight against kidney disease and view thousands of accepted poster abstracts. ASN is a member of the Healthcare Convention and Exhibitors Association (HCEA). Scientific Exposition Refreshment Breaks are supported by Fresenius Medical Care. Scientific Exposition Attendee Lounges are supported by Relypsa.
Scientific Exposition Hours Thursday, November 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9:30 a.m. – 2:30 p.m. Friday, November 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9:30 a.m. – 2:30 p.m. Saturday, November 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9:30 a.m. – 2:30 p.m.
Career Fair The ASN Career Fair offers an excellent opportunity to meet face-to-face with representatives of top employers in the nephrology field—all in one place. Visit with registered employers in Exhibit Hall C.
Children and Child Care ASN has obtained the name of a child-care provider used by several Philadelphia hotels to provide in-room child-care services. ASN makes no endorsement of these provides and accepts no liability should you employ their services. For further information and rates, contact Your Other Hands at 215-790-0990. Note: Children younger than 12 years of age are not permitted in any ASN meeting or session room, poster session, or the Scientific Exposition at any time.
“Locate Me” Kiosks—Posters/Exhibitors Poster and exhibit information can be found electronically at the “Locate Me” kiosks in Exhibit Halls A–C.
EXPOSITION
1b
Exhibitor Spotlights ASN has built a special theater in Exhibit Hall C to spotlight industry’s latest advances in nephrology practices, products, services, and technologies during 60-minute presentations (no Continuing Medical Education credits). Seating is first-come, firstserved and limited to 75 participants. All presentations include breakfast (morning presentations) or lunch (afternoon presentations.)
Spotlight Schedule Thursday, November 13 10:00 a.m. – 11:00 a.m. Current Concepts in Secondary Hyperparathyroidism
Thursday, November 13 12:30 p.m. – 1:30 p.m. Advancing Paradigm Changes in Type 2 Diabetes Management
Presented by Amgen
Presented by Janssen Pharmaceuticals, Inc.
Friday, November 14 10:00 a.m. – 11:00 a.m. Rituxan for the Treatment of GPA and MPA
Friday, November 14 12:30 p.m. – 1:30 p.m. Ferric Citrate: The Latest Advance in Iron Based Phosphate Management
Presented by Genentech, Inc./ Biogen Idec, Inc.
Presented by Keryx Biopharmaceuticals, Inc.
Saturday, November 15 10:00 a.m. – 11:00 a.m. The Science of Biosimilars
Saturday, November 15 12:30 p.m. – 1:30 p.m. Fabry Disease: A Nephrology Perspective
Presented by Hospira
Presented by Genzyme a Sanofi Company
2b
Innovators Place Innovators Place is designed to offer the opportunity for scientific discourse between medical device innovators and the nephrology community. Innovators Place is located in Exhibit Hall A.
Company/Product Descriptions for Innovators Place (as of 8/28/2014) FAST BioMedical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IP 1 FAST BioMedical is a clinical stage company with patented technology for measuring Plasma Volume and Kidney Function (mGFR). This first-in-class technology delivers these important metrics accurately and in a clinically actionable timeframe to guide existing therapies. A Phase II trial is in process in CKD and AKI patients. FibroGen, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IP 2 Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), currently in Phase 3 clinical development that represents a potential new treatment paradigm for CKD anemia. This program describes the physiology of HIF in health and disease and addresses the mechanism of action of prolyl hydroxylase inhibition in the treatment of anemia. Proteon Therapeutics Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IP 3 Proteon Therapeutics recently completed a Phase 2 study. PRT-201 demonstrated improvements in primary patency, maturation, rate of interventions, and secondary patency in radiocephalic AVFs. (Hye JVS, 2014) Proteon is interested in recruiting Investigators for Phase 3 studies and developing a dialog with the community on ways to improve vascular access outcomes. The Virtual Nephrologist, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IP 4 The Virtual Nephrologist is a stand-alone blood pump, powered by a DC source like an automobile battery, to support CVVH where conventional dialysis is not available to treat AKI. This complete RRT circuit can be carried in a bag, set up to start in an hour. No need for electricity, water, or technical machines.
EXPOSITION
3b
Kidney Week 2014 Exhibitor List (as of 8/28/2014) Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth AbbVie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513, 527 Acumen Physician Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1115 Alexion Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1801 Alport Syndrome Foundation, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716 American Board of Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1436 American College of Physicians/Annals of Internal Medicine . . . . . . . . . . . . . . . . . 1711 American Kidney Fund . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 American Nephrology Nurses’ Association . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501 American Physiological Society . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1036 American Regent, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1408 American Renal Associates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301 American Society for Apheresis (ASFA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 American Society of Diagnostic & Interventional Nephrology . . . . . . . . . . . . . . . . . . 613 American Society of Nephrology (ASN) Services . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327 AmeriWater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604 Amgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1601 Amicus Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735 Amyloidosis Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2005 Angelini Pharma Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712 AngioDynamics Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1813 Aohua Medical Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1518 Aprima Medical Software, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1537 Arbor Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2026 Asahi Kasei Medical America Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1527 Ascend Clinical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1413 Associates of Cape Cod, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710 AtCor Medical, Inc. (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805 AWAK Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1234 B. Braun Medical Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1001 Bard Peripheral Vascular . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907 Baxter Healthcare Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1717 The Binding Site, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309 Biomedica Medizinprodukte GmbH & Co KG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1927 BioPorto Diagnostics A/S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1035 Calmoseptine, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1635 CardioMed Supplies Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1239 Central Florida Kidney Centers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1912 Christopher Kidd & Associates, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1734 Chronic Disease Research Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1636 Cincinnati Children’s Hospital, Division of Nephrology . . . . . . . . . . . . . . . . . . . . . . 2030 ClearBridge Biophotonics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1641 CMIC Holdings Co., Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1012 Coalition for Supportive Care of Kidney Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . 2028 Covance Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1926 Covidien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1726
4b
5b
EXPOSITION
Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth CryoLife . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 935 Cystinosis Research Network . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 937 DaVita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601 Daxor Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1419 Dialysis Clinic, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1733 Diasol Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 936 DiaSorin Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2003 DoctorsXL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1135 DOPPS/Arbor Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2009 DSI Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1034 EKF Molecular Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730 Elsevier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900 Enovative Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728 ERA-EDTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334 Euroimmun US . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1630 Explore Transplant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1437 Falcon Physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801 The Fortus Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2013 Frenova Renal Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1810 Fresenius Medical Care – Fresenius Medical Services . . . . . . . . . . . . . . . . . . . . . . . 1011 Fresenius Medical Care – Fresenius Renal Therapies . . . . . . . . . . . . . . . . . . . . . . . . 1917 Fresenius Medical Care – Renal Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . 1101 Genentech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1310, 1339 Genzyme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1519 Hospira . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927 Houston Methodist Hospital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1736 HRA Healthcare Research & Analytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1618 Immucor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1629 Immundiagnostik AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1014 Immutopics International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915 Infian/HII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1215 Intelomed, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 International Society of Nephrology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1831 The JAMA Network . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 Janssen Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1620 Japanese Society of Nephrology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1037 JMS North America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 608 Kaneka Pharma America LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632 Karger Publishers, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1211 KDIGO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2031 Keryx Biopharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1611 Kibow Biotech, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1727 Klarvoyant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1634 LSU Health, Department of Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1338 Machaon Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1910 Mallinckrodt Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1227 Mar Cor Purification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1534 Mayo Clinic Referring Physician Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533 MedComp . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1134 Medical Devices Corporation Sdn Bhd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916
Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth Medical Education Institute, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505 Medical Indicators, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620 Medtronic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1931 MIQS Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 Mission Pharmacal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335 National Death Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2001 National Kidney and Urologic Diseases Information Clearinghouse . . . . . . . . . . . . . 507 National Kidney Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1314 Nature Publishing Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2027 NEJM Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1421 NephCure Kidney International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 633 Nephrocor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503 Nephrology News & Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1535 Nephrology Nursing Certification Commission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509 Nephropath . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718 Nephro-Tech, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1435 NIKKISO CO., LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 827 Nipro Medical Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 711 NxStage Kidney Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 934 NxStage Medical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1027 Otsuka America Pharmaceutical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1401 Otto Trading, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1337 Oxalosis and Hyperoxaluria Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1137 Oxford University Press . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1434 Patient First Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1235 Physician Software Systems, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2010 pMD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600 Polycystic Kidney Disease Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1929 Pulse Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919 Pure Life Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1237 Quality Dialysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627 Raptor Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 901 Relypsa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1019 Renal Physicians Association . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 Renal Research Institute . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1811 Rockwell Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 811 Sandoz, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727 Sanofi Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1315 Satellite Healthcare/Wellbound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1626 Sceptre Management Solutions, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834 SomaLogic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1536 Spectra Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1119 Teleflex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615 Terumo BCT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1627 Toray Medical Co., Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1738 Total Quality Medical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732 Transplant Genomics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 638 UKD Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1930 U.S. Renal Care, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1513 United States Renal Data System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2007
6b
Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth Vasc-Alert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 913 Visonex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 904 W.L. Gore & Associates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1111 WKD – World Kidney Day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1829 Wolters Kluwer Health – LNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817 Women In Nephrology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 835 Yale Pathology Labs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2029 ZS Pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1210
EXPOSITION
7b
Exhibitor/Company Product Descriptions (as of 8/28/2014) AbbVie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513, 527 Acumen Physician Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1115 Acumen Physician Solutions was formed to develop and deliver intuitive software tools to assist nephrologists in the practice of medicine. The Acumen solution was designed by nephrologists and made available under an Internet-based service model. Our products include: Acumen Practice Management, Acumen Plus, Acumen Mobile Charge Capture, Acumen nEHR, and Acumen PQRS. Alexion Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1801 Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development, and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Alport Syndrome Foundation, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716 The Alport Syndrome Foundation is a volunteer-led 501(c)(3) non-profit organization that gives a voice to all those affected by this genetic kidney disease and champions fundraising and research to find a cure. Our mission is to educate and support patients and families that have been affected by Alport Syndrome with the goal of funding research to find effective treatment protocols and a cure. American Board of Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1436 Certification by ABIM has meant that internists have demonstrated that they have the clinical judgment, skills, and attitudes essential for the delivery of excellent patient care. ABIM is not a membership society but a physician-led, non-profit, independent evaluation organization with accountability to the profession of medicine and the public. American College of Physicians/Annals of Internal Medicine . . . . . . . . . . . . . . 1711 ACP is a diverse community of internal medicine specialists and subspecialists united by a commitment to excellence. ACP and its 137,000 physician members lead the profession in education, standard-setting, and the sharing of knowledge to advance the science and practice of internal medicine. ACP is the largest medical-specialty society in the world. ACP is the publisher of Annals of Internal Medicine, with an impact factor of 16.1 and circulation of over 85,000. Come see our new CME/MOC options. American Kidney Fund . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 American Nephrology Nurses’ Association . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501 Visit the ANNA Booth for information on membership, chapter development, and ANNA products. Discover the many benefits of ANNA membership and how you can enhance your member experience and involvement.
8b
American Physiological Society . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1036 The American Physiological Society (APS; www.the-aps.org) is a nonprofit devoted to fostering education, scientific research, and dissemination of information in the physiological sciences. Featured is one of the APS’ cutting-edge journals, American Journal of Physiology-Renal Physiology. Stop by booth 1036, and pick up more information! American Regent, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1408 American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc., is the leading IV iron manufacturer and distributor in the U.S. In addition to Venofer® (iron sucrose injection, USP), American Regent now offers Injectafer® (ferric carboxymaltose injection), available in 750 mg/15 mL single-use vials. Please visit us at booth 1408 to learn more! American Renal Associates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1301 American Renal Associates is a national provider of dialysis services, employing exclusively the nephrologist partnership model. Together we provide exceptional care and serve over 9,500 dialysis patients. ARA believes that the dialysis clinic is an extension of the nephrology practice. The physician is empowered to ensure high quality care resulting in low staff turnover, excellent patient and staff satisfaction, rapid growth, and among the best clinical outcomes in the industry. American Society for Apheresis (ASFA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 The American Society for Apheresis (ASFA) is an organization of physicians, scientists, and allied health professionals whose mission is to lead the field of apheresis through patient and donor care, research, education, and advocacy. American Society of Diagnostic & Interventional Nephrology . . . . . . . . . . . . . . . 613 The American Society of Diagnostic & Interventional Nephrology (ASDIN) is a professional membership organization. Its mission is to promote the appropriate application of new and existing procedures in order to improve the care of patients with kidney disease. Programs include establishment of practice standards, physician certification programs, accreditation of training programs, and development of training tools/techniques. To learn more, visit www.asdin.org. American Society of Nephrology (ASN) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327 Visit ASN to access onsite services, including: Membership (renew your 2015 ASN membership); ASN Foundation Information; Kidney Health Initiative (KHI); General Meeting Information and Assistance; and Publications. Stop by to see a demo of the new Kidney Transplant Practice Improvement Module (KTPIM) and learn about “ASN Highlights: Translating Kidney Week into Clinical Practice.” AmeriWater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604 AmeriWater is a manufacturer, designer, and service provider of water treatment equipment to the healthcare industry, specializing in dialysis. AmeriWater’s products are FDA, ISO, ETL/UL certified. The complete line includes every component from the blending valve through the final filter, single patient systems, heat disinfect, water testing, and seminars. Ozone coming soon!
EXPOSITION
9b
Amgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1601 Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amicus Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735 Amicus Therapeutics is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amyloidosis Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2005 The Amyloidosis Foundation is a nonprofit whose mission is to raise awareness of the amyloidosis diseases and support research towards a cure. Angelini Pharma Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712 Established in the early 20th century, Angelini Pharma Inc. has grown to become an international player in the healthcare field. In January of 2013, Alcavis HDC and Angelini Labopharm were integrated into the parent company Angelini Pharmaceuticals and jointly operate as Angelini Pharma Inc. Angelini Pharma Inc. is now providing clients with the most advanced comprehensive products and services in the market. Our markets include: Dialysis, Wound Care, Devices, Pharmaceutical. AngioDynamics Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1813 Aohua Medical Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1518 Our company is a manufacturer of various disposable medical products, and the product line is especially concentrated on the Hemodialysis related products, including AV Fistula needles, Blood tubing sets, Syringes, Stopcocks, Filters, etc. Our company is committed to provide high quality products to improve patient care. Arbor Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2026 Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the hospital, cardiovascular, and pediatric markets. The company has 280 sales professionals in the field which promote its products to hospitals and physicians. Asahi Kasei Medical America Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1527 Asahi’s Therapeutic Apheresis Division provides innovative therapies and medical devices for diseases with breakthrough technology for extracorporeal apheresis. In the dialysis market, Asahi Kasei Medical offers REXEED™ series dialyzers. REXEED™, the high performance polysulfone dialyzer, offers unparalleled performance and patient safety and is offered in multiple sizes including 2.5 square meters. Ascend Clinical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1413 Ascend Clinical is the nation’s leader in ESRD laboratory testing for independent dialysis providers. Our Web-based software LabCheck™, Ascend Chart™, and mobile program LabCheck GO™ can distribute an integrated set of services with CROWNWeb interface, real-time results, electronic reporting, workflow, and treatment features that salvage time and provide flexibility.
10b
Associates of Cape Cod, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710 AtCor Medical, Inc. (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805 AtCor Medical’s new SphygmoCor® XCEL device measures brachial and central aortic blood pressures automatically in an easy-to-use, brachial cuff-based system, providing new insights in diagnosis and drug therapy management. The SphygmoCor® XCEL system. New insights, new solutions. AWAK Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1234 AWAK Technologies has developed an advanced sorbent technology for dialysate regeneration for both peritoneal dialysis and hemodialysis. The battery-powered sorbent design can be in any forms and sizes—making miniaturization and portability possible. The vision of having light-weight portable and wearable dialysis machine, providing freedom to patients, is now a reality. www.awak.com B. Braun Medical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1001 B. Braun does much more than simply manufacture top quality dialysis machines, dialyzers, and disposables. We offer an integrated system composed of perfectly harmonized components. These include a wide range of therapy options, software solutions for optimal and economical dialysis treatment, and full technical service support. Stop by booth 1001 to talk with an expert. Customers benefit from the expertise of an all-around system supplier. Or for more information call 800-848-2066. Bard Peripheral Vascular, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907 Bard Peripheral Vascular, Inc. features a range of vascular access products such as dialysis and chemotherapy catheters, as well as feeding tubes and draining systems. EquiStream® Long-Term Hemodialysis catheter used to clean and filter blood. Aspira® Home Drainage System which allows patients to drain fluid at home. Baxter Healthcare Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1717 Baxter enhanced its leadership in renal therapies with the acquisition of Gambro and now offers a comprehensive portfolio of therapeutic options across the home, in-center, and intensive care settings. The portfolio includes innovative technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, multi-organ extracorporeal support therapy, and additional dialysis services. The Binding Site, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309 Binding Site develops special protein assays and automated systems for the improvement of patient care. Our market-leading assay Freelite® for detecting free light chains is widely used in diagnosis and monitoring of myeloma, often complicated by kidney dysfunction. Our patented antibody production technology and medical educators, backed by clinical practice guidelines, provide healthcare professionals tools to significantly improve diagnosis and management of patients. www. thebindingsite.com
11b
EXPOSITION
Biomedica Medizinprodukte GmbH & Co . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1927 Biomedica provides fully validated ELISA kits for the measurement of cardiovascular and renal biomarkers for clinical research, e.g. (Big) Endothelin, proANP, Endostatin, Sclerostin, and Osteoprotegerin. Biomedica’s assays use serum based calibrators and controls enabling researchers to collect biologically reliable data.
BioPorto Diagnostics A/S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1035 BioPorto Diagnostics offers a wide range of products for analysis of the biomarker NGAL. The portfolio includes The NGAL Test™ for easy implementation and analysis on automated chemistry analyzers and a variety of ELISA kits for measuring NGAL in both humans and animals. For Research Use Only in the USA. Calmoseptine, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1635 Calmoseptine Inc. promotes Calmoseptine Ointment for the prevention and treatment of skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal and vaginal fistulas, and feeding tube site leakage. Calmoseptine Ointment temporarily relieves discomfort and itching. Small sample sizes available. CardioMed Supplies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1239 CardioMed Supplies is a manufacture of long-term dialysis catheters and short-term catheters, utilizing high quality materials and innovative designs. CMS is also proud to introduce the Supercath AZ; unlike needles Supercath’s AZ catheter minimizes the risk of damage to AV fistulas and grafts, enhancing the longevity of the access site. Central Florida Kidney Centers, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1912 Central Florida Kidneys Centers, Inc. is a non-profit organization that has served the Greater Orlando area for 40 years and counting. We are currently the only out-patient clinic that provides dialysis for pediatrics in the Orlando area. We provide services for in center hemodialysis as well as peritoneal dialysis. We have five locations with three conveniently located within 5-15 minutes to International Drive and our three major theme park attractions. Christopher Kidd & Associates, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1734 Christopher Kidd & Associates, LLC Architects, and Engineers is an established and respected firm practicing in 47 states. We are experts in the design of Dialysis Clinics, Nephrology Suites, Nocturnal Units, and Vascular Access Centers. We have successfully designed over 600 dialysis clinics. Proudly celebrating 18 years’ experience, we are award-winning, professional, and responsive. Our commitment to working with our clients as partners is foundational in our operation. Chronic Disease Research Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1636 Chronic Disease Research Group specializes in data-based public health studies in ESRD, CKD, cancer, transplantation, cardiovascular disease, and other chronic conditions. Projects include assessing disease trends, public health surveillance, health utilization and cost burden, and the impact of healthcare practices and policies. Cincinnati Children’s Hospital, Division of Nephrology . . . . . . . . . . . . . . . . . . . 2030 The Nephrology Clinical Laboratory at Cincinnati Children’s Hospital Medical Center specializes in diagnostic testing for thrombotic microangiopathies (atypical HUS and thrombotic thrombocytopenic purpura) and complement-mediated disorders such as membranoproliferative glomerulonephritis. Our internationally recognized Biomarker Laboratory offers a full array of biomarker measurement and discovery services for your clinical or translational research needs.
12b
ClearBridge Biophotonics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1641 Clearbridge Biophotonics, CBBP, is a technology company focused on creating groundbreaking clinical diagnostic tools for kidney disease and genitourinary cancers. CBBP’s strategy is to create unique capabilities through the combination of select biomarkers and advanced microscopy technology exclusively licensed from CalTech. CBBP has offices in both Singapore and Carlsbad, CA. CMIC Holdings Co., Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1012 L-FABP is useful renal biomarker originated from Japan. L-FABP enables early diagnosis of diabetic nephropathy, risk differentiation of renal dysfunction, monitoring of treatment effect of renal diseases, and prediction of onset of acute kidney injury. L-FABP is CE certified and Japanese reimbursed product. Coalition for Supportive Care of Kidney Patients . . . . . . . . . . . . . . . . . . . . . . . . 2028 The Coalition for Supportive Care of Kidney Patients (CSCKP) brings together people who care deeply about the quality of compassionate, supportive care for kidney patients. Comprised of professionals and laypersons from many disciplines, the Coalition strives to promote effective interchange among patients, families, healthcare professionals, and payers to ensure the provision of patient-centered supportive care for patients with kidney disease. Covance Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1926 As one of the world’s largest and most comprehensive drug development service companies, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription drugs in the marketplace today. Because of our broad experience and specialized expertise, we are in a unique position to supply insights that go above and beyond testing. Together with our clients, we create solutions that transform potential into reality. www.covance.com CryoLife . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 935 CryoLife® is a leader in the development and implementation of advanced technologies associated with vascular allograft processing and cryopreservation. CryoLife also has the HeRO Graft (Hemodialysis Reliable Outflow). HeRO Graft is the ONLY fully subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with central venous stenosis. Cystinosis Research Network . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 937 DaVita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601 DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company. A leading provider of kidney care in the United States, DaVita strives to improve quality of life for people with end-stage renal disease through clinical innovation, integrated treatment plans, and personalized care teams. Daxor Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1419 Daxor Corporation’s BVA-100® Blood Volume Analyzer is a semi-automated instrument patented for direct measurement of blood volume, red cell, and plasma volume. The system utilizes the Volumex® injection kit for a multi-sample blood volume. Measurement of blood volume is applicable for hypertension, CHF, transfusion, ICU/ CCU, anemia, orthostatic hypotension, and syncope. EXPOSITION
13b
Dialysis Clinic, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1733 Dialysis Clinic Inc., the nation’s largest non-profit dialysis organization, provides dialysis treatments in over 200 clinics, 70 hospitals, and in the home setting. With its own laboratory, pharmacy, and research department, DCI offers customized opportunities for dialysis affiliation. For 11 years the USRDS has recognized DCI for the lowest hospitalization and mortality rates among large dialysis providers. DiaSorin Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2003 DiaSorin is a world leader in high quality immunodiagnostics for the clinical laboratory. Our menu offering on the LIAISON® systems includes a specialty panel of endocrinology and the LIAISON® 25 OH Vitamin D TOTAL Assay. DiaSorin has distributed more than 200 million vitamin D tests. Visit booth 2003 for information. DoctorsXL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1135 DoctorsXL is the nation’s leading nephrology practice management specialist. Our expertise includes billing, practice management, EMR customization, payor contracting, practice assessments, and strategic consulting. DoctorsXL helps nephrology practices optimize their operations by increasing profitability, reducing costs and eliminating headaches. Excel at the business of medicine, visit www. DoctorsXL.com or call 1-877-370-3145 and ask for Shay Dusek to learn more. DOPPS/Arbor Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2009 The DOPPS Program currently includes: the international Dialysis Outcomes and Practice Patterns Study, Peritoneal Dialysis Outcomes and Practice Patterns Study, and the Chronic Kidney Disease Outcomes and Practice Patterns Study, www.DOPPS. org. The Program is coordinated by Arbor Research Collaborative for Health in Ann Arbor, MI, USA. DSI Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1034 DSI Renal is a leading provider of dialysis services in the US, offering state-of-the-art treatment for patients suffering from chronic kidney failure. Together with its physician partners, DSI owns and operates 88 clinics in 22 states. DSI plans for growth through acquisition and development of new clinics, as well as through establishment of additional joint venture partnerships with leading nephrologists for the clinic, hospital, and alternate settings. For more info, visit www.dsi-corp.com. EKF Molecular Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730 EKF Diagnostics Limited (formerly Argutus Medical) is a world leader in developing ELISA Tests and Rapid Tests for detection of acute injury to the kidney and liver. EKF are collaborating with the Joslin Diabetes Center to commercialize novel biomarkers, Tumor Necrosis Factor Receptor 1/2, to accurately identify diabetes patients with an increased risk of developing end-stage kidney disease. We also have a range of other assays and antibodies including OxyDNA, our unique test for genotoxicity. Elsevier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900 ELSEVIER is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners, and students. With an extensive media spectrum—print, online, and handheld, we are able to supply the information you need in the most convenient format. Enovative Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728
14b
ERA-EDTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334 ERA-EDTA is a society with over 6000 members. It organizes annual congresses, educational courses, data collection, and epidemiological studies. It supports fellowships and research projects. Its publications are NDT, CKJ, NDT-Educational. The 2015 congress will be held in London from May 28-May 31. More information at www.era-edta.org. EUROIMMUN US . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1630 EUROIMMUN is a world leader in medical diagnostics. Innovative technologies include: IFA BIOCHIPs, ELISA, Immunoblot, and Microarray, Designer and licensed technologies also play an important strategic role in product development. With a continuous addition of new products, EUROIMMUN offers one of the most extensive menus in the world. Explore Transplant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1437 Explore Transplant helps kidney patients make informed decisions about transplant as a treatment option and activate family and friends as living donors. We publish research-tested educational materials and partner with transplant programs and non‑profit organizations to train dialysis providers and nephrology practitioners to help their patients make informed transplant choices. Falcon Physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801 Falcon Physicians is a nephrology-focused, ONCHIT-certified electronic health record that was developed by health technology experts with input from nephrologists. As a cloud‑based solution, Falcon Physicians gives you access to critical patient data whenever and wherever you have Internet connectivity, from your computer, iPad, or iPad mini. The Fortus Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2013 The first full service executive search firm, specializing in Renal Care, Nephrology, Transplantation, providing recruitment and placement of all clinical and non-clinical dialysis professionals world-wide, including Permanent, Travel, and Locum Tenens positions. In addition, Fortus specializes in flexible turnkey solutions in dialysis development as well. Frenova Renal Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1810 Frenova Renal Research is your only clinical development partner dedicated exclusively to renal research. We offer complete Phase I-IV clinical services and exceptional bioinformatics capabilities, along with a world-class network of resources and access to 390,000+ active CKD and 183,000+ active ESRD patients. Trust the partner that’s completely renal—Frenova. Fresenius Medical Care – Fresenius Medical Services . . . . . . . . . . . . . . . . . . . . 1011 The mission of Fresenius Medical Services (FMS), a division of Fresenius Medical Care North America, is “Through UltraCare®, improving the Quality of Life of Every Patient, Every Treatment.” FMS considers its relationships with nephrology professionals to be critical in fulfilling that mission in providing exceptional patient care. Fresenius Medical Care – Renal Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . 1101 EXPOSITION
15b
Fresenius Medical Care – Fresenius Renal Therapies . . . . . . . . . . . . . . . . . . . . . 1917 The Renal Therapies Group of Fresenius Medical Care is the leading provider of dialysis products and services in the United States. In-center products include: Optiflux® dialyzers, the 2008® series hemodialysis machines, and Crit-Line®. Home therapy offerings include 2008k@home™ with WetAlert™, Liberty® cycler, and stay∙safe connectology. Our Renal Pharmaceutical team offers Venofer® iron sucrose injection, and PhosLyra® calcium acetate oral solution. To learn more, contact us at 800-662-1237. Genentech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1310, 1339 For more than 35 years, we have been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California. Genzyme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1519 Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Visit www.genzyme.com. Hospira . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927 Hospira, Inc., is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 17,000 employees. Learn more at www.hospira.com. Houston Methodist J.C. Walter Jr. Transplant Center . . . . . . . . . . . . . . . . . . . . 1736 HRA Healthcare Research & Analytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1618 HRA–Healthcare Research & Analytics provides solutions supporting decision-making/ strategy development across healthcare channels. Our portfolio encompasses quantitative/qualitative, custom and syndicated services supporting pharmaceutical/ biotech/medical device markets. Immucor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1629 Immucor is a global provider of transfusion and transplantation diagnostics. LIFECODES, our transplant diagnostics division, provides molecular and antibody‑based assays for HLA compatibility between donors and recipients. Laboratories use LIFECODES products to help determine the path for lowering the probability of rejection in recipients. ORGAN-I develops diagnostics to manage patients post-transplant. Immundiagnostik AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1014 Immundiagnostik is an internationally active diagnostics company that develops innovative immunoassays and other analytical methods for routine and research. The product portfolio is completed by a broad range of antibodies and antigens. We focus on providing effective tools for prevention, differential diagnosis, and therapy monitoring in the areas of gastroenterology, cardiovascular diseases, disorders of the skeletal system, and oxidative stress.
16b
Immutopics International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .915 ELISA test kits for FGF-23, several forms of PTH, Osteocalcin, Calcitonin, and related peptides are developed and manufactured by Immutopics. The company specializes in innovative assays for assessing calcium and phosphate regulation. Since 1989, it has been a leading source of immunoassay kits for pre-clinical studies of bone and mineral disorders in human, rat, mouse, and other mammalian models. Infian/HII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1215 Infian, formerly known as Health Informatics Intl (HII), is the leading provider of renal Electronic Health Records, medical billing services, and billing software. Infian’s TIME System is an ONC-Certified EHR Technology for Eligible Providers as a Complete EHR. Further, with our technology division Infian ensures your medical and billing data is secure, accessible, and ultimately improves the care you provide. Infian has been serving the renal industry for over 25 years. Please visit www.infian.com. Intelomed, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 The tool you’ve been waiting for. CVInsight™, Intelomed’s noninvasive, portable monitor for fluid management, enables tailoring of the dialysis treatment to protect against hypotensive episodes. CVInsight™ displays a real-time, patient-specific assessment of changes in pulse rate and pulse strength allowing the clinician a predictive measure of declining of cardiovascular stability. Visit our booth and learn about how CVInsight™ enables a new standard of care. International Society of Nephrology (ISN) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1831 The International Society of Nephrology (ISN) is a global not-for-profit membership‑based scientific society with a humanitarian mission dedicated to pursuing the global advancement of kidney care by supporting education, science, and patient health. It also aims to bridge gaps between the developing and developed world in preventing kidney disease. Kidney International, ISN’s official journal, is widely regarded as the world’s premier journal on the development and consequences of kidney disease. The JAMA Network . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 Building on a tradition of editorial excellence, The JAMA Network brings JAMA together with nine specialty journals to offer enhanced access to the research, viewpoints, and medical news shaping medicine today and into the future. Published continuously since 1883 by the American Medical Association, JAMA is one of the most widely circulated, peer-reviewed, general medical journals in the world. Janssen Pharmaceutical Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1620 Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: ADHD, general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurology (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, cardiovascular, and women’s health.
EXPOSITION
17b
Japanese Society of Nephrology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1037 The mission of the JSN is to aid in the practice and study of nephrology. In order to achieve this, the JSN conducts a range of activities. These include holding regular meetings as a forum for the diffusion of information, producing regular journals, coordinating clinical research, promoting cooperation with related societies in Japan and internationally, as well as providing recognition to those who have made significant contributions in the field of nephrology. JMS North America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 608 JMS is proud to display the SysLoc®MINI and WingEater® safety AVF needles and our buttonhole needle the Harmony® with site preparation tool. JMS North America’s mission is to provide products and services that offer optimal safety solutions for patients and medical professionals. Come by booth 608 for a demonstration. Kaneka Pharma America LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632 Karger Publishers, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1211 Publications on display include the journals American Journal of Nephrology, Blood Purification, Cardiorenal Medicine, Case Reports in Nephrology and Urology, Kidney and Blood Pressure Research, and Nephron; and the book series Contributions to Nephrology. KDIGO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2031 KDIGO is a Belgian non-profit foundation developing and implementing evidencebased, clinical practice guidelines in kidney disease. KDIGO has produced nine guidelines, with two updates and a new guideline currently under development. In addition, KDIGO has held 18 global controversies conferences on important issues in kidney disease and its treatment. Keryx Biopharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1611 Keryx Biopharmaceuticals Inc. is focused on the acquisition, development, and commercialization of medically important pharmaceutical products to address underserved needs. Keryx embraces change in a constantly evolving marketplace and is tenacious in achieving innovative excellence. Founded in 2006, Keryx is headquartered in New York City and is traded on the NASDAQ Stock Market under the symbol KERX. Kibow Biotech, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1727 Kibow Biotech specializes in the development of probiotic dietary supplements for improved health. Our flagship product Renadyl™ is a patented, probiotic formulation that promotes healthy kidney function. Clinical studies document that Renadyl™ helps stabilize and/or reduce uremic toxin levels in CKD patients resulting in an improved quality of life. Klarvoyant, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1634 LSU Health, Department of Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1338 LSU Health Shreveport now offers Renal Pathology Outreach Consultation Services which provides nephrologists the diagnostic expertise needed for personalized, quality patient care. We realize that quality and efficiency are of the utmost importance in delivering the best care possible, and we at LSU Health continuously strive to ensure that each client receives the highest quality, accuracy, technologically advanced, and personalized services on the market today at the most competitive prices.
18b
Machaon Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1910 Machaon Diagnostics is a clinical reference laboratory, specializing in the diagnosis, treatment, and monitoring of hemostatic and thrombotic conditions. Our 48-hour aHUS Genetic Panel is the fastest genetic test for this disease. Our vision is to deliver customizable reference lab testing to the healthcare and bioscience industries. Mallinckrodt Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1227 Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical and medical imaging company. The company’s new Autoimmune and Rare Diseases business (formerly Questcor Pharmaceuticals) includes H.P. Acthar® Gel (repository corticotropin injection), indicated for use in multiple specialties including neurology, rheumatology, nephrology, and pulmonology. Mallinckrodt’s other areas of focus include analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. To learn more about Mallinckrodt and Acthar, visit Exhibit #1227 or www.mallinckrodt.com/ard. Mar Cor Purification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1534 Mar Cor Purification provides complete turnkey 510(k) water treatment systems featuring heat disinfection technology for central RO’s using the CWP platform and acute program settings, the Millenium HX and WRO300H series portable RO’s; bicarbonate and concentrate mixing/distribution systems; consumables such as Minncare disinfectant and FIberFlo endotoxin filters with service from 24 offices nationwide. Contact us at 1-800-633-3080 or visit www.mcpur.com. Mayo Clinic Referring Physician Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533 Mayo Clinic is a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. MedComp . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1134 Medcomp advances patient outcomes through catheter innovation and design. Recognized as the world leader in long term dialysis catheters, Medcomp has leveraged its engineering expertise into the PICC and Port market. Medcomp continues to provide the highest quality products and support to advance patient care. Medical Devices Corporation Sdn Bhd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916 Medical Devices Corporation offer innovative renal replacement therapy for both Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD). We offer peritoneal dialysis solution for CAPD and APD. We are currently developing a low GDP and pH neutral peritoneal dialysis solutions and an innovative portable PD cycler. Medical Education Institute, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505 Medical Education Institute (MEI) is a non-profit organization dedicated to helping people with chronic disease learn to manage and improve their health. We conduct health behavior research and develop evidence-based patient education materials. MEI administers Life Options (www.lifeoptions.org), created Kidney School (www. kidneyschool.org), Home Dialysis Central (www.homedialysis.org), and KDQOL COMPLETE (www.kdqol-complete.org).
EXPOSITION
19b
Medical Indicators, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620 Medical Indicators supplies the Tempa•DOT and NexTemp® brand disposable clinical thermometers. The thermometers are manufactured in our FDA registered facility in Hamilton, NJ operating under an ISO 13485:2003 quality system. Making disposable thermometers a part of an infection control program will help to reduce nosocomial infections in a healthcare facility. MIQS Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 MIQS is the premier provider of medical record and financial software for dialysis. Our award-winning software supports your clinical efforts, billing needs, and regulatory compliance. Peer-reviewed publications show how we can help improve your patient survival. Mission Pharmacal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335 Mission Pharmacal Company is a privately held Pharmaceutical company based in San Antonio, Texas. For 65 years, the company has been dedicated to identifying unmet health needs in the marketplace and developing innovative prescription and over-the-counter products to meet them. National Death Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2001 The NDI is a central computerized index of death record information from the state vital statistics offices. The NDI is available to investigators solely for statistical purposes in medical and health research. For additional information visit our website http://www. cdc.gov/nchs/ndi.htm. National Kidney and Urologic Disease Information Clearinghouse . . . . . . . . . . 507 National Kidney Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1314 National Kidney Foundation offers the nephrology community the latest science and practical tools through clinical practice guidelines, community-based educational activities, continuing medical education programs, and professional memberships. Visit our booth 1314, to learn more about KDOQI™, KEEP Healthy™, NKF Education Materials, and our scientific journals: AJKD, ACKD, and JRN. Nature Publishing Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2027 Nature Publishing Group brings you leading scientific and medical research. The NPG portfolio combines the continued excellence of Nature, its associated research and review journals, and 50 leading academic and society journals in the life, physical, and clinical sciences. Visit booth 2027 for free sample copies. NEJM Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1421 NEJM Group creates high quality medical resources for research, learning, practice, and professional development designed for academic researchers and teachers, physicians, clinicians, and others in medicine and health care. The New England Journal of Medicine, NEJM Journal Watch, and NEJM Knowledge+ are produced by NEJM Group, a division of the Massachusetts Medical Society. For more information visit www.nejmgroup.org.
20b
NephCure Kidney International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 633 NephCure Kidney International (NKI) is the only organization committed exclusively to support research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome (NS), improve treatment, and find a cure. NCF is: committed to funding international research, the primary source of information on NS and FSGS, the leader for legislative action for more federal funding for research, and attracting researchers to this field. Nephrocor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503 Nephrocor® provides clinical and anatomic pathology laboratory services specializing in the monitoring of kidney health. Our services include renal biopsies, 24-hour urine testing, Fluorescence in-situ hybridization (FISH), stone analysis, serums, and cultures. In addition, we provide a urine-based test, RenalVysion®, used to identify the early stages of kidney injury through cytodiagnostic urinalysis. Nephrology News & Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1535 NEPHROLOGY NEWS & ISSUES is a peer-reviewed, monthly news journal that takes a global approach to covering the political, social, and economic issues surrounding the delivery of dialysis and transplantation. Our website, www.NephrologyNews.com, offers daily updates on the latest news developments, as well as an archive of NN&I webinars. Sign up for our three-times-weekly eNewsletters. Nephrology Nursing Certification Commission . . . . . . . . . . . . . . . . . . . . . . . . . . . 509 The Nephrology Nursing Certification Commission (NNCC) exists to establish credentialing mechanisms to promote patient safety and to improve the quality of care provided to nephrology patients. The Nephrology Nursing Certification Commission (NNCC) supports the philosophy that there should be a diversity of examinations that will effectively provide the opportunity for certification at various levels of education, experience, and areas of practice within nephrology nursing. Nephropath . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718 Nephropath is a private renal pathology laboratory offering over 30 years of experience interpreting renal biopsies. We understand the critical effect time to diagnose can have on the outcome of many renal diseases. With this in mind we provide Light, Immunofluorescence, and Electron Microscopy results on the same day we receive a biopsy. Nephro-Tech, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1435 Nephro-Tech, Inc. provides high quality pharmaceuticals at affordable prices. RenaPlex-D®, along with Vital-D Rx®, treats vitamin D (25-OH D) deficiency daily. It contains all the ingredients of a renal multivitamin plus 2000 IU of cholecalciferol. RenaPlex-D® is available at $12.00/100 through Nephro-Tech, Inc. Also available, Calphron®- 667mg calcium acetate and costs $15.00/200 through Nephro-Tech, Inc. Call 800-879-4755 for more information.
21b
EXPOSITION
NIKKISO CO., LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 827 The pioneer of hemodialysis machines in Japan, NIKKISO CO., LTD. is a leading company in Japanese dialysis market. Now we offer our technology in machines worldwide. Our sophisticated technologies offer reliable dialysis machines and disposable products to the world. To learn more, visit our booth (827) and www.nikkiso.com or www.nikkisoamerica.com.
Nipro Medical Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 711 Nipro Medical Corporation is a leading healthcare organization dedicated to developing hemodialysis products. Our commitment lies in delivering high-quality, value-added solutions to improve patient care. NxStage Kidney Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 934 NxStage Kidney Care is dedicated to helping our patients discover, achieve, and maintain freedom and flexibility while on a dialysis therapy that meets their needs. Our state-of-the-art dialysis centers are dedicated to providing top quality, compassionate, and individualized care. Our goal is to accommodate our patient’s lifestyle whether they dialyze at the center or we are guiding and educating them to confidently perform dialysis at home. For more information, please visit www.nxstagekidneycare.com. NxStage Medical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1027 NxStage® is more than a company; we are leading the renal revolution. Our innovative products are helping to shape and transform renal care. Making it simpler, portable, and expanding treatment options, to enhance patient freedom and fulfillment. Otsuka America Pharmaceutical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1401 Otsuka America Pharmaceutical, Inc. (OAPI) is an innovative, fast-growing healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S. With a strong focus on neuroscience, oncology, cardio-renal, and medical devices, OAPI is dedicated to improving the health and quality of human life. For more information, visit www.otsuka-us.com. Otto Trading, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1337 Oxalosis and Hyperoxaluria Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1137 Oxalosis and Hyperoxaluria Foundation (OHF) is the ONLY foundation in the world dedicated to finding a cure for Primary Hyperoxaluria (PH), a life-threatening kidney stone disease that affects adults and children. The OHF is recognized globally as both a leader and an innovator in the PH field and serves as a viable resource for patients and professionals. Stop by the OHF booth to learn about the PH patient registry, diagnosis, treatment, and grant opportunities. Oxford University Press . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1434 Oxford University Press publishes some of the most respected medical books and journals in the world including the Oxford Clinical Nephrology Series and, on behalf of the ERA-EDTA, Nephrology Dialysis Transplantation and Clinical Kidney Journal. Visit our stand to pick up free copies of the journals. Visit www.oxfordjournals.org and www. oup.com. Patient First Renal Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1235 Physician Software Systems, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2010 Physician Software Systems has developed an anemia management system, which enables physicians to simulate a dialysis patient’s response to ESAs, recommend an individualized ESA dosing regimen, and closely monitor stabilized hemoglobin levels. The anemia management system has been shown to decrease hemoglobin variability, reduce ESA usage, and minimize hospitalizations—improving care and patient quality of life, while reducing costs. www.PhySoft.com
22b
pMD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600 pMD’s mobile charge capture solution allows physicians to enter billing charges in the hospital setting from Android, iPhone, and iPad devices. pMD eliminates the tedious paper processes and administrative elements that burden physicians and their practices, while reducing charge entry lag from weeks to less than a day. Polycystic Kidney Disease Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1929 The PKD Foundation is dedicated to finding treatments and a cure for polycystic kidney disease (PKD), to improve the lives of those it affects. We do this through promoting research, education, advocacy, support, and awareness. Our goal is that one day no one will suffer the full effects of PKD. Visit www.pkdcure.org Pulse Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919 Pulse provides certified, integrated, electronic healthcare management systems to thousands of providers across more than 40 specialties nationwide. Pulse’s award‑winning, interoperable technology platform includes easy-to-use, cost-efficient EHR, Practice Management, ePrescribing, and Revenue Cycle Management solutions. Pulse helps Physician practices increase work flow efficiencies, reduce costs, and achieve meaningful use incentives. Pure Life Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1237 Pure Life Renal is a new dialysis organization that acquires, develops, and manages clinics in partnership with nephrologists to provide an exceptional patient care experience. We value the industry knowledge and clinical expertise that our physician partners provide, which is why we strongly embrace the partnership model. Our team has extensive experience, and we have built a reputation for being very physician friendly, patient-focused, and sensitive to our employees’ needs. Quality Dialysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627 Quality Dialysis was founded in 1993, with the primary purpose of providing Staff Assisted Home Hemodialysis. It is the first organization in the State of Texas to provide licensed nurses to administer dialysis services in the home. For 20 years, Quality Dialysis continues to educate patients/families about chronic kidney disease. Raptor Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 901 Relypsa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1019 Relypsa, Inc. is a biopharmaceutical company whose mission is to improve patients’ lives through the discovery, development, and delivery of therapeutics that leverage polymer science and other novel approaches. The company’s lead product candidate, which has completed Phase 3 clinical trials, is being developed for the treatment of hyperkalemia. Hyperkalemia is a life-threatening condition defined as abnormally elevated levels of potassium in the blood, which can present chronically and acutely. More information is available at www.relypsa.com.
23b
EXPOSITION
Renal Physicians Association . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 The Renal Physicians Association is a national organization with the expertise and successful track record of pro-actively defending the discipline of the nephrology practice. Membership is comprised of healthcare providers in the subspecialty of internal medicine known as nephrology. Stop by our booth to check out RPA’s latest programs and publications.
Renal Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1811 The Renal Research Institute (RRI) is dedicated to advancing therapy options for dialysis patients to provide the highest caliber of care based on advanced clinical technology. The Institute is committed to research and innovation that will lead to improved patient outcomes and quality of life. RRI strives for a compassionate approach to our patients and to fulfill the needs and expectations of our customers. www.renalresearch.com 212-331-1700 Rockwell Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 811 Rockwell Medical: Bio-pharma company offering Calcitriol (active-vitamin-D) injection, plus high-quality hemodialysis concentrates including acetate-free citric-based CitraPure®—the new standard in dialysate. Investigational iron-delivery-drug Triferic™ clinical data demonstrates that in place of IV-iron it delivers iron and maintains hemoglobin without increasing ferritin, while decreasing ESA 35%. Under review for FDA approval. Sandoz, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727 Sandoz, a Novartis company, is one of the two largest generics manufacturers worldwide. Sandoz is the pioneer and global market leader in biosimilars, also known as biopharmaceuticals, and is committed to increasing access to affordable, high‑quality medicines for all US patients. Sandoz is proud to be the healthcare company of choice for patients, healthcare professionals, and our customers. Sanofi Renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1315 Sanofi, a global and diversified healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new Genzyme. Sanofi 55 Corporate Drive Bridgewater, NJ 08807 www.sanofi.us Satellite Healthcare/Wellbound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1626 Satellite Healthcare, Inc., is one of the nation’s first not-for-profit providers of dialysis services and kidney disease care. With its expanded offerings Satellite Healthcare provides early patient wellness education (WELLBOUND), personalized clinical services and a complete range of dialysis therapy choices. This comprehensive offering allows Satellite Healthcare to advance the standard of chronic kidney disease care so patients can achieve a better life. Celebrating 40 years. Sceptre Management Solutions, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834 Nephrology and dialysis revenue cycle management/billing experts. Increase your reimbursement, decrease receivables, capture more billable items. We will help prepare you for ICD-10. We can work with any EMR; no additional software or hardware purchase required to use our services. Eliminate your billing software and billing staff headaches with our customer-friendly services. We offer customized monthly reports, patient statements, and diligent follow-up on unpaid claims. Spectra Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1119 Spectra Laboratories delivers renal-specific testing, analysis, and reporting with the reliability you require to ensure the best outcomes possible for your patients. We also provide central laboratory services to a variety of clinical trials worldwide through our Spectra Clinical Research division.
24b
Teleflex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615 Our ARROW Interventional Access Products are inspired by clinicians, based on the results they need to achieve—whether that is precise placement, quality flow rates, or clot management. We design every catheter to be easy-to-use, provide clinical benefits, and enable healthcare providers to improve outcomes and enhance patient outcomes. Terumo BCT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1627 Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. Toray Medical Co., Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1738 TORAY, a leading manufacturer of synthetic fibers, is dedicated to the advancement of dialysis products under its corporate slogan, “Innovation by Chemistry.” Toray supports high quality and advanced medical care with our biocompatible polymethylmethacrylate dialyzer, “FILTRYZER®”, as well as our polysulfone dialyzer and dialysis machine, “TR-8000”. Please visit our booth 1738 for more details. Total Quality Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732 Total Quality Medical Inc. has been supplying the medical/dialysis industry since 1995. Headquartered in Kennebunk Maine. TQM has been working with both large and small dialysis chains as well as individual facilities around the United States. TQM offers Quality Dialysis products and supplies at a cost savings with exceptional service. Stop by booth 732. Transplant Genomics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 638 U.S. Renal Care, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1513 U.S. Renal Care, Inc. works in partnership with nephrologists and health systems to develop, acquire, and operate quality outpatient treatment centers. USRC serves more than 14,400 patients with their choice of a full range of quality in-center, at-home hemodialysis, and peritoneal dialysis services. USRC operates more than 200 clinics and outpatient programs in 19 states and the territory of Guam. United States Renal Data System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2007 National data system that collects, analyzes, and distributes information about endstage renal disease (ESRD) in the United States. UKD Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1930 Vasc-Alert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 913 Vasc-Alert offers a vascular access surveillance service, identifying patients at risk for thrombosis by providing weekly reports to the facility. The program works by analyzing treatment data, testing the access every session without requiring staff time. Outcomes are improved while reducing catheters and costs related to access complications.
EXPOSITION
25b
Visonex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 904 Visonex, LLC—Excellence in Renal Services. Clarity for Dialysis—Dialysis-specific EHR services meeting the needs of the independent dialysis community. VISONEX ENHANCED SERVICES combines a dialysis-specific EHR with a dialysis-specific billing service. Proven Track Record—100% Success Rate. Visit www.visonex.com for more information or a demonstration. W.L. Gore & Associates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1111 The Gore Medical Products Division has provided creative solutions to medical problems for three decades. Over 35 million Gore Medical Devices have been implanted worldwide. Products include vascular grafts, endovascular and interventional devices, surgical materials, and sutures for use in vascular, cardiac, and general surgery. For more information, visit www.goremedical.com. Wolters Kluwer Health – LN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817 Lippincott Williams & Wilkins (LWW) is a leading international publisher of professional health information for physicians, nurses, specialized clinicians, and students. LWW provides essential information for healthcare professionals in print and electronic formats, including textbooks, journals, CD-ROMs, and via Intranets and the Internet. Products available include drug guides, medical journals, nursing journals, medical textbooks, and eBooks. WKD – World Kidney Day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1829 World Kidney Day’s mission is to spread the word about the importance of our kidneys to our overall health, and to reduce the frequency and impact of kidney disease worldwide. It is today the most successful initiative to raise awareness with the general public, medical professionals, and government health officials around the world about the dangers of kidney disease. This year, on March 12, 2015, the focus will on Chronic Kidney Disease. Come, visit us, and find out how to get involved! Women in Nephrology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 835 WIN was founded in 1983 by women in the field of nephrology. The overriding goal was to develop and provide mentors to women in the field. WIN strives to aid women develop exciting careers in the field of renal disease. WIN also advocates within the nephrology community for education and research relevant to women. Over the years, WIN has expanded its purpose to mentoring both professional men and women in the field of nephrology. Yale Pathology Labs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2029 Yale Pathology Labs is a comprehensive anatomic pathology service with the internationally recognized teaching and research expertise of Yale University School of Medicine. When you choose to use Yale Pathology Labs, you will find an exceptional medical community pooling it’s technical resources and its vast array of human talent to resolve the diagnostic question at hand. ZS Pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1210 ZS Pharma is a biopharmaceutical company focused on novel approaches to treat renal, cardiovascular, liver, and metabolic diseases. Headquartered in Coppell, TX, ZS Pharma is in late-stage clinical trials for the first product in its pipeline, ZS-9, a uniquely selective, high-capacity potassium ion trap for the treatment of hyperkalemia.
26b
NOTES
_______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________ _______________________________________________________________
2014
ASN
LEADING THE FIGHT AGAINST KIDNEY DISEASE
Corporate Supporters The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney disease. ASN gratefully acknowledges the following companies for their contributions in 2014.
Diamond Level
Platinum Level
Gold Level Genentech, Inc./Biogen Idec, Inc. Hospira Otsuka America Pharmaceutical, Inc. Relypsa ZS Pharma
Silver Level AstraZeneca OPKO Health Renal Division Takeda Pharmaceuticals International, Inc., U.S. Region
Bronze Level AbbVie Shire
As of September 3, 2014
Unlock the potential of Acthar by visiting Booth #1227 to learn more
H.P. Acthar ® Gel and Questcor ® are registered trademarks of Questcor Pharmaceuticals, Inc. ©2014 Questcor Pharmaceuticals, Inc. PM-01-03-1210 09/14 Printed in USA.
